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Summary 
The World Health Organization (WHO) estimates a worldwide burden of three to 
five million cases of severe illness and 250,000-500,000 deaths from influenza 
every year. Influenza occurs in two epidemiological forms: epidemics and 
pandemics. An epidemic is more localized, as observed with seasonal influenza 
outbreaks, as a large proportion of the population possesses cross-reacting 
antibodies against recent variants of the virus. Hence, severe disease and deaths 
occur primarily among young children, the elderly, pregnant women and persons 
with other underlying disease conditions. An influenza pandemic, on the other 
hand, is a large-scale worldwide outbreak of the disease. Pandemic influenza 
results from the emergence of a new subtype of influenza virus to which the 
population has no pre-existing immunity. The entire population, including young 
and healthy adults, may be affected and mortality tends to be higher during 
pandemics as compared to local epidemics. A pandemic in 1918, called the 
‘Spanish flu’, is believed to be the most devastating disease outbreak in recent 
history and resulted in 20-50 million deaths. The first influenza pandemic of the 
21st century, commonly referred to as ‘swine flu’, was declared in June 2009 
when outbreaks caused by the novel influenza A (H1N1) virus reached pandemic 
proportions. Although the 2009 pandemic was less severe than expected, it still 
resulted in an estimated 300,000 deaths worldwide. Other estimates indicated 
that as many as 200 million cases occurred globally. 
 
India was affected by the 2009 influenza pandemic. The district of Pune, which 
suffered a high burden, was considered a hotspot of the pandemic in India. 
During the pandemic, India officially reported 202,790 cases, of which 2,971 
were from Pune. These figures which refer to laboratory confirmed cases are 
underestimated. Pune is also home to a large vaccine manufacturer that has the 
capacity to produce intramuscularly injected inactivated influenza vaccine and 
intranasally administered live attenuated influenza vaccine. 
 
Vaccination is a cornerstone of influenza prevention and community acceptance 
of a vaccine is a critical determinant of its effectiveness. Limited vaccine uptake 
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was a problem worldwide during the 2009 pandemic. Consideration of local 
sociocultural concepts of illness is crucial in understanding vaccine hesitancy and 
is likely to influence vaccine acceptance. Studies exploring vaccine hesitancy and 
reasons for poor uptake that limit effectiveness of pandemic response have been 
largely restricted to high-income settings. Despite acknowledged cross-cultural 
differences in public response to pandemic influenza and need for country-
specific studies, few have been conducted in lower income settings.  
 
The overall aim of this thesis was to study sociocultural features of illness and 
acceptance of pandemic influenza vaccines from a community perspective in a 
developing country setting with influenza vaccine production capacity. Research 
findings are intended to contribute to state-level and national-level policy in 
India on improving pandemic preparedness and influenza control. 
 
A cross-sectional, mixed-method study was conducted in urban and rural Pune in 
2012-2013. Semi-structured interviews were developed based on the 
explanatory model interview catalogue framework for cultural epidemiology to 
obtain representative distributions of perceptions of pandemic influenza and the 
role of vaccines. Vignette-based interviews were administered to community 
residents (n=436) to study sociocultural features of illness, including illness-
related experience, meaning and behaviour. The interview examined awareness, 
experience and preference amongst available vaccines for pandemic influenza. 
Anticipated acceptance of pandemic influenza vaccines at different price levels 
was also assessed and sociocultural determinants of vaccine acceptance were 
identified with logistic regression models. Complementary components of the 
data set included quantitative data for comparative analysis and narrative data 
for qualitative thematic analysis and elaboration. Formative focus group 
discussions provided insight on the setting and guided development of other 
instruments. Additional in-depth interviews that elaborated personal experience 
with pandemic influenza and vaccination, and motivations for vaccine use and 
potential barriers or hesitancy, complemented the survey.  
 
Descriptive analysis of sociocultural features of pandemic influenza found that a 
majority considered the illness fatal if untreated, but with treatment 96% 
predicted a full recovery. A third of respondents identified the illness described in 
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the vignette as a respiratory illness and more urban respondents (36.7% vs. 
16.3% rural) identified the illness as ‘swine flu’. The emotional impact of the 
illness was considered more troubling than physical symptoms. The most 
prominently identified perceived causes—‘exposure to a dirty environment’ and 
‘cough or sneeze of an infected person’—were more prominently identified by 
urban than rural respondents. The most prominently identified home-remedy 
was herbal treatment; more rural respondents suggested reliance on prayer, 
while symptom relief was more of a priority for urban respondents. Sources of 
help outside home were government hospitals and private health services, and a 
general preference for private health facilities was noted. Among those reporting 
personal or family history of swine flu during the 2009 pandemic, treatment 
delays were noted.  
 
Community awareness of pandemic influenza vaccines was low (25%). Some 
respondents did not consider vaccines relevant for adults, but nearly all (94.7%), 
when asked, believed that a vaccine would prevent swine flu. Reported vaccine 
uptake was 8.3%; but this needs to be interpreted in context given that vaccines 
were not available during the first wave of the pandemic in Pune, and when 
available subsequently, had to be privately purchased. Main themes identified as 
reasons for uptake of influenza vaccines during the pandemic were having heard 
of a death from swine flu, health care provider recommendation or affiliation 
with the health system, influence of peers and information from media. Reasons 
for non-use were low perceived personal risk, problems with access and cost, 
inadequate information and a perceived lack of a government mandate 
endorsing influenza vaccines. A majority indicated a preference for injectable 
over nasal vaccines, especially in remote rural areas.  
 
Over 93% anticipated accepting a no-cost vaccine for ‘swine flu’ in the future, 
91.2% at INR 75, 87.8% at INR 150, 74.1% at INR 500 and 61.7% at INR 1000. 
Some respondents preferred low-cost over no-cost vaccines due to a lack of 
trust and scepticism about quality of a vaccine provided for free by the 
government. Sociocultural determinants of anticipated influenza vaccine 
acceptance that were positively associated included illness-related concerns 
about social isolation, contaminants (e.g., germs or dirt) identified as a 
perceived cause, private-hospital or traditional-healer help seeking, and a higher 
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income. Humoral imbalances as perceived cause, home remedies and increasing 
age were negatively associated. 
 
In conclusion, problems with access to vaccines and absence of organised mass 
vaccination, insufficient government priority and endorsement, and low 
community awareness limited vaccine coverage during the 2009 pandemic. High 
acceptability of pandemic influenza vaccines, however, indicates good prospects. 
Identified sociocultural determinants provide practical suggestions for pandemic 
preparedness and control using vaccines. Hesitancy arising from a lack of 
confidence in pandemic influenza vaccines appears to be less of an issue 
compared to factors including access, complacency, inadequate confidence in the 
health system and other sociocultural considerations.  
 
This work is a contribution to global advances in the study of vaccine hesitancy 
and it underscores the value of sociocultural study and community preferences 
in planning effective vaccine action. Large influenza outbreaks in India in 2015 
and local vaccine production capacity highlight a need for government policy to 
reconsider influenza vaccination priority beyond use in pandemics. 
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Zusammenfassung 
Die Weltgesundheitsorganisation (WHO) schätzt die weltweit jedes Jahr durch 
Infektionen mit dem Influenzavirus verursachte Krankheitslast auf drei bis fünf 
Millionen schwere Erkrankungen und 250‘000-500‘000 Todesfälle. Influenza tritt 
als Epidemie und Pandemie auf. Eine Epidemie, wie im Falle saisonaler Influenza, 
tritt lokaler auf, da ein grosser Anteil der Bevölkerung kreuzreagierende 
Antikörper gegen neuere Varianten des Virus in sich trägt. Daher treten 
schwerwiegende Erkrankungen und Todesfälle primär bei jungen Kindern, 
älteren Personen, Schwangeren und Personen mit Grunderkrankungen auf. Eine 
Influenzapandemie dagegen wird durch einen grossräumigen weltweiten 
Krankheitsausbruch charakterisiert. Influenzapandemien treten nach dem 
Auftauchen eines neuen Influenzavirus-Subtyps auf, gegen den die Bevölkerung 
keine bereits vorhandene Immunität besitzt. Dabei kann die ganze Bevölkerung 
inklusive junge und gesunde Erwachsene betroffen sein, wobei die Mortalität 
während Pandemien tendenziell höher ist als bei lokalen Epidemien. Die 
Pandemie von 1918, die ‚Spanische Grippe‘, wird mit 20-50 Millionen Todesfällen 
als verheerendster Krankheitsausbruch in der jüngeren Geschichte angesehen. 
Die erste Influenzapandemie des 21. Jahrhunderts, gemeinhin als 
‚Schweinegrippe‘ betitelt, wurde im Juni 2009 ausgerufen, nachdem Ausbrüche 
durch das neuartige Influenzavirus A H1N1 pandemische Ausmasse erreicht 
hatte. Obwohl die Pandemie von 2009 weniger schlimm als befürchtet ausfiel, 
verursachte sie doch geschätzte 300‘000 Todesfälle weltweit. Andere 
Schätzungen gingen von weltweit bis zu 200 Millionen Krankheitsfällen aus. 
 
Indien war durch die Pandemie von 2009 betroffen. Der Distrikt Pune, welcher 
eine besonders hohe Krankheitslast zu tragen hatte, wurde als Hotspot der 
Pandemie in Indien angesehen. Während der Pandemie wurden von Indien 
offiziell 202‘790 Fälle, davon 2‘971 aus Pune, gemeldet. Diese Zahlen beziehen 
sich auf laborbestätigte Fälle und sind unterschätzt. In Pune befindet sich auch 
eine grosse Impfstoffherstellerin, welche in der Lage ist, inaktivierte Impfstoffe 
zur intramuskulären und attenuierte Lebendimpfstoffe zur intranasalen 
Verabreichung gegen Influenza herzustellen. 
Zusammenfassung 
xii 
 
 
Impfen stellt ein wichtiger Eckpfeiler der Influenzaverhütung dar, wobei die 
Akzeptanz von Impfungen in der Bevölkerung entscheidend ist für deren 
Effektivität. Ein eingeschränkter Gebrauch von Impfungen stellte ein Problem dar 
während der Pandemie von 2009-2010. Die Berücksichtigung lokaler 
soziokultureller Krankheitserfahrungskonzepte ist entscheidend zum besseren 
Verständnis der Impfunschlüssigkeit und beeinflusst wahrscheinlich auch die 
Impfakzeptanz. Studien zur Impfunschlüssigkeit oder zum eingeschränkten 
Gebrauch von Impfungen, beides limitiert eine effektive Antwort auf Pandemien, 
waren bislang meistens auf Hochlohnländer beschränkt. Obwohl kulturell 
bedingte Unterschiede in der öffentlichen Antwort auf Influenzapandemien und 
der Bedarf an länderspezifischen Studien anerkannt sind, wurden nur wenige 
solche Studien in Ländern mit tieferen Einkommen durchgeführt. 
 
Das Hauptziel dieser Arbeit bestand darin, soziokulturelle Merkmale von 
Influenzaerkrankungen und die Akzeptanz von Impfungen gegen pandemische 
Influenza aus der Perspektive der Bevölkerung eines Entwicklungslandes, das 
über Impfstoffherstellungskapazitäten verfügt, zu untersuchen. Die Erkenntnisse 
dieser Forschungsstudie sollen den Unionsstaaten und der Zentralregierung in 
Indien zur Verbesserung der Pandemievorbereitung und der 
Influenzabekämpfung dienen. 
 
Eine auf einem Mixed-Methods-Ansatz basierende Querschnittsstudie wurde 
2012-2013 in urbanen und ländlichen Gebieten in Pune durchgeführt. Es wurden 
halbstrukturierte Interviews mit Vignetten entwickelt, die auf dem in der 
Kulturellen Epidemiologie eingesetzten Explanatory Model Interview Catalogue 
beruhten, um die in der Bevölkerung verbreiteten Wahrnehmungen zu 
pandemischer Influenza und zur Rolle von Impfungen zu untersuchen. Es 
wurden 436 Gemeindemitglieder interviewt, um soziokulturelle Merkmale einer 
Erkrankung, d.h. Krankheitserfahrungen, Bedeutungen und Verhaltensweisen, zu 
studieren. Das Interview untersuchte Bekanntheit, Erfahrungen und Präferenzen 
in Bezug auf verfügbare Pandemieimpfstoffe. Die Bereitschaft zum Gebrauch von 
Pandemieimpfstoffen in Abhängigkeit vom Preis wurde ebenfalls untersucht und 
soziokulturellen Determinanten der Impfakzeptanz anhand logistischer 
Regressionsmodelle identifiziert. Der Datensatz beinhaltete sich ergänzende 
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quantitative und narrative Komponenten zur vergleichenden bzw. thematischen 
Analyse und Interpretation. Formative Fokusgruppendiskussionen lieferten 
Einblicke in das Umfeld und halfen mit, die weiteren Forschungsinstrumente zu 
entwickeln. Zusätzlich durchgeführte Tiefeninterviews zu persönlichen 
Erfahrungen von Befragten mit Bezug zu pandemischer Influenza und Impfungen 
sowie zu Motivationen zum Impfstoffgebrauch bzw. mögliche Hürden oder 
Unschlüssigkeiten vervollständigten die Umfrage. 
 
Deskriptive Analysen der soziokulturellen Merkmale von pandemischer Influenza 
ergaben, dass eine Mehrheit diese Erkrankung ohne Behandlung als 
schwerwiegend einschätzte, wobei 96% nach Behandlung von einer 
vollständigen Genesung ausgingen. Ein Drittel der Befragten identifizierte die in 
der Vignette beschriebene Erkrankung als Atemwegserkrankung und mehr 
Befragte aus den urbanen Gemeinden (36.7% vs. 16.3% in ländlichen 
Gemeinden) identifizierten die Erkrankung als ‚Schweinegrippe‘. Emotionale 
Auswirkungen einer solchen Erkrankung wurden als beunruhigender eingeschätzt 
als körperliche Symptome. Die am prominentesten wahrgenommenen Ursachen 
— ‚Exponiertsein gegenüber einer dreckigen Umwelt‘ und ‚Husten oder Niesen 
einer infizierten Person‘ — wurden mehr von urbanen statt ländlichen Befragten 
geäussert. Als Hauptbehandlungsoptionen zu Hause wurden pflanzliche 
Behandlungen identifiziert; während ländliche Befragte eher auf Gebete 
hinwiesen, wurde die Linderung von Symptomen unter den urbanen Befragten 
prioritärer angesehen. Ausserhalb des Haushalts wurde Hilfe in öffentlichen 
Spitälern und privaten Gesundheitseinrichtungen in Betracht gezogen, wobei 
letztere von den meisten bevorzugt angegeben wurden. Bei den Befragten, 
welche angaben, selber (oder Mitglieder aus deren Familien) während der 
Pandemie von 2009 an der Schweinegrippe erkrankt zu sein, wurden 
Verzögerungen in der Behandlung bemerkt.  
 
Das Bewusstsein für Pandemieimpfungen in den befragten Gemeinden war 
niedrig (25%). Einige schätzten Impfungen für Erwachsene als nicht wichtig ein; 
jedoch glaubten fast alle (94.7%), nachdem sie befragt wurden, dass man die 
Schweinegrippe durch Impfungen verhindern kann. Gemäss eigenen Angaben 
hatten sich 8.3% impfen lassen; dies sollte mit Vorsicht interpretiert werden, da 
in Pune während der ersten Welle der Pandemie keine Impfstoffe verfügbar 
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waren und danach erhältliche Impfstoffe aus dem eigenen Sack bezahlt werden 
mussten. Hauptgründe, warum man sich während der Pandemie impfen liess, 
waren folgende: von einem Todesfall wegen Schweinegrippe gehört, von 
Gesundheitspersonal empfohlen oder im Gesundheitssystem tätig, 
Peerinformation und Medienberichte. Gründe, die gegen eine Impfung sprachen, 
bezogen sich auf ein als niedrig eingeschätztes persönliches Risiko, auf Zugangs- 
und finanzielle Probleme und auf ungenügende Informationen und die Annahme, 
dass die Regierung Influenzaimpfungen nicht unterstütze. Eine Mehrheit 
bevorzugte Injektionen statt nasale Impfungen, vor allem in entfernteren 
ländlichen Regionen. 
 
Über 93% der Befragten gaben an, in Zukunft eine kostenlose Impfung gegen 
die ‚Schweinegrippe‘ zu akzeptieren; 91.2% würden die Impfung für INR 150, 
74.1% für INR 500 und 61.7% für INR 1000 kaufen. Einige der Befragten 
bevorzugten Impfungen, die etwas kosteten, gegenüber kostenlosen Impfungen, 
da sie wenig Vertrauen hatten bzw. Skeptizismus zeigten gegenüber einer von 
der Regierung angebotenen Gratisimpfung. Soziokulturelle Determinanten, die 
positiv mit einer Impfabsicht gegen Influenza assoziiert waren, bezogen sich auf 
mit der Krankheit zusammenhängende Bedenken wegen sozialer Isolation, auf 
Kontaminanten (z. B. Keime oder Dreck) als wahrgenommene Ursachen, auf die 
Behandlung in Privatspitälern oder bei traditionellen Heilern sowie auf höhere 
Einkommen. Humorale Ungleichgewichte als mögliche Ursachen, häusliche 
Heilmittel zur Behandlung und zunehmendes Alter waren hingegen negativ 
assoziiert. 
 
Zusammenfassend kann gesagt werden, dass Probleme mit dem Zugang zu 
Impfungen und das Fehlen von Massenimpfungen, ungenügende Prioritäten und 
zu wenig Unterstützung seitens der Regierung, sowie ein niedriges Bewusstsein 
in der Bevölkerung die Durchimpfungsrate während der Pandemie von 2009 
eingeschränkt haben. Jedoch lässt die hohe Akzeptanz für Pandemieimpfungen 
auf bessere Aussichten schliessen. Die hier ermittelten soziokulturellen 
Determinanten liefern praktische Vorschläge zur Vorbereitung und zur 
Bekämpfung von Pandemien mittels Impfungen. Unschlüssigkeit gegenüber 
Impfungen, welche aus einem Mangel an Vertrauen in Pandemieimpfstoffe 
entsteht, scheint hier weniger ein Problem zu sein; folgenden Faktoren spielen 
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eine grössere Rolle: Zugang zu Impfungen, Selbstgefälligkeit, unzureichendes 
Vertrauen in das Gesundheitssystem sowie weitere soziokulturelle Erwägungen. 
 
Diese Arbeit, die zum globalen Fortschritt im Bereich der 
Impfunschlüssigkeitsforschung beitragen soll, hebt den Wert soziokultureller 
Studien und die Relevanz der Berücksichtigung von Bevölkerungspräferenzen bei 
der Planung effektiver Impfaktionen hervor. Grosse Influenzaausbrüche in Indien 
im Jahr 2015 zusammen mit lokalen Impfstoffherstellungskapazitäten deuten 
darauf hin, dass die Prioritäten in den nationalen Strategien zur 
Influenzaimpfung ausserhalb von Pandemien neu überdacht werden sollen. 
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सारांश  
जाग�तक आरोग् सघंटनेच्ा आकडवेार�नसुार जगभरातनू दरवष� ३०-५० लाख लोकं फल ूमळेु गभंीर आजार� 
पडतात, तर जवळजवळ २.५ त े५ लाख लोकं मतृ्मुखुी पडतात. फल ूहा आजार दोन पकारात �दसतो, स्ा�नक 
पातळीवरची सा्/उदेक आ�ण खंडव्ापी सा्. स्ा�नक पातळीवरची सा्/उदेक हा एखाद्ा �व�शष् 
�्काणापरुता सी�मत असतो. दरवष� �व�शष् ऋतमूध्े अशा पकारच्ा सा्ी �दसनू ्ेतात. बहुतांशी लोकांना 
दरवष� सा् घेऊन ्ेणार्ा फलचू्ा �वषाणू�वरधद प�तकार शकती आलेल� असत.े परंत ुप�तकार शकती कमी 
असलेल्ा व्कती, महणजे मखु्तवेकेन लहान मलु,ं जेष् नाग�रक, गरोदर िस््ा आ�ण रकतदाब, मधमेुह 
असे आजार असणार्ा व्कतीं, ्ांच्ामध्े साध्ा फलचू्ा �वषाणूंमळेुदेखील गभंीर आजार �कवा मतृ् ूहोऊ 
शकतो. खंडव्ापी फल ूमहणजचे एकाच वेळी जगाच्ा वेगवेगळ्ा भागात एकाच पकारच्ा फल ूआजाराचा 
झालेला उदेक. खंडव्ापी फल ूहा नवीन पजातीच्ा फल ू�वषाणूमळेु होतो. ह्ा नवीन �वषाणूचा सामना 
करण्ासा्ठ आवश्क अशी प�तकारशकती लोकांमध्े नसत.े त्ामळेु समाजातील सवर व्कतींना, अगद� 
तरण आ�ण सदुृ व्कतींना देखील ह्ा आजाराची लागण होऊ शकत.े ह्ा आजारामळेु होणार्ा मतृ्ूचंे 
पमाण हे साध्ा फलचू्ा सा्ीने झालेल्ा मतृ्ूचं्ा तलुनेत खूप अ�धक असत.े १९१८ साल� आलेल� खंडव्ापी 
फलचूी सा् ज्ाला ‘सपप�नश फल’ू महणून ओळखले जात,े ह� अल�कडील काळातील सवारत भ्कंर सा् मानल� 
जात.े ह्ा सा्ीत जवळपास २०-५० लाख लोकं मतृ्मुखुी पडले. तर जून २००९ मध्े इन्लएुनएा A H1N1 
ह्ा नवीन पकारच्ा �वषाणूमंळेु झालेल्ा आजाराचा उदेक एकाच वेळी जगातील वेगवेगळ्ा खंडांमध्े �दसनू 
आला आ�ण खंडव्ापी फलचूी सा् जाह�र करण्ात आल�. २१ व्ा शतकातील ह्ा प�हल्ा सा्ीला ‘सवाान 
फल’ूची सा् महणून ओळखले जात.े जर� २००९ मधील खंडव्ापी फलचूी सा् अपे�ेएवृ� गभंीर नसल� तर�, 
साधारणपणे ३ लाख व्कती ह्ा सा्ीत मतृ्मुखुी पडल्ा तर जगभरातनू जवळपास २० कोट� व्कती ्ा 
आजाराने बा�धत झाल्ा होत्ा.  
 
भारताला देखील ्ा २००९ सालच्ा खंडव्ापी फलचू्ा सा्ीचा सामना करावा लागला. पणेु िजलहा हा 
भारतातील खंडव्ापी फलचू्ा सा्ीचे क� दस्ान महणून ओळखला जातो कारण ्ा आजाराचे सवार�धक रगण 
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आ�ण मतृ् ूपणेु िजलह्ातनू न�द�वले गेले. अ�धकृत मा�हतीच्ा आधारे २००९ सालच्ा खंडव्ापी फलचू्ा 
सा्ीत भारतातनू २०२,७९० रगण न�द�वले गेले त्ापपकक २,९७१ रोगी पणेु िजलह्ातनू न�द�वले गेले. 
पणु्ामध्े एक वेगवेगळ्ा पकारच्ा लसी बनवणार� एक मो्ठ कंपनी आहे. ह्ा कंपनीत फल ूआजारापासनू 
बचाव करण्ासा्ठ दोन पकारच्ा लसी त्ार होतात, एक लस इंजेकशनदवारे �दल� जात ेतर दसुर� लस 
नाकादवारे �दल� जात.े 
 
फल ूप�तबधंासा्ठ लसीकरण हा खूप महतवाचा घटक आहे पण लसीकरणाची प�रणामकारकता ह� 
लसीकरणाला असलेल� लोकाचंी अनकुुलता ह्ा वेन ्रत.े २००९-२०१० च्ा खंडव्ापी फलचू्ा सा्ीदरम्ान 
खूप कमी पमाणात झालेले लसीकरण ह� जगभरात �दसनू आलेल� समस्ा होती. लोकाचंा लसीबदलचा सभंम 
समजून घेण्ासा्ठ, आजाराब�ल असलेल्ा स्ा�नक सामािजक-सांसकृ�तक सकंलपना जाणून घेणे महतवाच े
असत.े ज्ामळेु कदा�चत लसीकरणाचे पमाण वाृू शकेल. लसीबदल असलेला सभंम आ�ण लसीकरण कमी 
होण्ामागची कारणे जाणून घेणारे सशंोधन अभ्ास हे जासत केन �वक�सत देशांमध्ेच झालेले �दसतात. 
खंडव्ापी फलसूा्ठ केलेल� उपा््ोजना समजून घेण्ासा्ठ �वक�सत देशांबरोबरच �वकसनशील आ�ण 
अ�वक�सत देशांच्ा उपा््ोजनांचा अभ्ास करण्ाची गरज आहे, हे ल�ात ्ेऊनह� फारच कमी 
�वकसनशील आ�ण अ�वक�सत देशांमध्े अशा पकारचे सशंोधन अभ्ास केले गेले आहेत. 
 
्ा पबधंाचा सवरसाधारण उदशे, ज्ा �वकसनशील देशात खंडव्ापी फलचूी लस त्ार करण्ाची �मता आहे 
अशा देशातील स्ा�नक लोकाचं्ा दषट�कोनातनू फल ूआजाराच्ा तसेच खंडव्ापी फलचू्ा लसीच्ा सवीकृती 
बाबतच ेसामािजक-सांसकृ�तक घटक जाणून घेणे हा होता. ह्ा अभ्ासातनू आलेले �नषकषर खंडव्ापी 
आजाराचंा सामना करण्ाची त्ार� आ�ण फल ूआजार �न्ं् णाच्ा दषट�ने क� द�् तसेच राज् पातळीवरच े
धोरण ्र�वण्ासा्ठ मागरदशरक ्रतील. 
 
२०१२-२०१३ मध्े पणु्ाच्ा गामीण आ�ण शहर� भागांत सखं्ातमक आ�ण गणुातमक सशंोधन पदतींचा 
एक�्त वापर केन एक अभ्ास केला गेला. खंडव्ापी फल ू�न्ं् णात लसीची भ�ूमका ्ाबाबत लोकांची 
मत/ेसकंलपना जाणून घेण्ासा्ठ, Cultural Epidemiology ्ा सशंोधन पदतीत वापरल्ा जाणार्ा 
Explanatory Model Interview Catalogue ह्ा आराखड्ावर आधा�रत, मलुाखत अनसुचूी त्ार 
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केल�. एक छोट� गोषट सांगनू त्ापा्ोपा् वर�ल मलुाखत अनसुचुीच्ा आधारे, आजाराचे सामािजक-
सांसकृ�तक घटक, आजाराबदलचा अनभुव, समज आ�ण वतरणूक ्ांचा अभ्ास करण्ासा्ठ पणु्ातील ४३६ 
नाग�रकांच्ा मलुाखती सव� ण पदतीने घेतल्ा गेल्ा. ्ा मलुाखतींतनू खंडव्ापी फलसूा्ठ उपलबध 
असलेल्ा लसींबदलची मा�हती, जागेकता, अनभुव आ�ण पसतंी ह्ा गोषट� तपासल्ा गेल्ा. वेगवेगळ्ा 
�कमतींच्ा आधारावर भ�वष्ातील खंडव्ापी फलसूा्ठच्ा लसीची सवीकाहरता पडताळून पा�हल� गेल�. 
सखं्ाशास्ी् �वशलेषण पदतीचा (लॉिजिसटक �रगेशन) वापर केन खंडव्ापी फल ूलसीच्ा सवीकृतीवर 
प�रणाम करणारे सामािजक-सांसकृ�तक घटक शोधले गेले. ह्ा अभ्ासादवारे गोळा केलेल� काह� मा�हती ह� 
परूक मा�हती महणून वापरल� गेल�, जसे कक तलुनातमक �वशलेषणासा्ठ वापरण्ात आलेल� सखं्ातमक 
मा�हती तसेच गणुातमक �वशलेषणासा्ठ आ�ण सदंभर सपषट करण्ासा्ठ वापरण्ात आलेल� गणुातमक 
मा�हती. ह्ा अभ्ासात घेतलेल्ा गटचचा�मधून अभ्ास केला गेला त्ा भागाची अ�धक मा�हती �मळाल� 
तसेच अभ्ासासब�ंधत मा�हती घेण्ासा्ठची साधने त्ार करण्ासा्ठ गटचचा�मधून आलेल्ा मा�हतीचा 
उप्ोग झाला. त्ाच बरोबर खंडव्ापी फल ू्ा आजाराच ेआ�ण लसीकरणाच ेवप् िकतक अनभुव, लस 
घेण्ामागची कारणे, अडचणी, सभंम समजून घेण्ासा्ठ काह� सखोल मलुाखती घेण्ात आल्ा. 
 
खंडव्ापी फलशूी सबं�धत सामािजक-सांसकृ�तक घटकांच्ा �वशलेषणातनू असे �दसनू आले कक, बहुतांशी 
लोकांच्ा मत ेजर ह्ा आजारावर उपचार केले नाह� तर मतृ् ूउदव ूशकतो. पण ९६.०% लोकांच्ा मत ेजर 
उपचार केले तर हा आजार पणूर बरा होऊ शकतो. एक ततृी्ांश सहभागींनी हा  हा शवसनाचा आजार आहे असे 
सां�गतले, जासत केन शहर� सहभागींनी (३६.७% �वरद १६.३% गामीण) हा ‘सवाान फल’ू आहे असे सां�गतले. 
ह्ा आजारामळेु होणार्ा शार��रक ्ासापे�ा मान�सक ्ास हा अ�धक ्ासदा्क असल्ाचे सां�गतले गेले. 
जासत ्ळकपणे सां�गतल्ा गेलेल्ा आजाराच्ा कारणांमध्े, असवचछ/ घाण प�रसर हे कारण पामखु्ाने 
सां�गतले गेले. गामीण सहभागींच्ा तलुनेत अ�धक शहर� सहभागींनी बा�धत व्कतीचा ‘खोकला’ �कंवा 
‘�शकं’ हे आजाराच ेकारण सा�ंगतले. अ�धक ्ळकपणे न�द�वल्ा गेलेल्ा घरगतुी उपचारांमध्े औषधी 
वनसपती/ वनौषधींचा समावेश होता. पा्रना करणे हा उपा् गामीण भागामधून अ�धक पमाणात सां�गतला 
गेला तर ल�णांपासनू आराम �मळणे हे शहर� सहभागींच्ा दषट�ने महतवाच ेहोत.े घराबाहेरच्ा मदतीबदल 
�वचारले असता, सरकार� दवाखाना �कंवा खाजगी दवाखान्ात जाणार असे सां�गतले गेले, पण खाजगी 
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दवाखान्ाला अ�धक पाधान् �दले गेले. ज्ांनी २००९ च्ा खंडव्ापी सा्ीदरम्ान त्ानंा सवततला �कंवा 
त्ांच्ा घरच्ांना सवाान फल ूझाल्ाचे सां�गतले, त्ांच्ा बाबतीत उपचार �मळण्ासा्ठ �दरंगाा झाल्ाचे 
ल�ात आले.   
 
खंडव्ापी फलचू्ा लसीबाबत लोकांमध्े जागेकतचेे पमाण कमी �दसले(२५.०%). काह� सहभागींच्ा मत े
लस ह� पौृ व्कतींसा्ठ नसत,े परंत ुबहुतांश सहभागींना (९४.७%) लसीबाबत �वचारले असता, लस घेतल्ाने 
सवाान फल ूपासनू बचाव होाल असे वाटले. ह्ा अभ्ासात पत्� लस घेतलेल्ांचे पमाण हे केवळ ८.३% 
होत,े पण खंडव्ापी फलचू्ा सा्ीच्ा सरुवातीच्ा काळामध्े पणु्ात लस उपलबध नवहती, ती नतंरच्ा 
कालावधीमध्े उपलबध झाल� आ�ण त्ावेळेस ती मोफत उपलबध नसनू खाजगी सवरपात �वकत घ्ावी 
लागत होती, हा सदंभर  ल�ात घेणे गरजेचे आहे. खंडव्ापी फलचू्ा काळात लस घेण्ामागच्ा मखु् 
कारणांमध्े सवाान फलमूळेु कुणाचा तर� मतृ् ूझाला हे ऐकणे, डॉकटरांनी लस घेण्ाचा सलला देणे, आरोग् 
सेवांशी कु्ल्ातर� पकारे सबं�धत असणे, आजूबाजूचे लोकं आ�ण पसारमाध्माचा पभाव ह्ा कारणांचा 
समावेश होता. तसेच लस न घेण्ामागच्ा कारणांमध्े सवततला आजार होण्ाची शक्ता कमी वाटणे, 
लसीच्ा उपलबधतबेाबत आ�ण �कमती सब�ंधत अडचणी, लसीबदल अपरु� मा�हती, शासनाकडून फलचू्ा 
लसीकरणाला पषुट� देणार्ा आदेशाचा/ सचूनेचा अभाव ह� पमखु कारणे होती. बहुतांशी लोकांनी नाकादवारे 
घेतल्ा जाणार्ा लसीपे�ा इंजेकशनदवारे �दल्ा जाणार्ा लसीला अ�धक पसतंी दशर�वल�, ह्ात दगुरम 
गामीण भागातल्ा सहभागीचंे पमाण उललेखनी् होत.े 
 
साधारण ९३.०%पे�ा जासत सहभागींनी भ�वष्ात जर ‘सवाान फल’ू ची लस मोफत �दल� गेल� तर आमह� घेऊ 
असे सां�गतले. तर ९१.२% सहभागींनी र. ७५/-, ८७.८% सहभागींनी र१५०/-, ७४.१%सहभागींनी र. ५००/- आ�ण 
६१.७% सहभागींनी र. १०००/- ्ा �कमतींना लस घेण्ाची त्ार� दशर�वल�. काह� सहभागीनंी अगद� मोफत 
�मळणार्ा लसीपे�ा कमी �कमतीची लस घेण्ास पाधान् �दले कारण त्ांना शासनाकडून मोफत �मळणार्ा 
लसीच्ा गणुवततबेदल शकंा होती. एकककड,े हा आजार झाल्ास इतर लोकांपासनू वेगळे राहावे लागणे, आजार 
होण्ाचे कारण ‘जंत ू�कंवा घाण’, ह्ा आजाराच्ा उपचारासा्ठ खाजगी डॉकटरांकड े�कंवा पारंपा�रक उपचार 
घेणे आ�ण उतपनन, इत्ाद� सामािजक-सांसकृ�तक घटकामंध्े आ�ण  लस घेण्ाला अनकुुलता ह्ात �निशचत 
सारांश  
xx 
 
सबंधं �दसनू आला. तर दसुर�कड,े आजार होण्ाचे कारण-पकृतीदोष, घरगतुी उपचार आ�ण व् इत्ाद� घटक 
आ�ण लस घेण्ाला अनकुुलता ह्ात नकारातमक सबंधं �दसनू आला. 
 
्ोडक्ात, लसीच्ा उपलबधीसदंभारत असलेल्ा समस्ा आ�ण सवरसाधारण लोकांसा्ठच्ा लसीकरण 
का्र् माचा अभाव, शासनाकडून लसीकरणासा्ठ पाधान् �कंवा पषुट� न �दल� गेल्ाने २००९ सालच्ा 
खंडव्ापी फलचू्ा सा्ीच्ा दरम्ान लसीचा वापर हा खूप म्ार�दत रा�हला. ्ा अभ्ासात बहुतांशी लोकांनी 
खंडव्ापी फलचू्ा बचावासा्ठ लस घेण्ाची गरज आहे असे सां�गतले आहे, ्ातनू भ�वष्ात लसीकरणाच्ा 
पमाणात वाृ होण्ाच्ा दषट�ने चांगला वाव असण्ाची शक्ता �दसनू आल�. ्ा अभ्ासातनू �दसनू आलेले 
सामािजक-सांसकृ�तक घटक हे खंडव्ापी आजारांना त�ड देण्ासा्ठ तसेच ्ा आजारांच्ा प�तबधंासा्ठ 
लसीकरणाचा कसा उप्ोग करता ्ेाल ्ाबाबत उप्कुत सचूना देतात. खंडव्ापी फलचू्ा लसीच्ा 
उप्ोगाबदलच्ा साशकंततेनू �नमारण होणार्ा सभंमापे�ा लसीची उपलबधी, समाधान, आरोग् ्ं् णेबदल 
खा्ी न वाटणे तसेच इतर सामािजक-सांसकृ�तक सदंभर हे लसीच्ा वापराच्ा दषट�ने जासत महतवाच ेआहेत.   
 
जगभरात ‘प�तबधंातमक लसी बदल असलेल्ा दोला्मानतचेा अभ्ास’ ह्ा �वष्ासदंभारत जी नवनवीन 
पगती होत आहे, त्ात सदर सशंोधन अभ्ासाने मोलाची भर घातल� आहे. ्ा सशंोधनादवारे प�रणामकारक 
लसीकरण का्र् माच्ा �न्ोजनासा्ठ सामािजक-सांसकृ�तक घटकांचा अभ्ास आ�ण स्ा�नक लोकांकडून 
लसीला असलेले पाधान् ह्ांचे महतव अधोरे�खत झाले आहे. २०१५ साल� भारतात मोठ्ापमाणावर झालेला 
फल ूरोगाचा फप लाव आ�ण त्ाचबरोबर स्ा�नक पातळीवर प�तबधंातमक लस त्ार करण्ाची �मता ्ा दोन 
गोषट� ल�ात घेता शासनाने आगामी धोरण ्रवताना खंडव्ापी सा्ीच्ा फल ूखेर�ज सध्ा फलचू्ा 
प�तबधंासा्ठ लसीचा वापर करण्ाच्ा आवश्कतचेा पनु�वरचार करावा. 
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Introduction  
1.1 Global burden of influenza 
 Influenza, an acute viral infection, is responsible for substantial mortality and 
morbidity among persons of all ages, around the world1. The World Health 
Organization (WHO) estimates a worldwide burden of three to five million cases 
of severe illness and 250,000-500,000 deaths from seasonal influenza every 
year2. An annual attack rate of 5-10% in adults and 20-30% in children is 
estimated globally for influenza3. A recent study estimated that 28,000 adults 
are hospitalised due to influenza-associated critical illness every year in the 
United States (US)4. Although data on morbidity and mortality from influenza in 
developing countries are scare, influenza incidence is considered significantly 
higher in developing countries compared to developed countries. A recent 
systematic review and meta-analysis estimated that 99% of deaths from 
influenza-associated acute lower respiratory infections in children under five 
years of age occur in developing countries5. A systematic review of seasonal 
influenza epidemiology in Sub-Saharan Africa found that influenza accounted for 
10% of outpatient and 6.3% of hospital admissions for acute respiratory 
infections (ARIs) in children6. A review from India reported that 1.5%-14.5% of 
all ARIs were due to influenza7. In general, influenza burden in the tropics and 
subtropics are likely to be underestimated3,8.   
 
Particular risk groups for influenza include healthcare workers, who have a 
greater risk of exposure, and those who are at increased risk of developing 
severe disease resulting in hospitalisation or death3. The latter group includes 
pregnant women, children under five years of age and persons with other 
medical conditions. Influenza also imposes a significant economic burden on 
society through productivity and income losses, in addition to direct medical 
costs9-12.  
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Influenza exhibits a seasonal pattern with peak activity during the winter 
(December through March) in temperate climates13. In tropical regions, a 
seasonal pattern is less pronounced and influenza outbreaks may coincide with 
rainfall14, relative humidity15 and occur throughout the year3. 
1.1.1 Distinction between seasonal and pandemic influenza 
Among humans, influenza occurs in two epidemiological forms: epidemics and 
pandemics16. While an epidemic is more localized, as observed with seasonal 
influenza outbreaks, an influenza pandemic is a large-scale worldwide outbreak 
of the disease. In an influenza epidemic, a large proportion of the population 
possesses cross-reacting antibodies against recent variants of the influenza virus. 
Hence, severe disease and mortality occurs primarily among young children, the 
elderly, pregnant women and persons with other underlying disease conditions. 
Pandemic influenza which results from the emergence of a new subtype of 
influenza A virus or a new strain of a subtype, on the other hand, escapes 
control by strain-specific immunity in the population17. Since there is little or no 
existing immunity in the population, the novel virus with an efficient capacity for 
transmission between humans may spread rapidly around the world with high 
attack rates18. The entire population, including young and healthy adults may be 
affected. Mortality is also typically much higher during pandemics compared to 
local epidemics19. It is currently not possible to predict when the next influenza 
pandemic will occur20. As attention was focussed on H5N1 and on other strains 
of influenza for causing the next pandemic17, unexpectedly in 2009 the influenza 
A (H1N1) virus emerged21. 
1.1.2 The 2009 influenza A (H1N1) virus pandemic 
A novel influenza A (H1N1) virus was first identified in Mexico, and the first 
death from 2009 H1N1 influenza was reported in Oaxaca, Mexico, in April 
200921,22. Cases were also identified in California and New York, US, and quickly 
spread worldwide through transmission between humans23. On 11 June 2009, 
the first influenza pandemic of the 21st century was announced by the director 
general of WHO24. The 2009 influenza A (H1N1) virus was antigenically distinct 
from other human and swine influenza A (H1N1) viruses, but was found to be 
derived from viruses circulating in pigs18,21. This novel virus was the result of 
triple reassortment of recent North American H3N2 and classical H1N1 swine 
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viruses and Eurasian avian-like swine viruses. It contained genetic material from 
avian, swine and human influenza strains18. The strain was initially referred to as 
‘swine-origin influenza virus’ due to its likely swine origin21. However, there is no 
evidence indicating the role of pigs in the spread of the virus among humans25. 
Efficient human-to-human transmission of the virus caused the 2009 pandemic.  
 
The official number of laboratory-confirmed deaths worldwide from 2009 H1N1 
influenza reported to WHO was 18,449 for the period between April 2009 and 
August 201026 (Figure 1-1). This number is most likely an underestimate due to 
difficulties associated with laboratory-confirmed diagnosis, the absence of such 
laboratories or over-strained facilities in many countries and because most cases 
were clinically diagnosed rather than laboratory confirmed. A study estimated 
the actual worldwide burden of the 2009 influenza pandemic at 201,200 deaths 
from respiratory complications with an additional 83,000 deaths from 
cardiovascular complications27. Other estimates indicate that one out of six 
Americans had experienced 2009 H1N1 influenza as of December 2009 and that 
as many as 200 million cases occurred globally21.  
 
While the overall case fatality rate of the 2009 influenza pandemic in Mexico was 
estimated to be 0.4%28, other estimates have been lower29. These estimates are 
all much lower than the 2% case fatality rates for severe pandemics30. On the 
whole, the 2009 pandemic was less severe than expected and the overall 
mortality was significantly lower than previous pandemics. 
 
However, an important feature of the 2009 pandemic was that it 
disproportionately affected children and young adults as compared to older 
persons23,31-33. Most hospitalizations were recorded for young children and least 
for those aged above 65 years; although mortality was highest in the latter 
group22,33. Furthermore, a high burden on critical care services30 and an 
economic burden were also imposed by the 2009 pandemic. A study from the 
Republic of Korea noted considerable socioeconomic burden from the 2009 
influenza pandemic in 2009-2010 where total medical costs were 37 times 
higher than costs for seasonal influenza in 2007-200834.  
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Figure 1-1: Countries reporting pandemic (H1N1) influenza as of 15 August 2010 
Source: Adapted from WHO 
1.2 History of influenza 
Influenza is thought to derive its name from Italian for ‘influence’35. Sudden and 
widespread outbreaks in Italy were attributed to cosmic forces or a destructive 
influenza (influence) of the heavens or stars. Descriptions of disease outbreaks 
quite similar to influenza have been noted from Hippocrates as far back as 412 
B.C.E36. Historian August Hirsch noted an epidemic described in 1173-1174 C.E 
as the first clearly defined influenza epidemic, although this identification 
remains open to debate due to imprecision in depiction of symptoms and lack of 
a fixed medical identity in ancient chronicles. Medical historians have identified 
influenza with greater confidence in the 17th century and later from clinical 
accuracy of descriptions. By the end of the 18th century it was recognized as a 
distinct disease35. In the 18th and 19th centuries, twenty five influenza epidemics 
are believed to have occurred, and eight are thought to have been influenza 
pandemics37. 
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Until the late 1800’s, influenza was considered commonplace and not any more 
serious than a common cold35. Epidemics of influenza in the 1830s that often 
alternated with cholera brought attention to the disease, as did seminal work by 
statistician, William Farr, in the 1840s. Farr, who is considered a founding father 
of surveillance and epidemiology, developed a key concept of calculating excess 
mortality during certain seasons to demonstrate the impact of influenza38. 
Thereafter, the Russian flu of 1889-1890 which killed 110,000 people in Britain 
alone, causing panic and dread, transformed the perception of influenza35.  
1.2.1 Influenza pandemics of the 20th century 
Three major influenza pandemics occurred in the 20th century. The pandemic of 
1918-1919, also known as the ‘Spanish flu’ is believed to be the most 
devastating disease outbreak in recent history, resulting in 20-50 million deaths 
around the world39. It was caused by an influenza A (H1N1) subtype and mainly 
affected young adults. India was considered a focus of this pandemic in terms of 
mortality, as an estimated 10-20 million people died in the British-controlled 
provinces of India40,41.  
 
The next pandemic, popularly known as ‘Asian flu’ (H2N2 subtype), occurred in 
1957-195842. It caused approximately 1-4 million deaths and mainly affected 
children43. The third pandemic, ‘Hong Kong flu’, resulted in 1-4 million deaths 
between 1968 and 196942. All age groups were affected by this influenza A 
(H3N2) virus.   
1.3 Clinical and virological features of influenza infections 
Influenza is caused by an infection of the respiratory tract and sometimes the 
gastrointestinal tract. The incubation period of influenza is typically 1-4 days, 
with an average of 2 days3,44. Infected persons can transmit the virus through 
viral shedding a day before onset of symptoms and up to five days after for 
adults45, or right into the second week of clinical disease for infants and young 
children46. Symptoms can include fever, cough, sore throat, runny nose, 
headache, body ache and marked fatigue. Diarrhoea and vomiting may also be 
present as additional symptoms and this was seen more commonly during the 
2009 influenza pandemic47. Secondary bacterial pneumonia is a frequent 
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complication of influenza, particularly among the elderly and those with certain 
chronic conditions48.  
1.4 Influenza viruses 
Influenza viruses are single-stranded ribonucleic acid (RNA) viruses and belong 
to the family Orthomyxoviridae49. There are three types of influenza viruses—A, 
B and C—determined by their internal nucleoprotein. Influenza A and B 
commonly cause human disease, while influenza C rarely does1. Influenza A 
viruses tend to cause more severe disease, and are responsible for most 
seasonal epidemics and all recognized worldwide pandemics. They are diverse 
and classified into subtypes based on combinations of their surface glycoproteins, 
namely, hemagglutinin (HA) and neuraminidase (NA). HA allows attachment of 
the virus to the host cell, while NA digests sialic acid on the host cell surface 
enabling the virus to gain entry into the host cell49. So far, 17 HA and 10 NA 
proteins have been identified in at least one animal species, but only some 
subtypes have caused widespread transmission in humans50. These are viruses 
of subtypes H1, H2 or H3, and N1 or N2.  
1.4.1 Mechanisms of variation: antigenic drift and shift 
Influenza viruses have evolved efficient ways to promote antigenic variability50. 
A high rate of mutations from an error-prone viral RNA polymerase results in 
wide variability of the HA and NA antigens. Point mutations causing minor 
changes occur frequently, especially in the HA gene, and accumulate over time. 
This phenomenon known as antigenic drift, results in individuals lacking 
immunity to the drifted strain, despite having been previously immune to the 
original strain. Antigenic drift is responsible for seasonal outbreaks and limited 
epidemics during inter-pandemic years because a majority of the population 
have pre-existing antibodies that provide at least partial protection against the 
virus17. Influenza strains have usually undergone antigenic drift in a typical 
influenza season. A second mechanism of variation, known as antigenic shift, 
results from re-assortment of genetic material from different influenza A 
subtypes50. The segmented influenza genome allows for mixing of viral genes, 
and one influenza strain can acquire a new HA or NA gene resulting in a novel 
virus subtype. Antigenic shift can occur through re-assortment between two or 
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more different human strains or through cross-species transmission. Antigenic 
shift is less frequent than drift, but more sudden. It can result in larger 
epidemics or pandemics, particularly if people lack pre-existing immunity to the 
new virus and if there is sustained person-to-person transmission.  
1.4.2 Influenza virus as a noneradicable zoonosis 
Aquatic birds are a known large natural reservoir of influenza viruses51,52 and 
they cause no apparent signs of disease in their hosts53. Recently, bats have also 
been identified as a potentially important reservoir for influenza viruses54. 
Influenza A viruses are capable of infecting a range of mammals (e.g., pigs, 
horses, dogs, cats and marine mammals) and birds in nature or under laboratory 
conditions55. The high rate of mutations, dynamic genetic re-assortment of the 
segmented genome, and existence in multiple natural reservoirs, suggests that 
the influenza A virus is a noneradicable zoonosis and will remain a potential 
threat to the human population17. Strategies for eradication of the virus are 
impractical, and pandemic influenza control through limiting intermingling of wild 
bird and domestic animal populations may not be feasible. Preparedness for 
emergence of a novel influenza virus is therefore critical. 
1.5 Influenza control strategies 
A three-pronged approach is useful in preventing and containing influenza: this 
includes non-pharmaceutical interventions, treatment with antivirals and 
vaccination.   
1.5.1 Non-pharmaceutical interventions 
Non-pharmaceutical interventions are particularly useful in limiting transmission 
early in a pandemic, before a vaccine has been developed56. Non-pharmaceutical 
means of controlling influenza may include isolation of patients and quarantine 
of contacts, social distancing through closing school or public gatherings, and 
hand and respiratory hygiene. Compulsory isolation and quarantine that may 
limit disease transmission may be impractical and ineffective57. School closures 
have had mixed success and are hence not widely recommended. They have, 
however, been shown to be effective when implemented early in the pandemic in 
Hong Kong58. Handwashing was very effective in reducing influenza viruses on 
human hands under controlled conditions59. However, a recent systematic review 
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and meta-analysis found that hand hygiene alone had a modest effect, but in 
combination with facemasks was efficacious in preventing laboratory-confirmed 
influenza60. Combining non-pharmaceutical measures with use of antivirals and 
vaccination has been found to be quite effective in influenza control61,62.  
1.5.2 Treatment of influenza 
Neuraminidase-inhibiting drugs—oseltamivir, zanzamivir, and more recently 
peramivir and laninamivir—are recommended by WHO for those requiring 
antiviral treatment for influenza3. For uncomplicated clinical presentation of 
patients in high-risk groups, or severe clinical presentation in all patients, 
treatment with oseltamivir as soon as possible, is recommended63. Early and 
widespread treatment with antivirals has been associated with decreased risk of 
death during the 2009 pandemic64,65, although recent reviews question the role 
of antivirals in pandemic influenza control66,67. Antiviral treatment may also be 
used prophylactically68, however, development of antiviral resistance is a serious 
concern.  
1.5.3 Influenza vaccines 
Although non-pharmaceutical interventions and use of antivirals can be effective 
in slowing the spread of disease, vaccination remains the most effective means 
for controlling pandemic influenza56. Vaccines are thus the mainstay of influenza 
prevention and a global priority in pandemic response21,69. Currently available 
influenza vaccines include trivalent inactivated vaccines (TIVs) and live 
attenuated influenza vaccines (LAIVs)3. Both types of vaccines contain predicted 
antigenic variants of two influenza A strains and one influenza B strain. Antigenic 
characteristics of currently circulating viruses obtained from WHO global 
influenza surveillance and response system are used to predict the antigenic 
composition of the vaccines biannually70.  
1.5.3.1 Trivalent inactivated vaccines  
TIVs are administered intramuscularly. Vaccine efficacy in individuals under 65 
years of age is 70%-90% when the vaccine strain closely matches the circulating 
influenza viruses71. Vaccine efficacy is lower in those above 65 years. TIVs are 
generally considered safe72,73. Transient side-effects may include local reactions 
at the injection site, fever and malaise. TIVs have been associated with a slight 
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increase in the risk of Guillain-Barré syndrome (approximately 1-2 excess cases 
per million persons vaccinated), in certain influenza seasons and mostly among 
older adults74,75. The only influenza vaccines licensed for pregnant women, 
individuals over 50 years of age and children under 2 years are TIVs. No 
influenza vaccines are currently licensed for children under 6 months of age. 
However, TIVs given during pregnancy protect both expectant mothers and 
newborns against influenza76, and are a highly cost-effective intervention77.   
1.5.3.2 Live attenuated influenza vaccines 
LAIV is administered as an intranasal spray and its use is restricted to healthy 
persons between 2 to 49 years of age. Vaccine efficacy in healthy children above 
2 years of age was 82% against laboratory-confirmed influenza78. An additional 
benefit of LAIVs is community-wide indirect protection when given to school 
children79. LAIVs are considered safe when administered as per indications80. 
Side-effects may include runny nose, nasal congestion or fever3.    
1.5.3.3 Influenza vaccine production  
During the 2009 influenza pandemic, the number of doses of monovalent 
pandemic H1N1 vaccine produced by 1 December 2009 was 534 million81. Global 
influenza vaccine manufacturing capacity is currently higher than ever before82. 
A study assessing current or near-future global capacity in 2010 reported 41 
influenza vaccine production facilities distributed over 25 countries81. Although a 
large number of these facilities are located in WHO geographic regions of 
Western Pacific and Europe, there has also been an increase in the number of 
production facilities in low-and middle-income countries (LMIC), partly due to a 
WHO technology transfer initiative launched in 2008 to improve vaccine access 
in these countries83. In 2006, the estimated global annual production capacity of 
seasonal TIV was 350 million doses, which increased to over 800 million doses in 
201081. However, this impressive increase in production capacity may be 
undermined by insufficient demand, as evidenced by the 1.6 fold increase in 
production capacity between 2009 and 2011 without a corresponding increase in 
actual production84. Demand for seasonal vaccines in turn affects potential 
vaccine availability for pandemic influenza vaccination.  
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1.6 Global perspectives on vaccine hesitancy and acceptance 
Ensuring the ability to develop and rapidly produce large quantities of a well-
matched and efficacious vaccine has been a focus of pandemic preparedness at 
the global and national levels. Notwithstanding the importance of these 
preparedness measures, its availability and clinical efficacy alone may not be 
sufficient for the vaccine to be effective at a community level. 
1.6.1 From vaccine efficacy to vaccine effectiveness: the importance of 
community acceptance 
From epidemiological theory, the basic reproductive number, R0, is defined as 
the number of secondary infection cases caused by one primary case of infection 
introduced into a wholly susceptible population85. From a school outbreak in the 
US early in the 2009 influenza pandemic, an estimate for R0 ranged between 1.3 
to 1.786. Estimates of peak R0 from April through July 2009 in the Americas 
varied between countries and ranged from 1.3 to 2.187. The virus from the 1918 
influenza pandemic that was considered highly transmissible, had an estimated 
R0 of 3-488. Critical vaccination coverage, which is the proportion of susceptible 
individuals that need to be vaccinated in order to prevent an epidemic or to 
achieve eradication, pc, is equal to 1-(1/ R0)89. Given a perfect vaccine, the 
critical vaccination coverage using the 1918 pandemic as an example would be 
67%-75%. However, critical vaccination coverage is dependent on vaccine 
efficacy as well as actual coverage in the population. The importance of 
considering additional dimensions, including community priorities and 
acceptance, as determinants of community effectiveness of any intervention was 
proposed by Marcel Tanner in 199090. Factors influencing actual coverage may 
be viewed through the framework for access that refer to availability, 
accessibility, affordability, adequacy and acceptability, and includes health 
system and user dimensions91. Effectiveness of the vaccine, which is the 
multiplicative effect of all these factors and vaccine efficacy, tends to be much 
lower than expected even when individual factors have relatively high 
performance92. This concept of how interventions lose traction is explained using 
an example of an intervention with 100% efficacy which finally translates to less 
than 20% effectiveness at the community level (Figure 1-2)93. Similarly, vaccine 
effectiveness is lower than vaccine efficacy, and in order to improve 
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effectiveness, user and community acceptance need to be considered, in 
addition to vaccine efficacy and distribution through the health system.  
 
Figure 1-2: From efficacy to effectiveness or how interventions lose traction  
Source: Zinsstag et al.93 
1.6.2 Vaccine hesitancy 
Vaccines are considered one of public health’s greatest achievements94. Evidence 
demonstrating the benefits of immunization in eradicating diseases and in 
preventing significant mortality and morbidity is overwhelming95. Yet, public 
concerns and hesitancy towards acceptance of vaccines has been noted around 
the world for various vaccines. These problems are not new as opposition to 
vaccination has been noted since introduction of the first vaccine for smallpox96. 
Anti-vaccination movements are thought to have been spawned by compulsory 
vaccination introduced for smallpox in the mid-1800s97. Anti-vaccination groups 
of today, although considered to have similar beliefs including paranoia, 
concerns about unnaturalness of vaccines, lack of trust in establishment and 
false claims of vaccine harm among others, as in the past97i, now have 
unprecedented global influence through social networking and the internet98,99. 
Beyond the dichotomous groups of ‘vaccine acceptors’ and ‘vaccine rejecters’ are 
                                       
i In 1802, British citizens feared that the smallpox vaccine could turn people into cows. 
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a large group of persons who lie in the continuum between acceptors and 
rejecters and may delay vaccines, opt for schedules not backed by scientific 
evidence and accept only some vaccines but not others. To include this diverse 
group of individuals in the vaccine acceptance discourse, the term ‘vaccine 
hesitancy’ has been accepted in the literature100. A systematic review of 
published literature on determinants of vaccine hesitancy found that a variety of 
factors were associated with hesitancy and they were context-specific – varying 
across time, place and vaccines101. A definition of vaccine hesitancy put forth by 
the Strategic Advisory Group of Experts on Immunization (SAGE) Working Group 
on Vaccine Hesitancy is useful to provide context102: 
“Vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite 
availability of vaccination services. Vaccine hesitancy is complex and context 
specific, varying across time, place and vaccines. It is influenced by factors such 
as complacency, convenience and confidence.” 
 
The near disappearance of many childhood diseases in high-income countries of 
Europe and North America is thought to have contributed to vaccine hesitancy. 
Successful implementation of vaccine programmes over the past century has 
reduced public memory of these diseases and the value of preventing them. 
Excessive and often unfounded concerns about the safety of vaccines have 
overshadowed concerns regarding acquiring these diseases and thus, ironically, 
vaccines have become victim to their own success. While calling for action, Paul 
Offit emphatically states: “We’ve reached a tipping point. Children are suffering and 
dying because some parents are more frightened by vaccines than by the diseases they 
prevent. It’s time to put an end to this”97. A recent measles outbreak in 
Disneyland103 in the US highlights the problem of poor measles vaccination 
coverage in higher income countries104 (Figure 1-3).  
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Figure 1-3: “Do not give measles a chance” 
Poster in Basel encouraging measles vaccination highlights the problem of suboptimal measles 
vaccination coverage in Switzerland. Photograph: N. Sundaram 
 
In developing countries, although many vaccine-preventable diseases are still 
highly visible, vaccine hesitancy has been documented too. A classic example is 
the polio eradication campaign using oral polio vaccines in Northern Nigeria in 
2003105,106. Pressure from local communities and religious and political leaders 
brought the program to a grinding halt due to rumours that the vaccine was 
mixed with drugs intended to sterilize young Muslim girls107. This had dire 
consequences globally as the disease thereafter spread to previously polio-free 
countries such as Sudan and Indonesia. Similarly, a rumour in Cameroon led 
young girls to fear the tetanus vaccine for it was believed to cause sterility108. 
Other notable examples of vaccine hesitancy are reluctance to accept oral polio 
vaccines in Pakistan109 and suspension of the human papilloma virus (HPV) 
vaccination programme in India110. Political, economic, social and cultural 
influences play a role in influencing vaccine hesitancy. Rumours, personal or 
religious beliefs and other nuanced perceptions or ideas regarding vaccines 
highlight the complexity.  
1.6.3 Vaccine acceptance  
In some contexts, access to vaccines may be challenging due to a number of 
reasons including unavailability of vaccines, unaffordability of vaccines, lack of 
vaccination services or difficulties in accessing vaccination services. In such 
settings, problematic access to vaccination is the main reason limiting vaccine 
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uptake. Although vaccine hesitancy may also be present, it is not the primary 
driver, and the definition of vaccine hesitancy excludes these reasons that are 
not related to behavioural choices102. In many low-and-middle income settings, 
access to vaccination is a major problem limiting uptake. In order to capture the 
wide range of factors influencing vaccination uptake, including vaccine hesitancy, 
access and economic considerations, the term ‘vaccine acceptance’ has been 
used in this thesis.  
 
In a recent report, Heidi Larson and colleagues characterised vaccine acceptance 
as the outcome of the following three determinants: convenience, complacency 
and confidence111. The ‘3Cs’ provide a useful conceptual model. Convenience 
refers to ease of access, and complacency to risk perception of the disease and 
lack of perceived need for a vaccine. Confidence is defined as trust in the 
vaccine itself (safety and efficacy), trust in the system that delivers the vaccine, 
including reliability of health professionals, and lastly, trust in policymakers who 
make the vaccine recommendations. The report notes that “understanding vaccine 
confidence means understanding the more difficult belief-based, emotional, ideological 
and contextual factors whose influences often live outside an immunisation or even 
health programme but affect both”111.  
 
Additionally, it is widely accepted that consideration of local cultural concepts of 
illness, and community perceptions of vaccination in their sociocultural context, 
are crucial for local acceptance of immunization112-114.  
1.7 Vaccine hesitancy and acceptance for pandemic influenza  
Poor uptake of vaccines against influenza A (H1N1) was noted during the 2009 
pandemic. On one hand, considerable efforts went into scaling up production of 
vaccine against influenza A (H1N1), and rationing and prioritizing who should be 
given the vaccine, since supply was limited115. On the other hand, problems 
were noted among those who the vaccine was prioritized for and actively offered 
to, such as healthcare workers116-119 and pregnant women120. Problems in 
pandemic influenza vaccine uptake were also noted among the general 
population across different countries that offered the vaccine121-124.  
 
Introduction  
 
15 
A systematic literature review found that factors such as concerns regarding 
vaccine safety and vaccine efficacy, perceived seriousness of the disease and 
risk of getting the disease, social pressure, receipt of information from official 
sources, vaccine recommendation by a healthcare provider, uptake of seasonal 
influenza vaccines in the past and certain sociodemographic characteristics 
influenced uptake of pandemic influenza vaccines during the 2009 pandemic125. 
In some settings, the pandemic was perceived as similar to seasonal influenza 
and was hence not considered much of a threat126. A study in Switzerland found 
that some community members did not consider themselves at risk of pandemic 
influenza due to perceptions of discipline and individual responsibility of Swiss 
citizens and national affluence127. Mistrust of intentions of the pharmaceutical 
industry perceived to benefit from the pandemic and a general mistrust in 
motives of government and WHO were also reported to have negatively 
influenced vaccination decisions126. A review of risk communication during the 
pandemic reported many of the factors mentioned above and additionally 
reported factors such as comments by opinion leaders and consulting the 
internet as negatively influencing vaccination intentions128.   
 
Differences in national and cultural attitudes regarding the threat of pandemic 
influenza, and differences in national and public responses, including vaccination 
behaviour, were observed during the 2009 pandemic129,130. Despite cross-cultural 
differences and an acknowledged need for country-specific studies, relatively 
little research has focussed on determinants of pandemic influenza vaccine 
hesitancy and uptake in LMIC. A report by the SAGE working group on vaccine 
hesitancy further highlights a dearth of published research on vaccine hesitancy 
in LMIC in general131. A particular need for research in LMIC on individual and 
community determinants and contextual factors influencing vaccination 
hesitancy has been indicated132.  
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1.8 Pandemic influenza and research on influenza and 
vaccine acceptance in India 
1.8.1 Pandemic influenza in India and Pune 
Although the exact burden is not known due to poor surveillance in many 
developing settings, a high burden of disease from 2009 influenza A (H1N1) was 
borne by LMIC133,134. Even within higher-income countries such as Canada, New 
Zealand and the US, the pandemic had a disproportional impact among minority 
populations 135. Murray et al. estimate that if a pandemic of similar severity to 
the 1918 pandemic were to occur, 96% of deaths would be in developing 
countries136. In India, officially reported data indicated that among the 202,790 
persons who were tested for influenza through laboratory confirmation, 23% 
were positively identified and 6% of cases ended in death137. The attack rate was 
highest among 10-39 year-olds, while the highest case fatality was observed 
among those between 20-39 years of age, followed by young children under 5 
years of age.  
 
Figure 1-4: Cumulative incidence of confirmed cases of influenza A (H1N1), by month, in 
India  
June 2009-May 2010, Source: Adapted from Ali et al. 2013143 
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Maharashtra was particularly affected (Figure 1-4) and recorded 36% of all 2009 
H1N1 influenza-related deaths in the country. In a rural community in 
Maharashtra, 20% of all hospital admissions in the monsoon period (August 
2009 and August 2010) were due to 2009 influenza A (H1N1) viruses138. Pune, 
Maharashtra’s second largest city, recorded the country’s first death from 2009 
H1N1 influenza on 22 June 2009139 and was considered a hotspot of the 2009 
influenza pandemic in India140,141. Between June 2009 and August 2010, 246 
deaths and 2,971 laboratory-confirmed cases of 2009 influenza A (H1N1) were 
recorded in Pune142. However, similar to other incidence estimates for India, 
these figures refer to laboratory-confirmed cases only and are therefore likely an 
underestimate. 
1.8.2 Acceptance of vaccines for pandemic influenza in India 
Concerns with vaccination on political, social and cultural grounds have been 
documented since the introduction of smallpox vaccination in India. Reluctance 
by Hindu groups to accept a vaccine believed to come from cows which are 
considered sacred, and organized opposition to vaccination by groups involved in 
variolation who were afraid of losing employment, have been noted144. Culturally 
founded doubts about the efficacy of smallpox vaccination which only caused a 
mild reaction compared to variolation, have been also been documented112. More 
recently, vaccine hesitancy has been noted for oral polio vaccines111, HPV 
vaccines110, and Haemophilus influenzae type b vaccines145 in India. 
  
Acceptance of pandemic influenza vaccines during the 2009 pandemic in India 
varied widely. Although vaccines were not made available to the general public 
by the government, many purchased vaccines privately. Initially there was a 
high demand for vaccines, leading to stock-outs146,147. However, demand waned 
as time went by; and problems with vaccine acceptance were noted, especially 
among the high-risk group of healthcare workers to whom vaccines were made 
freely available by government148,149.  
 
The Pandemic Preparedness and Response Plan for India acknowledges vaccines 
as the “best preventive strategy to combat a pandemic”150. For effective control 
through vaccine action, it is essential to understand reasons for use or non-use 
of influenza vaccines and sociocultural determinants of vaccine acceptance. 
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Willingness to accept a vaccine indicates perceived need and demand. Local 
ideas of illness and social, cultural and economic factors that are known to 
influence vaccine hesitancy and uptake require careful consideration. 
1.8.3 Limitations in current research on pandemic influenza and vaccine 
hesitancy in India 
Four publications on community concepts of pandemic influenza in India were 
identified from a literature review. One assessed knowledge and awareness of 
swine flu among school children in Bareilly, Uttar Pradesh, and found that 98% 
of students had heard of swine flu and 97% reported masks as useful in 
preventing swine flu151. The second reported knowledge, attitudes and practices 
(KAP) regarding novel H1N1 influenza and reported insufficient awareness 
among paediatricians in Chandigarh152. The third study conducted among the 
general population in Udaipur, Rajasthan, was also a KAP study using a self-
administered questionnaire and showed that 83% were aware of influenza A 
(H1N1); but awareness varied on the basis of gender, age and education153. The 
fourth study assessed awareness of persons visiting swine flu screening booths 
in Belgaum, Karnataka, and found that approximately 50% believed that the 
disease was transmitted through proximity to pigs and by eating pork154. These 
studies were useful additions to the literature, but did not examine associations 
of perceptions with vaccination intentions.   
 
Published literature on pandemic (H1N1) influenza vaccine hesitancy or 
acceptance in India is also scarce, and only four studies were identified. Two 
studies considered reasons for pandemic influenza vaccine uptake in Pune. The 
study by Hiremath et al. among healthcare workers found that all participants 
considered vaccines important, but only 26% took a pandemic influenza vaccine 
due to safety and efficacy concerns155. A KAP study by Pandey et al. among 
healthcare workers and medical students found a 83% vaccination uptake and 
most commonly reported reasons for uptake were protecting self, relatives and 
recommendation by healthcare providers156. Two more studies conducted in 
Tamil Nadu among medical students and healthcare workers examined 
determinants of pandemic influenza vaccine acceptance and reported a lack of 
risk perception, and safety and efficacy concerns as limiting uptake157,158. These 
studies were conducted using convenience samples. The instruments used in all 
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four studies were limited in scope and depth by categories that were used to 
examine self-reported reasons for vaccine acceptance or refusal and were not 
guided by ethnographical insight. Moreover, some questions were leading in a 
detrimental manner with the potential to plant ideas that may not have 
previously been considered and could adversely affect the vaccine program. For 
example, a category noted in the self-administered survey by Suresh et al. was 
“I do not want to be an experimental animal”157.  
 
Although the literature indicates the nature of interest and approach of various 
KAP studies in India, many were not well-conducted, and none considered social 
factors or cultural influences in explaining vaccine acceptance. A careful study of 
social and cultural determinants of vaccine hesitancy is required. Furthermore, 
consideration of patterns of behaviour (i.e. intention to be vaccinated) and 
sociocultural determinants need not be limited to self-reported respondent 
accounts. Just as the evidence base for risk and treatment of disease relies on 
study of epidemiological patterns, rather than anecdotal clinical reports, the 
evidence base for social and cultural determinants of behaviour may also be 
rooted in evidence, based on study of how illness-, treatment- and vaccine-
related experience and meaning are related to behaviour, and with regard to our 
current interest, the acceptance of influenza vaccine. The approach and methods 
of cultural epidemiology have been developed to address such questions. 
1.9 Overview of research approaches 
1.9.1 Cultural epidemiology 
Culture has a powerful influence on the understanding of sickness and illness-
related behaviour159. The framework of cultural epidemiology used in this thesis 
was developed from integrating the frameworks and methods of anthropology 
and epidemiology to achieve an effective interdisciplinary collaboration (Figure 
1-5)160. Classical epidemiology through application of quantitative methods to 
study of occurrence and determinants of disease has greatly contributed to 
advances in control and management of diseases for public health. Findings from 
classical epidemiology, however, are not primarily concerned with context, or 
clarifying the nature and impact of locally-valid ideas of illness and risk 
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perception. Such understanding is required to ensure effectiveness of policy at 
the local level161. Medical anthropology focuses on the nature of local illness 
experience and understanding using ethnography and other largely qualitative 
methods to gain insights into the influence of social, cultural, historical and 
political forces affecting illness-related behaviour. However, most anthropological 
studies do not provide a sense of the distribution of ideas or facilitate 
comparative interests. Notwithstanding valuable contributions made by both 
disciplines in furthering the agenda of public health, efforts to integrate them 
have been limited160.  
 
Cultural epidemiology was thus developed to integrate the local validity of 
anthropology and the explanatory power of epidemiology through a mix of 
qualitative and quantitative research methods. Cultural epidemiology, as defined 
and operationalised by Mitchell Weiss, is the study of locally valid 
representations of illness and their distribution—specified by variables, 
descriptions, and narratives, accounting for illness experience, its meaning, and 
associated behaviour—in order to clarify the cultural basis of outcomes of 
practical significance to public health160. 
 
 
Figure 1-5: Integrative framework of cultural epidemiology 
Source: From ‘Cultural epidemiology: principles and practice’ course by Weiss M.G. 
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Frameworks that were influential in the development of medical anthropology 
have been extended for use in cultural epidemiology and they include first and 
foremost, distinguishing professional orientations (etic) from local ideologies 
(emic). Emic constructs, which are referred to as the insider’s perspective or a 
‘bottom-up’ approach, are “accounts, descriptions, and analyses expressed in terms of 
the conceptual schemes and categories regarded as meaningful and appropriate by the 
native members of the culture whose beliefs and behaviours are being studied”162. Etic, 
on the other hand, refers to the outsider’s perspective or a ‘top-down’ approach, 
which are conceptual schemes and categories regarded as meaningful by the 
scientific observers or professionals. Kenneth Pike formulated these terms by 
drawing from linguistics and linguistic anthropology162. The second influential 
framework is the distinction between disease and illness. While disease refers to 
abnormalities in bodily functions as understood through a scientific paradigm, 
illness refers to experiences by the patient that are disvalued. Leon Eisenberg, 
who first made this semantic distinction, noted that “patients suffer illnesses; 
physicians diagnose and treat disease”163. Thus a person with asymptomatic 
hypertension, may have a disease in the absence of illness. The third influential 
framework was the ‘explanatory model’ by Arthur Kleinman that gave priority to 
illness experience, causal explanations, help-seeking, and approach to 
treatment164. This formulation of illness explanatory models was developed to 
provide cultural validity in clinical practice.  
 
Semi-structured, explanatory model interview catalogue (EMIC) interviews, 
principal instruments of cultural epidemiological research, are rooted in the 
explanatory model framework, but allow systematic comparisons and have 
enhanced operational precision165. EMIC interviews assess locally relevant, 
sociocultural representations of illness—e.g. categories of somatic, emotional, 
and social symptoms constituting patterns of distress (PD), perceived causes (PC) 
and help seeking (HS)—from the perspective of affected persons. Local 
adaptation of interviews is required, so that they are indeed emic. They thus 
refer to a common framework of instruments known collectively as the EMIC to 
guide locally relevant research, rather than one definitive EMIC interview.  
 
The design of a cultural epidemiological research study begins with careful 
attention to context and concepts of illness through an ethnographic study. This 
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is followed by a survey that collects quantitative data for comparative statistical 
analysis between sub-groups of the study population. The interviews also rely 
heavily on qualitative narrative data that are useful in clarifying categories and 
in explaining their role and significance. An analytic component often includes 
univariable or multivariable analysis to examine the influence of sociocultural 
features of illness on behaviour. The health-related behaviour in question for this 
thesis was vaccine acceptance. However, cultural epidemiological studies using 
EMIC interviews have been carried out in many settings and for a variety of 
illness conditions such as psychiatric illness and depression166-169, malaria170, 
Buruli ulcer171, tuberculosis172,173, HIV/AIDS174 and diarrhoeal diseases175-178. 
1.9.2 Previous work and current collaboration 
The adaptation of EMIC interviews for the study of vaccine acceptance began in 
2008 with study of oral cholera vaccine (OCV) acceptance first in Zanzibar176,179, 
followed by Kenya177,180 and the Democratic Republic of Congo178. The current 
study was motivated by an interest in contributing to pandemic preparedness in 
developing countries by the Initiative for Vaccine Research, WHO. The 
Maharashtra Association of Anthropological Science (MAAS), a non-governmental 
organization in Pune, India was selected as a local scientific partner. This 
research study was developed in partnership with MAAS 
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CHAPTER 
2  
Research aims and objectives 
The overall aim of this thesis is to study social and cultural features of 
acceptance of pandemic influenza vaccines from a community perspective in a 
developing country setting. Research findings are intended to contribute to 
state-level and national-level policy in India on improving pandemic 
preparedness and influenza control.  
 
To achieve the aims of this thesis, research objectives were defined in the study 
context of Pune, India. Research objectives that have been elaborated in 
subsequent chapters of the thesis are as follows:  
 
• To examine experience, meaning and behaviour associated with pandemic 
influenza  among urban and rural communities in Pune, India (Chapter 4) 
 
• To determine community awareness, views and hesitancy for nasal and 
injectable pandemic influenza vaccines (Chapter 5) 
 
• To analyse experience and reasons for vaccination or non-vaccination against 
H1N1 influenza during the 2009 pandemic (Chapter 5) 
 
• To assess levels of anticipated acceptance of two available influenza vaccines 
at different levels of cost in urban and rural Pune (Chapter 6) 
 
• To identify social and cultural determinants of anticipated acceptance of 
pandemic influenza vaccines (Chapter 6) 
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CHAPTER 
3  
Study description 
3.1 Country and state context 
India is the world’s second most populous country with over 1.25 billion people 
and the seventh largest by area1. A recent report by the World Bank indicates 
that India “has the largest number of poor people in the world, as well as the largest 
number of people who have recently escaped poverty but are still vulnerable to falling 
back”2. Although it is categorized as a lower-middle income country1, India is 
among the world’s fastest growing economies3. India has also made progress in 
life expectancy, education and health2. However, despite rapid economic growth 
and development, income inequality is increasing, gender inequality remains 
high and society remains highly segmented. 
 
Figure 3-1: Map of India and Maharashtra displaying the location of Pune districtii 
Source: Adapted from Census of India 2011 
                                       
ii The boundaries and names shown and the designations used on this map do not imply the expression of any opinion 
whatsoever on the part of the author concerning the legal status of any country, territory, city or area or of its authorities or 
concerning the definitions of its frontiers or boundaries. 
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3.1.1 Population and density  
The State of Maharashtra, located in Western India, is the second most populous 
State in the country after Uttar Pradesh4. According to the 2011 national census, 
Maharashtra has a total population of 112,372,972 persons representing 9.3% 
of India’s population4. In 2013, Maharashtra comprised of 35 districts5, of which 
Thane district with a population of 9.8% was the largest followed by Pune district 
(8.4%) and Mumbai suburban (8.3%)4. The population density of Maharashtra is 
365 persons per km2 as compared to 382 persons per km2 at the national level5. 
Among districts in Maharashtra, population density is highest in Mumbai 
suburban (20,980 persons per km2), followed by Mumbai city (19,652 per km2) 
and Thane (1,157 per km2). Pune district is ranked fourth with 603 persons per 
km2. 
3.1.2 Sex ratio 
Sex ratio, defined as the number of females per 1,000 males, has increased in 
Maharashtra from 922 in the 2001 census to 925 in the 2011 census4. However 
it falls short of the national sex ratio estimate of 940. The sex ratio for Mumbai 
and Mumbai suburban are critically low at 838 and 857, respectively. The sex 
ratio for Pune district (910) also falls below the State average. The sex ratio 
among 0-6 year-olds is worse; the average for Maharashtra is 883 and for Pune 
district is 873.  
3.1.3 Literacy 
Effective literacy was defined in the 2011 census as the ability to read, write and 
understand at least one language (the definition excludes children under 7 years 
of age)4. By this definition, 82.9% of the population of Maharashtra is considered 
literate. The literacy rate for men and women in Maharashtra are 89.8% and 
75.5%, respectively, which are higher than the national literacy rates of 82.1% 
and 65.5%. Among districts, the highest literacy rates are found in Mumbai 
suburban (90.9%) and Nagpur (89.5%). Although Pune district has a relatively 
high literacy rate (87.2%), it is also home to the largest number of illiterate 
persons (1,071,181) after Thane (1,354,116) and has a notable gender disparity 
in literacy rates (92.7% for men vs. 81.1% for women).  
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3.1.4 Urban-rural features 
Of the 9.4 million persons who live in Pune district, 3.7 million (39.1%) live in 
rural areas and 5.7 million (60.9%) live in urban areas6. In comparison to the 
State, a relatively larger proportion of persons in Pune district live in urban areas 
(45.2%). Urban-rural inequities have been noted in access to healthcare in 
Maharashtra7. Although the overall healthcare infrastructure in Maharashtra is 
among the best in the country, a large proportion is catered by the private 
sector (83.4% based on estimates from 2005) while public expenditure on 
health by the State is very low7. Furthermore, most public health facilities in the 
State are concentrated in urban areas, making access difficult for rural persons.  
 
Figure 3-2: Urban-rural population distribution in Maharashtra 
Source: Census of India 2011 
3.2 Study setting 
This study was conducted in Pune district, in Western Maharashtra at the 
foothills of the Sahyadri mountain range. The district headquarters is Pune city, 
which has recently witnessed rapid growth. A major laboratory where virological 
testing was done during the 2009 influenza pandemic in India8, the National 
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Institute of Virology, and a large vaccine manufacturer, the Serum Institute of 
India, that manufactures influenza vaccines following a technology transfer 
initiative through WHO9, are both located in Pune.  
 
According to the 2011 census, Pune district is divided into 14 sub-districts10 
(taluks). The two urban study sites were located in Pune city. They were: a) 
densely-populated urban slums in an area known as Sangamwadi, on the 
extended border of central Pune near Pune railway station and b) middle-income 
neighbourhoods in an area known as Erandawane that has historically been a 
middle-income Maharashtrian area that has recently seen an influx of students 
and working professionals from other states. 
 
Figure 3-3: Urban study sites 
Photographs: N. Sundaram 
 
Two rural study sites were also selected for urban-rural comparative interests. 
Relatively remote villages were chosen in Velhe sub-district that comprises of 
124 villages and has a population of 54,51611. Maval sub-district which has a 
population of 377,559 was the second rural site. Villages that were more easily 
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accessible from Pune city due to their location along a highway were selected 
from Maval.  
 
Figure 3-4: Rural study sites 
Photographs: N. Sundaram and A. Kudale 
3.3 Study design 
This thesis is part of a larger project on pandemic influenza and vaccine 
acceptance in Pune, India12. While community study was central to the overall 
project, additional project components included hospital case studies, policy 
review and media review. This thesis focuses on the community component; the 
three research activities listed below were pivotal to the overall study: 
1. Formative qualitative research with focus group discussions 
2. Cross-sectional cultural epidemiological survey with semi-structured EMIC 
interviews 
3. Case studies among community members for in-depth elaboration on 
experience with pandemic influenza and vaccination  
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Details on participant selection, sampling and data collection for each of the 
research activities are provided in this section. Inclusion criteria for study 
respondents were adults between 18 and 65 years of age, permanent residence 
in the study community since 2009 and conversational fluency in Marathi. It was 
also ensured that respondents had the ability to mentally and physically 
withstand the interview or discussion. 
 
Formative focus group discussions (FGDs) provided insight on the setting and 
guided development of questions and categories for semi-structured interviews. 
A minimum of four FGDs were planned in the urban and rural study areas based 
on a convenience sample recruited by community leaders or community health 
volunteers. Separate FGDs were planned for men and women, and one mixed 
group with both men and women was planned in the urban area. FGDs were 
conducted by a bilingual senior researcher with a doctoral or masters level 
degree in social sciences, accompanied by a note taker. The discussions were 
audio recorded to supplement written notes. Facilitator and respondent 
characteristics were matched where possible.  
 
Semi-structured interviews (SSIs) were developed based on the explanatory 
model interview catalogue (EMIC)13 framework for cultural epidemiology14. A 
total of 400 interviews were planned with 100 interviews from two urban and 
two rural sites. A minimum sample of 328 was required in order to detect a 
difference of 0.5 in mean prominence (calculated for cultural epidemiological 
variables described in the next section on ‘data management and approach to 
analysis’), at a level of 95% significance and 80% power. This calculation was 
based on a two-sample t test assuming no underlying distribution in the data. An 
additional 20% of interviews were planned to accommodate potential 
deficiencies in completed interviews. Households were selected randomly from 
local voters’ lists for each of the study areas. The local registry of voters was the 
most comprehensive of available records. However, to avoid selection bias of not 
including persons not registered as voters, the house of the person identified on 
the voters’ list was located but not interviewed. The adjacent house to the right 
of the one located through the voters’ list was instead approached for interview. 
If no one in that household was eligible or willing to participate, the 
neighbouring household to the right was approached by interviewers until a 
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suitable respondent was found. An equal number of men and women, and 
younger and older adults were interviewed. SSIs were conducted by research 
assistants working in teams of two, with one person conducting the interview 
and the other maintaining data records. They received extensive training in 
interview skills and data management. Interviews were voice recorded for 
consenting respondents; without consent the data was based solely on interview 
notes. 
 
In the third stage of the community study, in-depth interviews (IDIs) were 
planned with a purposively-selected subsample from the SSIs. Respondents with 
a history of pandemic influenza, with a history of H1N1 influenza vaccination and 
with a history of not accepting H1N1 vaccine were interviewed. A total of six to 
eight interviews were planned with each group, with roughly equal numbers 
from the urban and rural areas. The IDIs were conducted by senior bi-lingual 
researchers, accompanied by a note taker. Interviews were voice recorded with 
permission to enhance interview notes.  
3.4 Instruments  
Instruments for FGDs, SSIs and IDIs were developed during several workshops 
in Pune with anthropologists and study investigators. SSIs were based on 
literature review and previous work on vaccine acceptance15-17. Instruments 
were revised based on feedback from other public health experts. They were 
pilot tested and further revised after translation into Marathi.  
 
The FGD agenda clarified background features of the setting, sociocultural 
features of influenza and experience during the pandemic of 2009-2010. It 
covered broad topics on ideas about vaccines including perceived benefits, 
problems and experience with pandemic influenza vaccines. FGDs also guided 
the construction of interview questions and coding categories for SSIs. 
 
EMIC interviews were used to examine the distribution of community ideas of 
illness-related experience, meaning and behaviour (Appendix 8.5). A vignette 
which described in simple terms a person with characteristic clinical symptoms of 
influenza, set in the time period of January 2010, was used to provide a focus 
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for questions of the interview (Appendix 8.6). The sex, age group and residence 
of the character in the vignette and respondent were matched. This vignette-
based approach elicited respondents’ views on priority symptoms, perceived 
causes, help-seeking and prevention of the illness, based on a presentation of 
the condition, rather than recognition of its name. Responses to open questions 
were coded followed by questions probing categories that were not mentioned 
spontaneously. Respondents were also asked about their personal and household 
experience in the 2009 influenza pandemic. The instrument then assessed 
willingness to take a vaccine to prevent swine flu, the local term most commonly 
used for H1N1 disease. Questions related to awareness, preferences, uptake of 
pandemic influenza vaccines and barriers to vaccine use were also enquired. 
Complementary components of the data set included categorical and numeric 
data for quantitative comparative analysis and narrative data for qualitative 
thematic analysis and elaboration.  
 
The agenda of in-depth interviews focused on actual experience and behaviour 
during the 2009 pandemic for those who had recovered from pandemic influenza. 
The experiences and motivations of those took the pandemic H1N1 influenza 
vaccine, and the views, potential barriers or hesitation among those who did not 
do so were discussed in detail.  
3.5 Data management and approach to analysis 
Quantitative and categorical data from semi-structured EMIC interviews were 
double-entered using range and logic checks in Epi Info v.3.5.3 (CDC, USA). 
Cultural epidemiological variables specifying categories of distress, perceived 
causes, help-seeking at home and outside, and prevention were evaluated based 
on relative importance ascribed to them. Prominence was assigned for each 
variable in the sets noted above which involved a weighted coding of responses 
based on whether and how each category was reported by a respondent. 
Spontaneously mentioned categories received a value of 2; categories reported 
only on probing received a value of 1, and if not reported at all was assigned a 
value of 0. A category that was also identified as most important was assigned 
an additional value of 3. Mean values summarized the prominence of each 
category with a possible range of 0-5. 
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Acknowledged differences in urban-rural subcultures, the influence of gender 
and age on behaviour, and differences in disease burden between age groups18 
and urban or rural residence, are factors that require attention. Comparative 
analysis would thus focus on the influence of gender, age and urban-rural 
features on community ideas of sociocultural features of influenza and 
acceptance of vaccines. Prominence means for categories were compared 
between groups using the Wilcoxon rank-sum test, while proportions were 
compared using Fisher’s exact test. Univariable and multivariable logistic 
regression analyses were used to identify determinants of vaccine acceptance. 
Analysis of quantitative data was performed with SAS V.9.2 (SAS Institute, USA) 
and STATA V.12 (StataCorp LP, USA).  
 
Qualitative data from FGDs, SSIs and IDIs were entered in a word processor in 
Marathi using a unicode Devnagari font. After translation into English, transcripts 
were imported and managed with MAXQDA 11 (VERBI software, Germany). 
First-level coding was done using deductive approaches. Inductive coding was 
also applied and a thematic analysis was carried out rooted in the objectives of 
the study. Page turn times that were noted down by the data recorder during 
the interview were imported into MAXQDA. This made rapid retrieval of relevant 
sections of the audio recording possible, facilitating thematic coding and analysis.  
 
Variables from the quantitative data set were imported into MAXQDA to select 
narratives of particular interest, facilitating integrated analysis of qualitative and 
quantitative data. Triangulation of data from the different data sources was also 
carried out as a part of the analytic process.  
3.6 Ethical considerations 
The study protocol received ethical approval from the Institutional Ethics 
Committee of the Maharashtra Association of Anthropological Sciences, Pune, 
WHO Research Ethics Review Committee and the Ethics Commission of Basel. 
Written informed consent was obtained prior to each interview. No financial or 
other incentives were given to respondents for participation. Data collected in 
this study are maintained with utmost confidentiality and were anonymised 
before analysis and reporting. 
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Abstract 
Objective  
To identify and compare sociocultural 
features of pandemic influenza with 
reference to illness-related experience, 
meaning and behaviour in urban and 
rural areas of India. 
Design  
Cross-sectional, mixed-methods, 
cultural epidemiological survey with 
vignette-based interviews. Semi-
structured explanatory model 
interviews were used to study 
community ideas of the 2009 influenza 
pandemic. In-depth interviews 
elaborated respondents’ experience 
during the pandemic. 
Setting 
Urban and rural communities, Pune district, western India.  
Participants 
Survey of urban (n=215) and rural (n=221) residents between 18 and 65 years 
old. In-depth interviews of respondents with history of 2009 pandemic influenza 
(n=6).  
Results 
More urban (36.7%) than rural respondents (16.3%, p<0.001) identified the 
illness in the vignette as ‘swine flu’. Over half (56.7%) believed the illness would 
be fatal without treatment, but with treatment 96% predicted full recovery. 
Worry (‘tension’) about the illness was reported as more troubling than somatic 
symptoms. The most common perceived causes – ‘exposure to a dirty 
environment’ and ‘cough or sneeze of an infected person’ –were more prominent 
in the urban group. Among rural respondents, climatic conditions, drinking 
contaminated water, tension and cultural ideas on humoral imbalance from heat- 
or cold- producing foods were more prominent. The most widely-reported home-
treatment was herbal remedies; more rural respondents suggested reliance on 
prayer, and symptom relief was more of a priority for urban respondents. 
Government health services were preferred in the urban communities, and rural 
residents relied more than urban on private facilities. Preventive measures 
emphasised were cleanliness, wholesome lifestyle and vaccines, and more urban 
respondents reported use of masks. In-depth interviews indicated treatment 
delays during the 2009 pandemic, especially among rural patients.   
Conclusions 
Although the term was well-known, better recognition of pandemic influenza 
cases is needed, especially in rural areas. Improved awareness, access to 
treatment and timely referrals by private practitioners are also required to 
reduce treatment delays.   
 
 Consideration of community experience, 
meaning and behaviour to inform effective 
pre-preparedness and control of pandemic 
influenza 
 Cultural epidemiological methods identify 
patterns of relevant social and cultural 
features of pandemic influenza 
 Urban and rural perceptions, priorities and 
illness behaviour have similar and 
distinctive features that are clarified 
locally 
 Integrated quantitative survey and 
qualitative ethnographic methods and 
triangulation effectively clarify relevant 
community experience for pandemic 
preparedness 
 Findings may change over time and in 
response to social changes or epidemics; 
relatively high non-participation rate 
 
Strengths and limitations  
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4.1 Introduction 
Influenza is responsible for substantial mortality and morbidity in all age groups, 
across the globe1. Three pandemics occurred in the previous century in 1918 
('Spanish flu’), 1957 (‘Asian flu’) and 1968 (‘Hong Kong flu’). The ‘Spanish flu’ is 
believed to be the single most devastating disease outbreak in human history, 
resulting in approximately 50 million deaths worldwide2. Influenza outbreaks 
caused by the novel influenza A virus H1N1 strain reached pandemic proportions 
in 2009 and the first influenza pandemic of the 21st century was declared3 4. 
Although the 2009-2010 (H1N1) influenza pandemic was milder than expected, 
it is estimated to have been responsible for over 280,000 deaths5.  
 
Between May 2009 and August 2010, India had recorded 39,977 laboratory 
confirmed cases and 2113 deaths from H1N1 influenza from 25 states and 6 
union territories6. The state of Maharashtra bore the highest mortality burden 
with 767 deaths (36.3% of all H1N1-related deaths). Pune, Maharashtra’s 
second largest city, recorded the first death in the country7 and was considered 
a hotspot of the 2009 influenza pandemic in India8 9.  
 
Pandemics can occur unpredictably and cause widespread disease10. 
Containment of pandemic influenza depends extensively on effectiveness of 
control measures, which in turn relies fundamentally on the public’s willingness 
to collaborate. In order to foster this support, identifying community priorities 
and views on illness causation and prevention is critical. The study of cultural 
concepts of illness which are known to influence community expectations, 
behaviour and outcomes is necessary for locally relevant and effective pandemic 
policy planning11 12. Examination of community views on the 2009 influenza 
pandemic is relevant for pandemic preparedness and influenza control.  
 
Although evidence of epidemiological differences in disease burden between 
urban and rural areas exist in Pune9, little is known about differences between 
urban and rural concepts and priorities for influenza control among affected 
communities. Given differences in urban-rural subcultures in terms of pandemic 
experiences, help-seeking, disease transmission9, access to health facilities and 
living conditions13, consideration of their commonalities and distinctiveness 
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should benefit planning for pandemic preparedness. The aim of this study is to 
examine and compare sociocultural features of pandemic influenza with 
reference to the distribution of illness-related experience, meaning and 
behaviour across urban and rural communities in Pune district, India.  
4.2 Methods 
4.2.1 Setting and study sites 
The study was conducted in Pune district, western Maharashtra, India. The 
district has a population of 9.43 million, of which 5.75 million live in urban and 
3.68 million in rural areas14. The district headquarters is Pune city, which has 
recently experienced rapid growth. One out of two major laboratories in India 
where virological testing was done during the pandemic, National Institute of 
Virology15, as well as a large manufacturer of influenza vaccines, Serum Institute 
of India, are located in Pune. 
 
Two urban study sites were densely-populated informal settlements in an area 
known as Sangamwadi and the middle-income neighbourhoods in an area called 
Erandawane in Pune city16. The rural sites were in two sub-districts, Velhe and 
Mawal. Selection was based on their relative accessibility to Pune city. Of 17 
villages in Velhe that were designated as relatively inaccessible, 10 were 
randomly selected for our study. Of 24 villages that were identified as accessible 
due to the presence of a road adjacent to the village, 10 were randomly selected. 
The number of persons selected from each village was proportionate to the 
village population.  
4.2.2 Instruments 
This study used semi-structured interviews based on the framework of the 
explanatory model interview catalogue (EMIC)17 for cultural epidemiology18 and 
in-depth interviews. Both interviews were developed in workshops in Pune with 
anthropologists and public-health experts. Instruments were translated into 
Marathi and refined based on experience and analysis of pilot-interview data and 
ethnographic focus group discussion data.  
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EMIC interviews were used to examine the distribution of community ideas of 
illness-related experience, meaning and behaviour. After questions about 
respondent characteristics, a vignette described in simple terms a person with 
characteristic clinical symptoms of influenza, set in the time period of January 
2010. The sex, age group and residence of the character in the vignette and 
respondent were matched. This vignette-based approach elicited respondents’ 
views on priority symptoms, perceived causes, help-seeking and prevention of 
the illness, based on presentation of the condition, rather than recognition of its 
name. Respondents were also asked about their personal and household 
experience in the 2009 influenza pandemic. Complementary components of the 
data set included categorical and numeric data for quantitative comparative 
analysis and narrative data for qualitative thematic analysis and elaboration. 
 
The agenda of in-depth interviews focussed on actual experience and behaviour 
during the 2009 pandemic. 
4.2.3 Study design and sampling 
The cross-sectional study required a minimum sample of 328. The sample size 
calculation is based on the ability to detect a difference of 0.5 in prominence 
means (calculated for cultural epidemiological variables described in the ‘data 
management and analysis’ section) with 95% significance and 80% power for 
urban-rural comparisons.  An additional 20% of interviews were planned to 
compensate for possible shortfall in completed interviews.  
 
Approximately 100 EMIC interviews were planned at each of the two urban and 
two rural sites16. Households were randomly selected from the local registry of 
voters. Of available records, voters’ lists were the most comprehensive. However, 
they do not include persons or households not registered as voters. Thus, to 
avoid selection bias, the household of the person identified on the voters’ list 
was located (but not interviewed) and the adjacent household to the right was 
approached for interview. Inclusion criteria were ages between 18 and 65 years, 
residency in Pune, conversational fluency in Marathi and ability to physically and 
mentally withstand an interview. If no member in the household satisfied the 
inclusion criteria or if there were no willing respondents, the neighbouring 
household to the right was approached, until a suitable respondent was found. 
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An equal balance of men and women, and younger and older adults was 
maintained. 
 
EMIC interview respondents who indicated having personal or household 
experience with influenza during the 2009 pandemic were approached for in-
depth interviews. These in-depth interviews with directly affected persons 
supplemented the EMIC interview survey to elaborate findings with narrative 
accounts of the subgroup of respondents with personal pandemic illness 
experience. 
 
Research assistants received extensive training in sampling procedures, 
obtaining informed consent, interviewing and data management during a two-
week workshop. They worked in teams of two, one conducting the interview and 
the other maintaining data records. Two supervisors reviewed data for accuracy 
and quality. Interviews were voice-recorded with permission. 
4.2.4 Data management and analysis 
Quantitative data were double-entered into an electronic database using Epi Info 
3.5.3 (Centers for Disease Control and Prevention, USA), programmed with logic 
and range checks. For analysis of sociocultural features of illness, prominence of 
categories was calculated based on whether a response was spontaneous to an 
open question (assigned a value of 2) or in response to probing for that category 
(assigned a value of 1).When a category was identified as most important 
among all, it was assigned an additional value of 3. Mean prominences were 
calculated for each category, with a range of 0-5. Through such consideration of 
prominence, categories were evaluated based on relative importance ascribed to 
them. Prominence means for categories were compared between urban and rural 
groups using the Wilcoxon rank-sum test, while proportions were compared 
using Fisher’s exact test. Analysis of quantitative data was done with SAS 9.2 
(SAS Institute, USA) and STATA 12 (StataCorp LP, USA).  
 
Narrative data for EMIC and in-depth interviews were entered in a word 
processor in Marathi using a unicode Devanagari font. After translation into 
English, data were imported into MAXQDA 11 (VERBI Software, Germany), using 
techniques for automatic first-level coding for narratives in response to specific 
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questions. Deductive and inductive coding approaches were applied. Thematic 
similarities and differences between urban and rural narratives were 
systematically analysed. Variables from the quantitative data set were imported 
into MAXQDA to enable selection of narratives of interest, facilitating integrated 
analysis of quantitative and qualitative data.  
4.3 Results 
4.3.1 Sample characteristics 
Field data were collected between July 2012 and February 2013. Among 
community members approached for interview, 50 in urban and 10 in rural areas 
did not satisfy the inclusion criteria and were excluded. A total of 822 persons 
approached refused to participate, and the refusal rate was higher in urban 
(76%, n= 681) compared to rural areas (36%, n=141). The reason for refusal 
indicated by the majority was that they were too busy to participate in the 
interview. Incomplete interviews (n=35) were excluded from analysis. 
 
Of the 436 completed interviews, approximately half were with women and half 
were from urban and rural sites (table 4-1). More urban residents were post-
graduates, graduates or had higher secondary school education, and more rural 
respondents had no education. Urban household incomes were higher than rural 
and more were reported as reliable and dependable. The most commonly 
reported occupation was agriculture among rural respondents. Self-employment 
or employment with a private organization was most frequently reported by 
urban respondents.  
 
Table 4-1: Sample characteristics of study respondents 
Socio-demographic features   
Overall 
sample, n=436   
Urban sites, 
n=215 
Rural sites, 
n=221 
P 
valuesa 
Gender (%) 
 
  
    Women   50.7 
 
50.2 51.1 
 Age (years)     
 
    
 Median (interquartile range)b   45 (29–55 ) 
 
45 (28–57) 45 (29–52) 
 Household size (number of persons)     
 
    
 Median (interquartile range)b   5 (4–7) 
 
5 (3–6) 5 (4–7) ** 
Occupation (%)***c     
 
    
 Agriculture   22.5 
 
0.0 44.3 *** 
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Socio-demographic features   
Overall 
sample, n=436   
Urban sites, 
n=215 
Rural sites, 
n=221 
P 
valuesa 
Unskilled labour   7.3 
 
8.4 6.3 
 Skilled labour   4.6 
 
6.5 2.7 
 Self-employment   9.9 
 
11.6 8.1 
 Business   2.1 
 
2.8 1.4 
 Service (public)   2.8 
 
2.8 2.7 
 Service (private)   9.6 
 
12.1 7.2 
 Student   5.0 
 
6.0 4.1 
 Housewife   24.1 
 
30.2 18.1 ** 
Retired    8.7 
 
14.4 3.2 *** 
Unemployed   3.4 
 
5.1 1.8 
 Highest education level attained (%)***c 
 
    
 No education   21.6 
 
11.6 31.2 *** 
Less than primary    7.3 
 
7.9 6.8 
 Primary school   38.3 
 
33.5 43.0 * 
Secondary school   12.8 
 
14.9 10.9 
 Higher secondary school   10.3 
 
14.0 6.8 * 
Diploma/ Professional course   1.6 
 
2.3 0.9 
 Graduation   4.8 
 
9.8 0.0 *** 
Post-graduation   3.2 
 
6.0 0.5 *** 
Years of school attended (years)     
 
    
 Median (interquartile range)b   7 (2–11) 
 
10 (5–13) 5 (0–10) *** 
Marital status***c     
 
    
 Single   15.1 
 
18.6 11.8 
 Married   77.3 
 
73.0 81.4 * 
Widowed   7.6 
 
8.4 6.8 
 Religion***c     
 
    
 Hindu   84.4 
 
74.9 93.7 *** 
Muslim   3.4 
 
6.5 0.5 *** 
Christian   1.1 
 
2.3 0.0 * 
Neo-buddhist   10.8 
 
15.8 5.9 *** 
Social category***c     
 
    
 Scheduled caste or tribe   25.0 
 
38.1 12.2 *** 
Other backward class   8.3 
 
10.2 6.3 
 Open/general category   59.6 
 
41.4 77.4 *** 
Vimukta jati nomadic tribes   3.4 
 
2.8 4.1 
 Undisclosed   3.4 
 
7.0 0.0 *** 
Monthly household income (Indian Rupees)  
 
    
 
Median (interquartile range)b   
10000  
(5000–17500) 
 
11000  
(6000–22500) 
7250  
(3375–13250) *** 
Unable to provide a response (%)c   21.6 
 
13.5 29.4 *** 
Household income reliability (%)c     
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Socio-demographic features   
Overall 
sample, n=436   
Urban sites, 
n=215 
Rural sites, 
n=221 
P 
valuesa 
Reliable and dependable   49.1 
 
60.9 37.6 *** 
Not reliable and dependable   44.5 
 
35.3 53.4 *** 
No response    6.4   3.7 9.0 * 
a * p≤0.05, ** p≤0.01, *** p≤0.001; b Wilcoxon test; c Pearson Chi2 or Fisher's exact test 
4.3.2 Awareness of pandemic influenza 
A third of respondents identified the condition as a respiratory illness (table 4-2) 
and more urban respondents (36.7% vs. 16.3% rural) identified it as “swine flu”. 
Alternative names for the illness condition such as H1N1 influenza or pandemic 
flu were seldom used. Towards the end of the interview, those who had not 
mentioned swine flu were specifically asked if they had heard of it – a majority 
said they had and only 10.3% of the entire sample (3.3% urban, 17.2% rural) 
had not.  
 
Illness identification was based on the following themes: physical symptoms, 
time period indicated in the vignette, and information available on contemporary 
diseases or ongoing outbreaks. A 45-year old urban woman who identified the 
illness through symptoms indicated the logic used in identification by stating, “It 
must be either dengue or swine flu. It could be chikungunya, if she has joint pain. If 
there is no joint pain but she is suffering from body ache, then she may have swine flu 
or dengue. Swine flu is more probable because dengue is characterized by a facial rash 
while sore throat and cold are the symptoms of swine flu.”  
 
For others, the time period of occurrence defined the condition, “Since it dates 
back to two years ago, it must be swine flu because it was on a high two years ago… 
swine flu is characterised by high fever.” (28 years, rural woman)  
 
The notion of swine flu as a new disease was common and contributed to illness 
identification. Information provided in the vignette associating the illness with an 
outbreak (multiple cases in the community) was also noted. The condition was 
sometimes conflated with dengue fever, inasmuch as a dengue outbreak was 
ongoing during the period of study interviews. A 65-year old woman stated, “If 
the disease was spreading in the neighbourhood then the name would have been 
mentioned on TV… swine flu, it is also called dengue. It was widespread in Pune - 
dengue and swine flu - both are the same disease. That one disease has two names.” 
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More rural respondents were unable to identify the illness by a name (39.8% vs. 
20.9% urban). Explanations were similar in both areas: (a) simply not knowing 
or being uneducated was commonly cited, (b) some indicated that only a doctor 
can name the illness, not a layman, (c) others displayed confusion between 
many well-known diseases. For example, a 46-year old rural woman stated, 
“Cough leads to TB. There are many different illnesses, isn’t it? There are different kinds 
of fever. Some contract Malaria, while others could suffer from typhoid or dengue. Some 
people take time to recover. I won’t be able to name the illness.” 
 
Table 4-2: Identification of illness presented in the vignette 
Illness identified asa   
Overall 
sample, 
n=436   
Urban 
sites, 
n=215 
Rural 
sites, 
n=221 P valuesb 
Group 1: Respiratory illness  
 
30.7 
 
40.9 20.8 <0.001 
Swine flu, H1N1 influenza or Pandemic flu 
 
26.4 
 
36.7 16.3 <0.001 
Seasonal or common flu 
 
1.6 
 
1.9 1.4 0.721 
Viral (fever/ infection) 
 
0.5 
 
0.9 0.0 0.243 
Common cold 
 
0.9 
 
0.9 0.9 1.000 
Combinations of fever, chills, cough 
 
1.4 
 
0.5 2.3 0.216 
Group 2: Other specified conditions 
 
38.8 
 
38.1 39.4 0.844 
HIV/AIDS 
 
3.2 
 
2.8 3.6 0.787 
Tuberculosis (TB) 
 
9.6 
 
10.2 9.0 0.746 
Typhoid 
 
3.4 
 
1.9 5.0 0.113 
Dengue 
 
8.3 
 
11.2 5.4 0.036 
Malaria 
 
5.3 
 
4.7 5.9 0.670 
Other 
 
8.9 
 
7.4 10.4 0.316 
Group 3: Unable to specify  
 
30.5 
 
20.9 39.8 <0.001 
Cannot say or Undecided   30.5   20.9 39.8 <0.001 
a Reported categories analysed as groups have been presented in italicised font. 
b Fisher's exact test used for cross-site comparison. Bold represents p≤0.05 
4.3.3 Perceived seriousness of illness 
No urban-rural differences were apparent for severity of the illness: 46.6% of 
the whole sample said it was very serious and 31.2% serious, but 8.7% thought 
it was not a serious illness. Remaining respondents were unable to provide a 
reply. Without treatment, 56.7% believed the illness would be fatal, 38.5% 
believed the condition would worsen but not necessarily lead to death and less 
than 1% anticipated a full recovery. With treatment, however, 96.1% predicted 
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a complete recovery, and less than 2% anticipated fatality or worsening 
symptoms.    
4.3.4 Categories of distress 
Social or emotional categories of distress had greater prominence in the urban 
than in the rural group: distress caused by isolation from others (prominence: 
urban=1.047, rural=0.742, p<0.001) and sadness or anxiety resulting from the 
illness (prominence: urban=1.363, rural=1.136, p=0.004). More rural 
respondents emphasised physical symptoms such as chills (p=0.001), nasal 
congestion (p<0.001) and breathlessness (p=0.024).  
 
In the overall sample, worry (“tension”) was most frequently reported (11.7% of 
sample) as most troubling among all physical symptoms and social or financial 
problems from the illness. This was followed by concern about course of illness 
(8.5%), loss of income (6.7%), costs from transport, food and drugs (6.2%) and 
interference with social relations (5.7%). The most troubling physical symptoms 
were identified as cough (5.7%) and fever (5.5%). No urban-rural differences 
were present in these findings. 
4.3.5 Perceived causes 
The two most prominent perceived causes, improper sanitation, dirty 
environment and cough or sneeze of an infected person (airborne transmission) 
were reported with greater prominence among urban respondents (figure 4-1). 
Explanations for a dirty environment were similar among all respondents and 
included references to accumulated filth, poor drainage, open gutters and 
sewage, open defecation and a general lack of cleanliness in surroundings. 
Narratives regarding airborne transmission largely referred to breathing in germs 
or droplets from another person’s cough or sputum. However, details were 
elaborated with reference to other categories by some. For example, “The germs 
could enter your body through inhalation while interacting with an infected person. The 
germs may spread through the air due to sneeze or cough. It also may have been 
caused due to mosquito bite, exposure to mosquitoes or infected tissue paper present on 
garbage containers.” (Man, 48 years, urban). No urban-rural differences were 
present for insect bite - the third most prominently reported cause. Mosquitoes 
were the most commonly mentioned insect vector.  
Cultural epidemiology of pandemic influenza in Pune   
 
54 
 
Drinking contaminated water ranked third in prominence in the rural group and 
ninth in the urban group. Most urban respondents attributed this cause to germs 
or dirt in the water. In the rural sites, however, in addition to this explanation, 
another theme emerged referring to a change in drinking water. This did not 
refer to contaminants in the water; it had to do with merely drinking water in 
different places. The narrative of a 35-year-old rural woman illustrates this 
theme: “This illness is also caused due to the water, the drinking water… Say we go to a 
particular village, and drink the water there, and then we go to another village and drink 
the water over there, some people cannot tolerate the change. Then we catch a cold 
because of drinking water of different villages.” The perception of a change in water 
as a cause was reported by approximately 35% of rural, but less than 1% of 
urban respondents who identified drinking water as a perceived cause.  
 
More rural than urban respondents reported climate or weather as a perceived 
cause and a few themes underlay its meaning. A majority referred to a change 
in weather or fluctuations in temperature, as in the following narrative, “Look at 
this climate. It happens due to such air, such climate. The climate varies between cold 
and hot. Sometimes it is hot while sometimes it is cold. This illness is related to the 
climate hence occurs due to it” (65-year-old rural man). Others attributed the 
illness to getting wet in the rain or being exposed to cold weather. Exposure to 
sunny weather was also reported as a cause, but mainly by rural respondents.  
 
“Tension” was reported as a perceived cause by 44.6%, with greater rural 
prominence. The term appeared self-explanatory to most and it was often 
indicated as a cause without further elaboration. When explained, respondents 
referred to mental worries caused by household and economic pressures leading 
to illness. A 63-year-old woman elaborated, “It happens because of worrying; worry 
could be due to household matters, tension or a difficult financial condition. If nobody is 
earning or family members are not getting along well with each other, then the person 
feels dejected and gets the illness.”   
 
Heat or cold in the body was reported with higher prominence at the rural sites, 
but explained in similar ways in both urban and rural areas. This cause referred 
to cultural ideas about humoral imbalances leading to illness as a result of 
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consuming foods that are sour, cold, cold-producing (e.g., yoghurt, cucumber), 
heat-producing (e.g., chicken, heavily-spiced food), unsuitable (e.g., guava) or 
oily. Other cultural or supernatural causes such as ‘violation of taboo’, ‘god, fate, 
karma’, ‘evil eye, sorcery’, and causes related to addiction (alcohol, tobacco, 
contraband drugs) were also emphasised by more rural than urban respondents.  
 
Figure 4-1: Perceived causes 
Spon: percentage of respondents who identified the category spontaneously (value=2). Prob: 
percentage of respondents who identified the category on probing (value=1). Most important: 
percentage of respondents who identified the category as most important among all others 
(value=3). Prom: mean prominence scores calculated for each site. Wilcoxon test used to compare 
prominence scores between sites. *p≤0.05, **p≤0.01, ***p≤0.001.  
4.3.6 Help-seeking 
4.3.6.1 Home-based treatment 
Rural respondents had a higher prominence than urban for prayer among home-
based treatments (figure 4-2). Drinking warm liquids and gargling, measures 
more directly related to alleviation of symptoms, however, had greater 
prominence among urban respondents. The value of prayer was seldom 
mentioned spontaneously at either site, but was reported by 61% on probing 
and highlighted as most important by 13.1% of all respondents.   
 
Herbal remedies were the most prominent category in the overall sample. 
Accounts included frequent mention of kadha - an herbal concoction brewed at 
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home. The second and third most prominently reported categories were doing 
nothing and feeding the patient with strength-providing food. Respondents, who 
suggested no home treatment, typically emphasised the priority of rushing the 
patient to hospital as quickly as possible.   
4.3.6.2 Help-seeking outside the home 
Government and private health facilities, and informal help were widely reported 
outside sources of help seeking (figure 4-2). More urban respondents than rural 
emphasised the value of government hospitals. Narrative accounts indicated that 
this preference among urban respondents tended to be specifically for treating 
swine flu. Rural respondents, however, emphasised the value of private facilities, 
even though they were acknowledged to be more expensive and hence not 
always feasible. Narrative data indicated a general preference in both groups for 
private over government health facilities, inasmuch as they were perceived to be 
more easily accessible, less crowded with shorter waiting times, and to offer 
better treatment and quality of care.  
 
Significantly more rural respondents reported relying on local health workers, 
informal help from friends, neighbours or relatives, traditional healers and faith 
healers. Although few spontaneously reported visiting a traditional healer (vaidu, 
jadibooti wala) or a faith healer, probing revealed that 37.8% and 30.7%, 
respectively, of all respondents, were likely to. This was usually after visiting an 
allopathic centre, and if the treatment was ineffective or services inadequate. 
The order of preference for outside treatment was explained succinctly by a 42-
year-old rural man, “If there is no other option [owing to financial constraints] then he 
would go to a doctor in the government hospital. If nothing happens there he would go 
to a private doctor. If there again he feels that nothing is happening, he would then go 
to the religious leader, bhagat (faith healer) and so on.” 
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Figure 4-2: Help seeking 
Spon: percentage of respondents who identified the category spontaneously (value=2). Prob: 
percentage of respondents who identified the category on probing (value=1). Most important: 
percentage of respondents who identified the category as most important among all others 
(value=3). Prom: mean prominence scores calculated for each site. Wilcoxon test used to compare 
prominence scores between sites. *p≤0.05, **p≤0.01, ***p≤0.001. 
 
4.3.7 Methods of prevention 
For prevention, more urban respondents emphasised the value of wearing masks, 
and more rural respondents suggested doing nothing, because the future was 
unpredictable. More rural respondents emphasised the value of ritual purification 
(agnihotra or dhoop - a Hindu religious process of purifying the atmosphere with 
smoke from a specially prepared fire) or protection from supernatural influence, 
although both were among categories with lowest prominence.  
 
Among overall community ideas about preventing the illness, cleanliness had the 
highest prominence, followed by a wholesome lifestyle – which referred to a 
proper diet and exercise – and then vaccines (figure 4-3). Cleanliness referred to 
both personal hygiene as well as cleanliness of the home and surroundings. 
Contradictory explanations were provided in the urban and rural areas for 
physical exercise in illness prevention. Rural respondents emphasised a need to 
avoid over-exertion from excessive work and exposure to the sun, but urban 
respondents highlighted the value of regular exercise. Vaccines were mentioned 
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spontaneously by only 2.5% of respondents, but 89.4% acknowledged its value 
when probed. Hand washing was seldom mentioned spontaneously or identified 
as most important and ranked tenth in prominence among all prevention 
categories. Minimizing exposure to infection and using masks ranked fifth and 
sixth in prominence, respectively.  
 
Figure 4-3: Prevention 
Spon: percentage of respondents who identified the category spontaneously (value=2). Prob: 
percentage of respondents who identified the category on probing (value=1). Most important: 
percentage of respondents who identified the category as most important among all others 
(value=3). Prom: mean prominence scores calculated for each site. Wilcoxon test used to compare 
prominence scores between sites. *p≤0.05, **p≤0.01, ***p≤0.001. 
4.3.8 Experience with swine flu 
Of the 436 persons interviewed, three reported a personal history of swine flu 
during the 2009 pandemic, and four a family history in the household. Three in-
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depth interviews each at the urban and rural sites were conducted among these 
persons. 
 
In-depth interviews elaborated a typical course of first help seeking at private 
clinics and a period without adequate treatment before referral to a larger 
hospital, if they were referred at all. After four days of medication had failed to 
alleviate symptoms for two of the urban patients, the private-clinic doctor 
recommended the government-run Naidu hospital; the third urban respondent 
visited that hospital of her own accord, and all three acknowledged receiving 
free treatment at the Naidu hospital. Only one rural respondent was referred to 
a government-run hospital, and that referral came only after 8 days of injections 
and medication at the private facility. This respondent reported spending INR 
25,000–30,000 (approximately USD 600) at the private hospital, compared with 
free treatment at the government hospital. The other two rural respondents 
were referred to private hospitals. One of them was transferred to three different 
private health facilities before receiving antiviral treatment and reported 
spending INR 500,000 (USD 10,000) on hospital bills, and the other spent 12 
days in an intensive care unit, which cost her INR 90,000 (USD 1,900).  
 
Only two of the six respondents provided a valid biomedical explanation for the 
cause of their swine flu, saying they caught it from other infected persons. 
Perceived causes reported by the others were getting wet in the rain, addiction 
to smokeless tobacco, air pollution, eating cold foods and mosquito bite.  
4.4 Discussion 
This is the first study to examine community-reported experience, meaning and 
behaviour of pandemic influenza in India using a cultural epidemiological 
approach. Taking community perceptions into account enables planning that is 
more responsive to local needs and thereby strengthens trust, authority and 
effectiveness of public health action19. Most studies evaluating pandemic 
influenza in India have focussed on the burden and clinical response8 20-24. A few 
have considered knowledge, attitudes and practices25 26. The scope of interest 
and methods have been limited in their ability to consider and compare the 
priority of community ideas based on how they are reported and what they 
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mean to respondents. Our approach benefits from a design integrating 
quantitative and qualitative methods for community study.  
4.4.1 Improving awareness in general and influenza recognition 
The vast majority of respondents were aware of pandemic influenza and 
considered it a serious illness that required treatment. Although 90% knew 
about the illness called swine flu, only 26% identified it from the characteristic 
symptoms (sore throat, cough, runny nose, body ache, fatigue and constant 
high fever) and setting described in the vignette. Confusion and conflation with 
other diseases were notable. Despite the priority of treatment during the 
pandemic outbreak, problems in community identification of risk associated with 
non-specific symptoms and poor awareness may have compromised timely, 
appropriate help seeking, diagnosis and treatment. In addition to general 
awareness, more attention to characteristic presentations, rather than just the 
name of the pandemic disease, appears warranted. Although common symptoms 
associated with laboratory-confirmed 2009 H1N1 influenza among patients 
diagnosed at hospitals in India – fever20 27 and cough27 – were the most troubling 
physical symptoms identified by our study respondents, they did not necessarily 
relate these symptoms to pandemic influenza in a characteristic case 
presentation. 
 
Although awareness of biomedically relevant airborne transmission of the illness 
was widely recognized, other causes were also identified, even by respondents 
with a history of pandemic influenza. This finding is consistent with another 
study in India that found high-school students referred to transmission of swine 
flu through food, water and mosquito bite26. Pluralism in the attribution of 
causes was notable in our study, including psychosomatic ideas about the role of 
tension and cultural ideas about the impact of humoral imbalances in the body 
resulting from effects of certain foods (referring to the cultural physiology rooted 
in concepts of Ayurveda28), that co-exist among various environmental, social 
and ingestion-related ones. 
4.4.2 Interventions for control  
Pandemic influenza control relies on prevention through vaccination, limiting 
exposure by promoting hand washing and minimising social contact. Timely 
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treatment with supportive care and antivirals also are important response 
measures29-31. 
 
Priority for vaccination and promoting awareness of non-pharmaceutical 
interventions  
Vaccination is a critical measure for influenza control to prevent spread of the 
virus and mitigate the impact of the disease10 30. Community recognition of 
vaccination, which was seldom reported spontaneously, was acknowledged by 
most respondents, but with relatively lower priority than cleanliness and lifestyle. 
A community-based study in Rajasthan, using self-administered questionnaires, 
found herbal treatment had been reported as least effective and vaccines as 
most effective for prevention of swine flu25. Inasmuch as our study asked about 
an illness described in a vignette, rather than a named disease, it was a different 
approach. While our findings suggest a priority for  vaccination based on the 
influence of ideas about perceived risk 32, further study of anticipated acceptance 
and actual uptake of vaccines for pandemic influenza in Pune is needed. 
 
Hand washing is an important component of the public health response to 
influenza, although compliance may be difficult to motivate; effects are modest 
but enhanced in combination with face masks33. These measures are especially 
important before a vaccine is developed for a specific strain of pandemic 
influenza. India’s pandemic preparedness and response plan for influenza control 
acknowledges the role of hand washing, social distancing and using masks as 
recommended non-pharmaceutical interventions34. Our study respondents 
prioritised other non-pharmaceutical forms of prevention (e.g., wholesome 
lifestyle and health education) for the illness described in the vignette. 
Respondents’ emphasis on a wholesome lifestyle may stem from messages 
disseminated to communities during the pandemic35, and additional efforts may 
be needed to promote community awareness and hand hygiene behaviour. 
Although they were acknowledged in rural areas, face masks were less of a 
priority and hence less likely to be used than in urban areas. In any case, 
promoting non-pharmaceutical interventions appears to be complementary and 
may enhance vaccination uptake36. 
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Medical care and treatment delay  
Timely help seeking, supportive care and admission in intensive care units when 
indicated are critical determinants of survival for patients with serious disease at 
risk of respiratory failure37. Treatment delay of more than two days with 
antivirals after onset of symptoms has been associated with increased risk of 
death38 39, although recent reviews question the role of antivirals for pandemic 
influenza control40 41. During the 2009 pandemic in India, intensive care units or 
ventilators were not available at all hospitals42 and antivirals were made 
available mainly through the public health system34. Treatment at government 
hospitals or private hospitals with adequate facilities enables quicker access to 
critical care. In our study, in-depth interview elaboration of illness experience for 
both urban and rural respondents with a history of pandemic influenza was 
consistent. They had all first consulted a private general practitioner (GP) 
without improvement in their condition. For these patients, the minimum time 
lag between first help-seeking at a private facility and referral to a larger 
hospital was four days. Problematic delay in hospital admission has also been 
noted in other studies27. Our data suggest that lack of awareness on the 
importance of adequate facilities for treating pandemic influenza, lack of access 
to such larger hospitals, poor perception of government health facilities, 
compared with private (reported in other studies too43-45), and delayed referrals 
by private GPs may all lead to delayed treatment, especially for rural 
respondents. 
 
As a component of the strategy for pandemic disease control, treatment delays 
may be avoided by a) sensitising the public to the capacity of government 
facilities for treating pandemic influenza, b) improving access to healthcare in 
rural areas c) reshaping public perception of the quality of government health 
facilities and d) training private GPs to identify and quickly refer potential 
influenza cases to hospitals with required treatment facilities.  
4.4.3 Urban-rural differences 
Analysis of illness experience showed that urban respondents were relatively 
more attentive to psychosocial symptoms, and rural respondents were more 
likely to emphasise somatic symptoms of illness. Reliance on the labour-
intensive basis of their agricultural livelihood may explain that. Rural 
Cultural epidemiology of pandemic influenza in Pune   
 
63 
respondents were also more likely to prioritize environmental causes (climate), 
limited resources (contaminated food and drinking water) and addictive 
behaviours. Rural respondents placed relatively more value in traditional cultural 
responses, both prayer as a home-based response and magico-religious 
protective measures for prevention. They were also more likely to acknowledge 
the futility of attempting to prevent the illness. Urban respondents focussed 
relatively more on measures to alleviate symptoms. The value of a face mask 
also had higher prominence in the urban areas.  
 
Less overall awareness at rural sites may be explained in part by the lower 
disease burden9 and reduced exposure to media in rural areas of Pune during 
the 2009 pandemic. Rural areas, however, were also affected by rapid spread 
and mortality as the pandemic progressed46. The challenge is especially clear in 
rural areas to improve awareness of pandemic influenza, including its causation, 
transmission, prevention and timely appropriate help-seeking. At the urban sites, 
where pandemic influenza-specific knowledge was more apparent, the need to 
improve awareness and recognition of cases nevertheless also remains 
challenging.  
4.4.4 Limitations 
Data collection commenced two years after the officially-declared end of the 
pandemic in 201047 and recall bias among respondents is a potential limitation of 
this study. However, extensive media coverage of “swine flu” in Pune during that 
period and persisting subsequently48 49 is likely to have maintained public 
memory of the illness. We also recognize the high refusal rate, particularly in the 
urban community, as a limitation. Refusals were carefully noted enabling us to 
document this problem. Although nonparticipation is increasingly problematic for 
community epidemiological responses, nonparticipation is not necessarily 
equivalent to nonparticipation bias50. Nevertheless, findings must be regarded as 
suggestive rather than conclusive. Meetings with local leaders in rural areas, 
prior to data collection, were intended to enlist cooperation. This was not 
possible at the urban site. Plans for community and professional dissemination of 
research findings aimed to highlight the value of the study for respondents and 
thereby motivate their participation.  
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Findings should be considered with reference to both historical context—
reflecting social changes and epidemics—and with reference to regional contexts 
across India and in other countries. Generalisation from the EMIC survey 
component of the study is therefore appropriate with reference to similar 
sociocultural settings, acknowledging differences elsewhere. Nevertheless, we 
expect the approach and methods for study of sociocultural features reported 
here to be generalizable and appropriate for consideration where cultural 
differences indicate the relevance of cross-site differences and the value of 
comparative study. Complementary qualitative elaboration, which may not be 
generalizable in other settings, provides locally relevant detail for health services. 
4.4.5 Conclusion 
Comparison of sociocultural features of urban and rural communities has 
identified common needs to better distinguish recognition of the illness from 
names of the condition and particular challenges of access, especially in rural  
areas. Consideration of community ideas and experience should guide effective 
planning for pandemic preparedness. The integrated cultural epidemiological 
approach enhanced by complementary qualitative in-depth interviews indicates a 
way to proceed. The value of such findings should be enhanced by community 
dissemination and to health policymakers. 
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Abstract 
Vaccination is a cornerstone of influenza prevention, but limited vaccine uptake 
was a problem worldwide during the 2009-2010 pandemic. Community 
acceptance of a vaccine is a critical determinant of its effectiveness, but studies 
have been confined to high-income countries. We conducted a cross-sectional, 
mixed-method study in urban and rural Pune, India in 2012-2013. Semi-
structured explanatory model interviews were administered to community 
residents (n=436) to study awareness, experience and preference between 
available vaccines for pandemic influenza. Focus group discussions and in-depth 
interviews complemented the survey. Awareness of pandemic influenza vaccines 
was low (25%). Some respondents did not consider vaccines relevant for adults, 
but nearly all (94.7%), when asked, believed that a vaccine would prevent swine 
flu. Reported vaccine uptake however was 8.3%. Main themes identified as 
reasons for uptake were having heard of a death from swine flu, health care 
provider recommendation or affiliation with the health system, influence of peers 
and information from media. Reasons for non-use were low perceived personal 
risk, problems with access and cost, inadequate information and a perceived lack 
of a government mandate endorsing influenza vaccines. A majority indicated a 
preference for injectable over nasal vaccines, especially in remote rural areas. 
Hesitancy from a lack of confidence in pandemic influenza vaccines appears to 
have been less of an issue than access, complacency and other sociocultural 
considerations. Recent influenza outbreaks in 2015 highlight a need to 
reconsider policy for routine influenza vaccination while paying attention to 
sociocultural factors and community preferences for effective vaccine action.  
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5.1 Introduction 
Vaccination is a critical tool for controlling influenza. When faced with a 
pandemic, swift deployment of vaccines is crucial to limiting spread of the 
disease before the virus acquires increased pathogenicity or antiviral resistance.1 
On 11 June 2009, the World Health Organization (WHO) declared a global 
influenza pandemic caused by a novel influenza A (H1N1) virus.2 Efforts were 
made to ensure adequate supply of vaccines. Yet, lower-than-anticipated uptake 
of the vaccine was a notable problem, even among high risk groups.3-7 Studies 
exploring vaccine hesitancy and reasons for poor uptake that limit effectiveness 
of a pandemic response have been largely restricted to high-income settings.8-11 
Despite acknowledged cross-cultural differences in public response to pandemic 
influenza and need for country-specific studies,12,13 few have been conducted in 
lower income settings.  
 
A large burden of 2009 H1N1 influenza was borne by low-income countries.14,15 
India reported 39,977 cases and 2,113 deaths from H1N1 influenza between 
May 2009 and August 2010.16 These numbers, which refer to laboratory-
confirmed cases, are likely underestimated. The city of Pune, which suffered high 
morbidity and mortality,17-19 is incidentally home to a large vaccine manufacturer, 
Serum Institute of India Ltd. Inactivated influenza vaccine (IIV, injectable 
administration) and live attenuated influenza vaccine (LAIV, nasal administration) 
were available for public purchase in Pune during the 2009 pandemic.20 While 
IIVs alone are licensed for certain groups (children under 2 years, persons 50 
years and above and pregnant women), both types of vaccines are considered 
efficacious and safe for the larger population.21-27  
 
Demand for vaccines varied widely in India. In some cases, influenza vaccines 
were eagerly sought28,29 but at other times there were few takers.30,31 This 
variability highlights the importance of understanding community acceptance 
and facilitators and barriers for vaccine uptake. Although nasally administered 
LAIV is generally considered less invasive than IIV by health professionals, and it 
was available at a lower cost than IIVs in Pune, it is nonetheless a relatively new 
form of vaccine administration in India and questions arise about its community 
acceptability for influenza vaccination.  Addressing questions about community 
preferences for one or other vaccine is likely to contribute to our understanding 
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of vaccine hesitancy or confidence in their sociocultural context, which are 
critical determinants of effective influenza vaccine action.   
 
Acknowledging sociocultural differences and differences in access to health 
services in urban and rural communities, we conducted a mixed-method study in 
low-resource and middle-income urban areas, and in accessible and remote rural 
areas of Pune, India.32 The first part of the study exploring community 
understanding and experience of pandemic influenza has recently been 
reported.33 In this paper, we focus on the community-perceived role of vaccines 
with the objectives of (a) determining community awareness and views of 
pandemic influenza vaccination, (b) analysing experience and reasons for 
vaccination or non-vaccination against H1N1 influenza during the 2009 pandemic 
and (c) clarifying community perceptions and preferences for either injectable or 
nasal influenza vaccines. A review of experience and community perceptions of 
vaccines for pandemic influenza in India provides a unique opportunity to inform 
planning for other immunization initiatives and recurring influenza outbreaks.  
5.2 Results 
5.2.1 Sample characteristics 
Focus groups discussions (FGDs) were conducted in July 2012, semi-structured 
interviews (SSIs) from August to December 2012 and in-depth interviews (IDIs) 
between March and April 2013. Five FGDs (each with 5-6 participants), 12 IDIs 
and 436 SSIs have been analysed (Table 5-1). Among SSI respondents, those 
from the urban sites had received more education and had higher incomes; 
more details have been reported elsewhere.33 
5.2.2 Awareness of vaccines: in general and for pandemic influenza 
Awareness of the role of vaccines in preventing illnesses was noted: “A vaccine is 
given for prevention of an illness which we may get in the future” (man, rural FGD). 
However, confusion about the preventive versus curative aspect of vaccines was 
also noted among some respondents. For example, a 65-year-old rural woman 
stated: “[By taking the vaccine] the illness could have been prevented and she would 
have got cured” (SSI).  
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Vaccines were sometimes distinguished by their mode of delivery. “It is an 
injection and it has medicine in it” (27 years, rural woman, IDI). They were also 
explained by terms appropriate for other vaccines that respondents were familiar 
with. A woman during a FGD in a rural area explained her idea of a vaccine by 
stating: “We call it dose - triple, polio”. 
 
Some respondents thought vaccines were relevant only for children and 
expressed concern about their use for adults. “All children are vaccinated. But adults 
are not vaccinated. I think the vaccine is effective for ages 1 to 5. We don’t have 
experience with vaccines being effective at later ages” (man, rural FGD). 
 
Over a quarter of respondents said they were aware of a vaccine administered 
as a nasal spray for swine flu (Table 5-2). There was a significant difference in 
awareness based on age group (the younger age group of 18-45 years had 
higher awareness than the older age group of 46-65 years) and area of 
residence, with highest awareness in the urban middle-income area (47.1%) and 
lowest in the rural remote area (8.3%). Slightly fewer respondents (23.4%) 
reported awareness of an injectable vaccine to prevent swine flu. 
 
When respondents were asked whether they had received advice regarding 
vaccines for swine flu from their health care providers, 15.8% of respondents 
reported that they had (Table 5-2). A larger percentage of these respondents 
were from the younger age group and from the urban sites. 
5.2.3 Views on benefits and problems with pandemic influenza vaccines 
Respondents were asked whether they thought a vaccine could have prevented 
swine flu. Most (94.7%) said yes, and significantly more who said yes were from 
the younger age group (97.3%) compared to the older age group (92.0%, 
p=0.017).  
 
An analysis of narratives indicated confidence and trust in vaccines by a large 
percentage of respondents. A 47-year-old man who was confident of the benefits 
of a pandemic influenza vaccine stated: “[If he had taken the vaccine] he would 
have been protected. Swine flu can happen only to those who have not taken the 
vaccine” (rural SSI). A few raised concerns about the efficacy of pandemic 
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influenza vaccines, while maintaining their support of vaccines in general. For 
example, an urban woman said: 
“Getting vaccinated is definitely a good thing but I am not sure whether this vaccine is a 
proven one like other vaccines. I knew 100 percent about the vaccines that were given 
in early times but is there any data available for this new vaccine which proves that 
those who have taken it have not got swine flu? If someone asks me to take it, I won’t 
deny. I would believe in it and would go for it” (45 years, SSI).  
 
Some who thought reported vaccines were helpful nevertheless had a fatalistic 
attitude towards the illness that did not preclude the vaccine. A 57-year-old 
urban woman explained: “The illness will happen anyhow if it has to happen but there 
is no harm in taking the vaccine” (SSI). 
 
Others, however, suggested that destiny made any precaution including vaccines 
irrelevant: “It will happen if it is destined to happen even if she maintains cleanliness or 
takes any other precaution” (56 yr, woman, rural SSI). Very few distrusted the 
vaccine itself or had serious safety concerns.  
 
Respondents were also specifically asked whether they knew of any problems 
with either the nasal or injectable pandemic influenza vaccines. Almost half 
(48.2%) said that nasal vaccines did not cause any problems and a majority 
(56.7%) said the same about injectable vaccines. Men were more likely than 
women to say there was no problem with pandemic influenza vaccines, and that 
perception was applicable to both nasal (57.7% men, 38.9% women, p<0.001) 
and injectable (65.1% men, 48.4% women, p<0.001) vaccines. A third of 
respondents were unable to say whether nasal or injectable vaccines caused any 
problems. The main anticipated problems for the nasal vaccine were discomfort 
or irritation in the nose and throat (12.8%) and runny nose or sneezing (4.4%). 
For injectable vaccines, identified problems included pain or swelling (8.9%) and 
fever or chills (3.7%). Only one person anticipated a serious adverse effect of 
the vaccines, and this person who lived in the urban low-resource area, said 
death might result from receiving the vaccine.   
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5.2.4 Experience with pandemic influenza vaccines 
Of the 436 SSI respondents, 8.3% reported having personally received a 
pandemic influenza vaccine and 10.6% said someone else in their household had 
taken it (Table 5-2). The urban middle-income area had the highest proportion 
of vaccine acceptors, while the remote rural area had the lowest proportion. The 
more accessible rural area had more vaccine acceptors than the low-resource 
urban area. 
5.2.5 Reasons for vaccine use 
Narratives of those who had indicated household experience with the pandemic 
influenza vaccine (either personal use or someone else in the household who 
received it), were analysed to identify key reasons for vaccine uptake. Salience, 
social and medical influences, and the influence of media were discussed.  
 
Salience of pandemic influenza: exposure to serious a swine flu-related illness or 
death  
The decision to vaccinate for pandemic influenza was strongly motivated by 
having seen someone suffer from the illness or having heard of a death from 
swine flu. A 31-year-old urban woman explained: “My sister's colleague's son 
suffered from it. He is alive but his friend who used to play with him died. When I heard 
about this, I became seriously concerned and I vaccinated my son” (IDI). A rural 
woman who had taken the vaccine explained that fear drove her to action after a 
pregnant woman in her village had died from swine flu: 
 “After one lady died and my son had swine flu, everyone was scared. They felt that if 
this continues, everyone in the village would die. Nobody from the government came 
here so members of a youth group called a private doctor so that our villagers would get 
the vaccine” (45 years, IDI).  
 
She also recounted her experience at the hospital while caring for her son with 
suspected swine flu illness as follows:  
“I observed that when a person was admitted with breathlessness, that person would die 
immediately. Yes, I have seen such people in Sassoon hospital. Once the person was 
taken inside the ICU, only their dead body would come out. People were therefore 
preoccupied with fear.” 
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Social influence 
Conduct of free vaccination camps in one’s neighbourhood or at school were 
reported as reasons for taking the vaccine. In a village where a vaccination 
camp was conducted, peer effects seemed to motivate vaccine uptake. A 45-
year-old rural woman explained: “Everyone in the village took the vaccine, so I also 
took it to prevent anything before it happens” (IDI).  
 
Medical influence  
Recommendation by a health care provider in the family influenced vaccine 
uptake for some. An urban woman explained her reasons for taking the vaccine 
as follows: “The epidemic was at a peak and my nephew is a doctor. He was giving the 
vaccine to his friends and relatives. He is our close relative and we trust that he will not 
cheat us.” (65 yr, IDI). Other connections with the health system, such as working 
in a hospital, also influenced vaccine uptake. An urban woman said: “I took the 
vaccine. I work as a security guard in a private hospital. It was given free of cost in our 
hospital. (33 yr, SSI) 
 
Influence of media 
Information from media reports was an important factor for people who actively 
sought the vaccine. An urban man explained: “When I read the newspapers, I 
understood its seriousness, and thought that I should not waste time and therefore took 
the vaccine immediately” (64 yr, IDI). But they acknowledged the importance of 
information on where they could get vaccinated from pamphlets from provided 
by the Pune Municipal Corporation or volunteers who came door-to-door. 
However, it was often noted that while the media was a useful source of 
information, doctors were consulted before taking the vaccine: “The media was 
discussing availability of vaccines. But we didn’t rely on the media, we always consulted 
doctors” (37 yr, urban IDI). 
5.2.6 Reasons for vaccine non-use 
When SSI-respondents were asked why they or anyone in their household had 
not taken the vaccine for swine flu, several common reasons were reported 
(Table 5-3). 
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Low perceived risk  
A majority (55.0%) indicated low risk attributed to influenza or a sense that they 
were not personally at risk. Men were more likely to say that than women. 
Common accounts referred to the following points: First, if there were no cases 
of swine flu in the respondent’s neighbourhood, a vaccine seemed unnecessary. 
In the urban areas, this was explained largely in terms of a lack of observable 
symptomatic cases in the neighbourhood: “If somebody from our housing society 
gets swine flu, then I would go and take it. If there are no such cases around, then why 
should I take the vaccine?” (57 yr, urban woman, IDI). Similar explanations were 
noted in the rural area, but complemented by assertions that swine flu was an 
urban problem that had not reached rural areas. A readily apparent epidemic 
was required to convince people of the salience of the illness. A man articulated 
this sentiment metaphorically: “Suppose, there is a violent and rampant dog biting 
everyone, only then will a concerted effort be made to kill him. Similarly, in the absence 
of an epidemic, people will not take the vaccine.” (rural FGD). Second, the 
respondent’s idea that personal strength and good health would confer 
protection from illness was mainly reported by men. For example: “We don’t need 
the vaccine. I am physically fit, I am a sportsman; mostly we won’t get it” (26 yr, rural 
man, SSI). Women frequently referred to reduced chances of contracting the 
illness because they stayed at home: “Men are exposed to the outside, but we are 
always at home, hence we do not consider ourselves at risk of catching the illness” (27 
yr, urban woman, SSI). Faith in God as a basis for perceived protection was also 
mentioned. “We believe in our god. We believed that we won’t ever get swine flu, and 
we haven’t” (35 yr, urban man, SSI). Lastly a low priority for prevention, due to 
confidence in effective treatment was also noted: “When there are illnesses in the 
rural areas, then a cure is made available there. Nobody takes prior care” (25 yr, rural 
woman, SSI).  
 
Other preventive measures make vaccines unnecessary 
Adequacy of other preventive measures apart from vaccines was reported by 
15.8% as a reason for not taking the vaccine, more so by urban than rural 
respondents (p<0.001). Widely mentioned alternative preventive measures 
included the use of face masks (often referred to tying a handkerchief around 
the nose and mouth), maintaining personal hygiene, keeping surroundings clean 
and avoiding crowds.  Some also referred to the use of preventive drugs, 
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specifically mentioning antiviral drugs: “We did not feel the need to take it since 
there were other things like masks and Tamiflu” (24 yr, urban man, SSI). A few also 
mentioned herbal preventive measures: “We used prevention measures – wearing a 
mask, using camphor and nilgiri [eucalyptus] oil. So, we did not feel the need to take the 
vaccine” (33 yr, urban man, SSI).There was also infrequent mention of chanting of 
prayer and ritual purification (‘agnihotra’). 
 
Lack of information about the vaccine 
Some (11.7%) respondents were unaware of the existence of a vaccine against 
pandemic influenza. The largest proportion of such respondents was from the 
rural remote area, followed by the urban low-resource area and the lowest 
proportion was from the urban middle-income area. A rural woman explained: 
“Two years ago when there was an outbreak of swine flu, we were not even aware that 
there was a vaccine for swine flu” (28 yr, SSI).  This reason was often mentioned in 
combination with problematic access, i.e., not knowing where to obtain the 
vaccine.  
 
Problems with access and cost 
Difficulties relating to obtaining the pandemic influenza vaccine were noted by 
14.7% of SSI respondents, with significantly more from rural than urban areas. 
The most frequently mentioned problem was that the vaccine was not delivered 
to the respondents’ neighbourhoods. Rural respondents expected that important 
interventions would be delivered by government health workers. They were not 
sure how or where to get a vaccine if it was not brought to their villages. A rural 
woman explained why she did not take the vaccine as follows: “The most 
important reason was that the vaccine did not come here, and we do not know where to 
go and get it” (35 yr, SSI). Another problem for accessing the vaccine was not 
having a clinic nearby. A few respondents also noted the vaccine was available 
only for children and not adults. A 22-year-old woman who also drew a parallel 
with polio vaccine campaigns said: “It hasn’t come here yet. For children up to 5 
years they come to give the polio vaccine. For swine flu also they came here to vaccinate 
children but not adults” (urban SSI). 
 
A few noted unavailability of the vaccine during the pandemic as a reason: 
“There was no vaccine at that time when the illness more widespread. The vaccine came 
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later” (46 yr, urban man, SSI). Nine respondents indicated that they wished to take 
the vaccine but were unable to do so as it was out of stock due to high demand. 
Seven respondents said they had no time to spare to go and get the vaccine. 
 
Financial constraints as a reason for not taking the vaccine were reported by 5%. 
Among these respondents, many stated that they would have taken it if the 
government had provided the vaccine for free or at a discounted price. 
 
Insufficient indication of vaccine priority 
Some respondents explained that health care providers, the government or 
people they knew had not clearly indicated the importance of vaccination or 
encouraged it. An urban woman stated: “No one forced me or urged me to take the 
vaccine. No one asked me to come along to take it. Had someone urged me, I would 
have taken it. Neither the doctor nor family members urged me” (57 yr, SSI). The lack 
of a mandate by the government for pandemic influenza vaccination was also 
indicated as a reason by some: “The government did not carry out any promotional 
activities and there was no compulsion by the government to take the vaccine” (62 years, 
rural man, RM223). 
 
Other concerns 
Four respondents expressed concerns about vaccine effectiveness; four indicated 
a general avoidance of medication, and one mentioned a fear of adverse 
reactions. No one indicated other concerns about the vaccine or type of 
administration as a reason for not having taken the vaccine. 
5.2.7 Preference for injectable or nasal vaccine 
Data indicate a strong preference for injectable over nasal vaccines. Twice as 
many respondents reported preference for an injectable vaccine and considered 
it safer (Table 5-4). Among those who considered a nasal vaccine safer, more 
were from the urban middle-income area, followed by the accessible rural area, 
the urban low resource and finally the rural remote area. When respondents 
were asked which vaccine they considered more powerful, 44.3% opted for the 
injectable and 32.6% for the nasal. Those who reported no specific preference 
for either vaccine referred to (a) a sense of urgency in obtaining whichever 
vaccine was available, (b) prioritizing convenience and getting the vaccine that 
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was most easily available, (c) the need to follow a doctor’s advice and to not 
question what the doctor recommends, or (d) lack of their own opinion due to 
lack of experience with this new illness. Main themes that emerged from the 
narrative data of SSIs and IDIs in explaining preference for either the injectable 
vaccine or the nasal vaccine are described in the next section, with narratives 
quoted in Table 5-5. 
5.2.7.1 Reasons for preferring an injectable vaccine  
Injectable vaccine considered more powerful than nasal one 
A commonly cited reason for preferring an injectable vaccine was that the 
vaccine would be directly absorbed in the blood and thus more effective. This 
account was frequently described in contrast to nasal vaccines, which were 
perceived as ineffective because they were likely to be expelled easily while 
breathing, and fail to reach all parts of the body. Ideas that injections work 
faster and had a longer duration of protection than nasal vaccines were also 
suggested to explain preferences. A few respondents said pain from an injection 
was an indication of its power. 
 
Fear of side effects from a nasal vaccine 
Many referred to fear of side effects from the nasal vaccine as a reason they 
preferred the injectable one. The numerous perceived side effects from nasal 
vaccines that were mentioned included irritation in the throat, burning sensation 
in the eyes, sneezing, pain in the nose, vomiting, breathlessness, a tingling 
sensation or numbness in the head, a bitter taste in the mouth and general 
discomfort. Others, who were unable to identify specific side effects, referred 
merely to being unable to tolerate a nasal vaccine.  
 
Experience and familiarity with injections 
Past experience and familiarity with injections compared to a relatively new 
nasal vaccine was another major reason for preferring injectable vaccines. Many 
respondents had an implicit trust in injections. Conversely, absence of familiarity 
and fear of relatively unknown nasal vaccines were frequently reported as 
reasons for preferring injectable vaccines.  
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Favourable attitude towards injections and preference regardless of perceived 
efficacy  
A favourable attitude towards injections in general was observed and while this 
is linked to the theme of perceiving an injectable vaccine as powerful, it was 
qualitatively distinct in that injections were considered a panacea for all illnesses 
and the best form of administering any drug. A 65-year-old man explained: “Now 
suppose you want to take a vitamin supplement. You get it in the form of tablets, 
injections and liquid. But, of these, the injection spreads throughout the body” (urban 
SSI). On a similar note, a rural woman said: “Weakness reduces on administering 
the injection...one feels better after taking them” (47 yr, SSI). A few respondents 
reported preference for an injectable vaccine, despite their belief that nasal 
vaccines were more effective. 
5.2.7.2 Reasons for preferring a nasal vaccine 
Nasal vaccine considered more powerful than an injectable one 
Those who preferred a nasal vaccine believed in the superior power of nasal 
vaccines to reach all parts of the body through one’s breathing. Immediacy of 
effect was also noted. Administration through the nose was a perceived 
advantage because that was also the point of entry for germs causing swine flu. 
Some referred to physical sensations after receiving the vaccine as an indication 
of the vaccine doing its job. This was considered a desirable side effect of nasal 
vaccines. On a similar note, the idea that the nasal vaccine can spread to the 
brain was lauded as a measure of its powerfulness by a few who explained their 
preference for nasal vaccines. However, the same point was regarded as an 
adverse effect for those shunning the nasal vaccine. 
 
Safety concerns for injectable vaccines and fear of needles  
Some preferred a nasal vaccine due to concern about the safety of needles, 
which might have been previously used. This concern was noted only by urban 
respondents. Pain or swelling from an injection was a reason for preferring a 
nasal vaccine, but stated only by a few.  
5.3 Discussion 
Findings suggest trust in vaccines in general and for pandemic influenza vaccines 
in rural and urban communities of Pune district. A clear understanding of the 
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rationale, however, of vaccines designed primarily for healthy individuals to 
prevent disease was lacking. Many respondents suggested no need for a 
pandemic influenza in the absence of fever or symptoms. A news report in Pune 
during the pandemic exemplifies the misconception. A young man suffering from 
symptoms of influenza who purchased a LAIV from a pharmacy and had it 
administered in a hospital subsequently died.34 Some respondents thought 
vaccines were only relevant for children and irrelevant for adults. Data from 
rural Pune during and after the pandemic suggest that incidence of hospitalized 
H1N1 influenza was highest among 5-29 year olds.35 Both the epidemiology and 
our findings suggest the need for promoting awareness of the public and health 
care providers of the value of vaccination for adults, and awareness of 
contraindications and precautions for vaccination.21   
 
Awareness of the role of vaccines in preventing pandemic influenza was 
relatively low at 25%. A study in Bareilly, Uttar Pradesh, during the pandemic 
reported awareness of vaccines against swine flu among 47% of studied school 
students.36  Notwithstanding low awareness in our study, most respondents, 
when asked about pandemic influenza vaccines, reported them as potentially 
helpful in preventing swine flu. Problems or side effects of the vaccine were 
mostly localized and seldom reported as a barrier to vaccine uptake. This is 
unlike studies from other countries9,10,37 or studies in India among health care 
workers38,39 where perceived side effects from the vaccine were reported as a 
deterrent to influenza vaccination intention. Although for the majority a vaccine 
with fewer side effects was preferred, the finding that for some, a localized 
reaction or physical sensation after vaccination was an indicator of vaccine 
efficacy and hence desirable, was unique to our study. It is also interesting to 
note that some considered an injection as less invasive than a nasal vaccine. It 
was said that “one does not feel anything or one feels good” after taking an injection, 
while nasal vaccines were perceived to have many more potential side effects. 
Fear of injections was noted by just a few and concerns about re-use of needles 
for injectable vaccines were reported largely in the urban middle-income area. 
 
Study findings show a majority community preference for injectable compared to 
nasal vaccines. Excessive, often unnecessary use of injections has been 
documented in India40 and in other parts of Asia.41,42 The placebo effect offered 
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by injections has provided an argument for widely using injections in India and is 
often demanded by patients. A study by Greenhalgh43 in 1987 questioned blind 
faith in injections, and our findings suggest that these perceptions continue to 
hold true. While inactivated injectable vaccines are required for special groups, 
live-attenuated vaccines offer practical advantages for control of pandemics the 
general population in a country as highly populated as India. They are easier to 
administer and easier to produce larger quantities at lower cost.20 Our findings 
suggest lack of community familiarity, rather than confidence, with this relatively 
new form of vaccine administration. Respondents from the urban middle-income 
area were more aware of nasal vaccines and more likely to consider them as the 
safer vaccine. Thus, gaining public support is not likely to pose a problem if 
implemented with effective communication and engagement. The success of the 
oral polio vaccine campaign in India demonstrates good prospects for 
widespread public acceptance of this new form of vaccine administration. 
Paterson and Larson recommend public engagement by building trust and 
learning about public concerns to be addressed,44 and by communicating openly, 
honestly and proactively with the public and other stakeholders.45 Our study 
identified the following key concepts that study communities attributed to the 
vaccine they preferred, either nasal or injectable, that should be well-understood 
and convincing, namely, the: ability of the vaccine to spread to all parts of the 
body and immediacy of effect. Properties of the vaccine itself – whether it was 
live attenuated or inactivated – were never mentioned spontaneously or 
questioned by any respondents. It is likely not a distinction of practical 
significance for respondents.  
 
Findings suggest a blurring of urban-rural distinctions in the rapidly urbanizing 
Pune district. Notwithstanding highest awareness and vaccine uptake in the 
urban middle-income area, awareness of nasal influenza vaccines, belief in 
safety of nasal compared to injectable vaccines and use of pandemic influenza 
vaccine were reported by more respondents from the accessible rural area than 
from the low-resource urban area. The urban-rural dichotomy may be 
superseded by other factors with regard to vaccine policy and planning in such 
rapidly urbanizing settings46 where people in accessible rural areas may have 
higher incomes and better access to information than persons in urban slums. 
More men than women had confidence in the power of nasal vaccines and 
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anticipated no problems with pandemic influenza vaccines; yet they were also 
more likely to perceive a low risk for themselves in getting swine flu. Age-
specific differences in awareness of nasal vaccines and in the ability of vaccines 
to prevent influenza indicate a need to inform older segments of the population.  
The reported swine flu vaccine uptake rate was 8.3% in our study, but 
limitations in production and access may help explain the low figure. Vaccines 
were only available many months into the pandemic.47,48 There was no state-
wide initiative for mass vaccination in Maharashtra although the Pune Municipal 
Corporation provided vaccines without charge to health care workers towards 
the end of the pandemic.49 Furthermore, some hospitals and groups conducted 
their own vaccination camps. The nature of vaccine uptake varied. It was 
passive acceptance for some when the vaccine was made available in their 
neighbourhood, and active demand for others who made an effort to go and get 
it themselves.50 The Indian Medical Association and Indian Academy of Pediatrics 
officially recommended the pandemic influenza vaccine,51 but individuals had to 
purchase it privately. The public health dissemination strategy for 
communication information from the state about vaccine recommendations was 
unclear. The media played a major role in public communication, but this did not 
appear to be state-directed. Furthermore, the response to the pandemic by the 
state government seemed to focus on treatment with antivirals rather than 
preventive measures.    
 
The influence of salience of the illness from personal experience with cases or 
deaths in the neighbourhood was a powerful motivator for vaccine uptake in our 
study. A similar finding was reported by SteelFisher et al10 in a study done in the 
United States of America (USA). A study using self-administered questionnaires 
among health care workers in Pune noted “self-protection against illness” as the 
main reason for accepting H1N1 influenza vaccination.52 Inasmuch as we 
surveyed community residents, we were able to identify additional practical 
reasons for vaccine acceptance, such as health system affiliation, health care 
provider recommendation, influence of peers and media impact.  
 
A majority considered the illness as very serious or serious.33 Nevertheless, 
some who acknowledged the seriousness did not consider themselves to be 
personally at risk. According to the health belief model, without perceived 
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personal risk, considering an illness as serious may not translate into protective 
behaviour.53 Gendered explanations of perceived personal risk were notable. 
Men regarded themselves as too strong to catch the illness (a ‘man of steel’ 
perception) and women considered themselves at reduced risk from being 
homebound. The above findings on low risk perception for oneself along with the 
belief that it was an urban but not a rural problem, suggest an optimism bias54 
where people consider themselves unlikely to catch an illness that they consider 
serious for others.  
 
Access was a barrier because of community expectations that a vaccine, if 
relevant, would be delivered through a campaign in one’s neighbourhood. Such 
expectations may be a result of community experience with the vertical polio 
vaccination programme in India. A clear message from the government 
endorsing pandemic influenza vaccines, which the community indicated was 
lacking in the 2009 influenza pandemic, may promote vaccine uptake. Education 
of health care providers needs to ensure they make appropriate 
recommendations of vaccines. With respect to the SAGE Working Group 
framework of vaccine hesitancy, 55 our findings indicate that lack of confidence in 
pandemic influenza vaccines may not be a serious problem for uptake, but 
convenient access, complacency, and other sociocultural considerations take 
precedence.  
5.3.1 Dissemination activities 
Community engagement was central to the study design. On completion of data 
collection and analysis, insights and information gained from the study were 
disseminated back to urban and rural study communities. The information-
sharing and open dialogue was attended by community members and village and 
sub-district policy makers in November 2014. This was accompanied by a health 
education and awareness activity guided by study findings that community 
members had requested during data collection. Further technical details and 
implications for local policy were shared at a meeting that invited policy makers 
and public health professionals from Pune.  
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5.3.2 Strengths 
The need and value in engaging the public in vaccination initiatives has been 
well-established.44,56,57 Recently documented challenges of introducing new 
vaccines in India,58-60 highlight the importance of studies that focus on 
understanding community perceptions, underlying issues and contextual 
influences that may influence vaccine acceptance. To the best of our knowledge, 
our study is the first to explore community views, preferences and uptake of 
pandemic influenza vaccination in India. One other study considered community 
perceptions of influenza during the pandemic in India,61 but was limited in its 
study of views of vaccines. Multiple methods used in our study – focus group 
discussions, semi-structured interviews and in-depth interviews – made 
triangulation of results possible. Quantitative survey findings indicated not only 
what the issues are but the relative frequency of particular perceptions and 
priorities; qualitative narrative data from SSIs helped explain what these ideas 
meant and IDIs enriched qualitative detail.  
5.3.3 Limitations 
The study was designed to provide relevant information and guidance in a local 
cultural context. Generalizations for other parts of the country must therefore be 
made with caution. The survey was cross-sectional, and community views and 
perceptions are subject to change over time and in response to other social or 
policy changes.  Vaccine uptake was documented through self-report and the 
idea of a preventive vaccine was not clearly appreciated by some respondents. 
We did not confirm whether respondents who said they had taken a pandemic 
influenza vaccine actually did. By assuring participants that there were no right 
or wrong answers, assuring confidentiality, and presenting interviewers as 
independent researchers we attempted to minimize response bias. A relatively 
high non-participation rate for the SSIs in the urban sites (76%) was a limitation 
and is increasingly problematic for community epidemiological studies. There is a 
possibility of recall bias since data collection for this study began two years after 
the officially declared end of the pandemic in 2010.62 Persisting media coverage 
of swine flu and consideration of vaccines, however, even during our data 
collection ensured a public memory of the illness and its control.  
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5.3.4 Conclusion 
This study has elucidated cultural perceptions and ideas about the value of 
vaccines for pandemic influenza among urban and rural communities of Pune, 
India, which have practical implications for pandemic influenza control. In the 
2009-2010 influenza pandemic, a community mass vaccination was not 
conducted in Pune. People had to pay the full price for a vaccine and display 
considerable initiative to obtain it. Our study examined reasons for use and non-
use of influenza vaccines in this context largely through qualitative approaches. 
Policy implications from study findings highlight good prospects for use of 
influenza vaccines for pandemic control given community trust in vaccines. If a 
mass vaccination is planned for influenza control in the future, the following may 
help enhance vaccination coverage: (1) Increase community awareness about 
influenza vaccines, (2) Emphasise their relevance for adults, (3) Emphasise risk 
for urban and rural communities, men and women, (4) Promote vaccination 
through health care providers, community leaders and government endorsement, 
(5) Deliver the vaccine to communities while keeping vaccine cost affordable, (6) 
If nasal vaccines are considered, they need to be accompanied by effective 
communication and engagement prior to vaccine implementation, (6) Plans 
should consider differences within urban (slum vs. middle-income) and rural 
(accessible vs. remote) communities and cater to these sub-populations based 
on their specific sociocultural features and community ideas. Questions about 
use of vaccines for control of seasonal influenza among high-risk groups and the 
general population also require further consideration and study. This is especially 
relevant in the light of recent large outbreaks of H1N1 influenza,63,64 which is 
now considered a seasonal strain. Lack of priority for routine use of influenza 
vaccines at present65 and ability to locally-produce vaccines in Pune, suggest 
that reconsideration of policy, and sociocultural community studies are needed 
to guide further development of vaccine policy for effective action.  
5.4 Methods 
5.4.1 Study area  
This study was conducted in Pune district, a focus of the 2009-2010 (H1N1) 
influenza pandemic in India. The district had a large number of cases and 
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recorded the country’s first death from H1N1 influenza in 2009. Study sites were 
selected in urban and rural areas. Two urban sites were low-resource densely 
populated (slum) settlements in Sangamwadi and middle-income 
neighbourhoods of Erandawane in Pune city. The rural sites comprised villages in 
Mawal subdistrict that were more accessible to Pune city due to their location 
along a highway and more remote villages in Velhe subdistrict that were 
relatively difficult to access. Further details on setting are reported 
elsewhere.32,33   
5.4.2 Study design 
A mixed-methods, cross-sectional and community-based study was conducted in 
urban and rural areas of Pune district. The present analysis focuses on 
community awareness, preference and use of vaccines to prevent pandemic 
influenza, and primarily had a qualitative focus. We employed multiple methods 
including focus group discussions, cultural epidemiological semi-structured 
interviews integrating qualitative and quantitative data, and qualitative in-depth 
interviews. Formative focus group discussions (FGDs) provided insight on the 
setting and guided development of questions and categories of semi-structured 
interviews (SSIs). SSIs were developed based on the explanatory model 
interview catalogue (EMIC)66 framework for cultural epidemiology67 to obtain 
representative distributions of perceptions of pandemic influenza and the role of 
vaccines. Additional in-depth interviews (IDIs) were conducted to gain a deeper 
understanding of experiences and motivations of those who took the pandemic 
H1N1 influenza vaccine, and the views, potential barriers or hesitation among 
those who did not do so. 
5.4.3 Instruments and respondent selection 
Inclusion criteria for FGDs, SSIs and IDIs were resident adults (18-65 years) in 
the community with conversational fluency in Marathi and ability to mentally and 
physically withstand the interview or discussion. 
 
Respondents for SSIs were randomly selected from voters’ lists for each of the 
study areas.33 Voters’ lists, which were the most comprehensive of available 
records, were obtained for each of the study areas. One hundred and ten 
households were randomly selected for each area using a random number 
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generator. To avoid selection bias inherent to use of voters’ lists, selected 
households were located but not interviewed. The neighbouring household to the 
right was approached for interview instead. If no member of the household 
satisfied the inclusion criteria or if there were no willing participants, the 
adjacent household to the right was approached, until a suitable respondent was 
found. An equal balance of men and women and younger (18-45 years) and 
older (46-65 years) age groups was maintained. Questions related to awareness, 
preferences, uptake of pandemic influenza vaccines and barriers to vaccine use 
were considered for this report. Quantifiable coded responses were collected and 
any quantitative data presented in this report came from the analysis of SSIs. 
Specific questions that the coded responses correspond to have been included as 
footnotes to the tables. Narratives in response to open questions in the SSIs 
complement the quantitative data. IDIs were conducted with a purposively-
selected subsample from the SSIs. The IDIs provided accounts enriched by 
context and reasons for vaccine use or non-use. FGDs were conducted in urban 
and rural study areas based on a convenience sample recruited by community 
leaders or community health volunteers. The FGD agenda covered similar broad 
topics on ideas about vaccines including perceived benefits, problems and use of 
pandemic influenza vaccines. 
 
We designed instruments for all three methods during several workshops based 
on a literature review and previous work on vaccine acceptance.68-70 Instruments 
were revised based on feedback from other experts and public health 
professionals. Instruments were pilot tested and further revised after translation 
into Marathi.  
5.4.4 Data collection  
Research assistants conducting the SSIs had Masters-level qualifications in social 
sciences, were native Marathi speakers and received training in interview skills 
and data management. They worked in pairs with one person conducting the 
interview and the other maintaining data records. SSIs lasted for 45 minutes on 
average. Data sheets were checked for accuracy and discrepancies resolved 
while in the field.  
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FGDs and IDIs were conducted by one of two bi-lingual senior researchers with 
doctoral and masters-level degrees in social sciences, accompanied by a note 
taker. The average duration of FGDs was 1 hour and IDIs was 40 minutes. 
Facilitators and note takers discussed impressions and compared notes after 
each FGD and IDI.  
 
Interviewer and respondent characteristics were matched where possible. For 
example, a female facilitator conducted focus groups with women. Researchers 
did not have a prior relationship with study participants. All interviews and 
discussion were conducted in Marathi. FGDs, SSIs and IDIs were audio recorded 
with participants’ consent. 
5.4.5 Data management and approach to analysis 
5.4.5.1 Qualitative analysis 
Narrative data from SSIs were first entered in a word processor in Marathi and 
then translated into English. Supervisors regularly checked transcriptions and 
translations for quality. FGD and IDI transcripts were translated into English and 
entered in a word processor on an ongoing basis while constantly monitoring 
data quality with reference to study objectives. 
 
FGDs, narrative data from SSIs and IDI data were imported into MAXQDA v.11 
(VERBI Software, Germany) for data management and analysis. Analysis was 
rooted in the objectives of this paper. Thematic coding was done using a 
deductive approach for first-level coding. Inductive coding was used for 
secondary and tertiary level codes. Qualitative data collected from the three 
different methods were regarded as complementary in this analytic process of 
triangulation.  
5.4.5.2 Quantitative analysis 
Quantitative data from SSIs were entered by the interview team into Epi Info v. 
3.5.3 (CDC, USA). For double-entry verification, a second entry of quantitative 
data was done independently by a member of another team. Questions that 
required affirmation or negation were coded on a four point Likert scale, ranging 
from a clear yes or no (values of 3 or 0), to a qualified yes or no (values of 2 or 
1) for responses. Variables with few qualified responses were dichotomised for 
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analysis. To assess the influence of gender, area of residence and age on views 
and vaccine uptake, systematic comparisons were analysed for age group, sex 
and study area. Significant differences at the 0.05 level have been presented in 
this paper, using Fisher’s exact test to compare proportions across different 
groups. Quantitative variables were also imported into MAXQDA to review 
narratives of interest based on quantitative associations, thus facilitating 
integrated analysis of quantitative and qualitative data. Data analysis was done 
with STATA v. 12.1 (StataCorp, USA) and SAS v. 9.3 (SAS Institute Inc., USA).  
5.4.6 Ethical considerations 
The Institutional Ethics Committee of the Maharashtra Association of 
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Table 5-1: Summary of sample characteristics 
  Number of participants 
 
Focus group 
discussion 
(FGD)a, n=28 
Semi-
structured 
interview 
(SSI), n=436 
In-depth 
interview 
(IDI), n=12 
Ageb       
18-25 5 76 1 
26-35 5 85 5 
36-45 5 62 2 
46-55 4 119 1 
56-65 3 94 3 
Sex 
   Female 13 221 10 
Male 15 215 2 
Site 
   Urban  10 215 6 
Rural 18 221 6 
Area 
   Urban middle-
income 5 102 5 
Urban low-resource 5 113 1 
Rural more 
accessible 6 113 6 
Rural less accessible 12 108 0 
 
a Five focus groups were conducted, each with 5-6 participants. Two focus groups were conducted 
with women, two with men and one with both men and women.  
b Specific ages for one focus group with 6 participants at the rural site were not collected. Hence, the 
total number of participants categorized by age for the focus groups does not add up to 28.
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Table 5-2: Awareness, health care provider recommendation and use of pandemic influenza vaccines 
  Overall (%)    Age group (%)a   Area of residence (%)   Sex (%) 
  
   
Younger Older 
P 
valueb 
 
Urban 
middle-
income  
Urban 
low-
resource 
Rural 
more 
accessible 
Rural 
less 
accessible P valueb 
 
Female Male 
P 
valueb 
  n = 436   n = 223 n = 213     n = 102 n = 113 n = 113 n = 108     n = 221 n = 215   
Awareness of vaccines to prevent swine flu 
              Nasal vaccinec 26.6 
 
31.4 21.6 0.023 * 47.1 25.7 26.6 8.3 <0.001 *** 25.8 27.4 0.745 
Injectable vaccined 23.4 
 
26.0 20.7 0.213 
 
28.4 26.6 17.7 21.3 0.221 
 
21.7 25.1 0.429 
Recommendation by health care provider  
              To take a swine flu vaccinee 15.8 
 
20.6 10.8 0.006 ** 23.5 20.4 13.3 6.5 0.002 ** 13.1 18.6 0.149 
Uptake of swine flu vaccine 
               Personal usef 8.3 
 
9.4 7.0 0.389 
 
13.7 6.2 9.7 3.7 0.049 * 5.9 10.7 0.082 
Others in householdg 10.6   NA NA     19.6 7.1 14.2 1.9 <0.001 *** NA NA   
 
a Younger age group: 18-45 years, Older age group: 46-65 years; NA: Not applicable 
b Fisher’s exact test was used to compare proportions across age groups, area of residence and sex: *p≤0.05, **p≤0.01, ***p≤0.001 
c Frequency of affirmative responses to the question: “Are you aware of a vaccine that is sprayed into a person’s nose to protect against swine flu?” 
d Frequency of affirmative responses to the question: “Are you aware of a vaccine that is injected into a person’s upper arm to protect against swine flu?” 
e Frequency of affirmative responses to the question: “Has your health care provider ever recommended your taking a vaccine to protect against swine flu?” 
f  Frequency of affirmative responses to the question: “Have you ever taken a vaccine to prevent swine flu?” 
g Frequency of affirmative responses to the question: “Has anyone else in your household ever taken a vaccine to prevent swine flu?” 
All questions were enquired in the local language, Marathi, and translations have been provided here.
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Table 5-3: Reasons for non-use of pandemic influenza vaccines 
Reasons for not taking the pandemic 
influenza vaccine (personally or for 
someone in the household)a 
Overall 
(%)   Area of residence (%)   Sex (%)   
 
 
Urban 
middle-
income 
Urban 
low-
resource 
Rural 
more 
accessible 
Rural less 
accessible 
p 
valueb 
 
Female Male 
p 
valueb   
n = 436   n = 102 n = 113 n = 113 n = 108     n = 221 
n = 
215     
Low risk attributed to influenza  55.0 
 
46.1 57.5 60.2 55.6 0.190 
 
49.8 60.5 0.027 * 
Sufficient precautionary measures already 
taken 15.8 
 
29.4 25.7 6.2 2.8 0.000 *** 15.8 15.8 1.000   
Access (where and how to get it) 14.7 
 
7.8 9.7 17.7 23.1 0.005 ** 11.8 17.7 0.104   
Unaware of vaccine  11.7 
 
2.0 13.3 12.4 18.5 0.001 *** 12.7 10.7 0.554   
Cost of vaccine 5.0   4.9 8.0 3.5 3.7 0.442   5.9 4.2 0.513   
 
a Response to the question: “For you or anyone in your household who did not take the vaccine for swine flu, were there any particular reasons not to take 
it? Can you explain why some (or all) did not take it?” were coded into categories described in the table. Multiple categories could have been mentioned 
and coded for each respondent. 7.3% of respondents did not provide a reason. Categories reported by less than 5% are not presented. They included: lack 
of encouragement by health care provider (3.9%), other miscellaneous (3.4%), vaccine shortage due to high demand (2.1%), no time to take the vaccine 
(1.6%), doubts about vaccine effectiveness (0.9%), and general avoidance of medication (0.9%). 
b Fisher’s exact test was used to compare proportions across area of residence and sex: *p≤0.05, **p≤0.01, ***p≤0.001. No differences were observed 
across age groups and they have hence not been presented. 
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Table 5-4: Preference for injectable or nasal pandemic influenza vaccine  
  Overall   Age group   Area of residence   Sex   
  
   
Younge
r Older 
p 
valuea 
Urban-
middle 
income  
Urban 
low-
resource 
Rural  
more 
accessible 
Rural 
less 
accessible 
p 
value
a Female Male 
p 
valuea 
  n = 436   n = 223 n = 213   n = 102 n = 113 n = 113 n = 108   n = 221 n = 215   
More powerful vaccine (%)b 
           
  
Neither  0.0 
 
0.0 0.0 
 
0.0 0.0 0.0 0.0 
 
0.0 0.0   
Both equal  3.0 
 
2.7 3.3 
 
2.9 3.5 1.8 3.7 
 
3.6 2.3   
Injection  44.3 
 
44.4 44.1 
 
42.2 51.3 40.7 42.6 
 
45.2 43.3   
Nasal spray  32.6 
 
36.3 28.6 
 
33.3 31.0 37.2 28.7 
 
26.2 39.1 ** 
Cannot say  20.2 
 
16.6 23.9 
 
21.6 14.2 20.4 25.0 
 
24.9 15.3 * 
Safer vaccine (%)c 
           
  
Neither  0.7 
 
0.5 0.9 
 
0.0 0.9 0.0 1.9 
 
0.9 0.5   
Both equal  9.6 
 
11.7 7.5 
 
9.8 5.3 14.2 9.3 
 
12.2 7.0   
Injection  57.1 
 
54.7 59.6 
 
46.1 64.6 54.9 62.0 * 55.2 59.1   
Nasal spray  27.5 
 
29.6 25.4 
 
42.2 24.8 25.7 18.5 ** 25.8 29.3   
Cannot say  5.0 
 
3.6 6.6 
 
2.0 4.4 5.3 8.3 
 
5.9 4.2   
Personal preference (%)d 
           
  
No preference  11.2 
 
8.1 14.6 * 9.8 6.2 10.6 18.5 * 12.7 9.8   
Injection  58.5 
 
59.2 57.8 
 
52.9 65.5 54.9 60.2 
 
59.3 57.7   
Nasal spray  30.3   32.7 27.7 
 
37.3 34.5 28.3 21.3   28.1 32.6   
 
a Fisher’s exact test was used to compare proportions across age groups, area of residence and sex, *p≤0.05, **p≤0.01, ***p≤0.001 
b Frequency of responses to the question: “Do you think either of these vaccines (the nasal spray or the injection) would be more powerful and better able 
to protect you against swine flu? … Why?” 
c Frequency of responses to the question: “Which one of these vaccines (nasal spray or injection) do you think would be safer for you? … Why?” 
d Frequency of responses to the question: “If you could choose either of these vaccines to protect yourself against swine flu, which one would you prefer, 
the nasal spray or the injection? … Why?” 
All questions were enquired in the local language, Marathi, and translations have been provided here. 
Community awareness, use, preference for pandemic influenza vaccines 
 
96 
Table 5-5: Reasons for preferring an injectable vaccine or a nasal vaccine for pandemic influenza 
A) Reasons for preferring an injectable vaccine 
Theme Illustrative quote 
Perceived powerfulness of vaccine 
Injectable vaccine spreads through the 
body from absorption in the blood 
“In our village it is believed that the medicine reaches the whole body 
only through an injection” (29 yr, rural woman) 
Injectable vaccine spreads faster in 
the body 
“An injectable vaccine spreads all over quickly. The nasal one takes 
time while the injection spreads faster” (23 yr, urban man) 
Injectable vaccine has longer lasting 
effects 
“Injectable vaccine because its effect will last for long” (31 yr, rural 
man) 
Nasal vaccine may be expelled while 
breathing, sneezing or in mucus 
“The injectable vaccine allows the medicine to disperse internally. 
The medicine if administered through the nasal route will get 
expelled through breath. It won’t go inside” (64 yr, rural man) 
Nasal vaccine may not reach all parts 
of the body 
“Injectable vaccine is better because the nasal vaccine will travel 
with the breath and only reach the lungs while the injectable one will 
circulate through the blood in the entire body” (60 yr, rural man) 
Pain caused by injectable vaccine is an 
indication of its powerfulness 
“Actually, pain at the injection site is considered as good sign” (rural 
woman, FGD) 
  
Side effects or safety concerns of alternative 
Fear of numerous side effects from 
nasal vaccine 
“If given in the nose then it creates irritation in the throat, and the 
whole mouth becomes bitter” (46 yr, rural woman) 
  
Familiarity and trust 
Past experience and familiarity with 
injections 
“I will prefer the injectable vaccine since we are used to taking 
injections. We have never taken it through the nose” (27 yr, urban 
man) 
Implicit trust in injections “Injection- all I can understand is that, it will be effective when we 
take it” (50 yr, woman) 
Fear of relatively unknown nasal 
vaccine 
“A person fears taking it through the nose. There is no fear in an 
injection. I fear the nasal one” (48 yr, rural woman) 
 
B) Reasons for preferring a nasal vaccine 
Theme Illustrative quote 
Perceived powerfulness of vaccine 
Nasal vaccine can reach all parts of the 
body through breath 
“[I prefer] nasal as when we breathe it reaches the whole body. 
Injection does not affect the body so fast” (59 years, urban woman) 
Nasal vaccine has a more immediate 
effect 
“Will take it through the nose. It will have an immediate effect” (50 
yr, rural woman) 
Nasal vaccine is administered through 
the nose where germs enter 
“Nasal [is preferred] because we would have the disease through 
there…Its effect would be more than injectable” (21 yr, rural man) 
Nasal vaccine has desirable side 
effects indicative of vaccine doing its 
job 
“Nasal administration must cause tingling and stinging….You don’t 
feel anything after taking the injectable vaccine but you can feel the 
medicine going inside and also the stinging caused when 
administered through the nose” (47 yr, rural man) 
  
Side effects or safety concerns of alternative 
Fear of needles or pain caused by 
injectable vaccines  
“The nasal one is better. With an injection, there is inflammation or 
pain later” (57 yr, urban man) 
Concerns regarding potential re-use of 
needles in injectable vaccines 
“There is a risk associated with the injection because an already used 
syringe may be used again, unlike in case of a nasal vaccine which I 
think spreads in the entire body in the vapour form” (65 yr, urban 
man) 
Table 5(A) lists main themes and illustrative quotes distilled from respondent narratives regarding 
why an injectable vaccine was preferred over a nasal one. Narratives data from focus group 
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discussions and open questions in semi-structured interviews were analysed thematically.  
Explanations provided were either perceived advantages of the injectable vaccine (text in black) or 
perceived disadvantages of the nasal vaccine (text in red). Similarly, in Table 5(B), explanations for 
preference of the nasal vaccine were due to either perceived benefits of the nasal vaccine (text in 
black) or perceived disadvantages of the injectable vaccine (text in red). As a part of the analysis, 
themes were grouped under broad domains of perceived powerfulness (or efficacy), side effects or 
safety concerns and familiarity, trust. 
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Abstract 
Background  
Community willingness to accept vaccines is a neglected component of pandemic 
preparedness. Despite an acknowledged need for such studies, few have been 
done in lower income countries. This study investigated community priority and 
determinants of pandemic influenza vaccine acceptance in Pune, India.  
 
Methods  
A cross-sectional, mixed-methods study used semi-structured explanatory model 
interviews to assess anticipated acceptance of nasal and injectable vaccines at 
different levels of cost among 436 urban and rural community residents. 
Sociocultural determinants of anticipated vaccine acceptance were identified 
using logistic regression models.  
 
Results 
Over 93% anticipated accepting a vaccine at no-cost, 91.2% at INR 75, 87.8% 
at INR 150 and 74.1% at INR 500. Some respondents preferred low-cost 
vaccines over free vaccines. Illness-related concerns about social isolation, 
contaminants (e.g., germs or dirt) identified as perceived causes, private-
hospital or traditional-healer help seeking, and income were positively 
associated with anticipated acceptance. Humoral imbalances as perceived cause, 
drinking warm liquids as home remedy and age were negatively associated.  
 
Conclusions  
High acceptability of pandemic influenza vaccines indicates good prospects for 
mass vaccination. It appeared that confidence was higher in the vaccines than in 
the health system delivering them. Sociocultural determinants influencing 
anticipated vaccine acceptance should be considered in vaccination programmes. 
 
Keywords  
Cultural characteristics, Influenza, Pandemics, Public participation, Social 
characteristics, Vaccination 
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6.1 Introduction 
The outbreak of novel influenza A (H1N1) was declared the first influenza 
pandemic of the 21st century by the World Health Organization (WHO) in June 
2009. Although the 2009 influenza pandemic turned out to be less severe than 
expected, it nevertheless imposed a substantial worldwide burden, notable for 
mortality affecting children and young adults.1 Pune, located in Maharashtra, 
was considered a focus of the 2009 influenza pandemic in India, and 
Maharashtra recorded 36% of H1N1-related deaths in the country.2  
 
Vaccines are a cornerstone of influenza control. Available vaccines include 
intramuscularly injected inactivated influenza vaccine (IIV) and intranasally 
administered live attenuated influenza vaccine (LAIV).3 Both are considered safe 
and efficacious. Although vaccines are not necessarily immediately available in 
case of a pandemic, they are essential to limit spread and mitigate severity.1 
 
The Pandemic Preparedness and Response Plan for India, acknowledges vaccines 
as the “best preventive strategy to combat a pandemic”.4 Vaccine safety, 
efficacy and manufacturing capability are necessary for pandemic preparedness. 
A Pune-based company, enabled by a WHO technology transfer initiative to 
strengthen the capacity of developing countries, can produce pandemic influenza 
vaccines.5 Community willingness to accept vaccines is an additional often-
neglected component of effective vaccine policy and action, and social and 
cultural features of illness that are known to influence vaccine acceptance 
therefore require careful consideration.  
 
Poor uptake of influenza vaccines during the 2009 pandemic was a problem 
noted worldwide.6,7 Although determinants of pandemic influenza vaccine 
acceptance have been studied, relatively little research has focussed on low-and-
middle-income countries. Acknowledged differences between countries in their 
pandemic response, and social and cultural influences on behaviour highlight the 
need for country-specific studies.7  
 
To our knowledge, only two studies have examined determinants of pandemic 
influenza vaccine acceptance in India, and they were convenience samples 
among healthcare workers8 and medical students.9 We undertook this study to 
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investigate the priority and factors determining vaccination intentions among the 
general population in Pune. The study aims to determine the level of community 
interest in accepting vaccines against pandemic influenza at varying levels of 
cost. We further aim to assess social and cultural determinants of anticipated 
acceptance of pandemic influenza vaccines.  
6.2 Methods 
6.2.1 Study design and setting  
This cross-sectional survey was conducted between July-December 2012 in two 
urban and two rural areas of Pune district, India. Selected urban sites comprised 
low-resource densely populated settlements and middle-income neighbourhoods 
in Pune city. The rural sites were remote villages in Velhe subdistrict that were 
difficult to access and relatively accessible villages in Maval subdistrict.  
 
Households were randomly selected from the local registry of voters in each of 
the four study sites. Eligibility criteria for participants included: ages between 
18-65 years, residence in Pune, fluency in Marathi and ability to withstand a 45-
minute interview. An equal number of men and women and younger (18-45 
years) and older (46-65 years) persons were interviewed. Further details of the 
study setting and sampling are available elsewhere.10 
6.2.2 Instruments 
Interviews based on the framework of the explanatory model interview 
catalogue (EMIC)11 are a principal tool for cultural epidemiological research.12 
The semi-structured EMIC interview for this study was developed in a workshop 
with study investigators and public health experts.  
 
Sex, site and age-matched vignettes describing a person with influenza 
symptoms, set in January 2010, provided a focus for questions of the interview. 
Prior ethnographic research guided categories for coding illness experience, 
meaning and behaviour. Responses to open questions were coded followed by 
questions probing categories that were not mentioned spontaneously. The 
instrument then assessed willingness to take a vaccine to prevent swine flu, the 
local term most commonly used for H1N1 disease. Vaccine acceptance questions 
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were posed at four different prices for both nasal and injectable pandemic 
influenza vaccines: free as in the case of many immunization campaigns; low, 
corresponding to a subsidized price of half the market rate (INR 75 for nasal; 
INR 250 for injectable vaccine), medium, the market price of influenza vaccines 
in Pune during the 2009 pandemic (INR 150 for nasal; INR 500 for injectable 
vaccine) and high, an inflated price of double the market rate (INR 300 for nasal; 
INR 1000 for injectable vaccine), based on a ‘black market rate’ for vaccines in 
short supply as they were early in the Pune pandemic. Each price level was 
questioned separately. Responses were recorded on a four point Likert scale, 
ranging from “yes” (clear positive response), “possibly” (qualified positive 
response), “uncertain” (qualified negative response) and “no” (clear negative 
response).  
 
Complementary numeric and narrative data were collected in an integrated data 
set. Interviews were conducted in Marathi by an interviewer and a data recorder. 
Interviews were voice recorded with permission to enhance interview notes.    
6.2.3 Data management and analysis 
Quantitative and categorical data were double-entered using range and logic 
checks in Epi Info v.3.5.3 (CDC, USA). 
 
Outcome variables 
Eight different outcomes were examined: anticipated nasal and injectable 
influenza vaccine acceptance each at four different prices of free, low, medium, 
high.  Each outcome variable was dichotomised as 1 (‘vaccine acceptance’) or 0 
(‘non acceptance’). 
 
Explanatory variables 
Explanatory variables included cultural epidemiological variables specifying 
categories of distress, perceived causes, help-seeking at home and outside, and 
prevention. Perceptions of vaccines, awareness of illness and sociodemographic 
characteristics were also considered. Selective variables were grouped to 
represent coherent themes. Prominence was assigned for each variable in the 
sets noted above based on whether and how each category was reported by a 
respondent. Spontaneously mentioned categories received a value of 2; 
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categories reported only on probing received a value of 1, and if not reported at 
all was assigned a value of 0. A category that was also identified as most 
important was assigned an additional value of 3. Mean values summarized the 
prominence of each category with a possible range of 0-5.  
 
Statistical analyses 
Fisher’s exact test was used to compare proportions across different 
classification groups and the Cochran’s Q test to compare probabilities of 
anticipated acceptance of free and low cost vaccines. 
 
To identify sociocultural and sociodemographic determinants of anticipated 
influenza vaccine acceptance, logistic regression analyses were performed. As a 
first step, bivariate associations between explanatory variables and each of the 
outcomes were analysed. These variables were then adjusted for sex, age and 
area of residence. Variables with p<0.2 from this analysis were selected for 
multivariable focal models. Focal models comprised of specific sets of variables 
such as perceived causes, prevention, etc. and provided insight into the 
influence of specific sets of sociocultural variables on anticipated influenza 
vaccine acceptance. Finally, a multivariable comprehensive model containing 
variables from all focal models with p<0.2 was developed for each outcome. 
Variables with p<0.1 were retained in the models while assessing relative quality 
of the model using the Akaike Information Criterion corrected for sample size 
(AICc). This stepwise variable reduction strategy was done in SAS v.9.3 (SAS 
Institute Inc., USA). Relative goodness of fit between various focal and 
comprehensive models were compared using ∆(AICc) which represents the 
difference in AICc between each model and the model with the lowest AICc for 
each outcome. Models with lower ∆(AICc) are considered better in explaining 
acceptance. Regression coefficients and two-tailed p-values are reported. 
Statistical significance is defined at the level of 5%.  
 
Qualitative data for integrated analysis 
Narrative data helped explain the nature of explanatory variables and identified 
associations. Narratives were translated into English and entered in a word 
processor. Transcripts were managed with MAXQDA 11 (VERBI software, 
Germany), and were coded thematically using primarily deductive approaches. 
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Variables from the quantitative data set were also imported into MAXQDA to 
select narratives of particular interest, facilitating integrated analysis of 
qualitative and quantitative data. 
6.3 Results 
A total of 436 interviews were completed in four study areas. The sample 
consisted of 50.7% women and 51.2% from the younger age group. Median 
household size was 5 persons. Median monthly household income among 342 
respondents who stated their income was INR 10 000. Regarding the highest 
level of education, 20% had higher education, 12.8% secondary school and 38.3% 
primary school; 7.3% had not completed primary school, and 21.6% had no 
education.  
6.3.1 Anticipated pandemic influenza vaccine acceptance 
Anticipated acceptance of no-cost nasal and injectable vaccines was over 93% 
(Table 6-1). A few who were willing to take a free vaccine, nevertheless, noted 
concerns:  
If available free of cost, we will definitely take it. But, we need assurance 
that a real vaccine is being given. We are not as educated as city people, 
so we are a little scared. I will make sure that the people who are 
vaccinating are doctors (rural woman, 27 years). 
 
In general, anticipated acceptance declined as vaccine price increased. An 
exception was the urban middle-income area, where acceptance rates at the low 
price (96% nasal, 95% injectable) were higher than the free vaccine (88% nasal, 
87% injectable). A 60-year-old urban woman questioned the efficacy of a no-
cost vaccine: “If they give it for free, it will not be effective, so I will not take it.” 
Other respondents elaborated concerns about corruption and a lack of trust in 
government initiatives:  
If it is free then its quality is reduced. If the government is giving it, that 
means there is a scandal. If we instead pay 500 rupees, there is a 
psychological reassurance that one has taken the medicine. We do not 
trust government schemes as the vaccine may be filled with water. So it is 
better to take it from a private practitioner since we can afford it. The 
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urban population has lost faith and trust (urban middle-income area, 
woman, 50 years).  
 
Few respondents, however, had more faith in public than private services. 
Referring to experience in the 2009 pandemic, an urban man explained:  
The vaccine was not being given through the government. It was available 
only through private providers, which is not guaranteed. We will take it if 
the government provides it, for that is guaranteed (65 years).  
 
Younger age group respondents were significantly more likely to accept nasal 
and injectable vaccines at all prices. Anticipated vaccine acceptance was highest 
at the remote rural area and lowest in the urban middle-income area when the 
vaccine was offered for free, but this pattern was reversed for the injectable 
vaccine priced at INR 500. Acceptance rates of men and women were similar 
except for the medium and high-priced injectable vaccines, where more men 
than women reported anticipated acceptance (medium price: women 67.4%, 
men 80.9%, p=0.001; high price: women 56.1%, men 67.4%, p=0.018).  
 
Each respondent’s pattern of acceptance at different levels of cost was analysed 
to determine whether acceptance was motivated by lower cost. For the nasal 
vaccine, 14.0% of respondents were less likely to accept as cost increased—35.6% 
for the injectable vaccine. Cost was not a factor for the 76.3% (nasal) and 53.8% 
(injectable) who anticipated acceptance at all prices and for the 3.5% (nasal) 
and 1.4% (injectable) who refused the vaccine at all prices. For some 
respondents, price appeared to be a counter incentive (6.3% for nasal and 10.6% 
for injectable vaccines), who anticipated purchasing the high-priced vaccine 
despite refusing lower-priced vaccines or were willing to buy higher-priced 
vaccines, though refusing the free vaccine. A 46-year-old woman, who 
considered the injectable vaccine priced at INR 500 unaffordable, explained why 
she would purchase it at INR 1000 if there was high demand: “If the epidemic 
spreads very much, everywhere, then one would take it”. 
6.3.2 Determinants of anticipated influenza vaccine acceptance 
Multivariable focal models examined the influence of specific sets of sociocultural 
features of illness (i.e., patterns of distress, perceived causes, home treatment, 
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help-seeking outside home, prevention and other ideas about illness and 
vaccines) and sociodemographics on anticipated vaccine acceptance (Table 6-2). 
Focal models were examined for three different outcomes: high-priced nasal, 
medium-priced injectable and high-priced injectable vaccine acceptance. Other 
outcomes lacked sufficient variability for multivariable analysis. Based on ∆(AICc) 
values, among nasal medium price models, almost all sociocultural focal models 
explained acceptance better than the exclusively sociodemographics model. For 
the injectable high price outcome, the focal model with only sociodemographics 
explained acceptance better than any of the sociocultural models. For all 
outcomes, the comprehensive model, which combines sociocultural and 
sociodemographic variables from all focal models, explained acceptance best 
(Tables 6-3—6-5). Several variables (e.g., use of facemasks or preventive drugs 
in prevention, illness identification) adjusted only for sociodemographics were 
associated with vaccine acceptance, but did not remain significant when adjusted 
for additional explanatory variables (see Supplementary table). 
 
Sociodemographic features 
Increase in age was strongly negatively associated with anticipated acceptance. 
In contrast, income was a positive predictor at the highest price level.   
 
Patterns of distress 
Reduced social contact as a troubling feature of the illness was positively 
associated with acceptance. Narratives indicate the nature of concerns about the 
social impact of the illness:  
It will affect him socially because people tend to avoid contact with such a 
person. He will feel bad that he is unable to interact with people or his 
family due to the illness. He will feel isolated. Others would ask him to 
keep away. (rural man, 60 years)      
 
Identification of loss of income and illness expenses were financial concerns 
associated with less likely acceptance.  
 
Perceived causes 
Perceived causes that were positively associated with anticipated vaccine 
acceptance were consumption of contaminated water or food, dirty surroundings 
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or improper sanitation and cough or sneeze of an infected person. Belief that the 
pandemic vignette illness was caused by another prior illness, by traditional 
medical ideas about the role of humoral imbalance or an unhealthy lifestyle was 
negatively associated.  
 
Help-seeking 
The priority of both private hospital and traditional healer help-seeking was 
positively associated with vaccine acceptance in all comprehensive models. 
Narratives indicate that traditional healers (referring to ayurvedic medicine 
providers or herbalists) were usually mentioned as a source of help secondary to 
allopathic doctors. A reported priority of home-remedies, such as drinking warm 
liquids, was negatively associated. 
 
Other ideas about vaccines 
Greater regard for safety of injectable compared with nasal vaccines was 
positively associated with injectable vaccine acceptance. Those who identified 
particular problems with the injectable vaccine were no less likely to anticipate 
acceptance than those who asserted there were “no problems”, but those who 
could not say whether there were problems were less likely to anticipate 
acceptance.  
6.4 Discussion 
This study was motivated by an interest in enhancing pandemic preparedness in 
a developing country with influenza vaccine production ability, by focusing on 
the user dimension of a vaccine intervention. High anticipated acceptance 
indicates community interest and acceptability of pandemic influenza vaccines. 
Anticipated acceptance for no-cost vaccines noted in our study (over 93%), are 
much higher than rates in other settings, such as Hong Kong (45%),13 United 
States (US; 50%),14 Australia (54%)15 and Malaysia (70%)16. During the 2009 
pandemic, access was difficult in India as vaccines were not actively made 
available to the general population. This is in contrast to many high-income 
countries where low confidence in influenza vaccines was a major obstacle. 
Findings suggest good prospects for community acceptance of influenza vaccines 
for pandemic control. 
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In addition to acceptance of free vaccines, this study clarified community 
willingness to purchase a vaccine, which is probably a better indication of 
behaviour in settings where the vaccine is only provided at some cost. Lower 
anticipated acceptance at higher prices indicates that at some level cost is 
clearly a barrier, particularly for women and persons from the remote rural area. 
Some level of subsidy would therefore be needed to implement effective mass 
vaccination in the framework of pandemic control. Although concerns about the 
epidemic increased the priority for purchase of high-priced vaccines, whether or 
not people would actually be able to afford them is another matter, as field 
experience suggests 
 
Contrary to expectations, free influenza vaccines were less valued than those 
with costs for some respondents, mostly from the urban middle-income area. 
This resulted from an explicitly stated lack of trust in government services, and 
scepticism about the quality of a free vaccine. Research from the US has noted 
that people often overreact to ‘free’ products as though zero price meant not 
only no cost, but also an increased value of the product.17 We found the opposite 
phenomenon as some were suspicious of a no-cost vaccine. Furthermore, 
confidence in the health systems delivering the vaccine appears lower than 
confidence in the vaccine itself. This finding is supported by a recent study which 
notes that among persons reporting a lack of confidence in immunization 
services, persons from India had relatively low vaccine hesitancy, compared to 
other countries.18  
 
Regression models that incorporated sociocultural features of illness explained 
influenza vaccine acceptance better than those with only sociodemographics. 
Identified sociocultural determinants provide data to enhance vaccine coverage 
and effectiveness of vaccine action in an actual campaign. However, as 
hypothesised, at the price of INR 1000—which is high given median household 
income and household size—sociodemographics, including income, explained 
acceptance best. 
   
Although influenza is not considered a traditionally stigmatized disease, like 
leprosy19 or AIDS,20 stigmatization of collectives has been noted,21 which can 
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hinder control efforts.22 In our study, fear of social isolation or interference with 
relationships positively influenced acceptance. In this sociocultural context, 
anticipated stigma translated into anticipated vaccine acceptance. 
Perceived causes influence vaccination intention and should be assessed while 
planning vaccination initiatives. Among perceived causes, those related to 
contaminants were positively associated with vaccine acceptance, including 
highly-relevant causes for influenza such as cough or sneeze of infected persons 
and biomedically less-relevant ones such as contaminated food and unclean 
surroundings. Those who believed in explanations unrelated to contaminants, 
such as cultural ideas about heat or cold in the body resulting in humoral 
imbalances were less likely to anticipate vaccine purchase.  
 
Interestingly, seeking counsel from traditional healers was complementary to 
vaccine acceptance. They are viewed as complementary rather than competing 
sources of help. This may be partly explained by the fact that the Ministry of 
Health and Family Welfare (MOHFW), India, promoted ayurvedic interventions 
for prevention and treatment of H1N1 influenza alongside recommendations to 
visit hospitals.23,24 Reporting of private hospitals to seek care may be an 
indication of financial ability, as these are typically more expensive than public 
services, or may be an indication of priority for managing influenza, as private 
services are perceived to provide better quality. The prominence of symptomatic 
relief through home remedies may have indicated a less serious condition, 
discouraging acceptance of the vaccine costing INR 500. 
 
Relatively minor problems with the vaccine, such as pain or fever, were 
spontaneously identified by respondents. Identification of problems with the 
vaccine did not negatively influence anticipated acceptance, but reporting 
uncertainty in identifying problems did. “Cannot say” may be a cultural response 
for larger concerns that, although not articulated, may discourage vaccine 
acceptance.   
 
In contrast to studies among the general public in the United Kingdom25 and 
US,14 in our study, older respondents were less likely than younger persons to 
intend to take pandemic influenza vaccines. Observed generational differences in 
anticipated acceptance highlight the need to communicate the value of influenza 
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vaccines for older adults, and perhaps target younger adults as early adopters in 
the context of a vaccination campaign.  
6.4.1 Context of vaccine policy 
H1N1 influenza, now considered a seasonal strain, has caused approximately 35 
000 cases in India this year as of April 2015.26 Control strategies have focussed 
on treatment with antivirals and non-pharmaceutical interventions such as 
encouraging handwashing, cough etiquette, and avoiding contact with infected 
persons.27 The MOHFW currently recommends vaccination for healthcare workers, 
but not the public.28 Vaccination is not advocated for indicated high-risk groups, 
such as individuals over 65 years, under-five-year olds, and pregnant women 
either. The rationale behind this policy decision is unclear, especially as a large 
percentage of deaths have been reported among people with comorbidities.29 
Furthermore, India has the capacity to produce influenza vaccine.5 Literature 
from other countries suggests previous experience with seasonal influenza 
vaccination is a major determinant of pandemic vaccine uptake.14,15 Thus, 
implementation of policy for seasonal influenza vaccination in India for high-risk 
groups, would not only decrease morbidity and mortality, but also contribute to 
pandemic preparedness by ensuring upkeep of facilities for influenza vaccine 
manufacture,30 and improving vaccine uptake in case of a pandemic.  
6.4.2 Limitations 
Actual vaccine acceptance rates are usually lower than anticipated rates, and it 
was not possible to estimate their relationship to actual uptake in this study 
since there was no public mass vaccination campaign during the 2009 pandemic 
in India. Anticipated rates are thus only a guide and indication of community 
priority rather than a perfect prediction. Data collection began two years after 
the pandemic potentially contributing to recall bias. Ongoing outbreaks of H1N1 
influenza nevertheless may have preserved public memory of the illness.  
6.4.3 Conclusion 
Our findings indicate community confidence in vaccines for influenza in a 
seriously affected city of India, in contrast with hesitancy in Euro-American 
settings, suggests good prospects for vaccine strategies in government planning 
for influenza control. Our cultural epidemiological study clarified sociocultural 
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determinants of anticipated pandemic influenza vaccine acceptance in Pune. 
Identified associations were explained by complementary narratives from an 
integrated design in a mixed-methods approach. By assessing vaccine 
confidence and determinants of anticipated use, this study highlights the value 
of social and cultural determinants and community study for influenza vaccine 
policy and implementation. 
 
Authors’ contributions 
All authors participated in study design. NS, CS1, LG, CS2 and MGW conceived 
the plan for analysis. NS, VP, SJ and AK coordinated the study and participated 
in data collection. LG and CS2 provided statistical guidance. NS analysed the 
data and drafted the manuscript. NS, CS1 and MW critically revised the 
manuscript. All authors reviewed and revised the manuscript for intellectual 
content, and all authors have approved the final manuscript. NS and MGW are 
guarantors of the paper.  
 
Acknowledgements 
The authors thank all community members who participated in this study for 
sharing their time, thoughts and experiences. The authors are also grateful to 
field supervisors and interviewers for their diligence and commitment to the 
study.  
 
Funding 
This study was supported by the WHO, Switzerland 
 
Competing interests 
None declared 
 
Ethical approval  
Ethical approval for this study was received from the Institutional Ethics 
Committee of the Maharashtra Association of Anthropological Sciences, Pune, 
the Ethics Commission of Basel and the WHO Research Ethics Review Committee. 
Participants were not given incentives for participation and written informed 
consent was obtained prior to the interview. All data were anonymized for 
analysis and maintained confidentially.  
  
Sociocultural determinants of anticipated influenza vaccine acceptance in Pune 
115 
 
Table 6-1: Anticipated pandemic influenza vaccine acceptance at different prices among 
community residents of Pune: comparison of age groups and areas of residence 
 
Vaccine price 
Anticipated vaccine acceptance (%) 
Overall 
 
Age group 
 
Area of residence   
 
  
 
18-45 
years 
46-65 
years 
 
Urban 
middle-
income 
Urban 
low-
resource 
Rural 
remote 
Rural 
accessible   
 n=436   n=223 n=213   n = 102 n = 113 n = 108 n = 113   
Nasal vaccine   
        
  
Free (INR 0; USD 0) 93.1 
 
97.8 88.3 *** 88.2a 95.6 97.2 91.2 * 
Low (INR 75; USD 1.4) 91.2 
 
96.8 85.2 *** 96.0a 91.8 89.8 87.6 NS 
Medium (INR 150; USD 2.8) 87.8 
 
93.7 81.7 *** 92.2 90.3 87.0 82.3 NS  
High (INR 300; USD 5.6) 82.6 
 
89.7 75.1 *** 87.3 79.7 84.3 79.7 NS  
Injectable vaccine 
         
  
Free (INR 0, USD 0) 94.5 
 
97.8 91.1 ** 87.3b 95.6 100.0 94.7 *** 
Low (INR 250; USD 4.7) 91.3 
 
94.6 87.8 * 95.1b 87.5 90.7 92.0 NS  
Medium (INR 500; USD 9.3) 74.1 
 
77.1 70.9 NS 84.3 70.8 67.6 74.3 * 
High (INR 1000; USD 18.7) 61.7 
 
70.4 52.6 *** 67.7 57.5 61.1 61.1 NS  
 
Fisher’s exact test was used to compare proportions across age groups and area of residence:  
NS: Not significant, p>0.05, *p≤0.05, **p≤0.01, ***p≤0.001;  
 
Cochran’s Q test for matched subjects used to compare proportions between free and low price 
vaccine acceptance. 
a Cochran’s Q test, p-value=0.05, exact p=0.092 
b Cochran’s Q test, p-value=0.03, exact p=0.057 
 
INR: Indian Rupee, USD: United States dollar, average exchange rate for 2012: 1 INR=0.0187 USD 
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Table 6-2: Adjusted analysis (focal models) of social and cultural determinants of anticipated pandemic influenza vaccine acceptance in Pune, India 
Focal models 
Nasal, high price (INR 300) Injectable, medium price (INR 500) Injectable, high price (INR 1000) 
Coefficient (95% CI)a P valueb ∆(AICc)c Coefficient (95% CI)a P valueb ∆(AICc)c Coefficient (95% CI)a P valueb ∆(AICc)c 
Patterns of distress 
  
16.36 
  
32.73 
  
33.62 
Vomiting, Nausea 0.37 (-0.25 to 1.02) 0.241   0.28 (-0.23 to 0.78) 0.281   0.36 (-0.09 to 0.81) 0.112   
Diarrhoea, appetite loss, abdominal pain 0.49 (-0.21 to 1.19) 0.167           
Headache 0.23 (-0.32 to 0.77) 0.418           
Breathlessness -0.53 (-0.99 to -0.08) 0.022   
  
  
  
  
Redness or rash 0.33 (-0.27 to 0.94) 0.278   
  
  
  
  
Social isolation and interference 0.34 (0.02 to 0.66) 0.038   0.28 (0.03 to 0.54) 0.030   
  
  
Sadness, tension     0.10 (-0.09 to 0.29) 0.322   0.11 (-0.05 to 0.28) 0.171   
Costs, lost income -0.19 (-0.40 to 0.03) 0.093           
Perceived causes 
  
17.62 
  
22.30 
  
27.41 
Contaminated water, unsafe food 0.24 (-0.05 to 0.52) 0.103   0.15 (-0.08 to 0.37) 0.197   0.12 (-0.07 to 0.30) 0.229   
Humoral imbalance, lifestyle -0.26 (-0.55 to 0.04) 0.087   -0.25 (-0.52 to 0.02) 0.074   
  
  
Prior illness -0.25 (-0.52 to 0.01) 0.062   
  
  
  
  
Dirty surroundings, improper sanitation 
  
  0.13 (-0.1 to 0.35) 0.274   0.23 (0.03 to 0.43) 0.028   
Lack of personal hygiene 
  
  0.39 (-0.02 to 0.81) 0.063   
  
  
Environmental germs 
  
  0.08 (-0.30 to 0.46) 0.692   0.10 (-0.23 to 0.42) 0.564   
Insect bite 
  
  
  
  0.13 (-0.05 to 0.3) 0.149   
Air pollution 0.14 (-0.21 to 0.49) 0.425   
  
  0.24 (-0.02 to 0.5) 0.069   
Cough or sneeze of infected person 0.24 (-0.09 to 0.57) 0.149   0.45 (0.16 to 0.74) 0.003   0.21 (0.01 to 0.42) 0.041   
Other contact   0.33 (-0.11 to 0.76) 0.139   0.15 (-0.17 to 0.47) 0.370   
  
  
Hospital-acquired 0.07 (-0.39 to 0.53) 0.773   
  
  
  
  
Self-treatment at home 
  
19.82 
  
31.36 
  
32.59 
Do nothing at home 
  
  
  
  0.14 (-0.01 to 0.28) 0.061   
Drink warm liquids 
  
  -0.23 (-0.47 to 0.01) 0.061   
  
  
Ayurvedic remedies 0.31 (-0.02 to 0.65) 0.069   0.26 (-0.02 to 0.53) 0.065   
  
  
Allopathic drugs 0.16 (-0.12 to 0.44) 0.250   0.13 (-0.09 to 0.35) 0.240   
  
  
Help-seeking outside home 
  
18.30 
  
29.77 
  
27.33 
Private hospital 0.20 (0.03 to 0.37) 0.023   0.13 (-0.01 to 0.28) 0.071   0.19 (0.01 to 0.38) 0.041   
Government hospital  
  
  
  
  -0.02 (-0.19 to 0.14) 0.793   
Informal help from friend or relative 
  
  -0.28 (-0.53 to -0.02) 0.036   
  
  
Traditional healer 0.29 (-0.06 to 0.65) 0.108   0.30 (-0.02 to 0.62) 0.064   0.24 (-0.05 to 0.52) 0.101   
Prevention 
  
17.69 
  
31.60 
  
29.73 
Ritual purification, supernatural forces 
  
  0.15 (-0.09 to 0.40) 0.224   
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Focal models 
Nasal, high price (INR 300) Injectable, medium price (INR 500) Injectable, high price (INR 1000) 
Coefficient (95% CI)a P valueb ∆(AICc)c Coefficient (95% CI)a P valueb ∆(AICc)c Coefficient (95% CI)a P valueb ∆(AICc)c 
Handwashing 0.24 (-0.21 to 0.68) 0.303   
  
  0.24 (-0.07 to 0.56) 0.130   
Cleanliness 0.13 (-0.05 to 0.31) 0.168   
  
  0.13 (-0.01 to 0.28) 0.073   
Wholesome lifestyle -0.19 (-0.40 to 0.02) 0.082   
  
  
  
  
Wearing a mask 0.29 (-0.05 to 0.63) 0.091   0.25 (-0.02 to 0.53) 0.072   0.22 (-0.01 to 0.45) 0.058   
Herbal remedies 
  
  0.11 (-0.25 to 0.48) 0.543   
  
  
Preventive drugs 0.34 (-0.19 to 0.86) 0.207   0.28 (-0.17 to 0.74) 0.225   
  
  
Vaccines 
  
  0.17 (-0.10 to 0.45) 0.212   
  
  
Health education 
  
  
  
  0.26 (-0.01 to 0.54) 0.060   
Other ideas about illness and vaccines 
  
21.90 
  
31.07 
  
27.60 
Seriousness of illness 
  
  
  
  0.16 (-0.05 to 0.37) 0.142   
Vaccine would prevent swine flu 
  
  0.34 (-0.00 to 0.67) 0.052   0.28 (-0.05 to 0.62) 0.098   
Awareness of nasal vaccines 
  
  0.09 (-0.12 to 0.30) 0.398   
  
  
Household experience with swine flu vaccine 
  
  0.19 (-0.15 to 0.53) 0.283   
  
  
Inj vaccine safer vs. no preference 
  
  0.70 (0.07 to 1.33) 0.030d   
  
  
Nas vaccine safer vs. no preference 
  
  0.71 (-0.01 to 1.43) 0.052d   
  
  
Inj vaccine  more powerful vs. no preference -0.38 (-1.03 to 0.28) 0.261e   
  
  
  
  
Nas vaccine more powerful vs. no preference 0.32 (-0.44 to 1.08) 0.409e   
  
  
  
  
Nas vaccine: cannot say vs. no problem 
  
  0.64 (-0.44 to 1.72) 0.246f   0.31 (-0.62 to 1.24) 0.511g   
Nas vaccine: problem specified vs. no problem 
  
  0.12 (-0.60 to 0.84) 0.736f   0.52 (-0.11 to 1.15) 0.106g   
Inj vaccine: cannot say vs. no problem -0.32 (-0.92 to 0.27) 0.289h   -1.22 (-2.26 to -0.18) 0.022i   -0.92 (-1.82 to -0.01) 0.047j   
Inj vaccine: problem specified vs. no problem -0.68 (-1.42 to 0.05) 0.069h   -0.45 (-1.27 to 0.36) 0.276i   -0.43 (-1.17 to 0.30) 0.249j   
Sociodemographics 
  
21.70 
  
24.23 
  
24.48 
Not currently married 
  
  
  
  0.38 (-0.17 to 0.93) 0.176   
Minority social category 
  
  
  
  -0.23 (-0.72 to 0.26) 0.356   
Occupation: Agriculture vs. reference 
  
  -0.67 (-1.47 to 0.13) 0.101k   
  
  
Occupation: Employed vs. reference 
  
  0.29 (-0.31 to 0.89) 0.351k   
  
  
Income: over INR 10,000 vs. under 0.38 (-0.27 to 1.03) 0.253l   0.58 (-0.01 to 1.16) 0.055m   0.90 (0.38 to 1.42) 0.001   
Income: cannot say vs. under INR 10,000 -0.31 (-1.02 to 0.40) 0.392l   0.01 (-0.61 to 0.62) 0.985m   -0.02 (-0.60 to 0.55) 0.937   
Identifying illness as swine flu 0.64 (-0.12 to 1.40) 0.100   0.97 (0.31 to 1.63) 0.004         
Sex (male vs. female) -0.01 (-0.54 to 0.52) 0.972  0.56 (0.06 to 1.06) 0.029  0.41 (-0.01 to 0.84) 0.058  
Age -0.03 (-0.05 to -0.01) 0.001  -0.01 (-0.03 to 0.01) 0.329  -0.04 (-0.05 to -0.02) <0.001  
Urban low-resource vs. middle-income area -0.61 (-1.41 to 0.19) 0.133n  -0.80 (-1.54 to -0.07) 0.032o  -0.19 (-0.84 to 0.47) 0.572p  
Rural remote vs. urban middle-income area 0.08 (-0.80 to 0.95) 0.859n  -0.02 (-0.98 to 0.94) 0.964o  0.10 (-0.57 to 0.77) 0.767p  
Rural accessible vs. urban middle-income area -0.60 (-1.41 to 0.20) 0.143n  -0.24 (-1.01 to 0.53) 0.544o  -0.26 (-0.88 to 0.37) 0.423p  
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Focal models considered for three different outcome variables: nasal high price vaccine (INR 300), injectable medium price (INR 500) and injectable high 
price vaccines (INR 1000). All variables included for each focal model have been presented. Each focal model was adjusted for age, sex and area of 
residence, which have been presented in the model containing only sociodemographic characteristics.  
a Logistic regression coefficient with 95% confidence interval 
b Bold values indicate p≤0.05 
c Difference in corrected Akaike’s Information Criterion [∆(AICc)] between focal each model and the respective comprehensive model that had the lowest 
AICc  and was assigned a value of zero (comprehensive model described in Table 6-3 for ‘nasal high price’, Table 6-4 for ‘injectable medium price’ and Table 
6-5 for ‘injectable high price’). Model with lower ∆ AICc) values are considered better fitted than those with higher values. Bold values indicate models 
better than sociodemographics alone 
d Variable with 3 categories, overall p=0.073 
e Variable with 3 categories, overall p=0.090 
f,g,l Variable with 3 categories, overall p>0.2 
h Variable with 3 categories, overall p=0.167 
i Variable with 3 categories, overall p=0.072 
j Variable with 3 categories, overall p=0.134 
k Variable with 3 categories, overall p=0.064; Reference group for baseline comparison was those who were students, housewives, retired or unemployed 
m Variable with 3 categories, overall p=0.137 
n Variable with 4 categories, overall p=0.172 
o Variable with 4 categories, overall p=0.103 
p Variable with 4 categories, overall p>0.2 
Inj: Injectable; INR: Indian rupees, average exchange rate for 2012: 1 INR=0.0187 USD; Nas: Nasal 
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Table 6-3: Multivariable analysis (comprehensive model) of determinants of anticipated nasal 
pandemic influenza vaccine acceptance at the high price (INR 300) 
 
Explanatory variablesa Coefficient (95% CI)b P valuec 
Patterns of distress 
  Diarrhoea, appetite loss, abdominal pain 0.65 (-0.06 to 1.36) 0.073 
Breathlessness -0.43 (-0.90 to 0.03) 0.069 
Social isolation and interference 0.44 (0.10 to 0.79) 0.012 
Costs, lost income -0.24 (-0.47 to -0.02) 0.037 
Perceived causes 
  Contaminated water, unsafe food 0.30 (0.0002 to 0.59) 0.050 
Humoral imbalance, lifestyle -0.36 (-0.68 to -0.05) 0.023 
Prior illness -0.32 (-0.62 to -0.02) 0.037 
Help-seeking 
  Ayurvedic remedies at home 0.36 (-0.01 to 0.73) 0.053 
Private hospital 0.19 (0.01 to 0.37) 0.037 
Traditional healers 0.47 (0.08 to 0.85) 0.017 
Prevention 
  Maintaining cleanliness 0.16 (-0.03 to 0.35) 0.101 
Sociodemographics   
Sex (male vs. female) 0.26 (-0.31 to 0.83) 0.376 
Age -0.05 (-0.07 to -0.02) <0.001 
Area of residence 
 
0.148 
Urban low-resource vs. middle-income -0.36 (-1.23 to 0.52) 0.424 
Rural remote vs. urban middle-income -0.09 (-0.97 to 0.78) 0.837 
Rural accessible vs. urban middle-income -0.86 (-1.72 to -0.003) 0.049 
 
aVariables identified in focal models (p<0.2) included in comprehensive model       
b Logistic regression coefficient with 95% confidence interval 
c Bold values indicate p<0.05 
INR: Indian rupees, average exchange rate for 2012: 1 INR=0.0187 USD 
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Table 6-4: Multivariable analysis (comprehensive model) of determinants of anticipated injectable 
pandemic influenza vaccine acceptance at the medium price (INR 500) 
 
Explanatory variablesa Coefficient (95% CI)b P valuec 
Patterns of distress 
 
 
Social isolation and interference 0.25 (-0.01 to 0.52) 0.058 
Perceived causes 
  Contaminated water, unsafe food 0.19 (-0.04 to 0.43) 0.105 
Humoral imbalance, lifestyle -0.29 (-0.57 to -0.004) 0.047 
Lack of personal hygiene 0.43 (-0.02 to 0.88) 0.059 
Cough or sneeze of infected person 0.34 (0.03 to 0.64) 0.032 
Help-seeking 
  Drink warm liquids at home -0.38 (-0.66 to -0.11) 0.007 
Private hospital 0.18 (0.02 to 0.33) 0.025 
Other ideas about illness and vaccines 
  Illness identified as swine flu 0.75 (-0.04 to 1.54) 0.062 
Comparative vaccine safety 
 
0.087 
Inj vaccine: safer vs. no preference 0.72 (0.08 to 1.37) 0.029 
Nas vaccine: safer vs. no preference 0.63 (-0.13 to 1.38) 0.102 
Problems with injectable vaccine 
 
0.015 
Cannot say vs. no problem -0.79 (-1.33 to -0.26) 0.004 
Problem specified vs. no problem -0.39 (-1.14 to 0.37) 0.318 
Sociodemographics 
  Sex (male vs. female) 0.48 (-0.02 to 0.98) 0.060 
Age -0.01 (-0.03 to 0.01) 0.475 
Area of residence 
 
0.265 
Urban low-resource vs. middle-income -0.74 (-1.55 to 0.07) 0.075 
Rural remote vs. urban middle-income -0.73 (-1.51 to 0.06) 0.069 
Rural accessible vs. urban middle-income -0.57 (-1.37 to 0.23) 0.161 
 
aVariables identified in focal models (p<0.2) included in comprehensive model    
b Logistic regression coefficient with 95% confidence interval 
c Bold values indicate p<0.05 
Inj: Injectable; INR: Indian rupees, average exchange rate for 2012: 1 INR=0.0187 USD; Nas: Nasal 
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Table 6-5: Multivariable analysis (comprehensive model) of determinants of anticipated injectable 
pandemic influenza vaccine acceptance at the high price (INR 1000) 
 
Explanatory variablesa Coefficient (95% CI)b P valuec 
Perceived causes 
 
 
Dirty surroundings, improper sanitation 0.26 (0.05 to 0.47) 0.014 
Help-seeking 
  Do nothing at home (go directly to hospital) 0.13 (-0.03 to 0.28) 0.101 
Private hospital 0.26 (0.12 to 0.40) <0.001 
Other ideas about illness and vaccines 
  Problems with injectable vaccine 
 
0.003 
Cannot say vs. no problem -0.83 (-1.31 to -0.34) 0.001 
Problem specified vs. no problem -0.06 (-0.72 to 0.61) 0.871 
Sociodemographics 
  Income under INR 10,000/month(ref) 
 
0.002 
Over INR 10,000 vs. under 0.98 (0.44 to 1.51) <0.001 
Cannot say vs. under INR 10,000 0.17 (-0.43 to 0.76) 0.579 
Sex (male vs. female) 0.28 (-0.17 to 0.73) 0.222 
Age -0.04 (-0.05 to -0.02) <0.001 
Area of residence 
 
0.726 
Urban low-resource vs. middle-income 0.03 (-0.65 to 0.7) 0.941 
Rural remote vs. urban middle-income 0.23 (-0.45 to 0.92) 0.506 
Rural accessible vs. urban middle-income -0.15 (-0.80 to 0.51) 0.662 
 
a Variables identified in focal models (p<0.2) included in comprehensive model   
b Logistic regression coefficient with 95% confidence interval 
c Bold values indicate p<0.05 
INR: Indian rupees, average exchange rate for 2012: 1 INR=0.0187 USD 
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Supplementary table: Association between each explanatory variable and anticipated pandemic 
influenza vaccine acceptance  
 
Explanatory variablesa 
Nasal 
medium price  
(INR 150) 
Nasal 
high price  
(INR 300) 
Injectable 
medium price  
(INR 500) 
Injectable 
high price 
(INR 1000) 
  Estb P valc Estb P valc Estb P valc Estb P valc 
Patterns of distress     
 
    
 
  
 Vomiting, nausea 1.04 0.001 0.68 0.017 0.34 0.178 0.37 0.103 
Diarrhoea, appetite loss, abdominal pain 0.49 0.186 0.66 0.048 0.06 0.802 0.10 0.651 
Headache -0.03 0.931 0.39 0.146 0.11 0.605 0.20 0.312 
Breathlessness -0.35 0.160 -0.36 0.096 0.12 0.579 0.10 0.598 
Redness or rash 0.78 0.017 0.54 0.047 0.12 0.609 -0.15 0.458 
Complications in lungs, liver 0.56 0.065 0.18 0.483 0.26 0.237 0.16 0.406 
Concern about course of illness 0.25 0.178 0.05 0.712 0.04 0.754 -0.02 0.816 
Social isolation and interference  0.37 0.044 0.34 0.028 0.31 0.014 0.12 0.217 
Sadness, tension 0.04 0.731 0.06 0.575 0.12 0.194 0.12 0.157 
Costs, lost income -0.18 0.154 -0.16 0.136 -0.02 0.806 -0.05 0.595 
Perceived causes     
 
    
 
  
 Contaminated water, unsafe food 0.36 0.036 0.26 0.054 0.17 0.114 0.16 0.095 
Shock, tension -0.12 0.389 -0.09 0.431 -0.17 0.115 -0.05 0.657 
Humoral imbalance, lifestyle 0.15 0.469 -0.20 0.174 -0.20 0.133 -0.10 0.420 
Prior illness -0.02 0.914 -0.26 0.051 -0.09 0.484 0.02 0.855 
Dirty surroundings, improper sanitation 0.04 0.778 0.02 0.874 0.19 0.099 0.27 0.008 
Lack of personal hygiene 0.13 0.606 0.18 0.386 0.47 0.024 0.19 0.234 
Environmental germs 0.70 0.040 0.05 0.823 0.32 0.139 0.23 0.184 
Insect bite 0.03 0.820 0.11 0.350 0.00 0.986 0.11 0.170 
Air pollution 0.26 0.225 0.27 0.141 0.00 0.988 0.30 0.027 
Cough or sneeze of infected person 0.29 0.146 0.34 0.036 0.50 0.001 0.20 0.054 
Other contact  0.19 0.396 0.38 0.072 0.21 0.193 0.07 0.640 
Hospital-acquired 0.16 0.563 0.31 0.185 0.20 0.329 0.07 0.679 
Home-based treatment     
 
    
 
  
 Do nothing at home -0.03 0.777 0.07 0.430 0.10 0.242 0.14 0.060 
Drink warm liquids 0.03 0.873 -0.04 0.755 -0.22 0.075 -0.05 0.659 
Ayurvedic remedies 0.66 0.006 0.35 0.043 0.26 0.054 0.12 0.264 
Allopathic drugs 0.37 0.057 0.22 0.138 0.17 0.143 0.12 0.231 
Prayer -0.15 0.175 -0.08 0.433 -0.07 0.402 -0.10 0.235 
Help-seeking outside home     
 
    
 
  
 Private hospital 0.17 0.080 0.19 0.031 0.13 0.074 0.21 0.001 
Government hospital  -0.05 0.563 0.03 0.705 -0.03 0.597 -0.11 0.055 
Local health worker 0.44 0.143 -0.04 0.823 -0.01 0.971 0.04 0.823 
Informal help from friend or relative 0.01 0.966 0.01 0.970 -0.26 0.045 -0.14 0.270 
Traditional healer 0.45 0.057 0.27 0.144 0.26 0.110 0.22 0.110 
Prevention     
 
    
 
  
 Ritual purification, supernatural forces 0.02 0.892 0.09 0.496 0.18 0.160 0.08 0.380 
Handwashing 0.21 0.415 0.34 0.134 0.05 0.753 0.30 0.074 
Cleanliness 0.21 0.054 0.15 0.087 0.09 0.243 0.12 0.071 
Wholesome lifestyle 0.10 0.493 -0.19 0.067 0.08 0.433 0.09 0.344 
Wearing a mask 0.90 0.001 0.37 0.035 0.34 0.018 0.22 0.059 
Herbal remedies 0.55 0.059 0.27 0.223 0.30 0.126 0.10 0.510 
Preventive drugs 1.23 <0.001 0.47 0.076 0.52 0.024 0.11 0.546 
Vaccines 0.18 0.390 0.20 0.272 0.24 0.090 -0.04 0.694 
Health education 0.05 0.797 -0.07 0.633 0.04 0.797 0.25 0.072 
Ideas about illness, vaccines     
 
    
 
  
 Seriousness of illness 0.06 0.672 0.04 0.775 0.07 0.544 0.17 0.105 
Vaccine would prevent swine flu 0.41 0.023 0.14 0.435 0.39 0.019 0.33 0.050 
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Explanatory variablesa 
Nasal 
medium price  
(INR 150) 
Nasal 
high price  
(INR 300) 
Injectable 
medium price  
(INR 500) 
Injectable 
high price 
(INR 1000) 
  Estb P valc Estb P valc Estb P valc Estb P valc 
Awareness of nasal vaccines 0.19 0.177 0.13 0.249 0.14 0.151 0.02 0.773 
Inj vaccine more powerful  vs. no preference -0.07 0.849 -0.34 0.297 0.14 0.611 0.05 0.841 
Nas vaccine  more powerful vs. no preference 0.84 0.064 0.33 0.386 0.32 0.302 -0.25 0.376 
Inj vaccine safer vs. no preference 0.06 0.880 0.37 0.292 0.65 0.034 0.26 0.388 
Nas vaccine safer vs. no preference 0.42 0.393 0.50 0.226 0.61 0.084 -0.11 0.730 
Nas vaccine: cannot say vs. no problem -1.56 <0.001 -0.30 0.330 -0.55 0.034 -0.53 0.026 
Nas vaccine: problem specified vs. no problem -1.39 0.002 -0.03 0.933 -0.04 0.911 0.34 0.234 
Inj vaccine: cannot say vs. no problem -1.16 0.001 -0.27 0.368 -0.76 0.003 -0.75 0.001 
Inj vaccine: problem specified vs. no problem -1.04 0.023 -0.66 0.076 -0.27 0.452 -0.14 0.655 
Household experience with swine flu vaccine 0.16 0.440 0.11 0.507 0.24 0.133 0.05 0.693 
Sociodemographics     
 
    
 
  
 Not currently married -0.14 0.709 -0.16 0.617 0.21 0.489 0.41 0.134 
Living in a joint family 0.40 0.189 0.23 0.387 0.15 0.518 0.12 0.565 
Household size 0.12 0.070 0.05 0.297 0.05 0.273 0.03 0.368 
Self as household head 0.73 0.082 0.36 0.307 0.26 0.418 0.04 0.895 
Occupation: Agriculture vs. referenced -0.89 0.079 -0.33 0.478 -0.65 0.109 -0.11 0.763 
Occupation: Employment vs. referenced -0.51 0.200 0.13 0.691 0.32 0.288 0.07 0.778 
Income: Over INR 10,000 vs. under INR 10,000 0.24 0.537 0.42 0.206 0.62 0.034 0.94 <0.001 
Income: Cannot say vs. under INR 10,000 -0.39 0.336 -0.33 0.366 -0.12 0.696 0.02 0.951 
Minority social category -0.28 0.426 0.15 0.633 -0.34 0.209 -0.36 0.144 
Identifying illness as swine flu 0.43 0.346 0.69 0.074 0.99 0.003 0.20 0.440 
Sex (male vs. female)e 0.45 0.134 0.09 0.709 0.72 0.001 0.48 0.015 
Agee -0.03 0.003 -0.04 <0.001 -0.02 0.026 -0.03 <0.001 
Urban low-resource  vs. middle-income areae -0.24 0.626 -0.56 0.139 -0.80 0.020 -0.43 0.127 
Rural remote vs. urban middle-income areae -0.56 0.230 -0.25 0.536 -0.95 0.006 -0.29 0.324 
Rural accessible vs. urban middle-income areae -0.93 0.036 -0.56 0.139 -0.62 0.075 -0.29 0.315 
 
a Four different outcome variables: nasal medium price (INR 150), nasal high price (INR 300), 
injectable medium price (INR 500) and injectable high price (INR 1000) vaccine acceptance. 
Association between each individual variable and outcome, adjusted for sex, age and area have been 
presented. Continuous variables associated with p<0.20 to at least one of the outcomes or 
categorical variables for which at least one level differs from the reference level with p< 0.20 for one 
of the outcomes are documented. Continuous explanatory variables and categorical explanatory 
variables with overall p<0.20 in an association were included in focal models.  
b Est: Logistic regression coefficient. Shades of green indicate variables positively associated with 
outcome and shades of red indicate variables negatively associated with outcome.   
c P val: P value. Darkest shade: p<0.01, Middle shade: p<0.05, Light shade: p<0.20 
d Reference group for baseline comparison was those who were students, housewives, retired or 
unemployed 
e Adjustment variables used for each association presented. Here, unadjusted estimates of these 
variables are given  
Inj: Injectable; INR: Indian rupees, average exchange rate for 2012: 1 INR=0.0187 USD; Nas: Nasal 
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CHAPTER  
7  
Discussion 
A WHO guidance document emphasises the importance of pandemic 
preparedness as follows1: 
“Influenza pandemics are unpredictable but recurring events that can have severe 
consequences on human health and economic well-being worldwide. Advance 
planning and preparedness are critical to help mitigate the impact of a global 
pandemic”. 
The emergence of pandemic influenza, the virus subtype and its impact are 
currently unpredictable. The highly pathogenic  H5N1 influenza virus was 
considered a likely candidate, but in 2009, the H1N1 subtype unexpectedly 
emerged to reach pandemic proportions2. Although the 2009 pandemic was less 
severe than expected, it is neither indicative of the severity of any future 
pandemics, nor does it change the risk of another pandemic emerging3. 
Taubenberger and Morens summarize decades of influenza research by stating4: 
“As our understanding of influenza viruses has increased dramatically in recent 
decades, we have moved ever further from certainty about the determinants of, 
and possibilities for, pandemic emergence”. 
 
Preparedness for pandemic influenza is thus critical. These efforts are doubly-
useful for managing seasonal influenza and for improving health systems in 
general. Major steps have been taken towards this end with setting up of global 
surveillance for early detection of potential pandemic viruses5, stockpiling of 
antivirals6, increasing surge capacity of hospitals, and creating detailed 
pandemic preparedness plans that outline non-pharmaceutical interventions for 
use in early stages of a pandemic1. However, as cases increase beyond the 
surge capacity of hospitals and anti-viral resistance emerges, the logistical, 
social and economic consequences, in addition to the medical burden of disease, 
become extremely challenging. Pandemic control therefore relies heavily on 
production and use of vaccines, which remain the cornerstone of influenza 
control.  
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Community acceptance of vaccines is a critical determinant for effective 
pandemic influenza vaccine action. This thesis focuses on community acceptance 
of influenza vaccines while examining social and cultural features of the illness. 
Research was conducted in a lower-income country, India, where such studies 
are lacking. The thesis aims to describe urban and rural community 
understanding of pandemic influenza in Pune, in terms of experience, meaning, 
behavioural response and ideas on prevention. Identified sociocultural features 
of pandemic influenza were used to explain anticipated acceptance of vaccines. 
Community interest in pandemic influenza vaccines was assessed as well as 
preferences, experience and reasons for use or non-use of vaccines during the 
2009 influenza pandemic. Hereinafter a discussion of findings from previous 
chapters and implications for policy, methodological considerations, future 
directions and practical implications are presented and discussed.  
7.1 Community-reported priorities in contrast to professional 
priorities 
Community ideas on influenza illness prevention, causes and burden did not 
always coincide with professional ideas of the disease and its control. For 
example, the community prioritized cleanliness and a wholesome lifestyle above 
vaccination (Chapter 4). Notwithstanding importance of community-indicated 
preventive measures, for rapid control of pandemic influenza, vaccination takes 
precedence for public health professionals7. Similarly, prevention, management 
and treatment of physical symptoms are more of a public health priority for 
pandemic influenza control, than emotional burden from the illness, which was 
prioritised by the community. Some community ideas on cause of the illness, 
such as humoral imbalances in the body, tension and magico-religious causes, 
also differed from professional concepts. Generating community interest in 
control interventions becomes problematic when there is a lack of concordance 
in concepts of disease etiology. Dissonance between professional and community 
priorities may affect the perceived relevance of public health recommendations 
and limit their value in control. Local sociocultural ideas of illness and community 
priorities thus require understanding to improve communication with the public, 
and in planning vaccine interventions8. Acknowledgement of similarities and 
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differences between professional and community-reported burden of influenza, 
and community ideas and priorities for control, are therefore necessary for 
effectiveness of control measures. On the public health response to the 2009 
influenza pandemic, Larson and Heymann provide a reminder of the need to: 
“…maintain perspective about other health concerns of the public. These concerns 
will be present for the long term, well after the current influenza A (H1N1) 
pandemic has resolved”.9 
7.2 Value and ways of studying sociocultural features of illness in 
explaining vaccine acceptance 
Incorporation of local sociocultural features of illness, such as meaning and 
behaviour, explained anticipated vaccine acceptance better than 
sociodemographic and economic characteristics alone. Pre-intervention 
assessments of community acceptance of influenza vaccines should thus not only 
consider social epidemiology10, but also sociocultural features of illness to better 
predict anticipated acceptance. A similar finding has been reported in studies 
considering anticipated acceptance of oral cholera vaccines in Kenya11 and 
Zanzibar12. However, this is only applicable to lower-cost vaccines as economic 
considerations become primary predictors of vaccine acceptance for higher-
priced vaccines.    
 
In addition to the explanatory power provided by sociocultural features of illness 
in predicting vaccination behaviour, they may also aid communication and 
improve effectiveness of other community interventions. Health education is a 
prime example. In their critique of conventional forms of health education, Lloyd 
et al. highlight how messages “from the top” are often misinterpreted when they 
reach target populations13. As a solution, they propose understanding day-to-day 
community experiences with the illness, to effectively communicate messages of 
educational value. Study findings were utilised by the research team to better 
communicate with communities during a dissemination that was conducted on 
completion of the study. More details are provided in section 7.7 on 
methodological implications. 
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While Chapter 6 relied on empiricism and identification of patterns of behaviour 
and associations through largely quantitative methods, in Chapter 5, principally 
qualitative analytic methods were used to study vaccine hesitancy and 
acceptance. The two approaches represent complementary ways of knowing and 
are both valuable inasmuch as they answer different questions and provide 
different perspectives to the same question. For example, we reasonably expect 
perception of causes to influence vaccination decisions but respondents may not 
be able to articulate it as such. By relying on empiricism, we are not limited to 
self-reported accounts alone to identify relevant patterns of behaviour. On the 
other hand, the immediate influence of social norms and peer pressure, or other 
surprising respondent insights from an actual vaccination decision would not 
have been revealed without ethnographic research. 
7.3 Distinguishing anticipated and actual vaccine acceptance 
Determinants of anticipated pandemic influenza vaccine acceptance (Chapter 6) 
differed from reasons for actual vaccine use during the 2009 pandemic (Chapter 
5). The main reason behind the differences may lie in the nature of vaccine 
acceptance, which may be characterised as passive acceptance when considering 
determinants of anticipated acceptance and active demand when considering 
actual reasons for use of vaccine during the 2009 pandemic. Nichter14 defines 
demand and acceptance as follows:  
“Active demand entails adherence to vaccination programs by an informed public 
which perceives the benefits of and need for specific vaccinations. Passive 
acceptance denotes compliance: passive acceptance of vaccinations by a public 
which yields to the recommendations and social pressure, if not prodding, of 
health workers and community leaders.”  
 
Vaccines were not available during the first phase of the 2009 pandemic in India 
and the Indian government subsequently imported influenza A (H1N1) vaccines 
from Sanofi-Pasteur in March 201015,16. Locally-manufactured vaccines were 
additionally made available from June of 201017,18. Vaccines were recommended 
by the government19 but were not promoted or provided to the public through 
government campaigns. Persons who actually took a pandemic influenza vaccine 
displayed considerable initiative in getting it, either through private purchase or 
through attendance at ad-hoc vaccination drives. Those who anticipated 
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accepting a vaccine in our study, on the other hand, noted willingness or 
compliance in the context of a vaccination campaign. An underlying expectation 
was that the vaccine would be brought to them and actively provided. Both 
anticipated acceptors and actual acceptors demonstrated confidence in the 
vaccine; however, determinants of acceptance varied. 
7.4 Treatment-seeking and health system considerations 
An implicit hierarchy in perceptions of health services with private services 
ranking above government facilities was noted in our study and in other studies 
in India20-22. Reports of treatment-seeking at private hospitals were also 
positively associated with anticipated vaccine acceptance in our study (Chapter 
6). Respondents who indicated use of private health services may represent 
proactive health-seeking persons with the ability to afford higher cost services. 
Respondents from our study who had experienced influenza during the 2009 
pandemic reported first help-seeking at a private health facility where treatment 
delays were noted (Chapter 4).  Treatment costs were high in private hospitals 
(up to USD 10,000), compared to free treatment at government hospitals. 
Ironically, a case-control study done in Tamil Nadu, India, using surveillance 
data of laboratory-confirmed H1N1 patients found that treatment in private 
hospitals was associated with death23. Thus, patients who paid high treatment 
costs either from lack of knowledge about the alternatives, or lack of access as 
in the case of rural respondents in our study, or pursuant to an active attempt to 
secure better quality of care, may have had poorer outcomes. This suggests a 
need for better coordination with, and regulation of, private health services in 
India. While this is true in general, it is especially important during a pandemic 
where the potential for exploitation of vulnerable persons is higher. It also 
exposes shortcomings in the public health system, which in addition to being 
absent in many areas and thus inaccessible to many segments of the population, 
has also gained a reputation for inefficiency and poor quality. The need for 
improving public health services, regulation of private services and coordination 
within the health system is critical in this setting. 
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7.5 Vaccine hesitancy around the world and need for local study 
The second of six strategic objectives of the Global Vaccine Action Plan (GVAP), 
endorsed by 194 member states of the World Health Assembly in May 2012, 
calls for: “Individuals and communities to understand the value of vaccines and demand 
immunization as both their right and responsibility” (Text box 7-1)24. This represents 
a change in paradigm in provision of health services that traditionally focussed 
more on supply rather than on demand25. While emphasising demand-generation 
for vaccines, GVAP discusses tackling vaccine hesitancy through improved 
communication, advocacy to counteract anti-vaccine groups, community 
participation and improving quality of services24.  
 
 
Figure 7-1: Six strategic objectives for achievement of goals of the Decade of Vaccines 
Source: WHO Global vaccine action plan (2011-2020)24 
Discussion 
 
133 
 
Vaccine hesitancy for pandemic influenza vaccines was relatively low in our 
study compared to that observed in higher-income settings. Vaccination 
intentions for pandemic H1N1 vaccines among the general population in other 
countries were 50% in USA26, 56% in UK27, 61% in France28, 53% in Greece29, 
45% in Hong Kong30 and 54% in Australia31. Much higher anticipated acceptance 
(93%) was reported in our study in India (Chapter 6). Lack of vaccine 
availability and convenient access, and lack of a clear policy for influenza 
vaccination in the general population (discussed further in the next section) 
largely limited uptake. Comments from experts at a conference on public 
confidence in vaccines indicated that the main reason behind low vaccination 
coverage in developing countries was lack of government support32. A proposed 
solution to overcome this problem was to generate public demand for vaccines. 
It is hoped that community interest in vaccines to prevent ‘swine flu’ in our 
study would set the stage for initiating discussions regarding routine influenza 
vaccination policy in India. 
 
The example above supports a traditional generalisation between developed and 
developing countries with the former thought to have access to vaccines but 
hesitancy in accepting them, and the latter thought to have confidence in 
vaccines but limited access to them. While this may be true to some extent, 
such dichotomisation would be oversimplifying a complex issue. The risk lies in 
assuming low vaccine hesitancy in settings where vaccine access is the main 
barrier, and not paying attention to vaccine hesitancy in these settings. History 
has proven this to be a major oversight, exemplified by vaccine boycotts and 
poor uptake of life-saving vaccines in many developing settings33-36. In our study 
too, aspects of vaccine hesitancy were documented although they did not 
necessarily disqualify acceptance. Furthermore, other studies conducted among 
healthcare providers and medical students in India indicate lower confidence and 
anticipated uptake of influenza vaccines, due to concerns of safety and 
efficacy37,38, similar to that reported for Euro-American settings. Hesitancy 
among paediatricians in India in recommending influenza vaccines due to safety 
and efficacy concerns has also been noted39. It is thus critical to monitor vaccine 
hesitancy in lower-income settings, in different segments of the population, and 
even when current acceptance appears high, to avoid failing to address 
questions or concerns that may potentially erupt into crises of breakdown in 
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vaccine confidence and trust40. This thesis contributes to a growing body of 
knowledge and expertise on identifying and responding to vaccine hesitancy to 
improve vaccine uptake. 
 
During the influenza epidemic of 1847 in Britain, William Farr demonstrated that 
increases in mortality observed for diseases such as pneumonia and asthma 
were attributable to influenza41. In an attempt to convince others to look beyond 
the narrow constraints of local disease and to adopt a wider view of disease 
burden he is known to have said:  
“…there is a strong disposition among some English practitioners not only to 
localize disease but to see nothing but the local disease. Hence, although it is 
certain that the high mortality on record was the immediate result of the 
epidemic of influenza, the deaths referred to that cause are only 1,157.”  
Farr’s insights have helped shape the field of epidemiology42 and advances have 
been moving steadily towards analysis of diseases and their distributions on a 
global scale. Our understanding of disease and disease control has benefited 
tremendously from these advancements. However, there also remains a place 
and a need for local study. Some global questions may not have easily 
generalizable answers. What factors influence influenza vaccine hesitancy and 
acceptance in local settings is one such question.  
 
Recognising the importance of community and context, WHO guidelines 
specifically indicate incorporation of values such as perspectives of the 
population and sensitivity to local contexts when making recommendations for 
health interventions43. Although research suggests that these values are not yet 
being incorporated when WHO develops recommendations for member states44, 
recognition of the importance of community and context brings us a step closer 
towards finding local answers to global questions. This thesis is a contribution to 
that endeavour. 
7.6 Context of influenza vaccination policy 
Community understanding of influenza and vaccines, reasons for use or non-use 
of vaccines during the 2009 pandemic, and determinants of anticipated uptake 
of influenza vaccines in the context of mass vaccination have been explored in 
the previous chapters to identify practical suggestions for effective vaccine 
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implementation. This research and other specialized research activities that are 
currently ongoing in India with regard to dynamics of influenza seasonality for 
enhancing protection through vaccination45,46, characterising disease burden47-49 
and costs of respiratory infections50 are based on an assumed value of influenza 
vaccination. Acknowledgement of the value of influenza vaccination through 
national recommendations and policy is imperative to lending practical value and 
usefulness to the findings resulting from such research activities.  
7.6.1 Influenza vaccination policy around the world 
The WHO position paper on vaccines for influenza recommends annual 
vaccination, particularly for high-risk groups51. In addition to a vaccination policy 
for high-risk groups, in 2008, the United States endorsed a universal paediatric 
influenza vaccination policy, becoming the first country in the world to do so52. 
In light of disease burden and transmission, the new recommendation stated 
that annual vaccination be administered to all children between 5-18 years of 
age53. In 2013, the United Kingdom also began implementation of routine 
influenza immunization to all children aged 2-16 years, in addition to clinical risk 
groups54. 
7.6.2 Influenza vaccination policy in India 
The Pandemic Preparedness and Response Plan (PPRP) that was prepared by the 
Government of India for managing the 2009 pandemic, emphasises the 
importance of vaccination as the “best preventive strategy to combat a pandemic” 
while acknowledging lack of vaccine availability during the first wave of the 
pandemic19. The plan indicates that high-risk populations and those providing 
essential services would be prioritised for vaccination, followed by the rest of the 
population. Vaccinating the entire population is indicated as desirable in case of 
sufficient vaccine availability, while recognising that this scenario may be 
unlikely.  
 
The PPRP further highlights a lack of priority or policy recommendations for 
seasonal influenza vaccination in India due to insufficient knowledge of seasonal 
influenza disease burden in the country. The plan emphasises the need for an 
effective influenza surveillance network to provide burden data to thereafter 
facilitate public private partnerships between local vaccine manufacturers and 
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the government. The plan also indicates the value of seasonal influenza vaccine 
production in upkeep of facilities for pandemic preparedness and notes that the 
“Drug Controller General and the ICMR (Indian Council of Medical Research) would 
facilitate in establishing this capacity at the earliest”. The government promise of 
robust influenza surveillance systems after the 2009 influenza pandemic, 
however, has remained unfulfilled as evidenced by the influenza outbreak in 
early 2013 when high mortality rates were documented but disease burden was 
difficult to ascertain55. Furthermore, well-laid-out plans to deal with recurrent 
influenza outbreaks are notably missing.  
7.6.3 Recent seasonal influenza outbreaks in India 
The influenza A (H1N1) virus that caused the pandemic in 2009-2010 currently 
circulates as a seasonal influenza strain in India. Mortality and morbidity caused 
by this virus strain has persisted beyond the officially declared end of the 
pandemic56. An influenza A (H1N1) outbreak in northern and western India 
between 1 January and 24 February 2013 caused 2,267 laboratory-confirmed 
cases and had a greater case fatality rate than during the 2009 pandemic57. 
During this outbreak, high mortality was noted among apparently healthy people 
without comorbidities or underlying conditions55. In 2015, large outbreaks 
caused by influenza A (H1N1) were once again documented in India58. As of 
5 April 2015, approximately 35,000 cases and 2,123 deaths have been 
recorded59. A large proportion of these H1N1 influenza-related deaths have been 
among pregnant women and persons with comorbidities60,61. 
7.6.4 Hesitancy in influenza vaccination recommendations 
In the latest available online update on influenza A (H1N1) published by the 
Indian Ministry of Health and Family Welfare (MOHFW), vaccination has been 
recommended for health care workers, but not the public62. Recommendations 
for vaccination of high-risk groups are also notably absent, although a document 
detailing the epidemiology of seasonal influenza on the same website indicates 
the elderly, pregnant women, young children and people with co-morbidities as 
high-risk groups63. Moreover, in a statement to the public titled “Do’s and Dont’s” 
published on the MOHFW website and also presumably circulated widely, MOHFW 
inform64 (Figure 7-2, in Appendix 8.1): 
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“People with certain chronic medical conditions, adults 65 years or older, children 
younger than 5 years old and pregnant women are at higher risk for severe 
illness.” 
However, there is no mention of vaccines that offer a reliable means of 
protection for these high-risk groups. Thus, seriousness of the illness for high-
risk groups has been acknowledged, with a marked hesitancy in recommending 
vaccines. 
7.6.5 Willingness to promote alternative means of prevention 
The conservatism applied by the MOHFW in recommending vaccines is not 
extended to recommendation of ayurvedic, unani and homeopathic prevention 
methods65, most of which are untested. The National Health Portal website 
hosted by the MOHFW, details ayurvedic perspectives on prevention of swine flu 
illustrated in Figure 7-3 (in Appendix 8.1)66. Particularly curious 
recommendations for preventing swine flu include: “high level of mental strength 
with fearlessness”, “maintenance of self-restraint and celibacy”, and “prevention of 
waking at night”. Potential reasons for this policy encouraging prevention through 
traditional medicine include: the convenience of a recommendation that does not 
require additional planning, infrastructure or implementation by the government, 
known cultural acceptance of traditional forms of medicine, and political 
motivations67.   
7.6.6 Need for a coordinated and focussed national response to seasonal 
influenza 
Experts with decades of research on influenza virus evolution acknowledge 
insufficient scientific knowledge at present to identify when and where the novel 
2009 influenza A (H1N1) virus originated or in which species the re-assortment 
took place, although evolution in swine is a likely hypothesis68. Yet, the National 
Health Portal that promises to be the “gateway to authentic health information” 
states: “This virus infects the wind pipe (respiratory tract) of pigs and later it gets 
transmitted to human beings” (Figure 7-4, in Appendix 8.1)69, implying a direct 
transmission of the virus from pigs to humans. Publication of scientifically 
unestablished and misleading facts about influenza by the MOHFW is a cause for 
concern and is indicative of confusion and a lack of coordination in the national 
response to influenza. The lack of focus, practicality and accuracy of government 
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guidelines for treating seasonal influenza during the 2015 outbreaks has also 
been noted by paediatricians in India70. Furthermore, neglect of vaccination 
policy for endemic influenza makes preparedness for pandemic influenza difficult 
and ineffective71. 
 
In conclusion, it is unclear why MOHFW hesitates to recommend vaccination, 
especially for high-risk individuals. The Indian Academy of Pediatrics (IAP) holds 
a slightly different view and recommends seasonal influenza vaccination only for 
“high risk children”i in their position paper on influenza vaccination72. Lack of 
sufficient data on burden and target groups for India has been cited as a reason 
for not recommending routine use of seasonal influenza vaccines72. A systematic 
review and meta-analysis estimated that over 400,000 children under five years 
of age die each year of pneumonia in India, and that 6.5% of these death are 
due to influenza73. Individual studies in India have also demonstrated a high 
burden of influenza and recommend the use of existing data to initiate 
discussions about influenza vaccine policy recommendations at the national 
level47,49,74. It was also hoped that the experience of the 2009 pandemic would 
encourage policy discussions and articulation of policy for control of endemic 
influenza, but this was not the case75. In our study, communities noted lack of 
government endorsement as a reason for non-use of influenza vaccines (Chapter 
5). Policy response to current influenza outbreaks appears confused and not 
entirely evidence-based. Slow vaccine introduction has been described as a 
characteristic of vaccination history in India76. Unfortunately, the cost of lethargy 
in influenza control policies in India is paid by thousands of potentially vaccine-
preventable deaths every year. 
7.7 Methodological implications 
Ethnographic methods with focus group discussions and in-depth interviews, and 
a survey using semi-structured interviews were employed in this study. Multiple 
methods used in the study allowed for triangulation of data and analysis of aims 
                                       
i It is not entirely clear what the group of “high risk children” as stated in the position 
paper by the IAP means. One of the categories listed in this group is “laboratory 
personnel and health care workers” who definitely cannot be children. This is therefore 
most likely an error. 
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from different perspectives. The study capitalised on the strengths of both 
qualitative and quantitative approaches, and integration of these approaches, 
which lies at the heart of cultural epidemiology.      
 
This study benefited from previous experience studying OCV acceptance in 
Kenya, Zanzibar and the Democratic Republic of Congo using EMIC interviews. 
This study tried to overcome shortcomings that were discovered during field 
experience in the OCV studies. For example, more ethnography was conducted 
to provide detailed insight and to explain identified associations. To gain a better 
understanding of the topic, additional stakeholders such as policy makers, 
clinicians and media persons were interviewed, and an analysis of media reports 
and policy documents was undertaken.  These additional research activities, 
including analysis of findings on common influenza, are currently ongoing. 
Although beyond the scope of this thesis, findings are intended to be published 
soon. Innovations in automated coding of audio files and use of tablet computing 
for conducting a mixed-methods interview was an offshoot research activity from 
this study77. 
 
Relevant OCV studies with which the author of this thesis was directly involved 
in have been presented as Appendicesii. A comparison of sociocultural features of 
                                       
ii On a slightly less-relevant but nevertheless interesting note, the connection between influenza 
and cholera dates further back from this thesis, to the 1800’s, due to the tendency of both 
diseases to cause large outbreaks. An English physician, Theophilus Thompson, known for his 
writings on influenza noted78: “nothing in the history of the succession of epidemics is of more 
impressive interest that the intercurrency of influenza and cholera”. (The author of this thesis is 
equally fascinated by the intercurrency of influenza and cholera vaccine acceptance!) This 
statement was made by Thompson before the discovery of the germ theory of disease when the 
notion that influenza and cholera were linked was popular. In fact, influenza in the early 1800s 
was considered an inconvenience rather than a particularly terrifying disease. Epidemic outbreaks 
in the 1830s and 1840s, and William Farr’s recording of disease burden changed that perception41. 
An editorial in The Times on 10 February 1848 brought attention to the seriousness of influenza by 
comparing it to cholera as follows78: 
In this climate of chills and catarrhs we account a cold the natural death of an Englishman, 
and view an increased mortality under this head only as an extraordinary number of 
fashionable departures…Nothing has imparted so much terror to the influenza as the hint 
that it preceded the cholera—a much less destructive visitation.  
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cholera in the three countries is presented in Appendix 8.2, a study using meta-
analytic techniques to synthesise common and distinctive determinants of OCV 
acceptance across the three settings in Sub-Saharan Africa is presented in 
Appendix 8.3, and an assessment of sociocultural determinants of anticipated 
OCV acceptance in Western Kenya is presented in Appendix 8.4. 
7.7.1 Community participation and engagement 
The value of community engagement and participation has been acknowledged 
in many examples of successful disease control programmes79. The goal of 
community participation either as a means to an end (the objective is to control 
a specific disease and community participation enables this) or an end in itself 
(the objective is empowerment of communities to make autonomous choices 
regarding priorities and health) has been debated.  
 
The primary purpose of the OCV research study in Kenya and the present study 
in India was to collect information. No financial or other incentives were provided 
to participants. Yet, in both studies, a majority of participants spontaneously 
mentioned their appreciation for being listened to and indicated having found the 
process meaningful. Back in 1986, Tanner et al. emphasised the need to “listen 
to the people” prior to, or during programme development80. Another surprising 
observation was respondents’ reports of feeling informed and increased 
awareness after the interview process despite our careful attempts to listen, but 
not advise. Information gathering in itself was a form of community mobilization.  
 
After completing the field research and initial analysis, a community 
dissemination was conducted in Pune in November 2014 to share study findings. 
This was often requested during the interviews, but could not be provided at the 
time as research staff was not qualified to provide advice and to maintain 
integrity of the study. In consultation with local health experts and officials, 
insights and information gained from the study were presented to urban and 
rural study communities at their respective study sites after data collection. A 
dissemination workshop was also held in Pune for various levels of policy makers. 
Officials from the central government, municipality and subdistricts participated. 
A brochure for community residents and a policy brief for policy makers was 
prepared, distributed and discussed at these events. Feedback received from the 
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dissemination was useful in improving analysis and distilling relevant findings. 
Conducting the dissemination early enough to allow incorporation of feedback 
into analysis was a useful approach and is thus recommended.   
 
Other studies have noted challenges in community participation in low-resource 
settings81. We had greater participation from wider and more representative 
community members during the dissemination activities in Kenya than in India. 
Although this may be due to several factors, more hierarchical and rigid social 
structures in India are likely to have also played a role in limiting participation. A 
study in Tamil Nadu, India, found that community-directed treatment for 
lymphatic filariasis was less successful (in terms of outcomes and community 
satisfaction) than health services treatment; and this approach was deemed 
unsuitable given the local social and cultural context82. Notwithstanding the need 
and crucial role played by community-based research and community 
engagement, there is also the need to consider the nature and approach for 
community participation based on the sociocultural milieu. 
7.7.2 Limitations 
Limitations of this particular research study and strategies to mitigate potential 
limitations have been discussed in earlier chapters of this thesis. An overall 
limitation has been in finding generalizable answers for influenza vaccine 
acceptance and broader questions of vaccine hesitancy. Determinants may have 
opposite effects in different settings and are hence difficult to generalise. For 
example, higher education has been associated with higher and lower rates of 
hesitancy83. The powerful influence of culture and context on human behaviour 
and beliefs may make local study more relevant than generalizability.  
 
Another limitation is relating anticipated to actual vaccine acceptance. It was not 
possible to estimate this relationship in our study as there was no public mass 
vaccination initiative during the 2009 pandemic in India. Although we identified 
reasons for use among community members who had history of pandemic 
influenza vaccination, they represented a group of active vaccine-seekers and 
were relatively few in number. Anticipated rates, which we expect to be higher 
than actual rates if there were to be a vaccine implementation84, are thus a 
guide and indication of community priority rather than a perfect prediction. 
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7.8 Future research 
Conclusions presented in this thesis for pandemic influenza vaccines may 
reasonably apply to seasonal influenza vaccines, inasmuch as community 
members did not distinguish between concepts of epidemic versus pandemic 
disease and were largely only familiar with the concept of “swine flu”. However, 
key differences including need for annual vaccinations for seasonal influenza, 
compared to one-time vaccinations in case of a pandemic, and the current 
applicability of seasonal vaccination for high-risk individuals rather than the 
general population in India, make specific study of seasonal influenza vaccine 
hesitancy and acceptance necessary topics for future research. 
 
Information gathering in itself as a form of community mobilization was touched 
upon earlier in this chapter. Experience in the field prompted the question of the 
effect that conducting a sociocultural assessment of illness and ideas about a 
vaccine could have on vaccine uptake. Asking questions and active listening may 
have a significant influence on health-promoting behaviour, perhaps even more 
than passively provided recommendations ‘from the top’. We have no concrete 
evidence for this yet, but measuring the impact of a sociocultural assessment on 
vaccine uptake warrants study.  
 
A generic tool to assess contextual and individual sociocultural aspects 
contributing to vaccine hesitancy and other access-related and economic-related 
barriers is needed to document vaccine acceptance. Absence of standardised and 
validated tools to measure vaccine hesitancy and its determinants, especially in 
lower income countries, have been noted as a limitation of current research83. 
They have been noted as especially lacking in lower income countries. Routine 
monitoring of vaccine hesitancy through survey, followed by in-depth qualitative 
research to understand the nature of hesitancy has also been recommended85. 
Validation of such generic survey tools is needed not only for their ability to 
collect relevant information across varied settings. Validation of the usefulness of 
findings in guiding and improving vaccination outcomes is also required.  
A primary driver of vaccine policy is economic considerations. A global review of 
studies estimating costs of influenza illness or cost-effectiveness of influenza 
vaccine conducted in 2013 found that no studies had been conducted in low and 
lower-middle income countries86. The authors thereafter estimated costs of ARIs 
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in Northern India50, however more specific economic evaluations for influenza 
and vaccine cost-effectiveness are lacking. Economic data is influential in 
supporting vaccine policy87 and such research for influenza vaccination is needed 
in India.   
 
Poor worldwide uptake of influenza vaccination has resulted in the trial of various 
interventions, including vaccination mandates for healthcare workers and 
provision of financial or other incentives88.  Behavioural economics, a field that 
extends the microeconomic models of rational-choice to emphasize the social, 
psychological and emotional aspects of decision-making, including the 
importance of context and environment, is an innovative perspective with 
applicability in study of vaccine hesitancy and acceptance. Theory holds that 
humans are not always rational decision makers; however, certain departures 
from rationality are systematic and predictable. Daniel Kahneman’s seminal work, 
Thinking, Fast and Slow89, refers to cognitive biases that humans are prone to. 
For example, individuals tend to have excessive loss aversion, resulting from 
weighting losses and gains asymmetrically. This may lead to individuals 
preferring to maintain status quo, even if unfounded, rather than making an 
active decision. Individuals also have trouble thinking statistically and are prone 
to common errors in probabilistic thinking. This may have implications for 
vaccination decisions, such as being overly optimistic about disease and 
disregarding need for prevention. How choices are framed also affect acceptance 
or rejection, even when both choices represent the same probabilities. Thaler 
and Sunstein’s recommendation of use of nudges and improving choice 
architecture to address problems90 is another useful approach in tackling vaccine 
hesitancy. They refer to peer group norms and social cues that may exert strong, 
unrealized influences upon preferences. Some of these aspects such as peer 
group norms and optimism bias were touched upon in our work. Further 
research is needed through integration of insights and frameworks from 
behavioural economics to develop innovative solutions to improve vaccine 
uptake even in lower-income countries. 
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7.9 Practical implications and conclusions 
Study findings highlight the following recommendations for policy and practice in 
Pune, India.   
• High anticipated uptake and community interest in vaccines to prevent 
pandemic influenza suggest good prospects for use of influenza vaccines for 
pandemic control 
• There is need for a clearly-defined and evidenced-based policy for pandemic  
influenza vaccination in India 
• After such a policy has been implemented, the following considerations may 
help increase influenza vaccine coverage in the context of mass vaccination: 
Awareness 
o Improving community awareness about the illness, prevention and 
causes 
o Emphasising relevance of vaccines for adults and the elderly 
o Emphasising risk for urban and rural communities, men and women 
Access and economic considerations 
o Delivering the vaccine to communities, especially in rural areas, where 
this is expected 
o Providing vaccines at no cost or at a low cost to ensure equitable 
access for all 
o Providing vaccines at some cost, but not free, in higher-income urban 
areas 
Programmatic considerations  
o Introducing nasal vaccines with effective communication regarding 
their efficacy and safety to address community concerns 
o Engaging with communities and leaders prior to a vaccine campaign to 
ensure cooperation and to alleviate potential concerns 
o Use of behavioural nudges: emphasising seriousness of condition and 
cases, without scaremongering; indicating descriptive social norms 
Health system considerations 
o Government commitment and acknowledgement of priority for 
vaccination 
o Training of health care providers to recommend vaccines 
Considering setting-specific differences with urban and rural areas when drawing 
up plans 
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7.10 Conclusion 
This thesis investigates illness-related experience, meaning and behaviour for 
pandemic influenza, and sociocultural determinants of acceptance for pandemic 
influenza vaccines in Western India. It also addresses oral cholera vaccine 
acceptance across three settings in Africa: Zanzibar, Western Kenya and 
Southeastern Democratic Republic of Congo. In addition to providing practical 
suggestions for effective vaccine implementation, this thesis indicates an 
approach to study the influence of community determinants on disease control 
interventions, and an approach to promote awareness and use through 
community engagement. In conclusion, this work is a contribution to global 
advances in the study of vaccine hesitancy and it underscores the value of 
sociocultural study and community preferences in planning effective vaccine 
action. 
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Figure 7-2: “Do’s and Don’ts” for the community regarding seasonal influenza 
Posted on the website of the Ministry of Health and Family Welfare, Government of India (24 April 
2015)64  
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Figure 7-3: Recommendations for Ayurvedic remedies to prevent swine flu  
Source: National Health Portal, MOHFW, Government of India (2014)66 
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Figure 7-4: Incorrect information about the direct transmission of swine flu from pigs 
Source: National Health Portal, MOHFW, Government of India (2014)69 
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studies to guide local program planning for cholera control and elimination.
Keywords: Endemic cholera, Sociocultural features, Community study, Eastern Africa* Correspondence: mitchell-g.weiss@unibas.ch
1Department of Epidemiology and Public Health, Swiss Tropical and Public
Health Institute, Socinstrasse 57, PO Box, 4002, Basel, Switzerland
2University of Basel, Petersplatz 1, 4003 Basel, Switzerland
Full list of author information is available at the end of the article
© 2013 Schaetti et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Schaetti et al. BMC Medicine 2013, 11:206 Page 2 of 16
http://www.biomedcentral.com/1741-7015/11/206Background
Cholera is an ancient enteric disease that originated
from the Ganges delta [1]. It is caused by the bacterium
Vibrio cholerae that exists in the aquatic environment
independent from human hosts [2,3]. V. cholerae pro-
duces an enterotoxin, which is the direct cause of acute
watery diarrhea in humans. Cholera is characterized by
loss of large volumes of rice-water-like stool leading to
severe dehydration and concurrent electrolyte depletion
[4]. Case fatality rates without treatment may reach 50%
[5]. Timely administration of oral rehydration solutions
or infusions is the principal treatment [6].
Global cholera burden and sub-Saharan Africa as a hotspot
Cholera case estimates officially reported to the World
Health Organization (WHO) ranged between 190,000
and 320,000 for the years 2008, 2009 and 2010, and
between 5,000 and 7,500 deaths were reported [7-9].
These figures, however, are highly under-reported
because of limitations in surveillance, including case
definitions, and also fear of trade-related and travel-
related sanctions; they likely represent less than 10% of
the true burden [10]. A recent study estimated the
number of people at risk of endemic cholera globally at
1.4 billion, with an annual burden of endemic cholera of
2.8 million cases and 91,000 deaths [11]. Cholera thrives
mostly in low-income and middle-income countries in
Africa, Asia and the Caribbean [12].
According to the latest estimates, 39% of the popula-
tion in sub-Saharan Africa lived without safe water in
2010 (vs 51% in 1990), with an urban share of 17% and a
rural share of 51% [13]. Use of improved sanitation in
the same region has been increasing from 26% to 30%
since 1990. Similar to the estimates on water supply,
there is also an urban/rural divide: 43% of urban people
benefited from improved sanitation in 2010 versus only
23% in rural areas.
The public health burden of cholera is still intolerable
in sub-Saharan Africa despite the above noted progress
in the provision of safe water and sanitation. Conse-
quently, and because of the recent huge outbreaks in
Zimbabwe, Pakistan and Haiti, the 64th World Health
Assembly adopted a new resolution in 2011 to streng-
then the global fight against cholera [14].
The WHO recommends provision of sufficient, safe
water and adequate sanitation and hygiene (WASH) as
the mainstay to prevent cholera [15]. Official recommen-
dations also include the use of oral cholera vaccines
(OCVs) as a supplementary public health tool for pre-
emptive or reactive control of cholera outbreaks [16].
Professional versus community-reported burden of cholera
The burden of cholera may be characterized with re-
ference to professional indicators, and it may also bestudied with reference to the local vantage point of
community experience. The public health importance of
cholera with reference to professional indicators has
been extensively studied (that is, disease-related mor-
bidity and mortality, characterization and distribution of
pathogens, classical epidemiologic risk factors, economic
costs and so on) [2-4,11,17-19]. It is widely recognized
that cholera can spread rapidly and easily within countries
(for example, Kenya [20]) and across continents. Official
WHO policy recommends the development of ‘national
and subregional action plans that include cross-border
collaboration […] to enhance multidisciplinary prevention,
and preparedness and response activities’ for effective
cholera control [15].
In contrast with public health professionals, commu-
nities may prioritize other issues. Lay people may care
more about illness-related costs than morbidity, and
they may perceive the risk of illness with reference to
their local rather than regional experiences. Community
perceptions of the causes of illness may also differ from
professional concepts, and this may affect their per-
ceived relevance and value of recommended strategies
for control. Neglecting or underestimating local socio-
cultural aspects of cholera and priorities for control may
limit the effectiveness of interventions and control
programs [21-23]. This point has been elaborated in a
review of social science research on neglected tropical
diseases of poverty, which highlights the ‘importance of
community participation for the successful introduction,
acceptability, and adherence of innovative vector control
interventions and new drugs and diagnostics’ [24].
Notwithstanding the acknowledged importance of
community-based studies, there are very few in Africa.
Some have considered questions about perceived vulner-
ability and social and environmental aspects of cholera
[23,25], but systematic assessment of cholera-related
experience, meaning and behavior is lacking. In res-
ponse to this dearth of community-based research,
three sociocultural field studies were undertaken in a
WHO initiative to examine local urban and rural fea-
tures of cholera and community willingness to accept an
OCV in eastern Africa. A project in Zanzibar (Tanzania)
examined sociocultural features of cholera with a se-
mistructured interview and estimated anticipated accept-
ance and uptake of OCVs in endemic areas in 2008/2009
[26]. Two additional surveys using an almost identical
instrument were conducted in 2010 in endemic set-
tings in western Kenya and southeastern Democratic
Republic of Congo (SE-DRC). These three databases
on community views of cholera have been analyzed
with a focus on site-specific similarities and differen-
ces [27,28] (Merten S, Manianga C, Weiss MG, Lapika B,
unpublished data). A second set of analyses has examined
sociocultural determinants of anticipated OCV acceptance
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http://www.biomedcentral.com/1741-7015/11/206in all three settings [29-31], and of OCV uptake in
Zanzibar [32,33].
The aim of the present work is to review and sys-
tematically compare local cholera-related recognition,
risk perceptions, experience, and meaning in endemic
African settings. Knowledge of prevention, help-seeking
behavior and perceived vulnerabilities are also considered.
Data come from the three cross-sectional interview-based
surveys mentioned above. Particular attention is given to
site (that is, urban vs rural) and gender-specific features.
Given the vastness of eastern Africa, it is expected that
some features may be common while others may be lo-
cally distinctive, and that a systematic assessment of their
distribution in cholera-endemic communities is likely to
be relevant for informing a regionally tailored cholera con-
trol strategy.
Methods
Study settings by country
Study sites for the survey in Zanzibar were chosen in
2008 based on a review of the local cholera burden and
deliberations between the Ministry of Health and mass
vaccination campaign implementers. Study sites in
western Kenya and SE-DRC were selected in 2010
based on (i) epidemiological data collected from
recent cholera outbreaks, (ii) comparability of urban
and rural sites with reference to the survey sites in
Zanzibar and (iii) considerations regarding the se-
curity of the research team (SE-DRC) and accessibility
(western Kenya). The following is a brief description
of the urban and rural study sites in each setting,
including the national and local cholera situation and
related control activities around the time of the
surveys. More details can be found in the individual publi-
cations mentioned previously.
SE-DRC: Katanga province, southeastern Democratic
Republic of Congo
The survey took place in Kasenga district, in DRC’s
southeastern Katanga province. The first waves of the
current seventh cholera pandemic reached DRC in 1974
(then called Zaïre). DRC has reported outbreaks of
cholera every year since 1990. The eastern part of the
country, which borders the African great lakes region,
has traditionally been a focus of cholera, and Katanga
province is among the four most affected provinces
[34,35]. In 2010, 13,884 cases were reported by the
WHO for DRC [9]. In 2011, the United Nations Office
for the Coordination of Humanitarian Affairs (OCHA)
reported 22,233 cases, with 2,701 cases (12%) coming
from Katanga province [36]. In the absence of a proper
water and sanitation infrastructure in the area, cholera
transmission dynamics and severity of outbreaks are
mainly driven by environmental (for example, seasonalrainfall, the El Niño phenomenon) and human factors,
such as travel and trade [37].
Primary healthcare in DRC is in principle free, but
user fees in the form of a low flat rate or full cost
recovery have also been introduced in certain areas [38].
Even if no formal user fees are expected, patients will
rarely be treated anywhere in the country if they do not
pay informal fees; this and the fact that health centers
are often out of stock and understaffed reflects the poor
state of the public healthcare system in DRC.
Cholera control activities have been mainly reactive
with a focus on patient treatment in the epidemic-prone
lakes region. Public awareness and information cam-
paigns have been conducted after outbreaks in bigger
cities in southern Katanga region (that is, Lubumbashi,
Mbuji-Mayi, and so on) [34]. Outbreak response usually
includes setting up of treatment centers organized by
governmental and non-governmental institutions.
The small town of Kasenga, located 208 km east of the
provincial capital Lubumbashi, was chosen as the urban
site. Kasenga is situated on the Luapula River that shares
a border with Zambia. Kasenga is divided into eight
districts (known as ‘quarters’) with a total population of
27,000 inhabitants on a surface area of 10 km2. The
town is predominantly populated by Bemba-speaking
people. Kasenga is the terminus for land and water
transportation systems in the area, including buses from
Lubumbashi and boats from Pweto, located north of
Kasenga on Lake Mweru. Residents of Kasenga depend
mainly on three means of livelihood: agriculture, fishing,
and commerce. The urban site in SE-DRC was in a
quarter of Kasenga called Mwalimu, which was inhabited
by approximately 10,300 inhabitants and is characterized
by a high density of buildings. No sanitation is available
and a water supply that works only sporadically has been
installed only in the last few years.
The island of Nkolé, situated approximately 120 km
downstream from Kasenga in Lake Mweru, was chosen as
the rural site. Approximately 7,000 mostly Bemba people
live in Nkolé; they are mainly engaged in agriculture and
fisheries. One part of the population is seasonally migra-
ting to cultivate their fields along the river between
November and March when fishing is usually prohibited.
Availability of sound data on cholera morbidity is a
problem in the area. A manual review of case registers
over the last 3 years at the health posts serving both study
sites confirmed the seasonal influence as there were more
cholera episodes during the rainy season. Kasenga was
itself identified as ‘sanctuary’ for cholera outbreaks among
six other cities in eastern DRC [39]. The true cholera
burden, however, is likely to be higher because of under-
reporting due to the limited accessibility of health services
during the rainy season and due to rumors accompanying
cholera outbreaks in the past.
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Both survey sites in Kenya were in Nyanza province,
which borders Lake Victoria. The Lake Victoria region
has been regularly affected by the current cholera pan-
demic since 1977/1978. Cholera outbreaks have dis-
proportionately affected Nyanza province in recent years
in comparison to the rest of Kenya [40]. More than
14,000 cholera-related hospital admissions were reported
in the province in 1997/1998, with a case fatality rate
(CFR) of 4% [41]. Another large cholera outbreak started
in late 2007 in the aftermath of post-election violence,
causing high mortality rates [42]. In 2009, more than
11,000 countrywide cases were reported to the WHO [8].
Apart from public healthcare facilities, there are pri-
vate healthcare facilities owned by different stakeholders,
including multinationals such as the Aga Khan Founda-
tion, faith-based organizations and individuals. They are
thought to offer better services but are very expensive
(minimum of KES500 per visit). After the large out-
break of 2009, control activities in the affected areas
entailed health talks given to the communities. The
health talks were intended to promote awareness of
cholera, its mode of transmission, prevention and clinical
presentations.
Cholera treatment centers (CTCs) are organized only
during an outbreak and all the services are supposed to
be free of charge. Private healthcare facilities too are not
permitted to charge for treating cholera, according to
government policy.
Urban interviews were performed in the provincial
capital Kisumu, which is the third largest city in Kenya.
In 2004, about 60% of Kisumu’s population lived in
slums [43]. Migration into Kisumu from surrounding
districts has been predominantly motivated by better
resources and employment opportunities. Migrants are
most likely to settle in the already impoverished slum
areas.
The urban site was Nyalenda A, a slum in West Kolwa
location of Kisumu district, characterized by a high
population density (23,731 residents living on a 2.8 km2
surface area in 1999), poor planning, insufficient infra-
structure and a severe shortage of basic facilities such as
sanitation, safe water, sewerage and electricity [44]. Only
one dispensary and one private clinic served this com-
munity at the time of the study. Disposal of solid waste
is a major problem. The rural site in Siaya district com-
prised nine villages in the Kakum Kombewa sublocation.
According to a 2007 survey, 3,729 people lived in 1,013
households in the study area [45]. No healthcare facility
was available to villagers in the rural site in early 2010.
Since then, however, three dispensaries have been
constructed [46]. Access to the Siaya district hospital is
difficult because of irregular motorized transport. A
survey conducted in 2007 revealed that almost everyhomestead of Kakum Kombewa was dependent on
water from unprotected sources and latrine coverage
was 74% [45].
Zanzibar archipelago, Tanzania
The survey in Zanzibar, which is an archipelago 50 km
off the coast of mainland Tanzania, was performed on
its two major islands, Unguja and Pemba. Approximately
1.2 million people live in Zanzibar, which is a major
tourist destination. It is believed that cholera reached
Zanzibar as early as 1821 during the first pandemic [1],
with subsequent outbreaks in later pandemics. In the
current pandemic, cholera was reported for the first time
in 1978 [47]. More than 13 outbreaks followed since
then and the annual incidence rate reached 0.5 per 1,000
population between 1997 and 2007 [48]. Outbreaks
usually follow a seasonal pattern (that is, they occur
during flooding in the rainy season), and cholera inci-
dence on the archipelago was shown to be positively
influenced by rainfall and temperature [49]. Estimates
from the Ministry of Health reported a total of 48 cases
with a cholera diagnosis admitted to healthcare facilities
in 2008, 736 cases in 2009 and 248 cases in 2010 [50-52].
The public healthcare system in Zanzibar is divided
into three levels: primary, secondary and tertiary. Each
of the two islands constitutes a zone, headed by a zonal
medical officer. Over 100 primary healthcare units serve
the population; these units are open during the day to
outpatients, provide basic services and are within easy
reach for over 90% of the population. Four primary
healthcare centers (two per zone) operate on a 24-h
basis. These centers can admit up to 30 patients.
Cholera is a recognized priority disease in Zanzibar
and control activities follow national guidelines [53].
Once an outbreak has been declared, a concerted re-
sponse follows that usually involves deployment of chol-
era treatment kits, personnel for outbreak investigation,
clinical treatment and follow-up activities. CTCs are set
up in government health facilities or schools close to
communities where the outbreak has occurred. Medical
treatment (that is, infusions, antibiotics, oral rehydration
solution (ORS)) for suspected cholera patients is free;
affected families mainly incur direct costs to feed the
patient [19].
Chumbuni, in Urban district on Unguja Island, was
selected as the urban study site for the survey; Mwambe,
a village in Mkoani district on Pemba Island, was the
rural study site. Chumbuni was inhabited by approxi-
mately 11,000 people at the time of the study [27]. This
periurban slum-like extension of the capital of Zanzibar
is characterized by a high population density of 15,300
people/km2 and brick houses with corrugated roofs.
Mwambe was less densely populated (800 people/km2),
with a population of approximately 8,000 people living
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Survey design and instrument
The survey in Zanzibar was conducted from June to
August 2008 in collaboration with the Ministry of Health
and the Public Health Laboratory, Ivo de Carneri; the
survey was followed by a mass vaccination campaign in
early 2009. The survey in western Kenya was performed
from March to May 2010 in collaboration with Maseno
University, Kisumu. The survey in SE-DRC was conducted
from August to September 2010 along with researchers
from the Universities of Kinshasa and Lubumbashi.
A semistructured explanatory model interview based
on the Explanatory Model Interview Catalogue (EMIC)
framework [54] was used in all three settings. Each
version was developed and adapted to the local context
(see Additional files 1, 2, 3).
A random sample of adults was interviewed in each
survey. The interview was introduced with a vignette
telling the respondents a story about a local person with
the key signs and symptoms of cholera. The vignette
used in Zanzibar is available as an additional file in
Schaetti et al. [27]. It was the basis for adaptation and
use of vignettes in western Kenya and SE-DRC. Variables
elicited from responses to questions about the condition
depicted in the vignette were related to several domains:
identification; perceived seriousness, fatality and past
personal and household episodes of cholera; illness-
related experience (operationalized as patterns of dis-
tress indicating priority symptoms and concerns about
the illness); meaning (perceived causes); priorities for
prevention (for example, hygiene and sanitation); behav-
ior (help seeking at home and outside the household);
and perceived vulnerability to the illness. Sociodemo-
graphic characteristics were also recorded. Interviews
were conducted in Kiswahili (in all three settings), and
additionally in CiBemba (SE-DRC) and Dholuo (western
Kenya).
Ethics statement
Ethics approval to conduct interviews was obtained by
each individual study from the following review bodies:
WHO Research Ethics Review Committee (western
Kenya, Zanzibar), the University of Kinshasa (SE-DRC),
the Kenya Medical Research Institute (western Kenya)
and the Ministry of Health Ethics Committee of Zanzibar
(Zanzibar). All participants had provided written informed
consent prior to being interviewed.
Approach to analysis
Interview items were analyzed according to both fre-
quency and prominence. Calculation of the promin-
ence was based on whether a category was mentionedspontaneously by the respondent in response to an open-
ended question (assigned value of 2), only probing specific
categories (assigned value of 1), and accounting for whe-
ther it was identified as paramount among all reported ca-
tegories (additional value of 3). Each domain is presented
in a table by setting, divided into panels for overall results,
urban and rural site comparisons and gender comparisons.
The three most prominent categories for each setting and
any category with a significant difference between site and
between genders are presented for the domains of illness
experience, meaning, knowledge of prevention and be-
havior. Cross-setting comparisons of the three most pro-
minent categories and site and gender comparisons were
performed using the non-parametric Wilcoxon or Kruskal-
Wallis test for ranked prominence data and the χ2 or
Fisher’s exact test for proportions. More detailed and com-
prehensive data stratified by site for western Kenya and
Zanzibar have been published elsewhere [27,28].
Results
Sample characteristics
Approximately equal numbers of men and women from
urban and rural sites were interviewed in SE-DRC
(n = 360), western Kenya (n = 379) and Zanzibar
(n = 356). Detailed sample characteristics for all three
settings have been presented elsewhere [27,29,31]. In sum-
mary, the community samples in all settings were mostly
engaged in agriculture (>25%). This occupation was more
frequent in the rural sites except in SE-DRC, where the
rural site was a fishing village. Fishing was the major activ-
ity of 16.4% of people in SE-DRC (only men) and of 7.3%
in Zanzibar (all men except one woman), primarily from
the rural sites. Self-employment (that is, informal busi-
ness, petty trading, and so on) was also an important oc-
cupation reported by more than 17% across all settings.
Mean age was comparable across settings, varying be-
tween 32.8 and 38.8 years. Men were on average older
than women in SE-DRC and Zanzibar, and rural people in
western Kenya were older than urban people. Average
household size was lowest in western Kenya (mean of 4.5)
and higher in SE-DRC (6.2) and Zanzibar (6.8). Respon-
dents in western Kenya and SE-DRC were predominantly
Christian and respondents in Zanzibar were Muslim. Be-
tween 69% (Zanzibar) and 88% (western Kenya, SE-DRC)
reported to have completed primary or secondary school.
Men and urban respondents were better educated across
all settings. A reliable income was reported least in SE-
DRC (35.3%), and higher in western Kenya (47.8%) and
Zanzibar (55.9%).
Identification, perceived seriousness, fatality and past
experience of cholera
The condition described in the cholera vignette was identi-
fied as cholera in local terms by 96% of respondents in SE-
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(P <0.001) (Table 1). There were no gender differences in
illness recognition, and only a site difference in SE-DRC
and Zanzibar. Almost every respondent in SE-DRC was
afraid of death due to cholera; fewer respondents in
western Kenya (50%) and Zanzibar (78%) expected a fatal
outcome (P <0.001). Cholera was reported as ‘very serious
illness’ by >8 out of 10 respondents in all settings. Almost
half of the interviewed people in SE-DRC (44.4%) reported
having witnessed a cholera episode within the household,
and more so in the urban site. Among the 22.4% of
respondents reporting this in western Kenya, urban
residents and men were more prevalent; there was no
gender difference in SE-DRC and Zanzibar. More rural
residents were among the 15.5% who reported household
episodes in Zanzibar.
Patterns of distress: priority symptoms and psychosocial
impact
Excluding symptoms that were mentioned in the vi-
gnette (that is, muscle cramps, vomiting, frequent and
large amounts of rice-water-like stool), weakness wasTable 1 Identification, seriousness, fatality and past episodes
Category SE-DRC, n = 360
Overall %
Identification of illnessa*** 96.4
Seriousnessb*** 81.1
Expected fatal outcome without treatmentc*** 99.7
Past household episodes*** 44.4
Past personal episodes* 8.3
Site comparison Urban, % Rural, % P va
Identification of illnessa 93.9 98.9 0.0
Seriousnessb 85.6 76.7 0.0
Expected fatal outcome without treatmentc 99.4 100.0 0.3
Past household episodes 52.2 36.7 0.0
Past personal episodes 7.7 8.9 0.7
Gender comparison Female, % Male, % P va
Identification of illnessa 97.8 95.0 0.1
Seriousnessb 79.0 83.2 0.2
Expected fatal outcome without treatmentc 99.5 100.0 0.3
Past household episodes 43.1 45.8 0.5
Past personal episodes 7.8 8.9 0.6
‘Overall’: comparison between settings based on the χ2 test (identification of illness
household episodes), *P <0.05, ***P <0.001. ‘Site comparison’ and ‘Gender comparis
Fisher’s exact test (identification of illness and personal episodes) and Wilcoxon tes
Democratic Republic of Congo (SE-DRC) in ‘Overall’ section from Merten et al. [31]. D
Data for Zanzibar in ‘Overall’ and ‘Site comparison’ sections from Schaetti et al. [27]
aIdentified as cholera in local language based on vignette.
bCoded as ‘very serious’.
cCoded as ‘usually fatal without treatment’.identified as the most prominent symptom in all set-
tings (see Additional file 4). Unconsciousness (SE-DRC,
Zanzibar) and sunken eyes (all three settings), which are
signs of dehydration, were also prominently reported.
Somatic symptoms were mainly differentiated between
urban and rural sites in SE-DRC and Zanzibar. In SE-
DRC, where urban community residents have more ex-
perience with cholera, signs of dehydration and rectal
pain received greater prominence than in the rural site.
In western Kenya, lack of awareness about additional
symptoms for cholera, coded as ‘cannot say,’ was signifi-
cantly higher than in SE-DRC and Zanzibar, and with a
higher prominence in the rural site.
Cholera was perceived as having a significant impact
on people’s lives in all three settings (Table 2). The social
impact of cholera was mainly characterized by financial
concerns that were manifested by people reporting loss
of family income and interference with work-related ac-
tivities in all three settings, albeit with significantly differ-
ing prominences. Men in SE-DRC and Zanzibar reported
more negative influences of cholera on the household
economy. In western Kenya, direct costs related to choleraof cholera in endemic areas of three African settings
Western Kenya, n = 379 Zanzibar, n = 356
% %
75.2 88.2
91.3 96.6
49.9 77.5
22.4 15.5
11.6 5.3
lue Urban, % Rural, % P value Urban, % Rural, %
P value
20 72.6 77.8 0.285 95.5 80.8 <0.001
30 91.6 91.0 0.832 95.0 98.3 0.084
17 60.0 39.7 <0.001 84.4 70.6 0.002
04 27.4 17.5 0.044 6.7 24.3 <0.001
03 13.2 10.1 0.423 2.8 7.9 0.035
lue Female, % Male, % P value Female, % Male, %
P value
70 78.8 71.5 0.122 88.3 88.1 >0.999
95 91.2 91.4 0.907 96.1 97.2 0.577
20 52.9 46.8 0.151 74.9 80.2 0.257
63 15.5 29.6 0.003 12.9 18.1 0.172
80 8.3 15.1 0.053 3.4 7.3 0.104
and personal episodes) and Kruskal-Wallis test (seriousness, fatality and
on’: figures in bold designate significant differences at P <0.05 based on the
t (seriousness, fatality and household episodes). Data for Southeastern
ata for western Kenya in ‘Site comparison’ section from Nyambedha et al. [28].
.
Table 2 Comparison of the psychosocial impact of cholera in endemic areas of three African settings, by site and gender
Category SE-DRC, n = 360 Western Kenya, n = 379 Zanzibar, n = 356
Overall Total reported Prominence Total reported Prominence Total reported Prominence
Interference with
work/daily activities***
96.9 1.64 98.7 2.19 96.9 2.35
Loss of family
income***
92.5 2.41 96.3 2.63 95.5 2.13
Sadness, anxiety,
worry***
97.8 2.70 98.2 1.84 97.5 1.89
Site comparison Urban Rural Urban Rural Urban Rural
Total
reported
Prominence Total
reported
Prominence P value Total
reported
Prominence Total
reported
Prominence P value Total
reported
Prominence Total
reported
Prominence P value
Costs (transport,
food, drugs)
87.8 1.40 94.4 1.42 0.575 97.9 1.51 87.3 1.28 <0.001 97.2 2.07 96.0 1.67 0.142
Disruption of health
services
68.9 0.96 71.7 0.84 0.229 55.3 0.57 51.9 0.58 0.627 48.0 0.54 88.1 0.94 <0.001
Interference with
social relationships
67.2 1.12 86.7 1.56 <0.001 84.2 1.35 78.8 1.33 0.379 65.4 0.82 74.6 1.28 <0.001
Loss of family income 91.1 2.57 93.9 2.25 0.174 97.9 2.94 94.7 2.31 <0.001 98.3 2.11 92.7 2.16 0.463
Sadness, anxiety, worry 97.8 2.43 98.3 2.96 <0.001 100.0 1.90 96.3 1.78 0.064 100.0 2.06 94.9 1.72 <0.001
Gender comparison Female Male P value Female Male P value Female Male P value
Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence
Disruption of health
services
69.6 0.88 70.9 0.92 0.754 46.9 0.47 60.5 0.69 0.004 73.2 0.78 62.7 0.69 0.051
Interference with
work/daily activities
95.0 1.46 98.9 1.82 0.005 98.5 2.07 98.9 2.32 0.085 95.5 2.36 97.2 2.33 0.704
Loss of family income 94.5 2.55 90.5 2.27 0.112 96.4 2.74 96.2 2.51 0.178 93.9 1.96 97.7 2.31 0.007
Categories ordered alphabetically, except for ‘cannot say’. Total reported = percentage of categories reported spontaneously and upon probing. ‘Prominence’ = mean prominence of categories based on how reported
(spontaneous = 2, probed = 1, most troubling = 3). ‘Overall’: figures in bold designate top three prominent categories; comparison between settings based on the Kruskal-Wallis test, *** P <0.001. ‘Site comparison’ and
‘Gender comparison’: figures in bold designate significant differences at P <0.05 based on the Wilcoxon test. Data for Southeastern Democratic Republic of Congo (SE-DRC) in ‘Overall’ section from Merten et al. [31].
Data for western Kenya in ‘Site comparison’ section from Nyambedha et al. [28]. Data for Zanzibar in ‘Site comparison’ section from Schaetti et al. [27].
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concern.
Perceived causes
Problems with unsafe drinking water and a dirty envir-
onment in general, were the most common perceived
causes for cholera in all settings (Table 3). However, lo-
cally embedded explanations (for example, witchcraft)
were still widespread, especially in rural areas (SE-DRC
and Zanzibar). Lack of latrines was also a prominent per-
ceived cause in western Kenya (not elicited in Zanzibar).
There were site differences in 10 out of 12 categories in
Zanzibar, while only 3 categories in SE-DRC and 4 cat-
egories in western Kenya had significant urban/rural dif-
ferences. A dirty environment was often reported more in
urban sites of western Kenya and Zanzibar, which may re-
flect conditions that residents are unable to control. Flies
were particularly prominent in Zanzibar, without differen-
tiation between site and gender. Flies, which can act as
disease vectors for cholera, were mostly mentioned in
connection with food handling in Zanzibar.
Knowledge of prevention and priority of hygiene and
sanitation
Safe food and water and vaccines were prioritized for
prevention in SE-DRC (Table 4). Although safe water
was also a priority in western Kenya, respondents in
western Kenya and Zanzibar identified sanitation issues
(stool and garbage disposal) as priorities for prevention.
Health education was reported with equal priority across
all settings (P = 0.925). Differing ideas on prevention be-
tween sites and between men and women existed mainly
in western Kenya, and least often in SE-DRC. Vaccin-
ation as a preference was not reported differently be-
tween sites and gender.
Help-seeking behavior
Use of ORS and rehydration in general was a top priority
for home-based treatment of cholera patients in all
three settings (Table 5). Self-administration of drugs was
an additional prominent treatment option in SE-DRC
(mainly antibiotics) and western Kenya (tetracycline and
metronidazole (Flagyl®) most frequently mentioned).
Herbal treatment was the most prominent option in
Zanzibar, with a rural preference. Less commonly re-
ported practices were praying, which showed a higher
prominence in urban than rural western Kenya, and
drinking alcohol. The latter category, which was not eli-
cited in the Muslim society of Zanzibar, was higher
among men than women in SE-DRC and western Kenya.
Healthcare facilities were universally mentioned in all
three settings (Table 6), with an urban preference in
western Kenya and Zanzibar and a rural preference in
SE-DRC based on the assessment of the most preferredhealth provider. Other help-seeking practices were far
less common: advice from friends and colleagues was
the second most prominent category in western Kenya
and Zanzibar, also preferred more by rural and male
respondents. Visiting pharmacies/or purchasing over-
the-counter drugs was the third most prominent
category across all settings; it had the highest priority in
western Kenya and was reported with a significantly
higher prominence in rural than in urban Zanzibar.
Vulnerability to the illness
Respondents in SE-DRC reported cholera as a condition
affecting almost everybody (>84%) without differen-
tiating much between sex, age and class (Table 7). This
percentage was a little lower in Zanzibar (>74%). Re-
spondents in western Kenya differentiated more between
women and men and identified children and the poor as
most vulnerable to cholera.
Discussion
Based on data from almost 1,100 interviews in 3 en-
demic settings, this paper represents the first systematic
study of the nature and distribution of local sociocul-
tural features of cholera in urban and rural communities
at high risk in eastern Africa. The following points may
be worth considering in planning local educational activ-
ities to increase public awareness of interventions for
cholera control, and to advise communities of practical
ways of preventing cholera and managing cases. Study
findings may also be used to promote advocacy among
decision makers for investment in strategies and action
for better control or elimination of cholera.
Implications for regional cholera control policy and action
This study identified more differences between urban
and rural communities than between men and women
across all domains. This suggests a need for an approach
in program planning that is sensitive to setting-specific
disparities in all three settings. Findings also indicate
that local terms for cholera are recognized and adequately
understood in all settings by over three-quarters of the
surveyed populations. Use of these terms in health educa-
tion and control activities is advisable.
There is a past collective experience and memory of
cholera-related symptoms in all settings. In SE-DRC,
where poverty levels are higher and the public health
system is weaker than the other settings, people rely
heavily on social networks since income-generating
activities are less available. Thus, social networks may be
more important in SE-DRC (and probably also in DRC
in general) in order to meet needs. Cholera causes
primarily a considerable economic impact in all settings
represented by fears of absence from work or income-
generating activities and reported loss of family income.
Table 3 Comparison of perceived causes for cholera in endemic areas of three African settings, by site and gender
Category SE-DRC, n = 360 Western Kenya, n = 379 Zanzibar, n = 356
Overall Total reported Prominence Total reported Prominence Total reported Prominence
Dirty environment*** 93.3 1.83 96.3 1.97 97.8 2.99
Drinking contaminated
water***
94.7 2.68 95.5 2.21 95.2 1.65
Eating unprotected/
spoiled food***
94.7 1.94 93.1 1.75 94.9 1.44
Flies* 95.3 1.44 96.0 1.30 96.9 1.60
Lack of latrinesa*** 93.3 1.72 95.8 1.79 NA NA
Site comparison Urban Rural P value Urban Rural P value Urban Rural P value
Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence
Contact with
contaminated water
84.4 1.17 89.4 1.12 0.657 55.8 0.64 63.0 0.75 0.115 85.5 1.07 91.0 1.58 <0.001
Dirty environment 91.7 1.83 95.0 1.82 0.631 97.9 2.29 94.7 1.63 <0.001 99.4 3.68 96.0 2.30 <0.001
Drinking contaminated
water
93.3 2.34 96.1 3.02 <0.001 97.4 2.18 93.7 2.23 0.778 96.1 1.65 94.4 1.66 0.384
Eating forbidden food 20.6 0.23 13.3 0.15 0.094 11.6 0.12 14.8 0.15 0.365 27.4 0.27 54.8 0.48 <0.001
Eating soil 53.9 0.65 41.7 0.45 0.006 60.0 0.60 52.4 0.52 0.136 36.9 0.37 48.6 0.49 0.023
Eating unprotected/
spoiled food
92.8 1.89 96.7 1.99 0.100 95.3 1.75 91.0 1.74 0.432 95.5 1.60 94.4 1.27 <0.001
Flies 93.3 1.37 97.2 1.52 0.236 96.3 1.35 95.8 1.25 0.004 99.4 1.62 94.4 1.58 0.163
God’s will 40.0 0.56 42.2 0.55 0.668 8.9 0.09 7.4 0.07 0.586 93.3 1.22 86.4 1.83 0.001
Malaria 26.1 0.30 20.0 0.21 0.115 19.5 0.21 24.9 0.25 0.243 15.1 0.15 48.0 0.49 <0.001
Witchcraft 47.8 0.64 69.4 0.86 <0.001 9.5 0.09 11.6 0.12 0.494 20.7 0.21 45.8 0.50 <0.001
Worms 36.1 0.39 36.7 0.39 0.976 23.2 0.24 39.7 0.40 0.001 13.4 0.13 46.9 0.47 <0.001
Cannot say 4.4 0.11 3.9 0.14 0.638 2.1 0.42 11.6 0.77 0.005 1.1 0.02 13.6 0.27 <0.001
Gender comparison Female Male P value Female Male P value Female Male P value
Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence
Dirty environment 92.3 1.77 94.4 1.89 0.251 96.9 1.84 95.7 2.10 0.043 97.8 2.91 97.7 3.07 0.334
Eating soil 51.9 0.61 43.6 0.49 0.092 45.4 0.45 67.6 0.68 <0.001 43.6 0.44 41.8 0.42 0.772
Cannot say 5.0 0.15 3.4 0.10 0.620 7.7 0.65 5.9 0.54 0.476 11.2 0.22 3.4 0.07 0.005
Categories ordered alphabetically, except for ‘cannot say’. ‘Total reported’ = percentage of categories reported spontaneously and upon probing. ‘Prominence’ = mean prominence of categories based on how
reported (spontaneous = 2, probed = 1, most important = 3). ‘Overall’: figures in bold designate top three prominent categories; comparison between settings based on the Kruskal-Wallis test, *P <0.05, ***P <0.001.
‘Site comparison’ and ‘Gender comparison’: figures in bold designate significant differences at P <0.05 based on the Wilcoxon test. Data for Southeastern Democratic Republic of Congo (SE-DRC) in ‘Overall’ section
from Merten et al. [31]. Data for western Kenya in ‘Site comparison’ section from Nyambedha et al. [28]. Data for Zanzibar in ‘Site comparison’ section from Schaetti et al. [27].
aNot elicited in Zanzibar.
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Table 4 Comparison of prevention options for cholera in endemic areas of three African settings, by site and gender
Category SE-DRC, n = 360 Western Kenya, n = 379 Zanzibar, n = 354
Overall Total reported Prominence Total reported Prominence Total reported Prominence
Health education 92.5 1.75 98.9 1.89 95.5 1.90
Safe disposal of
garbage***
95.0 1.79 97.9 1.61 98.6 2.09
Safe disposal of stool*** 93.9 1.53 97.9 1.81 98.3 2.09
Safe food*** 95.3 1.92 98.4 1.67 97.5 1.66
Safe water*** 93.3 2.06 98.2 1.93 96.9 1.74
Vaccines*** 87.2 2.00 87.9 1.15 86.2 1.20
Site comparison Urban Rural Urban Rural Urban Rural
Total
reported
Prominence Total
reported
Prominence P value Total
reported
Prominence Total
reported
Prominence P value Total
reported
Prominence Total
reported
Prominence P value
Health education 90.0 1.80 95.0 1.71 0.371 98.9 2.27 98.9 1.51 <0.001 96.6 1.93 94.3 1.88 0.581
Preventive drugs 59.4 0.87 65.0 1.04 0.331 86.3 1.05 91.5 1.20 0.049 83.7 1.01 88.6 1.18 0.040
Protection from
supernatural influencea
10.6 0.13 5.0 0.05 0.047 7.4 0.09 21.7 0.22 <0.001 NA NA NA NA NA
Safe disposal of garbage 93.9 1.71 96.1 1.87 0.154 98.4 1.53 97.4 1.69 0.257 99.4 2.51 97.7 1.66 <0.001
Safe disposal of stool 91.7 1.53 96.1 1.54 0.911 97.4 1.66 98.4 1.96 0.026 99.4 1.96 97.2 2.21 0.301
Safe food 94.4 1.86 96.1 1.98 0.298 98.9 1.76 97.9 1.58 0.002 98.3 1.78 96.6 1.53 0.001
Gender comparison Female Male Female Male Female Male
Total
reported
Prominence Total
reported
Prominence P value Total
reported
Prominence Total
reported
Prominence P value Total
reported
Prominence Total
reported
Prominence P value
Health education 91.7 1.66 93.3 1.84 0.361 98.5 1.87 99.5 1.92 0.571 95.5 1.72 95.4 2.10 0.014
Protection from
supernatural influencea
5.0 0.05 10.6 0.13 0.044 13.4 0.14 15.7 0.17 0.533 NA NA NA NA NA
Safe disposal of garbage 95.6 1.78 94.4 1.79 0.500 97.4 1.52 98.4 1.70 0.026 98.9 2.13 98.3 2.05 0.906
Safe food 94.5 1.98 96.1 1.86 0.206 98.5 1.69 98.4 1.65 0.888 98.3 1.78 96.6 1.53 0.013
Safe water 92.3 2.15 94.4 1.98 0.159 98.5 2.04 97.8 1.82 0.019 97.2 1.77 96.6 1.71 0.926
Categories ordered alphabetically. ‘Total reported’ = percentage of categories reported spontaneously and upon probing. ‘Prominence’ = mean prominence of categories based on how reported (spontaneous = 2,
probed = 1, most useful = 3). ‘Overall’: figures in bold designate top three prominent categories; comparison between settings based on the Kruskal-Wallis test, *** P <0.001. ‘Site comparison’ and ‘Gender comparison’:
figures in bold designate significant differences at P <0.05 based on the Wilcoxon test. Data for Southeastern Democratic Republic of Congo (SE-DRC) in ‘Overall’ section from Merten et al. [31]. Data for western Kenya
in ‘Site comparison’ section from Nyambedha et al. [28].
aNot elicited in Zanzibar.
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Table 5 Comparison of home-based self-treatment options for cholera in endemic areas of three African settings, by site and gender
Category SE-DRC, n = 360 Western Kenya, n = 379 Zanzibar, n = 356
Overall Total reported Prominence Total reported Prominence Total reported Prominence
Drinking water/liquids*** 55.6 0.86 89.4 2.00 69.1 1.32
Herbal treatment*** 50.3 0.84 33.2 0.62 66.3 1.79
ORS*** 92.8 3.26 87.1 2.20 66.3 1.45
Self-administered drugs*** 56.1 1.19 73.9 1.89 58.4 1.30
Site comparison Urban Rural P value Urban Rural P value Urban Rural P value
Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence
Doing nothing at home 5.6 0.09 10.6 0.24 0.109 0.5 0.03 5.3 0.12 0.020 27.9 1.25 19.8 0.53 0.005
Drinking water/liquids 66.7 1.07 44.4 0.64 <0.001 87.9 1.93 91.0 2.07 0.493 68.7 1.58 69.5 1.05 0.006
Herbal treatment 50.0 0.79 50.6 0.89 0.912 30.0 0.61 36.5 0.63 0.292 49.7 1.29 83.1 2.31 <0.001
Prayers 44.4 0.80 50.6 0.74 0.497 51.1 0.68 32.3 0.37 <0.001 55.9 0.74 47.5 0.73 0.229
Self-administered drugs 48.3 1.03 63.9 1.36 0.006 76.8 1.95 70.9 1.83 0.251 44.7 1.03 72.3 1.57 <0.001
Gender comparison Female Male P value Female Male P value Female Male P value
Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence
Alcoholic drinka 4.4 0.05 11.2 0.12 0.019 4.1 0.06 10.8 0.14 0.014 NA NA NA NA NA
Herbal treatment 47.0 0.78 53.6 0.91 0.147 25.8 0.42 41.1 0.83 0.001 70.9 1.92 61.6 1.67 0.149
ORS 91.7 3.27 93.9 3.26 0.790 90.2 2.38 83.8 2.01 0.017 65.4 1.36 67.2 1.53 0.492
Self-administered drugs 50.3 1.07 62.0 1.32 0.023 69.6 1.87 78.4 1.91 0.585 61.5 1.35 55.4 1.25 0.363
Categories ordered alphabetically. ‘Total reported’ = percentage of categories reported spontaneously and upon probing. ‘Prominence’ = mean prominence of categories based on how reported (spontaneous = 2,
probed = 1, most helpful = 3). ‘Overall’: Figures in bold designate top three prominent categories; comparison between settings based on the Kruskal-Wallis test, *** P <0.001. ‘Site comparison’ and ‘Gender
comparison’: Figures in bold designate significant differences at P <0.05 based on the Wilcoxon test. Data for Southeastern Democratic Republic of Congo (SE-DRC) in ‘Overall’ section from Merten et al. [31]. Data for
western Kenya in ‘Site comparison’ section from Nyambedha et al. [28]. Data for Zanzibar in ‘Site comparison’ section from Schaetti et al. [27].
aNot elicited in Zanzibar.
ORS oral rehydration solution.
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Table 6 Comparison of outside help-seeking options for cholera in endemic areas of three African settings, by site and gender
Category SE-DRC, n = 360 Western Kenya, n = 379 Zanzibar, n = 356
Overall Total reported Prominence Total reported Prominence Total reported Prominence
Faith healers 19.4 0.31 18.5 0.23 14.9 0.18
Healthcare facility 100.0 4.79 100.0 4.76 100.0 4.64
Informal help*** 13.6 0.18 54.6 0.72 55.9 0.86
Pharmacy/OTC*** 19.4 0.20 59.1 0.70 34.0 0.36
Site comparison Urban Rural P value Urban Rural P value Urban Rural P value
Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence
Healthcare facility 100.0 4.69 100.0 4.90 0.001 100.0 4.87 99.5 4.65 0.005 100.0 4.87 100.0 4.41 <0.001
Informal help 15.6 0.22 11.7 0.13 0.263 44.2 0.54 65.1 0.90 <0.001 38.5 0.52 73.4 1.21 <0.001
Pharmacy/OTC 20.6 0.22 18.3 0.18 0.546 55.3 0.61 63.0 0.79 0.072 27.4 0.27 40.7 0.44 0.007
Traditional healers 9.4 0.14 4.4 0.09 0.075 12.1 0.16 17.5 0.19 0.187 3.9 0.04 9.6 0.12 0.031
Gender comparison Female Male P value Female Male P value Female Male P value
Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence Total
reported
Prominence
Healthcare facility 100.0 4.77 100.0 4.82 0.976 100.0 4.79 100.0 4.72 0.475 100.0 4.77 100.0 4.51 0.013
Informal help 10.5 0.12 16.8 0.23 0.078 49.5 0.62 60.0 0.83 0.026 50.8 0.69 61.0 1.03 0.014
Traditional healers 5.0 0.08 8.9 0.15 0.159 10.3 0.12 19.5 0.22 0.014 7.8 0.08 5.6 0.07 0.418
Categories ordered alphabetically. ‘Total reported’ = percentage of categories reported spontaneously and upon probing. ‘Prominence’ = mean prominence of categories based on how reported (spontaneous = 2,
probed = 1, most helpful = 3). ‘Overall’: figures in bold designate top three prominent categories; comparison between settings based on the Kruskal-Wallis test, *** P <0.001. ‘Site comparison’ and ‘Gender
comparison’: figures in bold designate significant differences at P <0.05 based on the Wilcoxon test. Data for Southeastern Democratic Republic of Congo (SE-DRC) in ‘Overall’ section from Merten et al. [31]. Data for
western Kenya in ‘Site comparison’ section from Nyambedha et al. [28]. Data for Zanzibar in ‘Site comparison’ section from Schaetti et al. [27].
OTC over-the-counter drugs.
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Table 7 Perceived vulnerability to cholera in endemic
areas of three African settings
Category SE-DRC,
n = 360
Western Kenya,
n = 379
Zanzibar,
n = 356
Sex
No differentiation 90.6 63.6 87.1
Women more vulnerable 6.9 24.5 10.4
Men more vulnerable 2.5 11.9 2.5
Age
No differentiation 84.4 26.9 79.5
Adults more vulnerable 8.1 22.4 8.1
Children more vulnerable 7.5 50.7 12.4
Class
No differentiation 86.3 44.9 74.4
Rich more vulnerable 0.6 2.9 0.0
Poor more vulnerable 13.1 52.2 25.6
SE-DRC Southeastern Democratic Republic of Congo.
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probably reflecting the fact that the latter are usually
covered by the healthcare system (during CTCs) or by
non-governmental organizations in all three settings. In
Zanzibar, laboratory-confirmed cholera patients reported
almost three-quarters of private costs as indirect costs
[19]. Differences in costs anticipated between rural and
urban areas (different options for generating income)
and genders (men more often generating a cash income)
were not consistent across all settings.
In line with the high recognition of the clinical vi-
gnette and the reported severity and help seeking, infec-
tious pathways of cholera are widely acknowledged, even
though local causal explanations continue to coexist in
all settings. The predominance of environmental and
sanitation-related factors and ingestion of contaminated
water or food hygiene as perceived causes points to
interventions needed in infrastructure. Because of this
relatively high overlap between biomedical facts and
local ideas about cholera, future community interven-
tions may preferably address environmental and infra-
structural issues, rather than solely reemphasize
education about causes of cholera. It cannot be ruled
out, however, that for those who subscribe to traditional
causes such as sorcery (primarily in DRC), classical
control activities may not be sufficient.
The three settings differ considerably in terms of water
supply and sanitation infrastructure. Use of improved
drinking water sources (45%) and improved sanitation
(24%) was lowest in 2010 in DRC [13]; the same indicators
were higher in Kenya (59%, 32%) and Zanzibar (53%, 53%;
numbers for Tanzania). Despite this relative variation, but
in line with the commonly prioritized environmental
and water and food-related perceived causes, the mostprominent prevention options referred to infrastruc-
tural aspects (water and sanitation) in all settings.
Similar to the prominence of biomedical meanings,
overall help seeking at home reflected a relatively high
awareness about professional cholera treatment in all
three settings. Rehydration to treat patients at home was
prominently reported in all three settings. Antibiotics
were the third most prominent treatment option in SE-
DRC and western Kenya. They were more prominent in
rural areas in SE-DRC and Zanzibar, even though rural
villagers are generally poorer and antibiotics have to be
purchased. This may be a consequence of limited access
to health facilities in the rural areas, while at the same
time indicating the availability of antibiotics in remote
areas. This suggests that future interventions should pri-
marily focus on rehydration, but also reconsider the role
of antibiotics and their potential of being used inappro-
priately. Antibiotics are part of the treatment regimen as
the WHO recommends antibiotics for severe cases [55]
(though some recommend it also for moderate cases
[56]), but indiscriminate use may jeopardize their effec-
tiveness and was shown to induce resistance [57]. Anti-
biotic use also means out-of-pocket expenditures that
may be better used for purchasing ORS packets or salt
and sugar for home-made oral rehydration solutions.
Herbal treatment, which is still important today for
diarrhea management in many African settings despite
westernization and modernization, may potentially con-
flict with effective cholera treatment. Herbs were among
the most important self-help options in rural Zanzibar;
this may call for more emphasis about their potential to
delay initiation of rehydration and the use of ORS.
The lower priority for herbal treatment in SE-DRC and
western Kenya may suggest less attention is needed in that
regard for effective information, health education and
communication campaigns.
While limited accessibility to health posts or CTCs may
still hinder patients or caretakers from seeking care for
cholera, the consistent and pronounced priority for pro-
fessional treatment of cholera across the three settings is
another important finding for policy makers in the region.
The underutilization of health services may be explained
by various factors, such as distance, perceived quality of
care, competing obligations, recognition of a need for
treatment, and so on. Further study of the role of these
reasons locally would be relevant for cholera control.
Concerning questions about the vulnerability of some
segments of the population to cholera, in western Kenya
respondents were more likely to acknowledge differences.
They were consistently less likely than respondents in the
other settings to report ‘no differentiation,’ and they more
frequently identified women or men, adults or children,
and the poor as more vulnerable. The findings suggest
both greater cultural sensitivity to vulnerability in general,
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and children to cholera. Respondents at the other settings
were less likely to distinguish the vulnerability of these
specific subgroups. In the comparison of SE-DRC and
western Kenya, this may reflect less access to health
services and lower levels of overall development, which
affect everyone. In Zanzibar, the finding may reflect less
emphasis on vulnerability in health policy. However, this
is unclear and the reasons for acknowledging the
vulnerability of some groups require further study. In any
case, the relative priority of the needs of the general popu-
lation and of specific subgroups requires consideration in
cholera control and for strategies to integrate services in
the general health system. Acknowledgement of children
and pregnant women as high-risk groups that should be
prioritized for cholera vaccines [58] suggest more atten-
tion to the relative vulnerability of subgroups would be
appropriate in health education in SE-DRC and Zanzibar.
Vaccination has also been recommended by the WHO
as an additional measure to WASH in epidemic and en-
demic situations [16]. Although no vaccination campaigns
have been conducted in the study sites before the surveys,
the use of vaccines for prevention was identified by a ma-
jority in all settings and it received the highest priority in
SE-DRC. Vaccine action was a matter of sufficient priority
for the government of Zanzibar that it conducted an OCV
mass vaccination campaign in 2009. Additional analyses
on community demand for oral cholera vaccination con-
firm a high regard for vaccination with anticipated accep-
tance rates above 93% in the three surveys [29-31]. While
an analysis of sociocultural determinants of anticipated
OCV acceptance across the three settings using meta-
analytical techniques is in preparation, the descriptive
findings presented here indicate good prospects for future
vaccination campaigns in the region. It should be noted,
however, that a high acceptability, constituting only one
component of access to health (care), does not directly
relate to a high effectiveness. Unlike other multicountry
comparisons of people’s ideas about illness and willingness
to receive a not-yet-existing vaccine [59,60], finhdings
from this study are directly relevant for public health prac-
tice. Two cholera vaccines are available and prequalified
by the WHO, and planning is underway to increase their
use in populations at risk [61].
This study is limited by the fact that findings are based
on cross-sectional surveys, which do not take into ac-
count the possibility of changes in the studied domains
over time. The strengths of this three-country compari-
son lie in the use of three individual community surveys
that were planned and implemented in a highly consis-
tent manner. All surveys used the same, although locally
adapted, interview schedule; this enabled maximum
comparability in the analysis of sociocultural features of
cholera across the three settings.Conclusions
Based on this comprehensive review of local under-
standings of cholera-related diarrhea and priorities for
cholera control in southeastern Democratic Republic of
Congo, western Kenya and Zanzibar, local program plan-
ners are encouraged to intensify control activities in this
region. Sustainable cholera control, let alone elimination,
is only possible through improvements in the local water
supply and sanitation infrastructure. Due to political and
economic realities in the region, which are improving
much too slowly, control of cholera continues to depend
mostly on response activities (that is, ensuring timely
rehydration through local treatment centers) in the fore-
seeable future. This study indicates that such an approach
is likely to be very effective in areas with endemic cholera
in eastern Africa. At the same time, regional decision
makers may also consider using vaccines in popula-
tions at risk of recurrent cholera outbreaks; such in-
termediate activities would help mitigate morbidity and
mortality while programs for improving water and sanita-
tion are underway.
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Abstract 
Background: Controlling cholera remains a significant challenge in Sub-Saharan Africa. In 
areas where access to safe water and sanitation are limited, oral cholera vaccine (OCV) can 
save lives. Community acceptance of vaccines, however, is critical. This study identifies and 
compares sociocultural determinants of anticipated OCV acceptance across Southeastern 
Democratic Republic of Congo, Western Kenya and Zanzibar.  
Methods: Cross-sectional studies were conducted using similar but locally-adapted 
semistructured interviews among 1095 respondents in three African settings. Logistic 
regression models identified sociocultural determinants of OCV acceptance from these 
studies in endemic areas of Southeastern Democratic Republic of Congo (SE-DRC), Western 
Kenya (W-Kenya) and Zanzibar. Meta-analytic techniques highlighted common and 
distinctive determinants in the three settings.  
Results: Anticipated OCV acceptance was high in all settings. More than 93% of community 
respondents overall indicated interest in a no-cost vaccine. Higher anticipated acceptance was 
observed in areas with less access to public health facilities. In all settings awareness of 
cholera prevention methods (safe food consumption and garbage disposal) and relating 
ingestion to cholera causation were associated with greater acceptance. Higher age, larger 
households, lack of education, social vulnerability and knowledge of oral rehydration 
solution for self-treatment were negatively associated. Setting-specific determinants of 
acceptance included reporting a reliable income (W-Kenya and Zanzibar, not SE-DRC). In 
SE-DRC, intention to purchase an OCV appeared unrelated to ability to pay. Rural residents 
were less likely than urban counterparts to accept an OCV in W-Kenya, but more likely in 
Zanzibar. Prayer as a form of self-treatment was associated with vaccine acceptance in SE-
DRC and W-Kenya, but not in Zanzibar.  
Conclusions: These cholera-endemic African communities are especially interested in no-
cost OCVs. Health education and attention to local social and cultural features of cholera and 
vaccines would likely increase vaccine coverage. High demand and absence of 
insurmountable sociocultural barriers to vaccination with OCVs indicate potential for mass 
vaccination in planning for comprehensive control or elimination.  
 
Keywords 
Vaccine acceptance; Cholera vaccine; Social determinants; Cultural epidemiology; Meta-
analysis; Africa 
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Background 
Cholera results from ingesting pathogenic strains of the bacterium Vibrio cholerae in 
contaminated water or food [1]. Although cholera should not be fatal,  if untreated, case-
fatality ratios for severe cholera may be as high as 50% [2]. An estimated 1.4 billion people 
are at risk for cholera in endemic countries [3]. Controlling cholera remains a significant 
challenge in Sub-Saharan Africa. Access to safe water and sanitation remain low in the 
region, about 61% and 30%, respectively [4]. Needed development requires major 
investments in infrastructure that proceed very slowly. 
In the interim, oral cholera vaccines (OCVs) can save lives in epidemics and endemic 
areas. The World Health Organization (WHO) recommends OCVs as a short-term control 
strategy for high-risk populations to complement long-term water and sanitation 
improvements [5]. Two safe OCVs — ShancholTM, with a protective efficacy of 66%  [6], 
and Dukoral®, with 79% direct protection [7] — are currently available for international use. 
Efficacy is not enough, however, for vaccines to be effective. People must also be willing to 
accept them. Local social and cultural ideas about illness, vaccines and community 
preferences are critical considerations. Past programme experience provides valuable lessons 
that underscore the priority of social and cultural aspects of vaccine acceptance and effective 
vaccine action [8-11]. A recent review of vaccine hesitancy suggests community 
effectiveness may depend on particular features of setting, health problem and vaccine [12]. 
Studies of sociocultural aspects of cholera [13-15] were undertaken in three cholera-
endemic settings in Africa. A comparison of sociocultural features of cholera from these three 
studies have been reported by Schaetti and colleagues [16], and sociocultural determinants of 
anticipated OCV acceptance in each setting were also studied [15,17,18]. The analysis 
reported here compares determinants of anticipated OCV acceptance across the three settings 
in Democratic Republic of Congo, Kenya and Zanzibar. Common and distinctive 
sociocultural features of endemic settings that may affect uptake and effectiveness of OCVs 
in cholera-endemic areas of Sub-Saharan Africa are presented.  
 
Methods 
Meta-analytic techniques were used to synthesise and compare data on sociocultural 
features of illness and anticipated OCV acceptance from research studies with comparable 
designs in three settings: Southeastern DRC (SE-DRC) [15], Western Kenya (W-Kenya  [18] 
and Zanzibar [17].  
Setting 
In SE-DRC, the study was conducted in Kasenga district of Katanga province. In 
Western Kenya, it was conducted in Kisumu and Siaya districts of Nyanza province, located 
on the banks of Lake Victoria. In Zanzibar, a semi-autonomous part of the United Republic 
of Tanzania, study sites were located on Unguja and Pemba Islands. Zanzibar is the only one 
of the three settings where a mass OCV vaccination was implemented [7], but study data 
analysed here were collected before the mass vaccination.   
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In the years 2008 and 2009 a total of 53, 049 cholera cases were reported to the WHO 
from DRC, 14,516 cases were reported from Kenya and 10,611 cases for Tanzania [19,20]. 
Reported cholera cases are estimated to represent only a fraction of the actual cases due to 
substantial underreporting [21,22]. All three settings lack universal access to safe water and 
sanitation.  
Individual study design and data collection 
Data for the current analysis are from three cross-sectional studies of adults in the 
general population who were interviewed. Similar, but locally adapted semi-structured EMIC 
(Explanatory Model Interview Catalogue) interviews [23] were used at each setting. Patterns 
of distress, perceived causes, help-seeking and methods of prevention associated with a 
cholera-like illness (presented to respondents using a clinical vignette describing a person 
with cardinal cholera symptoms) were assessed based on a cultural epidemiological 
framework [24]. Quantitative and narrative data were collected. The instrument also assessed 
respondents’ willingness to accept OCVs at different prices: ‘free’ as in the case of many 
mass vaccination campaigns; ‘low cost’, approximately USD 1; ‘medium cost’, USD 4-5 and 
‘high cost’, USD 8-11. OCV prices were stated in the near-equivalent local currency as price 
per vaccine course. Data collection proceeded from June through August 2008 in Zanzibar, 
March through May 2010 in Kenya, and August through September 2010 in SE-DRC. 
Further details on sampling and data collection are provided in published reports of these 
studies [15,17,18,25].  
Approach to analysis 
In each setting, prominence scores were calculated for sociocultural variables (e.g., 
categories of distress and perceived causes) depending on how they were reported. A 
category reported spontaneously by the respondent received a higher prominence (value=2) 
than responses provided only on probing (value=1); if a category was identified as most 
important among all categories, a value of 3 was added. Mean prominence, which 
encompasses more information than a mere ‘yes’ or ‘no’, was calculated for each variable 
and used in analysis. SAS statistical software, version 9.2 (SAS Institute Inc., USA), was 
used.  
Univariable logistic regressions were done for each setting. Anticipated OCV 
acceptance at each price level were outcome variables for analysis of sociocultural and 
sociodemographic explanatory variables.  
Meta-analytic techniques were employed to combine and compare associations 
between OCV acceptance and explanatory variables at the three settings. Variables with 
consistent combined estimates (p<0.1) and lacking heterogeneity (p>0.1) were selected and 
individually adjusted for core sociodemographic features. A fixed-effects meta-analysis of 
the adjusted estimates was done, and results are presented in forest plots, generated using 
STATA, version 10.1 (StatCorp LP, TX, USA). Figures 2 and 3 in this report display 
multiple forest plots, and each is an individual model. Variables whose association with 
anticipated OCV acceptance showed heterogeneity at a level of p<0.1 between the settings 
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and a significant association in at least one of the settings (p<0.05) are presented in tables. 
These variables were not meta-analysed owing to significant heterogeneity.  
It should be noted that our analysis refers exclusively to anticipated acceptance or 
non-acceptance, rather than vaccine coverage.  
Ethics statement 
Ethical approval was obtained from the Ministry of Health Ethics Committee of 
Zanzibar for the study conducted in Zanzibar, Kenya Medical Research Institute for the study 
in W-Kenya and from the University of Kinshasa for the study conducted in SE-DRC. 
Furthermore, ethical approval was obtained for all three studies from the WHO Research 
Ethics Review Committee. All participants provided written informed consent before they 
were interviewed. 
  
Results  
Data from a total of 1095 respondents were analysed—360 from SE-DRC, 379 from 
W-Kenya and 356 from Zanzibar. Sample characteristics have been presented in reports of 
these studies [16]. 
Anticipated OCV acceptance  
High anticipated OCV acceptance rates (>93%) were found in all settings when 
offered for free (Fig. 1), and acceptance decreased with increasing cost. W-Kenya had the 
highest number of respondents willing to take the low-price and no-cost vaccine, while SE-
DRC had the greatest number willing to purchase the medium-price and high-price OCVs. 
Zanzibar had the lowest anticipated OCV acceptance at all prices. 
 Common determinants of OCV acceptance across all three settings 
Near universal (>95%) anticipated acceptance reported for the no-cost and low price 
OCV at some sites, made it unnecessary to further consider determinants at these cost-levels. 
The medium price (USD 4-5) model approximates the cost for a full-course of ShancholTM 
(USD 1.85 per dose [26,27] = USD 3.70 for 2 doses). The high price (USD 8-10) model 
reflects the cost of Shanchol along with other programmatic and indirect costs. The high price 
also crudely approximates the market price for DukoralTM (USD 5.25 per dose [26]), which 
was used for mass vaccination in Zanzibar.  
Sociodemographic determinants 
Similar sociodemographic variables were significantly associated with anticipated 
OCV acceptance at the medium price of USD 4–5(Fig. 2) and high price of USD 8–11 (Fig. 
3). Increasing age and living in a larger household were associated with decreasing 
willingness to accept an OCV. Lack of education was a predictor of OCV non-acceptance at 
the high price. It was marginally significant at the medium price (p=0.06, not represented in 
Fig. 2).  
Sociocultural determinants 
Sociocultural variables associated with anticipated OCV acceptance at the medium 
price were distinct from the high price. Only two were significantly associated at the high 
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price, compared to six at the medium price. The following sociocultural determinants were 
common to all settings: 
Attention to garbage disposal and consumption of safe food as measures to prevent 
cholera were predictors of OCV acceptance (Fig. 2).  
Those identifying worms (Fig. 3) or the cultural practice of eating soil (Fig. 2) as 
causes of cholera were more likely to accept OCVs. Narrative accounts related the practice of 
eating soil to the fact that it is unclean, even though the practice may be culturally acceptable, 
especially for women. Eating unhygienic substances produced worms in the stomach. 
Respondents explained that they were trapped in an unclean environment, and though aware 
of the importance of hygiene, they felt there was little they could do to prevent cholera.  
Knowledge of ORS for home-treatment of cholera was negatively associated with 
OCV acceptance at the high price (Fig. 3).  
Identification of physical symptoms of dehydration such as loose skin and confused 
thinking were negatively associated with OCV acceptance (Fig. 2).  
Social vulnerability 
Respondents with more prominent concern about the effects of cholera on social 
relationships with others were less likely to anticipate purchasing OCV in all settings. The 
association was clearest in SE-DRC (Fig. 2).  
Setting-specific determinants of OCV acceptance 
Sociocultural features of vaccine acceptance that were significantly heterogeneous 
across the three settings at the medium and high prices are presented in Tables 1 and 2.  
SE-DRC 
In SE-DRC, additional aspects of social vulnerability were apparent. ‘Fear of 
infecting others’ and ‘interference of cholera with work and daily activities’ were negatively 
associated with high-price OCV acceptance. These issues indicate a link between social 
vulnerability and lack of confidence in ability to pay for an OCV in SE-DRC. Psychological 
and personal emotional impact of cholera with reference to sadness and anxiety, on the other 
hand, was positively associated with OCV acceptance at the high price.  
Zanzibar 
Acknowledging the social disapproval of others in response to cholera was positively 
associated with acceptance of the medium-price vaccine in Zanzibar. Another cultural 
meaning of cholera, however—witchcraft as a perceived cause—was associated with non-
acceptance of the medium-price OCV. Prayer was significantly associated with high-price 
OCV acceptance at both SE-DRC and W-Kenya, but not Zanzibar.  
W-Kenya 
Reporting a regular and dependable household income was positively associated with 
OCV acceptance in W-Kenya and Zanzibar. Narratives in W-Kenya included repeated 
community requests for a no-cost vaccine to provide access to everyone  [18]. In W-Kenya, 
acceptance was less in the rural site for both medium- and high-priced OCVs.  
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Discussion 
Experience with OCV in vaccination campaigns has been steadily increasing [28]. To 
the best of our knowledge, this analysis is the first review of common and distinctive 
sociocultural determinants of anticipated OCV acceptance across multiple settings in Africa. 
Comparable research methods enabled a systematic meta-analytic approach. The findings 
identified patterns that would be unapparent in the individual studies. The quantitative 
associations, derived and presented through forest plots, show how priority symptoms, 
perceived causes and options for help-seeking may influence OCV acceptance positively or 
negatively. Some factors have common effects across sites and others are setting-specific, 
indicating the value of local study to enable locally effective vaccine action. Although our 
methods are not a traditional meta-analysis, use of meta-analytic techniques highlight key 
sociocultural determinants common to three African settings and the importance of studying 
them.     
Although anticipated acceptance may not perfectly reflect actual acceptance, observed 
priority for OCVs indicate that these communities desire benefits from such vaccination 
initiatives. The finding that fewer determinants of anticipated acceptance were identified for 
the high priced vaccine (two), compared with the medium price (six), clearly shows that 
increased cost imposes an economic barrier making other features of acceptance and demand 
irrelevant.  
Paradoxically, SE-DRC has the greatest number willing to purchase the medium-price 
and high-price OCVs. People in W-Kenya and Zanzibar are economically better off as seen 
from gross domestic product per capita [29] and self-reported reliability of income among 
study respondents [16]. The seeming contradiction of greatest willingness to purchase OCVs 
among those with least economic resources may be explained by the serious trouble caused 
by cholera in SE-DRC, where public health facilities are often inaccessible or non-functional. 
Another point worth noting is that vaccines in SE-DRC are usually provided for free. The 
ability to pay is often overestimated when the scenario is hypothetical and respondents do not 
have to actually make the payment from their own pockets [30,31]. The finding indicates 
community priority for a desired vaccine, rather than capacity to pay or prospects for 
effective uptake at the high price.  Zanzibar has the lowest anticipated OCV acceptance at all 
prices. This may be an unintended consequence of a more accessible and effective public 
health system there compared to the other settings. Cholera camps instituted during an 
outbreak are accessible to most of the population who anticipate a fairly rapid response from 
local authorities [17]. Hence, the priority to pay for a vaccine may be reduced when timely 
life-saving treatment is assumed to be readily available compared with SE-DRC, where such 
confidence in lacking. 
When vaccine price is high, motivation to purchase appears low among those with 
knowledge of feasible treatment options such as ORS. Vaccination and ORS seem to be 
competing interventions in the public mind. Zwisler et al. [32] found substantial satisfaction 
with ORS in treating diarrhoea among caregivers in Kenya and likely re-use of ORS in 
treatment if it had ever been used before. The marginal value of an OCV that users consider 
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costly may be more limited in areas where ORS is well-known and widely used. Furthermore, 
priority for treatment may be valued more highly than prevention. 
All study respondents were adults, and anticipated OCV acceptance was higher 
among younger adults. Lack of education in our study was associated with OCV non-
acceptance. Other studies report a significant positive association between education and 
cholera-related knowledge [33]. Youth and better educated community residents may be a 
resource for vaccination campaigns to mobilize for community awareness of the benefits of 
vaccines.  
Household size imposes economic constraints; more mouths to feed leaves less 
money available for other expenses, even if desired, including vaccines. OCVs are especially 
important for larger households which are more likely to be crowded and burdened by limited 
sanitation. Sharing a latrine with many households is a reported risk factor for cholera in 
Kenya [34]. Economic limitations affecting the most vulnerable segments of the community 
with the least resources highlights the priority of making OCVs available without cost to 
users. If provided at a low cost, incentives or discounts for larger families may increase 
vaccine uptake.  
Contrary to expectations, knowledge of dehydration symptoms decreased the priority 
of OCVs for prevention. Symptoms of dehydration, which are clearly related to cholera for 
health professionals, do not seem to be core features of a vaccine-preventable formulation of 
cholera in the community. Symptoms of dehydration may be linked in local perceptions to 
other forms of diarrhoea making a “cholera” vaccine less relevant. Although most 
respondents in the three studies identified the illness of the vignette as cholera or its local 
language equivalent (>85%) [14,15,18], its link to dehydration appears less well understood. 
In SE-DRC, social and economic vulnerability are interrelated, and both may 
constrain access to vaccines for those who may need it most. In Zanzibar, cholera-related 
stigma appears to motivate OCV acceptance, presumably to avoid stigma. However, vaccine 
acceptance was impeded by local magico-religious ideas, possibly reflecting a conflict 
between public health and interests of local healers.  
In Zanzibar, religious influences appear less enabling for OCV acceptance. Although 
no active resistance from religious leaders is foreseen in Zanzibar, engaging religious leaders 
for vaccine action in all settings is important to build alliances and pre-empt opposition that 
may affect uptake [35], as indicated by notable opposition to polio vaccines in Nigeria [9,36]. 
On the other hand, prayer and religious influences of a predominantly Christian population in 
SE-DRC and W-Kenya may promote vaccine use.  
In W-Kenya, lower anticipated acceptance at the rural compared to the urban site, 
may result from urban-rural income disparities in W-Kenya, which was the only setting 
where fewer rural than urban respondents reported reliable and dependable incomes 
(p<0.001) [18]. Access and uptake would appear to be more sensitive there to the effect of 
cost. In Zanzibar, however, rural respondents were more likely to accept the high-price OCV. 
These findings suggest that urban-rural differences in vaccine acceptance may vary across 
settings based on local conditions and priorities. 
  
178 
 
Data for this analysis were collected between 2008 and 2010 during a period of high 
cholera burden in all three settings. More recent WHO data indicate a persisting cholera 
burden in SE-DRC (33, 661 cases), however, United Republic of Tanzania reported fewer 
cases (286), and Kenya reported no cases of cholera in 2012 [37]. The decline in cholera 
cases in Kenya was attributed to effectiveness of water, sanitation and hygiene (WASH) 
interventions by public health officials (Personal communication, Public Health Officials in 
Kisumu and Siaya. Conversations during a dissemination activity conducted by the research 
team at study sites in Western Kenya, 2013). Zanzibar appears to have benefitted from the 
OCV campaign that was undertaken there. While OCVs are not indicated in settings with no 
more cholera, findings of this study and community priority for preventing cholera remain 
relevant not only for consideration in future outbreaks but also for implementation of other 
WASH interventions.  
The community perspective is relevant not only for OCVs but also for consideration 
of hesitancy, demand, access and other community-related determinants of vaccine 
effectiveness. A rapid assessment of such community interests can be expected to contribute 
to the effectiveness of vaccine action. Based on experience with this approach for community 
assessment, development and validation of rapid assessment tools are needed to demonstrate 
the usefulness of the approach for enhancing uptake in programme settings.  
 
Conclusion 
The identified sociocultural determinants of OCV acceptance show that cost 
constraints are an essential consideration for effective use of OCVs. Paradoxically, awareness 
and appreciation of the value of treatment with ORS was associated with less enthusiasm for 
the OCV, and the setting with best prospects for treatment showed least interest in prevention 
with OCV. Findings indicated community interest and demand for cholera interventions. The 
absence of major sociocultural barriers to vaccination with OCVs suggest good prospects for 
translating vaccine efficacy into programme effectiveness in epidemic and endemic settings 
where vaccines have a role to play in control and elimination of cholera. 
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Figure 1. Anticipated oral cholera vaccine acceptance rates in three African settings at 
different price levels  
OCV prices were stated to respondents in the local currency which was approximately equal 
to USD 1 (low price), USD 4–5 (medium price) and USD 8–11 (high price). Y-axis denotes 
percentage of respondents who provided an affirmative response when asked whether they 
would be likely to purchase the vaccine at the stated price.  
For data source refer to Merten et al.[14], Sundaram et al. [17] and Schaetti et al. [16].  
OCV: Oral cholera vaccine; SE-DRC: Southeastern Democratic Republic of Congo; W-
Kenya: Western Kenya  
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Figure 2. Sociocultural determinants of anticipated OCV acceptance at USD 4-5 
(medium price) common to all settings  
Forest plots depict the influence of socio-demographic and socio-cultural variables on 
anticipated oral cholera vaccine acceptance at the medium price (USD 4–5) in three African 
settings. The weight of the study from each setting is represented by the area of the box 
whose centre represents the point estimate of effect from that study. The combined summary 
estimate of all three studies is represented by the centre of the diamond figure whose left and 
right extremes represent the corresponding confidence interval. 
a Logistic regression coefficient with 95% confidence interval. Estimates have been adjusted 
for core socio-demographic features.  
SD: Socio-demographics; PC: Perceived causes of cholera; SI: Social impact of cholera; PS: 
Physical symptoms identified for cholera; WP: Ways to prevent cholera; OCV: Oral cholera 
vaccine; SE-DRC: Southeastern Democratic Republic of Congo; W-Kenya: Western Kenya 
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Figure 3. Sociocultural determinants of anticipated OCV acceptance at USD 8-11 (high 
price) common to all settings 
Forest plots depict the influence of socio-demographic and socio-cultural variables on 
anticipated oral cholera vaccine acceptance at the high price (USD 8–11) in three African 
settings. The weight of the study from each setting is represented by the area of the box 
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whose centre represents the point estimate of effect from that study. The combined summary 
estimate of all three studies is represented by the centre of the diamond figure whose left and 
right extremes represent the corresponding confidence interval. 
a Logistic regression coefficient with 95% confidence interval. Estimates have been adjusted 
for core socio-demographic features. 
SD: Socio-demographics; PC: Perceived causes of cholera; HT: Home-based treatment, 
anticipated use of oral rehydration solution as a first-step at home in treating cholera; OCV: 
Oral cholera vaccine; SE-DRC: Southeastern Democratic Republic of Congo; W-Kenya: 
Western Kenya 
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Table 1. Sociocultural features of OCV acceptance heterogeneous across the three settings at USD 4-5 (medium price) 
Featuresa 
Heterogeneity 
p-value 
Setting-specific estimates (95% CI)b 
SE-DRC W-Kenya Zanzibar 
Vulnerability: Poor perceived more vulnerable 0.048 1.38 (0.18, 2.58) -0.24 (-0.71, 0.23) -0.06 (-0.67, 0.55) 
Stigma: Others make patient feel ashamed 0.079 0.08 (-0.18, 0.33) -0.12 (-0.33, 0.08) 0.24 (0.00, 0.48) 
Physical symptom: Loss of appetite 0.069 -0.01 (-0.27, 0.25) -0.54 (-0.90, -0.17) -0.13 (-0.58, 0.31) 
Physical symptom: Unconsciousness 0.032 -0.26 (-0.47, -0.05) -0.03 (-0.28, 0.22) 0.12 (-0.07, 0.30) 
Perceived cause: Witchcraft 0.048 0.24 (-0.11, 0.59) 0.28 (-0.50, 1.06) -0.60 (-1.19, -0.01)c 
Regular, dependable income 0.002 -0.21 (-0.75, 0.34) 1.02 (0.53, 1.50) 0.98 (0.39, 1.56)c 
Married 0.018 -0.25 (-0.96, 0.46) 0.24 (-0.22, 0.70) 1.37 (0.49, 2.24)c 
Rural vs. urban site 0.049 0.11 (-0.42, 0.63) -0.63 (-1.09, -0.17) 0.12 (-0.40, 0.65) 
 
Sociocultural and sociodemographic features that are heterogeneously associated with oral cholera vaccine acceptance across three endemic African settings at the medium 
price of USD 4-5 
a Variables with heterogeneity (p-value < 0.1) and a significant estimate (p<0.05) in at least one of the settings are presented  
b Setting-specific logistic regression coefficient with 95% confidence interval 
c Individual estimates for Zanzibar already presented in Schaetti et al [16]. 
Figures in bold represent associations with p<0.05 for individual settings 
SE-DRC: Southeastern Democratic Republic of Congo; W-Kenya: Western Kenya 
  
188 
 
Table 2. Sociocultural features of OCV acceptance heterogeneous across the three settings at USD 8-11 (high price) 
Featuresa 
Heterogeneity 
p-value 
Setting-specific estimatesb 
SE-DRC W-Kenya Zanzibar 
Emotional impact: Sadness, anxiety, worry 0.046 0.18 (0.03, 0.34) -0.14 (-0.35, 0.07) 0.14 (-0.13, 0.40) 
Social impact: Fear of infecting others 0.009 -0.33 (-0.57, -0.08) 0.02 (-0.18, 0.22) 0.23 (-0.04, 0.50)c 
Social impact: Interference with work/daily activities 0.064 -0.31 (-0.52, -0.10) -0.04 (-0.19, 0.11) 0.01 (-0.19, 0.22) 
Physical symptom: Pus in stool 0.033 -0.18 (-0.54, 0.18) 0.08 (-0.24, 0.41) 0.75 (0.15, 1.36)c 
Physical symptom: Nausea 0.098 -0.50 (-0.89, -0.1) -0.23 (-0.65, 0.19) 0.31 (-0.31, 0.93) 
Home treatment: Prayers 0.008 0.38 (0.13, 0.63) 0.39 (0.09, 0.69) -0.24 (-0.58, 0.11)c 
Regular, dependable income <0.001 -0.31 (-0.77, 0.14) 0.92 (0.49, 1.34) 0.94 (0.29, 1.59)c 
Married 0.006 -0.45 (-1.05, 0.15) 0.18 (-0.24, 0.60) 1.51 (0.46, 2.56)c 
Rural vs. urban site 0.002 -0.03 (-0.47, 0.42) -0.67 (-1.08, -0.25) 0.64 (0.04, 1.23)c 
 
Sociocultural and sociodemographic features that are heterogeneously associated with oral cholera vaccine acceptance across three endemic African settings at the high price 
of USD 8–11 
a Variables with heterogeneity (p-value < 0.1) and a significant estimate (p<0.05) in at least one of the settings are presented  
b Setting-specific logistic regression coefficient with 95% confidence interval 
c Individual estimates for Zanzibar already presented in Schaetti et al [16].  
Figures in bold represent associations with p<0.05 for individual settings; SE-DRC: Southeastern Democratic Republic of Congo; W-Kenya: Western Kenya 
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SUMMARY
Determinants of anticipated acceptance of an oral cholera vaccine (OCV) were studied in urban
and rural communities of Western Kenya. An explanatory model interview administered to 379
community residents assessed anticipated vaccine acceptance at various prices from no cost to
full-cost recovery, socio-cultural features of cholera and social characteristics. Nearly all (99%)
residents indicated willingness to accept a no-cost OCV, 95% at a price of US$ 0.8, 73% at US$
4.2 and 59% at US$ 8.4. Logistic regression models analysed socio-cultural determinants of
anticipated OCV acceptance. Prominence of non-specific symptoms for cholera was negatively
associated with acceptance. A cholera-specific symptom (thirst), self-help referring to prayer,
income and education were positively associated. In the high-cost model, education was no longer
significant and reliance on herbal treatment was a significant determinant of vaccine non-
acceptance. Findings suggest high motivation for OCVs, if affordable. Socio-cultural
determinants are better predictors of anticipated acceptance than socio-demographic factors
alone.
Key words : Cholera, Kenya, oral cholera vaccine, social and cultural determinants, vaccine
acceptance.
INTRODUCTION
Among infectious diseases, diarrhoeal diseases rank as
the third leading cause of mortality and morbidity in
low- and middle-income countries [1]. It is estimated
that diarrhoeal diseases account for 1.78 million
deaths per year and 58.7 million disability-adjusted
life years. Cholera, a rapidly dehydrating diarrhoeal
disease, is estimated to cause the death of 100 000–
130 000 persons and account for 3–5 million cases
per year [2]. Kenya suffers from a high burden of
cholera, having reported 11 425 cases and 264 deaths
in 2009 [3].
Cholera transmission is closely associated with en-
vironmental conditions, spread by faecal contami-
nation of water and food [4]. Access to safe water and
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adequate sanitation are fundamentals of cholera pre-
vention. In many countries, however, implementing
relevant measures has proved difficult and slow [2, 5].
Furthermore, improvements may not reach the most
vulnerable populations, such as those living in slums
and remote rural areas, in the near future [5]. Vaccines
may therefore have a critical role as a provisional
public health tool in cholera control in these com-
munities. In 2005, the World Health Organization
(WHO) first suggested oral cholera vaccines (OCVs)
be used in cholera-endemic areas as a supplementary
control strategy [6] and they strengthened that
recommendation in 2010 [4].
Two OCVs are currently pre-qualified by the WHO
for international use. Both Dukoral1 (Crucell, The
Netherlands), containing recombinant cholera toxin
B subunit and killed whole-cell V. cholerae O1, and
ShancholTM (Shantha Biotechnics Ltd, India), con-
taining killed V. cholerae O1 and O139, have been
shown to be efficacious in endemic settings [7, 8].
Although safety, efficacy and an efficient health system
to distribute the vaccine are critical, understanding
cultural preferences and the willingness of communi-
ties to accept the vaccine are also essential. Assessing
socio-cultural features of the illness and willingness to
accept a vaccine indicate perceived need, demand and
cultural barriers that may reduce coverage in a vac-
cine campaign. Notwithstanding recognized value
of such research [9, 10], studies have been largely
confined to high-income countries [11, 12]. Cholera
vaccine acceptance studies focus mainly on socio-
demographics and willingness to pay [13–15], while
studies that have considered socio-cultural aspects of
cholera have concentrated on Asia [16, 17]. Research
is lacking on cultural dimensions and social determi-
nants of cholera vaccine acceptance in Kenya.
This study was conducted in Nyanza province of
Western Kenya due to the disproportionately high
number of cholera cases reported there compared to
the rest of Kenya [18]. Two large cholera outbreaks
occurred there in 1997–1998 and 2008 that accounted
for 43–47% and 72%, respectively, of all cholera
cases in Kenya [19, 20]. Urban and rural sites were
chosen because they differ significantly in terms of
environmental conditions, population density, resi-
dents’ income and occupation; the implication being
that the findings from one setting may not be at-
tributable to the other. Cultural epidemiological
methods [21] were employed to understand com-
munity experience, meaning and behaviour with a
cholera-like illness. The objectives of this paper are to
(a) assess community willingness to accept an OCV
in urban and rural populations in Western Kenya,
(b) analyse socio-cultural determinants of anticipated
OCV acceptance and (c) clarify the role of socio-
cultural features of illness in explaining anticipated
OCV acceptance by comparing models that consider
socio-cultural determinants with exclusively socio-
demographic models.
METHODS
Setting
This study was conducted at both urban and rural
sites in Nyanza province, Western Kenya, where
cholera is considered endemic. The urban site at
Nyalenda A, Winam division, Kisumu district is a
heavily populated informal settlement and the rural
site is comprised of villages at Kakum Kombewa sub-
location, Boro division, Siaya district.
The urban site covers an area of 2.8 km2, has 23 731
residents and a population density of 8475 persons/
km2 [22]. The majority of residents do not have ac-
cess to piped water and largely rely on shallow wells
that are subject to a high level of contamination due
to the predominance of pit latrines [22, 23]. There are
no government health facilities in Nyalenda A and
private health services involve higher costs to be
borne.
The rural site is comprised of nine villages at
Kakum Kombewa with a population density of
around 270 individuals/km2 [24]. Main sources of
water in this region are untreated streams and bore-
holes. The majority (73%) of the population have
access to latrines ; however, over 24% of these are in a
poor state and hence not used [24]. Lack of public
transport makes access to Siaya district hospital,
which is located about 15 km away, difficult.
Study design and sampling
This cross-sectional study required a minimum sam-
ple size of 328 to allow for cross-site comparisons with
95% significance and 80% power [25]. Men and
women from the general population between the ages
of 18 and mid-60s were included.
At the urban site, only an estimate of the popu-
lation size was obtainable, hence, systematic prob-
ability sampling was done. The area was divided into
seven roughly equal segments and every fifth house-
hold was approached to get a total of 28 households
640 N. Sundaram and others
per segment. At the rural site, detailed household lists
were accessible through community health workers. A
specific number of households per village, pro-
portional to the total number of households in that
village, which had been identified in advance through
random selection, were approached. At both sites,
one willing adult of the household was interviewed;
selection was made to maintain a roughly equal bal-
ance between men and women. When more than one
eligible adult was available, we asked them to decide
whom we should interview. If a household had no
suitable, willing candidate, the neighbouring house-
hold was approached.
Instrument and data collection
This study used a semi-structured explanatory model
interview based on the framework of the Explanatory
Model Interview Catalogue (EMIC) for cultural epi-
demiology [26]. It was developed for the study of
cholera to assess locally valid features of illness-
related experience, meaning and behaviour from the
perspective of community residents [27]. The illness
was introduced to participants using a clinical vignette
that described a person with physical symptoms of
cholera. Respondents were asked what they would
call such an illness and the term for the illness pro-
vided by the respondent was used when asking further
questions. In addition to questions on socio-cultural
features of illness (i.e. physical symptoms, social im-
pact, perceived causes, help-seeking behaviour), the
interview also included questions on respondents’
socio-demographic characteristics and their ideas on
general vaccination. Quantitative and qualitative data
were both collected.
Respondents were also asked if they would be
willing to take a vaccine that is swallowed to prevent
cholera. Details of efficacy and duration of protection
were not discussed. OCV acceptance questions were
posed at four different prices : ‘high’, based on esti-
mated full production cost recovery for manufacture
of two doses of Dukoral (KES 650/US$ 8.4)# ; ‘me-
dium’, which is half the high price (KES 325/US$
4.2) ; ‘ low’, close to the US$ 1 price that is considered
a realistic vaccine price for low- and middle-income
countries (KES 65/US$ 0.8) [16] and ‘free ’, fully
subsidized as in the case of many immunization cam-
paigns.
Interviews were conducted between March and
May 2010, in Kiswahili, Dholuo and English.
Interviewers received extensive training in sampling
procedures, interviewing and obtaining informed
consent. The interviewers were science or social sci-
ence graduates from Maseno University and in-
troduced themselves accordingly. Interviews were
voice-recorded with permission.
Data management and analysis
EMIC interview data were double-entered using Epi
Info software version 3.5.1 (Centers for Disease
Control and Prevention, USA), programmed with
logic and range checks. For analysis of socio-cultural
features of illness, prominence of categories was cal-
culated based on whether a response was reported
spontaneously (assigned value of 2) or after probing
(assigned value of 1). When a category was identified
as most important among all others, it was assigned
an additional value of 3. A mean prominence was
then calculated for each category. Through this
method of prominence calculation, categories were
evaluated based on relative importance ascribed to
them by local cultural ideas.
Logistic regression analyses were done to empiri-
cally identify socio-cultural determinants (i.e. socio-
cultural features of illness and socio-demographic
characteristics) associated with anticipated OCV
acceptance at various prices. Dichotomized antici-
pated OCV acceptance variables, reflecting vaccine
acceptance or non-acceptance, were used as outcome
variables. Separate regression analyses were per-
formed for anticipated OCV acceptance at the me-
dium price and at the high price, but not for the low
price or no-cost models as acceptance rates over 95%
did not allow for it.
In crude analysis, associations between OCV
acceptance and explanatory variables that were
reported by 5–95% of respondents were analysed.
Variables with P<0.2 were considered for multi-
variate analysis. ‘Focal ’ models of socio-cultural
features of illness for specific groups of variables
(i.e. related to physical symptoms, social impact,
perceived causes, help-seeking), adjusted for socio-
demographic variables, were run. Focal models
for socio-demographic factors alone were also con-
sidered. Interaction of site with each of the variables
was tested and site-interaction terms with P<0.1
were included. To estimate the combined influence
of all categories identified in the focal models on
# Exchange rate : Kenya shilling (KES) 1=US$ 0.01287 as of
1 March 2010 (www.oanda.com).
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anticipated OCV acceptance, a ‘comprehensive’
model was calculated using variables with P<0.2
and site-interaction terms with P<0.1 from focal
models. Corrected Akaike’s Information Criterion
(AICc) values were computed to compare relative
goodness of fit in various focal and comprehensive
regression models. D(AICc) which represents the
difference in AICc between each model and the
model with the lowest AICc, was used to make this
comparison. Models with lower D(AICc) values
are considered better in explaining OCV acceptance
than those with higher values. Quantitative analysis
was done with SAS version 9.2 (SAS Institute Inc.,
USA).
Narrative accounts were translated into English
and entered in word processor software. Additional
detail from key questions of the interview was ad-
ded by transcribing relevant voice records. Typed
data were then imported into MAXQDA version 10
(VERBI Software, Germany) for qualitative data
management and analysis. Text segments were the-
matically coded based on the interview structure.
Variables were imported into MAXQDA to enable
the selection of narrative records of interest based
on results from the quantitative analysis. This ap-
proach enabled integrated analysis of quantitative
and qualitative data.
Ethical considerations
The study protocol received ethical approval from the
Kenya Medical Research Institute and the WHO
Research Ethics Review Committee. Interviews were
conducted after obtaining written informed consent.
No financial or other incentives were provided to re-
spondents. Data collected in this study was main-
tained with utmost confidentiality and anonymized
for reporting.
RESULTS
Sample characteristics
Of 379 respondents interviewed, 50% were from the
urban site and 51% were female (Table 1). All re-
spondents at the rural site and 96.8% at the urban site
identified Christianity as their religion. The median
personal monthly income was KES 2500 (US$ 32) at
the urban site and KES 1000 (US$ 13) at the rural
site (P=0.01). Significantly more respondents at the
urban site reported a dependable source of income.
Self-employment (e.g. petty trading and skilled
labour) was the most frequently mentioned primary
occupation at the urban site ; and agriculture at
the rural site. Urban respondents were better edu-
cated: more in the urban sample had a secondary
education or higher ; more in the rural sample had
no education. The rural site had significantly more
individuals living within a household than at the
urban site.
Past experience with vaccination and general ideas
on vaccines
Two-thirds (66.8%) of all respondents reported
having personally received a vaccination in the
past. Fewer respondents reported prior vaccination
experience at the rural (51.3%) than at the urban
(82.1%, P<0.001) site.
All but four respondents (98.9%) stated that in
their experience, vaccines were helpful. The idea that
vaccines were beneficial in preventing disease was
reported pervasively. More knowledgeable respon-
dents provided accounts with a scientific basis, such
as, ‘Vaccines are helpful ; they boost the immune sys-
tem and prevent future infections ’ (urban woman,
22 years). There also seemed to be a high level of
confidence in the protective effect of vaccines, as seen
in this narrative, ‘ I rarely get sick because I was vac-
cinated’ (urban man, 30 years).
When asked whether some vaccines were also likely
to cause problems, 27.7% of the respondents agreed;
pain at the injection site, infection/abscess, fever
and disability were frequently cited problems. Of re-
spondents who believed that vaccines were not likely
to cause problems, there was a significant difference in
terms of site (P=0.036) and gender (P=0.007), with
more women and more urban respondents espousing
this view.
Anticipated OCV acceptance
Almost all respondents (98.7%) reported an interest
in accepting an OCV if it were to be made available
free of charge (Fig. 1). At the low price, 95.3% re-
spondents were willing to accept the vaccine. At the
medium and high prices, 72.8% and 58.8% re-
spondents, respectively, were interested in the vaccine.
More urban than rural respondents were willing
to accept an OCV at the medium (P=0.008) and high
(P=0.002) prices. Anticipated OCV acceptance rates
between men and women were similar.
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Narrative accounts demonstrate an active demand
for cholera vaccines. A sense of urgency in obtaining
cholera vaccines was communicated as follows:
We have a water problem because there is a lot of pollution
in the water and water points are scarce. We are also far
from the hospital in Siaya. So I ask, when will this vaccine
come? Or will you just disappear after the research? We
really need the vaccine (rural man, 32 years).
A highly mentioned reason for willingness to pur-
chase an OCV was that it would be more cost-effective
than spending money on cholera treatment in the
future.
Vaccine cost was a critical point of consideration
for many respondents. While requesting a free vac-
cine, a 35-year-old rural woman explained:
If a vaccine is introduced, let it be free of charge so that it
can help everyone. If it is brought with a price, others will
die if they cannot afford it.
However, demand for a vaccine was high enough for
respondents to offer suggestions that could enable
vaccine purchase, even if it could not be availed for
free.
If you bring the vaccine, tell us in advance so that we have
enough time to collect money to pay for it. If you come
without notice, we may not have the money ready (rural
woman, 26 years).
The idea that health was more important than money
was widespread and many stated: ‘You cannot com-
pare your life to money. ’
Determinants of anticipated OCV acceptance at the
medium price and high price
Focal regression models considered specific groups
of explanatory variables in explaining anticipated
OCV acceptance at the medium and high prices
(Tables 2 and 3). As per their D(AICc) values, at
the medium price, ‘ somatic symptoms’ and ‘self-
treatment at home’ models explained acceptance bet-
ter than the focal model with only socio-demographic
Table 1. Socio-demographic characteristics of study respondents
Overall (n=379) Urban (n=190) Rural (n=189) P valued
Gender (%)
Female 51.2 52.1 50.3
Age (years)
Mean (S.D.)a 32.8 (13.1) 28.9 (10.1) 36.8 (14.5) ***
Median (range)b 29 (18–69) 25 (18–63) 33 (18–69) ***
Household size (persons)
Mean (S.D.)a 4.5 (2.3) 4.3 (2.1) 4.7 (2.6) *
Main occupation (%)c
Agriculture 25.3 1.6 49.2 ***
Self-employed 26.6 36.8 16.4 ***
Formal employment 12.4 16.8 7.9 *
Housewife 9.0 14.7 3.2 ***
Casual labourer 9.2 12.1 6.3
Student 5.5 6.3 4.8
Not active/retired 9.5 10.0 9.0
Highest education level attended (%)c
No education 3.7 0.5 6.9 ***
Primary school 50.1 44.7 55.6 *
Secondary school 37.7 46.8 28.6 ***
Vocational school 1.8 0.0 3.7 **
College and above 6.6 7.9 5.3
Household income (%)c
Regular and dependable 47.8 66.8 28.6 ***
S.D., Standard deviation.
a t test.
b Wilcoxon test.
c Fisher’s exact test. Only categories with overall reported percentages>1.5% are displayed.
d P value obtained from a comparison between the urban and rural site ; * Pf0.05 ; ** Pf0.01 ; *** Pf0.001.
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characteristics. At the high price, all socio-cultural
focal models were better than the exclusively socio-
demographic model. Comprehensive models, which
combined significant variables from all focal models,
explained OCV acceptance best.
Most variables that were significant in the focal
models remained so in the comprehensive models.
Socio-cultural determinants identified in the compre-
hensive models that were associated with anticipated
OCV acceptance at the medium price and the high
price are shown in Tables 4 and 5, respectively.
Although different explanatory variables were ident-
ified in the analyses at the two price levels, they refer
to coherent themes explaining anticipated OCV ac-
ceptance: specificity of symptoms for cholera, level of
education, restricted preference for treatment and
financial viability.
Identification of physical symptoms that were
unrelated to cholera such as bloody stool, and non-
specific for cholera such as loss of appetite and
confusion, were negatively associated with OCV ac-
ceptance. A cholera-specific symptom of being ‘very
thirsty’ was positively associated.
Having attended secondary school was positively
associated with OCV acceptance at the medium price.
However, this did not remain significant at the high
price.
With an increase in price of the vaccine from
medium to high, the reporting of herbal treatment
as a home remedy became significantly negatively
associated with acceptance. In contrast, the reporting
of prayer as a form of self-treatment at home was
positively associated with OCV acceptance at both
prices. An analysis of qualitative accounts revealed
that prayer and medical interventions are considered
complementary forms of treatment, carried out in
parallel. Prayer and medicine are believed to have
different, but non-conflicting roles, in treatment.
‘Prayer must be conducted to have God’s inter-
vention while pharmacy drugs help in controlling the
situation’ (urban woman, 22 years). However, medi-
cal help was often implicitly assigned a greater pri-
ority while prayer was recommended in addition.
Even a respondent who stated, ‘Prayer helps because
God is above everything, even above drugs’, further
mentioned that she would first give the patient
water and drugs to combat diarrhoea, and thereafter
pray.
Household income and household size signifi-
cantly influenced OCV acceptance. The former was
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Fig. 1. Anticipated oral cholera vaccine (OCV) acceptance at different prices among urban and rural residents of Western
Kenya. OCV price mentioned in Kenya shillings (KES) to respondents : low (KES 65/US$ 0.8), medium (KES 325/US$ 4.2),
and high (KES 650/US$ 8.4) (exchange rate : KES 1=US$ 0.01287). Y axis denotes percentage of respondents who provided
a favourable response when questioned on whether they were likely to buy the vaccine at the stated price. Fisher’s exact test
was used for comparison of percentages between the two sites. ** Pf0.01.
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Table 2. Multivariate analysis (focal models) of socio-cultural determinants of anticipated oral cholera vaccine
acceptance at the medium price (US$ 4.2) and assessment of models
Focal modelsa Coefficient (95% CI)b P valuec Intd D(AICc)e
Patterns of distress : somatic symptoms 3.25
Bloody stool (urban site) 0.35 (x0.30 to 1.00) 0.288
Bloody stool (rural site) x0.43 (x0.75 tox0.11) 0.008 *
Very thirsty 0.61 (0.02 to 1.21) 0.044
Loss of appetite x0.73 (x1.16 tox0.31) 0.001
Palpitations x0.08 (x0.41 to 0.26) 0.652
Confusion x0.52 (x0.92 tox0.12) 0.012
Patterns of distress : social impact 22.6
Fear of infecting others 0.17 (x0.10 to 0.45) 0.217
Perceived causes 24.43
Eating soil 0.09 (x0.41 to 0.60) 0.723
Malaria x0.29 (x0.87 to 0.28) 0.318
Violation of taboo/tradition x0.17 (x0.59 to 0.26) 0.437
Other causes (urban site)f 0.13 (x0.28 to 0.54) 0.527
Other causes (rural site)f x0.37 (x0.64 tox0.09) 0.010 *
Cannot say x0.15 (x0.34 to 0.05) 0.137
Self-treatment at home 17.27
Drinking more water or liquids 0.11 (x0.06 to 0.28) 0.212
Herbal treatment x0.23 (x0.44 tox0.01) 0.040
Prayers 0.43 (0.07 to 0.79) 0.021
Drink with alcohol 0.53 (x0.24 to 1.31) 0.178
Socio-demographicsg 22.08
Primary school vs. no education 0.58 (x0.57 to 1.73) 0.325
Secondary school vs. no education 1.02 (x0.17 to 2.22) 0.093
Regular and dependable household income
(urban site)
1.54 (0.79 to 2.30) <0.001
Regular and dependable household income
(rural site)
0.12 (x0.58 to 0.82) 0.739 **
Household size x0.07 (x0.17 to 0.03) 0.189
Occupation : housewife, student, retiredh x0.26 (x0.98 to 0.46) 0.474
Occupation : self-employed, formally employed,
casual labourh
0.23 (x0.42 to 0.88) 0.479
Gender (male vs. female) 0.25 (x0.26 to 0.76) 0.330
Site (rural vs. urban) 0.36 (x0.35 to 1.07) 0.316
a Each of the four focal models (somatic symptoms, social impact, perceived causes, self-treatment at home) were adjusted
for socio-demographic characteristics.
b Logistic regression coefficient with 95% confidence interval.
c Bold values indicate Pf0.05.
d Interaction with site : refers to rural compared to urban site, with urban site as the baseline. Site-specific effects on variables
considered only if P<0.1 for site-interaction term. * Pf0.05, ** Pf0.01.
e Difference in corrected Akaike’s Information Criterion [D(AICc)] between each model and the model with the lowest AICc.
Comprehensive model (Table 4) had the lowest AICc and was assigned a value of zero. Models with lowerD(AICc) values are
considered better fitted than those with higher values. Bold values indicate models that are better than the model containing
only socio-demographic characteristics.
f ‘Other causes’ refers to responses that could not be coded within designated categories of the interview. The variety of
responses coded under ‘other causes’ included contact with infected persons, unprotected sexual intercourse, cold weather,
mosquitoes, breathing in contaminated air and eating cold food.
g Variables with which each focal model was adjusted.
h Compared with the occupation of agriculture.
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positively associated while an increasing household
size was negatively associated.
Site-specific interactions were not observed for any
variables at the high price and were present for just
one variable at the medium price.
DISCUSSION
Findings from this study indicate high levels of ac-
ceptance for an OCV among urban and rural residents
inWesternKenya. Quantitative and narrative analysis
showed that respondents perceive a general benefit
from immunization. The extensive interest and de-
mand for OCVs indicates a likelihood of good cover-
age during mass vaccination initiatives. The study
also showed that 91.3% of the respondents con-
sidered the illness as very serious and 96.3% believed
that it had life-threatening consequences. The pros-
pect of an effective vaccine campaign is further sup-
ported by this data given the widely acknowledged
Table 3. Multivariate analysis (focal models) of socio-cultural determinants of anticipated oral cholera vaccine
acceptance at the high price (US$ 8.4) and assessment of models
Focal modelsa Coefficient (95% CI)b P valuec Intd D(AICc)e
Patterns of distress : somatic symptoms 11.9
Abdominal pain/discomfort 0.30 (x0.01 to 0.60) 0.055
Loss of appetite x0.63 (x1.03 tox0.23) 0.002
Weakness x0.12 (x0.35 to 0.12) 0.319
Palpitations 0.07 (x0.25 to 0.39) 0.669
Confusion (urban site) 0.21 (x0.41 to 0.83) 0.502
Confusion (rural site) x1.02 (x1.66 tox0.39) 0.002 **
Perceived causes 32.22
Other causes (urban site)f 0.08 (x0.30 to 0.46) 0.691
Other causes (rural site)f x0.35 (x0.63 tox0.08) 0.013 #
Self-treatment at home 24.08
Drinking more water or liquids 0.07 (x0.10 to 0.23) 0.421
Herbal treatment x0.27 (x0.48 tox0.06) 0.010
Oral rehydration solution x0.12 (x0.26 to 0.02) 0.094
Prayers 0.43 (0.11 to 0.76) 0.009
Socio-demographicsg 33.54
Primary school vs. no education 0.58 (x0.61 to 1.77) 0.339
Secondary school vs. no education 0.78 (x0.43 to 1.99) 0.209
Regular and dependable household income 0.72 (0.25 to 1.18) 0.002
Household size x0.07 (x0.17 to 0.02) 0.122
Occupation: housewife, student, retiredh x0.12 (x0.80 to 0.55) 0.716
Occupation: self-employed, formally employed,
casual labourh
0.02 (x0.58 to 0.62) 0.950
Gender (male vs. female) 0.33 (x0.12 to 0.78) 0.153
Site (rural vs. urban) x0.34 (x0.87 to 0.20) 0.216
a Each of the three focal models (somatic symptoms, perceived causes, self-treatment at home) were adjusted for socio-
demographic characteristics.
b Logistic regression coefficient with 95% confidence interval.
c Bold values indicate Pf0.05.
d Interaction with site : refers to rural compared to urban site, with urban site as the baseline. Site-specific effects on variables
considered only if P<0.1 for site-interaction term. # P<0.1, ** Pf0.01.
e Difference in corrected Akaike’s Information Criterion [D(AICc)] between each model and the model with the lowest AICc.
Comprehensive model (Table 5) had the lowest AICc and was assigned a value of zero. Models with lower D(AICc) values are
considered better fitted than those with higher values. Bold values indicate models that are better than the model containing
only socio-demographic characteristics.
f ‘Other causes ’ refers to responses that could not be coded within designated categories of the interview. The variety of
responses coded under ‘other causes ’ included contact with infected persons, unprotected sexual intercourse, cold weather,
mosquitoes, breathing in contaminated air and eating cold food.
g Variables with which each focal model was adjusted.
h Compared with the occupation of agriculture.
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Table 4. Multivariate analysis (comprehensive model) of socio-cultural
determinants of anticipated oral cholera vaccine acceptance at the medium
price (US$ 4.2)
Explanatory variables Coefficient (95% CI)a P valueb
Patterns of distress : somatic symptoms
Bloody stool x0.29 (x0.56 tox0.01) 0.042
Very thirsty 0.57 (x0.01 to 1.15) 0.054
Loss of appetite x0.77 (x1.19 tox0.34) <0.001
Confusion x0.54 (x0.94 tox0.13) 0.009
Perceived causes
Other causesc x0.16 (x0.38 to 0.07) 0.166
Self-treatment at home
Herbal treatment x0.16 (x0.37 to 0.06) 0.153
Prayers 0.46 (0.09 to 0.82) 0.015
Socio-demographics
Primary school vs. no education 0.70 (x0.60 to 2.00) 0.291
Secondary school vs. no education 1.37 (0.03 to 2.71) 0.045
Regular and dependable
household income
0.93 (0.40 to 1.46) 0.001
Household size x0.10 (x0.21 to 0.01) 0.063
a Logistic regression coefficient with 95% confidence interval.
b Bold values indicate Pf0.05.
c ‘Other causes’ refers to responses that could not be coded within designated
categories of the interview. The variety of responses coded under ‘other causes’
were contact with infected persons, unprotected sexual intercourse, cold weather,
mosquitoes, breathing in contaminated air and eating cold food.
Table 5. Multivariate analysis (comprehensive model) of socio-cultural
determinants of anticipated oral cholera vaccine acceptance at the high price
(US$ 8.4)
Explanatory variables Coefficient (95% CI)a P valueb Intc
Patterns of distress : somatic symptoms
Abdominal pain/discomfort 0.27 (x0.04 to 0.58) 0.085
Loss of appetite x0.64 (x1.04 tox0.23) 0.002
Confusion (urban site) 0.19 (x0.46 to 0.83) 0.568
Confusion (rural site) x1.08 (x1.73 tox0.42) 0.001 **
Self-treatment at home
Herbal treatment x0.27 (x0.48 tox0.06) 0.012
Oral rehydration solution x0.11 (x0.25 to 0.03) 0.113
Prayers 0.42 (0.09 to 0.74) 0.013
Socio-demographics
Gender (male vs. female) 0.39 (x0.09 to 0.87) 0.107
Site (rural vs. urban) 0.73 (x0.17 to 1.62) 0.111
Primary school vs. no education 0.95 (x0.41 to 2.31) 0.172
Secondary school vs. no education 1.28 (x0.12 to 2.67) 0.074
Regular and dependable
household income
0.81 (0.31 to 1.30) 0.001
Household size x0.11 (x0.21 tox0.01) 0.031
a Logistic regression coefficient with 95% confidence interval.
b Bold values indicate Pf0.05.
c Interaction with site : refers to rural compared to urban site, with urban site
as the baseline. Site-specific effects on variables considered only if P<0.1 for site-
interaction term. **Pf0.01.
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observation that perceived severity of a disease is
closely associated with likelihood of vaccine uptake
[10, 28].
This study demonstrated that socio-cultural de-
terminants explained anticipated vaccine acceptance
better than socio-demographic factors alone. Identific-
ation of such socio-cultural determinants of OCV
acceptance provides data relevant to ensure better
coverage in an actual campaign. Past cholera control
campaigns that have faced severe community resist-
ance [29], and free treatment initiatives for other
diseases that were rejected [30], further underscores
the importance of paying attention to local socio-
cultural environments prior to interventions. Com-
munity studies are necessary to plan and prepare for
vaccine campaigns [31]. This study provides an ap-
proach to integrate qualitative and quantitative em-
pirical data, explain local cultural concepts of illness
and guide disease control.
Several determinants of anticipated OCV accept-
ance were notable. Thirst, a cholera-specific symp-
tom, was associated positively with acceptance.
Non-specific physical symptoms for cholera were as-
sociated with a lower priority for the vaccine. Bloody
stool, a characteristic symptom of other diarrhoeal
illnesses, such as shigellosis, amoebic dysentery, cam-
pylobacteriosis, etc., was also negatively associated
with OCV acceptance. The ability to discern cholera
symptoms from symptoms of other diarrhoeal ill-
nesses argues for a high level of awareness in the
community. These findings also indicate that efforts
to promote community awareness during control
interventions need to highlight cholera-specific
symptoms. Furthermore, given the definitive ideas of
cholera possessed by the community, non-specific
reference to diarrhoeal illness may lead to unreason-
able expectations that the OCV will prevent all
diarrhoea, leading to disappointment and possible
discrediting of a useful vaccine.
Education was a predictor of vaccine acceptance.
Interestingly, health education was reported as the
most useful method of preventing cholera by the
majority of respondents, and was frequently re-
quested. A similar finding was reported from a study
in Pakistan where education and knowledge about
vaccines were associated with vaccine uptake [32].
These findings highlight the value of education and
promoting health awareness in cholera control. How-
ever, at the high price, secondary school education
was no longer significantly associated with OCV ac-
ceptance, indicating that education too has the ability
to influence acceptance only to a certain extent.
Above a certain price, economic factors may play a
more prominent role in influencing OCV acceptance.
At the high price, self-help with herbal treatment
was a significant negative determinant of acceptance.
It appears that higher cost of the vaccine makes
alternative, less expensive forms of treatment prefer-
able. This finding is consistent with other literature
in Kenya noting that the high cost of conventional
Western drugs often makes them inaccessible, thereby
promoting reliance on traditional remedies [33].
Pluralistic health-seeking practices, including tra-
ditional remedies, are widely used in other African
countries [34] ; however, in our study they appear to
compete with biomedical interventions, especially
when the higher cost of vaccine becomes a barrier.
The priority of prayer, on the other hand, was
complementary to vaccine interventions – an ad-
ditional, rather than alternative source of help. Other
studies suggest religious beliefs may be antagonistic to
vaccine intervention [35, 36]. A study in Benin found
that vaccination was rejected in some religious com-
munities because they believed that they ‘require only
prayer to protect and heal them in times of illness ’
[37]. The finding in Kenya, that reporting self-help
with prayer was significantly associated with OCV
acceptance, suggests a possible role played by re-
ligious institutions in encouraging the use of bio-
medicine. Although religious sectarian differences
may influence the perceived benefits of medical inter-
ventions, we found no differences in anticipated OCV
acceptance in members of the Legio Maria church,
which some studies suggest may promote faith healing
and reject biomedicine [38], and members of other
church groups.
Financial viability, based on reporting a regular
household income and a smaller household size, in-
fluenced OCV acceptance. While this finding is
what would be expected for relatively high-priced
vaccines, it underscores the importance of keeping
costs reasonable. Furthermore, as the price of OCV
was increased, determinants that had influenced vac-
cine acceptance at a lower price, such as education,
were no longer relevant. The increasing price levels of
OCV were introduced to provide an indication of
priority and demand for the vaccine. Findings suggest
that regardless of priorities and commitment to ob-
tain an OCV, above a certain price it was simply
beyond the means of many. In this study, the high
price was the threshold. Hence, a full-cost recovery
model with Dukoral may not be considered in this
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setting. However, it may be considered for OCVs
that can be produced at a far lower cost, such as
Shanchol [39].
Analysis of OCV acceptance did not reveal signifi-
cant site-specific determinants; socio-cultural factors
influencing OCV acceptance for urban and rural
residents were similar. However, enthusiasm for an
OCV was significantly higher in urban than rural
respondents at the medium and high prices. This may
be explained by the presence of greater disposable
income and better education as has been observed
in another vaccine study [32] or by higher perceived
risk and vulnerability to the disease. In this study,
both hypotheses remain plausible, as the urban
respondents have better incomes and education than
their rural counterparts. They also may attach a
greater priority to receiving an OCV given the more
crowded and unsanitary conditions that they have to
contend with.
The main limitation of this study is the ability to
relate anticipated acceptance with actual acceptance
in the context of a vaccine campaign. Recognizing that
there is a difference between what people say and
what they actually do [40] anticipated acceptance
may not perfectly guide actual acceptance. Inasmuch
as this study provided a community assessment of
vaccine demand and findings on predictors of OCV
acceptance which support reasonable expectations
(e.g. secondary school education was a predictor for
OCV acceptance), further research addressing the
nature of the relationship between anticipated and
actual acceptance is needed. It also remains to be seen
whether the predictors of anticipated OCV acceptance
would remain significant in the context of an actual
mass vaccination campaign.
Further research could include an assessment of
whether findings from this study may be generalized
across other settings. At some level we expect broad
similarities in factors influencing OCV acceptance;
however, particular priorities may be culture-specific.
It would be fruitful to develop a framework for vac-
cine acceptance by conducting more such studies in
different settings to explain common features and
context-specific differences.
In conclusion, this study found high levels of
interest for an OCV in community residents in
Western Kenya, although vaccine cost was revealed as
a critical consideration. Socio-cultural factors played
an important role in anticipated OCV acceptance
and specific determinants were identified. This re-
search also provides an approach for the study of
socio-cultural determinants and barriers to vaccine
acceptance in other settings.
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Date of interview 
(dd-mm-yyyy) __ __ - __ __ - __ __ __ __  
EMIC ID: 
[U,R][D,N / V,M]### __ __ __ __ __ 
 
Site identification 
  Tick one only:   
Site 1 Urban 2 Rural  Name of setting in urban site/  
Name of village in rural site: 
  
  Tick one only:  
Area DMH area Velhe Taluka   
 NH area Maval Taluka 
 Place of 
interview 1 Household 2 Field 98 Other, specify____________ 
 
General information 
Tick one only: 
Start time of interview (hh:mm) :  Sex F Female M Male 
      
“Thank you for agreeing to participate in this study. As we begin, we would like to ask you a few 
questions about your background.” या अभयाााामय् ाहभागी होणयाा आपण तयार झाला तयााबल धनययाा. 
ाुलाखतीला ाुरयात करताना आमहह काहह प्न तुाचयााबल य तुाचया कुटंुाााबल �यचारणार आहोत. 
Approximate age (in years)   
 
Tick one based on the reply to the age question 
“How old are you?”  
तुाच ्यय �कती/ काय आह्?   years 
Age group 1 18-45 yrs 2 46-65 yrs  
1 Socio- economic and demographic information 
Marital status 
1.1 “Are you currently married?” तुमहह �यया�हत आहात का? 
Tick one only:       
1 Never married  2 Married  3 Separated  4 Divorced  5 Living together  6 Widowed  99  Cannot say  
Type of family 
1.2 “What is the relationship of all of the people who currently stay with you in this household?” 
ामया तुाचया ारात ती ााणा् राहतात तयांच ्तुाचयाची काय नात ्आह्? 
Tick one only:   
1 Single person 2 Nuclear family  3 Joint family/ Extended family 
Other detail: _____________________________________________________________________________________ 
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Household size 
1.3 “How many people altogether are currently staying in your 
household?” ामया तुाचया ारात एकूण �कती तण राहतात?  Persons 
“How many of these people are under 5 years-of-age?” तयातील �कती 
तण ५ यषारखालहल आह्त ? 
 Children (<5 yrs) 
1.4 “What is your relationship to the household head?” या ाराचया कुटंुापाुखाची तुाच ्काय नात ्आह् ? 
(“Respondent is household head’s__________?”,“तुम्ह कुटंुबप्ुमुखा_____________?” ) 
Tick one only:  Tick sex of household head: 
1 Self  2 Wife / Husband  
3 Mother / 
Father  
4 Sister / 
Brother  
5 Daughter/ 
Son  
6 Daughter-
in-law / 
Son-in-law 
98  Other, 
specify:______ Sex  F M 
Education 
1.5 “Have you ever attended school?” तुाच ्�च�ण �कती 
झाल् आह्? तुमहह कधी चाळ्त ग्ला आहात काय? 
1 Yes  2 No  99  Cannot say/ Undisclosed  
{If “yes”, enquire further, otherwise go to Q 1.8} 
Years of education                       Fill in number of years OR tick the box if undisclosed:          
1.6 “How many years of education have you had in total?”   
तुाच ्�च�ण एकूण �कती यषर झाल् आह्? 
 years   Cannot say/ Undisclosed 
1.7 “What is the highest standard/level that you have completed in school or college?”           
तुाच ्चाल्य / कॉल्त �च�ण कुठपय�त झाल् आह्?                                                                   
Tick one only: 
1 Less than 
primary 
2 Primary school 
4th std 
3 Secondary 
10th std  
4 Higher secondary 
12th  
5 Diploma course/ Professional 
course (Computers, Typing etc.)  
6 Graduation (Degree, BA, 
B.Com, etc.)  
7 Post-graduation (Masters 
degree, MA, M.Com, etc.) 98  Other, specify_________ 
Other detail: _____________________________________________________________________________________ 
Main occupational status 
1.8 “What is your main occupation?” तुमहह काय काा करता ? तुाचा ाुखय वययााय काय आह्?  
Occupation 
1 Agriculture 
2 Unskilled labour 
3 Skilled labour 
4 Self-employment (small 
business, petty trade) 
5 Business (other) 
6 Service (public sector) 
7 Service (private sector) 
8 Professional,  
      specify___________________ 
9 Student 
10 Housewife 
11 Retired 
12 Unemployed 
98 Other,  
        specify_________________ 
99 Cannot say 
 
 
Enter the number of the category of occupation that fits best, one only:    
 
Other detail: ________________________________________________________________________________________________  
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1.9 Income                                      
For a & c, enter monthly OR annual income but not both, as reported, OR tick “Cannot say”  (b & d)Tick one only: 
 
a) “What is your monthly personal income?” 
तुाच ्सयततच ्/ यैयिकतक ाा�ाक उतपनन �कती आह्? Rs 
/month  
  Cannot say /year  
{If response to Q 1.9 (a) is “zero”, then go to Q 1.9 (c)} 
   
b) “Is your personal income reliable and 
dependable?” तुाच ्सयततच ्/ यैयिकतक उतपनन 
�नय�ात आ�ण ठरा�यक आह् का?  
1 Yes 2 No 99  Cannot say 
    
c) “What is your monthly household income?” 
तुाचया कुटंुााच ्ाा�ाक उतपनन �कती आह्? Rs 
/month  
  Cannot say /year  
      
d) “Is your household income reliable and 
dependable?” तुाचया कुटंुााच ्उतपनन �नय�ात 
आ�ण ठरा�यक आह् का? 
 1 Yes  2 No 99 Cannot say 
 
Other detail: ________________________________________________________________________________________________  
 _____________________________________________________________________________________________  
 _____________________________________________________________________________________________  
Religion 
1.10 What is your religion? तुाचा धार कोणता आह्? 
Tick one only: 
1 Hindu 2 Muslim  3 Christian  4 Sikh 5 Neo-Buddhist 98  Other, specify _______  99  Undisclosed  
 
Denomination / other detail: _______________________________________________________________________  
Social category  
1.11 What social category do you belong to? तुमहह कोणतया ााााितक पयगारत / कॅट्गरहामय् य्ता? 
Tick one only: 
1 Scheduled caste/ 
Scheduled tribe 
2 Other 
backward class 
3 Open / general 
category 98  Other, specify __________ 99  Undisclosed  
 
Other detail: ____________________________________________________________________________________  
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Introduction to vignettes 
“Now we would like to talk to you about a few health problems that affect people in your 
community. We want to understand how you think about them. It is your ideas that we are 
interested in, so please don’t feel shy to tell us your personal opinion. You may recognize these 
problems, or perhaps they may be unfamiliar. In either case we would like to understand your 
ideas.” आता आपण तुाचया भागातील लोकायंर प�रणाा करणारया काहह आरोगय प्नांयर ाोलुयात. तुमहह या 
प्नांाबल काा �यचार करता ह् आमहाला ताणून घयायच ्आह्. तुाच ्�यचार आाचयाााठठ ाहतयाच ्आह्त तयााुळ् 
तुमहह ाोकळ्पणान् ाोलाय् अची आाची इच्ा आह्. तुमहाला या आरोगय प्नांाबल काा�चत ाा�हती अा्ल �कंया 
ना्ल तरहहह आमहाला या आरोगय प्नांाबलचया तुाचया कलपना ताणून ा्णयाची इच्ा आह्.   
3 Vignette P 
“Now I would like to talk to you about someone else. [Prakash / Pradnya / Prabhakar / Pratibha] (P) 
had a different health problem. Let me tell you about it.” आता आमहह तुमहाला ााुरया एका वयकतीाबल 
ाांगणार आह्. [पकाच/ प ा/ पभाकर/ प�तभा  [पी  ला एक ााुरा आरोगयाचा ताा / आतार आह्. 
{Replace P with the name in the vignette for each of the questions that follow. य्थून पुढहल प्नांामय् 
“पी” ऐयती िवह�नय्टच ्अाल्ल् नाय ांाोधूनच प्न �यचाराय्त.} 
{Read the vignette aloud.  See attached sheet.} 
3.1 “What do you think is the problem that [P] had? What is the name of this disease? (By what 
name would you describe the condition to someone else?)” तुाचया ात ्[पी  ला कोणता ताा/ 
ाासया अाायी? या आताराच ्नाय काय आह्? तर तुमहाला ााुरया कोणाला तरह [पी  चया या आतारााबल 
ाांगायच ्अा्ल तर तुमहह कोणतया नायान् ाांगाल?  
Specify name, summary term or short description in respondent’s own words. If ‘other’, specify term and explain here: ाुलाखत ा्णारयान् 
ाां�गतल्ल् आताराच् नाय तयांचयाच चबाात �लहाय्. तर खालहल पयारय ाोोून इतर नाय अा्ल तर ता् सप्ट �लहाय्.  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________________  
 _____________________________________________________________________________________  
Name of illness/ disease 
1 Common cold  6 Swine flu/ H1N1 Influenza/ Pandemic flu 11 Dengue 
2 Fever (nonspecific) 7 Viral (infection / fever) 12 Malaria 
3 Fever and chills 8 HIV/AIDS 13 Diptheria 
4 Cold and cough  9 Tuberculosis (TB) 98 Other, specify:____________ 
5 Common flu / Seasonal flu 10 Typhoid 99 Cannot say / Undecided 
 
Code only one name from the above-numbered list. If multiple answers are provided by the respondent, ask them to choose 
one answer that they consider most likely, and code that name here. If respondent cannot identify a single best category, code 
“Cannot say 
 
वरहल पय रुयुंपपकक का वव  कख पय रुय क क करुर .र ्ुलुमत तादुणयु ा्  कुपा ु .ु त स्तरात पय रुय य्वकला नवतलल तर ्युं्ु वयायुत .ु त 
शकयतु क द्यु ा.ुरुखल नवाल ा् ेवखुच् ्युप्ुदा क क करुर .र ्लुुमत तादुणयुलु  क्ह पय रुय य्वकतु ालु ्ु्ह तर ‘Cannot Say’ 
क क करु 
 
{In the questions that follow use the name identified for this disease instead of referring to “disease,” 
and use the name of the person mentioned in the vignette instead of “P.” य्थून पुढहल प्नांामय् ाुलाखत 
ा्णारयान् ाां�गतल्ल्च आताराच ्नाय यापरन ता्च “पी” ऐयती िवह�नय्टच ्अाल्ल् नाय ांमाोधूनच प्न �यचाराय्त.} 
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3.2 “Can you think of any other symptoms that [P] is likely to experience besides the ones we 
have already mentioned?” आमहह आधी ती ल�णं ाा�ंगतलह ती ाोोून [पी  ला अतून इतर काहह ल�ण् 
ताणयलह अातील अा् तुमहाला याटत ्का?  
Summarize the respondent’s account of problem in his/her own words:  
 
*Spontaneous narrative: ______________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
Based on the respondent’s account tick problems that are mentioned under the Spon column indicating a spontaneous response to the 
open-ended question above. Probe for any categories not mentioned and tick in the Prob column. If a category is not reported 
spontaneously or in response to probe, make a cross in the prob column. If no physical symptoms are reported spontaneously, tick 
“Cannot say” in the spon column.  
Physical symptoms Spon Prob  Physical symptoms Spon Prob 
1 Extreme coldness (chills, shivering) 
थोंी, हुोहुोी भरण् 
   
12 Diarrhoea तलुाा/ हगयण 
  
2 Headache ोोक्ाखुी    13 Loss of appetite भूक न लागण्   
3 Fever ताप    14 Abdominal pain पोटात ाखुण्   
4 Sore throat ााा ाखुण्, खयखयण्    15 Nausea ाळाळ   
5 Runny nose नाक याहण्/ ाा� 
   16 Irritated, watering eyes ोोळयातून पाणी य्ण्/ ोोळ् 
चरुचरुण् 
  
6 Body ache अगं ाखुण्    17 Extreme fatigue (or weakness) थकया,अचकतपणा   
7 Cough खोकला    18 Redness or rash अगं लालार होण्   
8 Sneezing �चकंा य्ण्    19 Joint pain ाांध्ाखुी     
9 Nasal congestion नाक च�ाण् 
   20 Complications in lungs, liver etcर फुपफुा �कंया 
यकृतात �ाााो/ गुतंागुतं  
  
10 Breathlessness ाा लागण्    98 Other इतर, specify ___________________   
11 Vomiting उलटह होण्      99 Cannot say ाांगता य्त नाहह   
 
*Probed narrative: __________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 
InfVaccPune_EMIC_20120827_Int.doc  EMIC ID:  __ __-__ __ __   Pg turn time (hh:mm):  __ __:__ __ Pg 6 of 21 
3.3 “How do you think that this [disease] will affect [P] socially, emotionally and financially in 
[his/her] daily life?” या [आतारााुळ्  [पी  चया रोतचया तीयनात कोणत ्ााााितक, भाय�नक आ�ण आ�थरक 
प�रणाा होऊ चकतील अा् तुमहाला याटत?् 
Summarize the respondent’s account of problem in his/her own words:  
 
*Spontaneous narrative: ______________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
Based on the respondent’s account tick problems that are mentioned under the Spon column indicating a spontaneous response to the 
open-ended question above. Probe for any categories not mentioned and tick in the Prob column. If a category is not reported 
spontaneously or in response to probe, make a cross in the prob column. If no psychosocial problems are reported spontaneously, tick 
“Cannot say” in the spon column. 
Psychosocial problems Spon Prob   Spon Prob 
Social impact    Financial impact   
21 Isolation from others इतर लोकांपााून य्गळ् 
राहाय् लागण् 
   28 Costs (transportation, foods, drugs) 
आतारााुळ् होणारा खचर   
22 Fear of infecting others इतर लोकांना 
आपलयााुळ् आतार होईल हह भीती 
   29 Loss of personal/ family income 
सयततचया/ कुटंुााचया उतपननाच् नकुाान     
23 Interference with work/daily activities ाैन�ंान 
कााात अोथळ्  
   
Miscellaneous   
24 Interference with social relations ााातातील 
ांाधंांयर/ यायरायर प�रणाा  
   
100 Other इतर, specify:______ 
  
Emotional impact     101 Cannot say / None    
25 Sadness, anxiety, ातुख, �चतंा       
26 Concern about course of illness आताराच् 
काय होईल हह काळती 
   
 
 
27 Tension, worry ट्नचन, काळती      
 
*Probed narrative: __________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.4 “Among all these problems or perhaps something else--considering not only physical 
symptoms but also emotional, social or financial problems--which one do you consider the 
single most troubling?” हया ागळयात �कंया आणखी इतर ाासयांपैकक महणत ्फकत चारह�रक तााच नवह् 
तर ााााितक, भाय�नक आ�ण आ�थरक ाासयांाधून कुठल ंएक ल�ण �कंया ाासया तुमहाला ागळयात तासत 
ताााायक याटत?् 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
Code the most troubling category from list of physical symptoms or psychosocial problems in questions 3.2 and 3.3.  
If respondent cannot identify any single category or cannot say, code “0”  
3.5 “How serious is this [disease] for [P]?” [पी  ााठठ हा आतार �कतपत �ारहअा अा्ल अा् तुमहाला याटत?् 
Tick one only: 
2 Very serious  1 Serious  0 Not serious 99 Cannot say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 
InfVaccPune_EMIC_20120827_Int.doc  EMIC ID:  __ __-__ __ __   Pg turn time (hh:mm):  __ __:__ __ Pg 7 of 21 
3.6 “How long do you think this [disease] for [P] is likely to have lasted without treatment?” 
औषधोपचार ा्तल् नाहहत तर [पी  चा आतार �कती �ाया तााच राहू / �टकू चकतो अां तुमहाला याटत ्? 
Tick one only: 
4  Greater than 1 mo   3  Up to 1 mo  2  Up to 2 wks  1  Up to 1 wk  0  Less than 3 days  99 Cannot say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.7 “If [P] takes no outside treatment, what do you think is the most likely health outcome of this 
[disease]?” तर [पी  न् ााह्रन औषधोपचार ा्तल् नाहहत तर या आतारााुळ् तयाचया आरोगयायर काय 
प�रणाा होईल/ होतील अां तुमहाला याटतं? 
Tick one only: 
3  Fatal  2  Worsening but not fatal  1  Recovery  99  Cannot say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.8 “If [P] gets appropriate treatment what do you think is the most likely health outcome of this 
[disease]?” तर [पी  न् योगय औषधोपचार ा्तल् तर या आतारााुळ् तयाचया आरोगयायर काय प�रणाा होईल/ 
होतील अां तुमहाला याटतं? 
Tick one only: 
3  Fatal  2  Worsening but not fatal  1  Recovery  99  Cannot say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.9 “As I mentioned earlier, people may explain health problems like this in various ways. 
Everyone does not explain such problems or their causes the same way. That is okay and 
there is nothing wrong with that. We recognize that various people each have their own 
ideas, and we would like to know what you think has caused [P]'s problem?" आधी आमहह 
ाां�गतलयापााण्, आपलयापैकक पतय्कतण आपलयाला होणारा आरोगय�यषयक ताा/ आतारांची कारण् य्गय्गळया 
पदतीन् ाांगू चकतो. पतय्काची आपलयाला होणारया तााााबल/ आतारााबल ाांगणयाची पदत एक ाारखी 
नात.् ह् ारोार अाून तयात चुककच ्अा् काहहहह नाहह. पतय्क ााणााचया आतारपणााबलचया अचा सयततचया 
काहह कलपना अातात, �यचार अातात त् आमहाला ताणून घयायच ्आह्त तुमहाला काय याटतं [पी  ला हह 
ाासया/ ताा/ आतार  कोणतया कारणांाुळ् झाला अााया? 
Summarize the respondent’s ideas about causes in his/her own words:  
 
*Spontaneous narrative: ______________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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Based on the respondent’s account tick perceived causes that are mentioned under the Spon column indicating a spontaneous 
response to the open-ended question above. Probe for any categories not mentioned and tick in the Prob column. If a category is not 
reported spontaneously or in response to probe, make a cross in the prob column. If no perceived causes are reported spontaneously, 
tick “Cannot say” in the spon column. 
Perceived causes Spon Prob  Perceived causes Spon Prob 
Ingestion 
   15 Lack of personal hygiene ययैिकतक 
असयच्ता 
  
1 Drinking contaminated water              
ा�ुषत पाणी �पण् 
   16 Environmental germs, infection यातायरणातून 
ततंूंचा पााभुारय / ांागर 
  
2 Eating unprotected/spoiled/ 
contaminated food ा�ुषत/ न झाकल्ल्/ 
नााल्ल्, खराा, असयच् अनन खाण् 
   
17 Insect bite ककटक/�कोा चायण् 
  
3 Drinking alcohol ाार �पण्    18 Air pollution याय ूपाषूण   
4 Smoking cigarettes/ beedis, Consuming 
tobacco/ mishri �ाोी/ �ागार्ट ओढण्, 
तंााकू खाण्, �ाशी लायण् 
   
19 Climate, weather- hot/ cold हयााानात ााल 
  
5 Consuming contraband drugs चरा, 
गांता, अफू ा्यन करण् 
   20 Air borne: cough / sneeze of infected 
person हय्तून पााभुारय: आतारह वयकतीचया 
खोकला �कंया �चक्ंतून 
  
Health and Illness 
   21 Other contact with infected person आतारह 
वयकतीचया ांपकारत आलयााुळ्  हय्तनू पााभुारय 
ाोोून) 
  
6 Prior illness पयू�चा आतार 
   22 Hospital-acquired infection ायाखाना / 
हॉिसपटल ाधनू ांागर  
  
7 Physical exertion चारह�रक शा/ क्ट    Cultural and supernatural   
8 Low immunity प�तकारचकती काी अाण् 
   23 Violation of taboo/ misbehaviour धा�ारक 
�रती�रयात न पाळण्/ �न�चद गो्टह करण् 
  
9 Constitutional weakness अचकत पकृती 
   24 Heat/ cold in body, humoral उ्ण/ थों, यात 
�पतत, कफ - पकृ�ताोष 
  
10 Heredity अनयु�ंचकता    25 God, fate, stars, karma ा्य, नचीा, गह, कार   
11 Blood problems (raktha dhosh) रकतात 
ाोष 
   
26 Evil eye, sorcery करणी, तााटूोणा 
  
Psychological    Miscellaneous   
12 Stressful event/ shock ातुखाायक ाटना, 
धकका 
   27 Unhealthy lifestyle अयोगय / अपायरकारक 
तीयनपदती 
  
13 Tension- mind, thoughts, worry ट्नचन, 
�चतंा 
   
98 Other, इतर specify __________________ 
  
Environmental / Social    99 Cannot say ाांगता य्त नाहह   
14 Improper sanitation, dirty surroundings 
असयच्, ााण प�रार 
   
 
  
 
*Probed narrative: __________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.10 “Which one of these causes that you have mentioned, or perhaps something else, do you 
consider the single most important cause?” या ायर �कंया आणखी काहह कारणांाधील कुठल् एक कारण 
तुमहाला ायारत तासत ाहतयाचं याटत?् 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 
Code the most important category from the above-numbered list of perceived causes:  
 
InfVaccPune_EMIC_20120827_Int.doc  EMIC ID:  __ __-__ __ __   Pg turn time (hh:mm):  __ __:__ __ Pg 9 of 21 
3.11  “Would someone like [P] with this [disease] use home-remedies before looking for treatment 
or help outside their homes? If so, what are they most likely to do at home?” [पी  ाारखा आतार 
झाल्लह वयकती ााह्र उपचार ा्णयाआधी काहह ारगुती उपाय / उपचार कर्ल का?  हो अालयाा) त ्कोणकोणत ्
ारगुती उपाय / उपचार करतील?   
Summarize the respondent’s account of home-based treatment in his/her own words:  
 
*Spontaneous narrative: ______________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
Based on the respondent’s account tick categories of home-based treatment that are mentioned under the Spon column indicating a 
spontaneous response to the open-ended question above. Probe for any categories not mentioned and tick in the Prob column. If a 
category is not reported spontaneously or in response to probe, make a cross in the prob column. If no categories of home-based help 
are reported spontaneously, tick “Cannot say” in the spon column.  
Home-based treatment  Spon Prob 
1 Nothing कु्हख ्ु्ह   
2 Drink warm liquids गरा प्य् �पण्   
3 Gargling गुळणया करण्   
4 Vapour inhalation याफ ा्ण्   
5 Cold compress गार पाणयाचया पटय्ा ठ्यण्   
6 Strength-providing foods ताका याढयणार् पााथर खाण्   
7 Herbal remedies (roots, bark, leaves, flowers) यनौषधी/ औषधी यनसपती  कंा, ाुळ्, पान्, 
फुल्), काढा इतयााहंचा यापर करण्  
  
8 Self-prescribed ayurvedic/unani medicines सयततहून आययु� ाक/ यनुानी औषध् ा्ण्   
9 Self-prescribed homeopathic medicines सयततहून हो�ाओपॅथी औषध् ा्ण्   
10 Self-prescribed allopathic drugs सयततहून अॅलोपॅथी औषध् ा्ण्     
11 Prayers, pooja, bhajan पाथरना, पतूा, भतन करण्   
98 Other इतर, specify:______         
99 Cannot say ाांगता य्त नाहह   
 
*Probed narrative: __________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.12 “Which one of all these things people do at home, or perhaps something else, do you think is 
likely to be most helpful?” या ायर ारगुती उपाय / उपचारांपैकक कोणता एक उपाय / उपचार ायारत तासत 
गुणकारह/ ाहाययकारह होईल अां तुमहाला याटतं? 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
Code the most helpful category from the above-numbered list of home-based treatments: 
 
 
3.13 “Where will someone like [P] usually go to seek help/ treatment outside [his/her] home?” [पी  
ाारखी वयकती  औषधोपचार ा्णयाााठठ ाराााह्र कोठ् य कोणाको ्ताईल/ ताऊ चकत ्अां तुमहाला याटत?्  
Summarize the respondent’s account of outside treatment in his/her own words: 
 
*Spontaneous narrative: ______________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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Based on the respondent’s account tick categories of outside help seeking that are mentioned under the Spon column indicating a 
spontaneous response to the open-ended question above. Probe for any categories not mentioned and tick in the Prob column. If a 
category is not reported spontaneously or in response to probe, make a cross in the prob column. If no categories of outside help 
seeking are reported spontaneously, tick “Cannot say” in the spon column.  
Outside help-seeking Spon Prob 
1 No outside help ााह्रन कुठलहहह ाात न ा्ण्   
2 Private health facility / doctor खातगी ायाखाना, हॉिसपटल, ोॉकटर    
3 Government health facility / doctor ारकारह ायाखाना, हॉिसपटल, ोॉकटर   
4 Local health-worker सथा�नक आरोगय कारचारह   
5 Informal help from a friend, neighbour or relative �ात,च्तारह �कंया नात्याईकांकोून ाात ाागण्/ा्ण्   
6 Consult with a chemist or pharmacist औषध �यक्तयाचा /क्�ासटचा ालला ा्ण्   
7 Traditional healers (vaidu, jhadi-booti wala) पारंपा�रक याै,ू हकका, तोी-ाटुहयाला   
8 Faith healers (devrishi, bhagat) ा्यॠषी, भगत   
98 Other, इतर  specify:______   
99 Cannot say ाांगता य्त नाहह    
 
*Probed narrative: __________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.14 “Which one of all these sources of help [P] might consult do you think is likely to be most 
helpful?” या ागळया आरोगय ाु�यधांपैकक य ायर वयकतींामय् कोणा  एकाची ाात ायारत तासत होऊ चक्ल 
अां तुमहाला याटतं? 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
Code the most helpful category from the above-numbered list of outside help-seeking:  
3.15 “Is there anything that could have been done that might have prevented [P]’s [disease]?” [पी  
ला हा आतार होऊ नय् महणून काहह करता आलं अातं अां तुमहाला याटतं का?  या आताराला प�तांधक 
उपाय/ उपचार महणून काय करता आल् अात ्अां तुमहाला याटतं ? 
Summarize the respondent’s account of prevention options in his/her own words: 
 
*Spontaneous narrative: ______________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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Based on the respondent’s account tick categories of prevention that are mentioned under the Spon column indicating a spontaneous 
response to the open-ended question above. Probe for any categories not mentioned and tick in the Prob column. If a category is not 
reported spontaneously or in response to probe, make a cross in the prob column. If no categories of prevention are reported 
spontaneously, tick “Cannot say” in the spon column.  
Prevention Spon Prob 
1 Nothing काहहच नाहह   
2 Handwashing हात धण्ु   
3 Cleanliness सयच्ता    
4 Wholesome lifestyle (diet / rest / exercise) आरोगयाायक तीयन पदती  आहार/ आराा/ वयायाा)   
5 Minimize exposure to infection (crowds, infected persons, shared utensils etc.) ांागारपााून 
चकय �ततका ाचाय करण्  गा�, आतारह वयकती, उ्टह भांोी इ. टाळण्)  
  
6 Good ventilation at home and work ार आ�ण काााचया �ठकाणी ख्ळती हया, याययुीतन   
7 Wearing a mask ाासक ाालण्   
8 Herbal remedies (Nilgiri tel, camphor), tonics, immunity boosters (Chywanprash, vitamins, 
etc.) औषधी यनसपतीं यार् उपचार  �नल�गरह त्ल, कापरू) टॉ�नका, प�तकारचकती याढयणारह औषध्  चययनपाच, 
तीयनातय्, इ.) 
  
9 Preventive drugs प�ताधंाताक औषध्    
10 Vaccines लाी   
11 Health education to reduce transmission ांागर टाळणयाााठठ आरोगय �च�ण   
12 Protection from supernatural influence (tabiz etc.) अाानयी चकतींपााून/ ााध्पााून ाचाय   
13 Ritual purification (agnihotra, dhoop etc.) �यधीचासत/ पारंपा�रक पदतीन् चुदी  आिगनहोत, धपू)   
98 Other, इतर specify:______       
99 Cannot say ाांगता य्त नाहह    
 
*Probed narrative: __________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
3.16 “Which one of these ways of preventing the [disease] do you think is likely to be most 
useful?” या ाया�पैकक ायारत तासत उपयोगी/ पभायी प�तांधक उपाय कोणता अा्ल अां तुमहाला याटतं? 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 
Code the most useful method from the above-numbered list of preventive measures:  
4 Influenza vaccine questions 
“Here is an update of the story of [P] who fell ill in January 2010. As suggested, [he/she] did visit a 
doctor at a hospital. After consulting with the doctor [he/she] was informed that [he/she] had the 
Swine flu/ H1NI Influenza. Now we have a few more questions for you...” [पी’  तो तान्यारह २०१० ामय् 
आतारह पोला होता तयाला �ाल्लया ाललयानुाार तो तव्हा ोॉकटरांको ्ग्ला तव्हा ोॉकटरांनी तयाला ाां�गतल् कक तयाला 
सयाईन फलू झाला आह्. आता तुमहाला तयााबल काहह प्न �यचारणार आह्. 
4.1 Awareness of Swine flu and vaccine 
{If Swine flu was identified for either vignette, tick the following box and go to 4.1 c} 
a) Swine flu identified previously 3  Yes 0  No 
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b) “Have you heard about the health problem called Swine flu?” तुमहह या सयाईन फलू आतारााबल 
ऐकल् आह् का? 
Tick one only: 
 3  Yes   2  Possibly   1  Uncertain  0   No  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
c) “If [P] had taken a vaccine, do you think that would have protected [him/her] from getting 
the Swine flu?” तर [पी  न् ला ा्तलह अाती तर [तो/ ती  सयाईन फलू होणयापााून सयततचा ाचाय कर 
चकला अाता/ चकलह अाती अा् तुमहाला याटत ्का? 
Tick one only: 
 3  Yes   2  Possibly   1  Uncertain  0   No  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
4.2 “Are you aware of a vaccine that is sprayed into a person’s nose to protect against Swine 
flu?” तुमहाला अचा कुठलया लाीाबल ाा�हती आह् का, कक ती सयाईन फलूपााून ाचायाााठठ नाकायाट् �ालह 
तात?् 
Tick one only: 
3  Yes   2  Possibly   1  Uncertain  0   No  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
4.3  “Are you aware of a vaccine that is injected into a person’s upper arm to protect against 
Swine flu?” तुमहाला अचा कुठलया लाी ाबल ाा�हती आह् का, कक ती सयाईन फलूपााून ाचायाााठठ ांोायर 
टोचलह तात?्      
Tick one only: 
3  Yes   2  Possibly   1  Uncertain  0   No  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
4.4 “Do you think either of these vaccines (the nasal spray or the injection) would be more 
powerful and better able to protect you against Swine flu? … Why?” सयाईन फलू पााून ाचायाााठठ 
या पैकक कोणती ला  नाका याट् �ालह ताणारह �कंया इंत्कचन) अ�धक तासत प�रणााकारक अाल् अा ्तुमहाला याटत?् 
...का? 
Tick one only: 
3   Nasal spray 
more powerful 
 2  Injection more 
powerful   1  Both equally powerful   0  Neither powerful  99 Cannot say 
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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4.5 “If you could choose either of these vaccines to protect yourself against Swine flu, which one 
would you prefer, the nasal spray or the injection? … Why?” तर सयाईन फलूचया ाचाया ााठठ तुमहाला 
हया पैकक एका लाीची �नयो करायची अाती तर तुमहह कोणती ला �नयोलह अाती, नाकायाट् �ालह ताणारह �कंया 
इंत्कचन ंयार्? ...का? 
Tick one only: 
2  Nasal spray preferred  1  Injection preferred  0  No preference indicated  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
“Both vaccines, the spray and the injection, that we were asking about are currently available to 
protect against Swine flu. Both are considered safe, and they protect against Swine flu for a year or 
more.” सयाईन फलू पााून ाचायाााठठ आमहह जया लाींाबल �यचारत आहोत, महणत ्नाकायाट् �ालह ताणारह आ�ण 
इंत्कचनंयारा �ालह ताणारह या ाोनहह लाी ामया ााताराामय् उपलबध आह्त. या ाोनहह लाी ाुर��त आह्त आ�ण 
सयाईन फलू पााून एखाा् यषर �कंया तयाहून तासती काळाााठठ ला ा्णारयाचा ाचाय करतात.   
{If the respondent had indicated a preference in question 4.5 for nasal spray, or indicated no 
preference, then proceed directly with questions about the nasal spray vaccine in the left-hand 
column below before asking about acceptance of the injectable vaccine in the right-hand column. If 
the respondent indicates a preference for the injectable vaccine, proceed directly with questions in 
the right-hand column before questions about acceptance of the nasal spray vaccine in the left-hand 
column.} 
     
Nasal spray vaccine acceptance Injectable vaccine acceptance 
  
{Skip this introduction if you ask first about the 
nasal spray vaccine.} 
 
{Skip this introduction if you ask first about the 
injectable vaccine.} 
“If only the nasal spray vaccine is available, and 
it is not possible to get the injectable vaccine, 
we would like to know if you would consider it.” 
इंत्कचनंयार् �ालह ताणारह ला �ाळण् चकय ना्ल आ�ण 
नाकायाट् �ालह ताणारह लाच उपलबध अा्ल तर तुमहह ती 
घयाल का या ाबल आमहाला ताणून घयायच ्आह्. 
“If only the injectable vaccine is available, and it 
is not possible to get the nasal spray vaccine, 
we would like to know if you would consider it.” 
नाकायाट् �ालह ताणारह ला �ाळण् चकय ना्ल आ�ण 
इंत्कचनंयार् �ालह ताणारह लाच उपलबध अा्ल तर तुमहह ती 
घयाल का या ाबल आमहाला ताणून घयायच ्आह्. 
4.6 “ The current market price of the nasal 
spray vaccine is Rs. 150. Would you pay 
that price to take it?” नाकायाट् �ालया ताणारया 
लाीची ामयाची ाातारातील �कंात १५० रपय् अा्ल तर 
तुमहह ती घयाल का? 
4.6 “ The current market price of the 
injectable vaccine is Rs. 500. Would you 
pay that price to take it?” इंत्कचनंयार् �ालया 
ताणारया लाीची ामयाची ाातारातील �कंात ५०० रपय् 
अा्ल तर तुमहह ती घयाल का? 
Tick one only: Tick one only: 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
 
*Narrative:_________________________________________ 
______________________________________ 
 
*Narrative:_________________________________________ 
______________________________________ 
{If “yes,” then go to question 4.8 directly below.} {If “yes,” then go to question 4.8 directly below.} 
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Nasal spray vaccine acceptance Injectable vaccine acceptance 
4.7 “ If the Government were to make the 
nasal spray vaccine available at a 
subsidized cost, Rs 75, would you pay that 
much to take it?” तर ारकारन् नाकायाट् �ालह ताणारह 
ला ायलतीचया �कंातीत महणत ्७५ रपयाला उपलबध 
क्लह तर तुमहह ती घयाल का? 
4.7 “ If the Government were to make the 
injectable vaccine available at a subsidized 
cost, Rs. 250, would you pay that much to 
take it?” तर ारकारन् इंत्कचनंयार् �ालह ताणारह ला 
ायलतीचया �कंातीत महणत ्२५० रपयांना उपलबध क्लह 
तर तर तुमहह ती घयाल का? 
Tick one only: Tick one only: 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
 
*Narrative:_________________________________________ 
______________________________________ 
 
 
*Narrative:_________________________________________ 
______________________________________ 
4.8 “ If the Government were to make the 
nasal spray vaccine available free of cost, 
would you take it?” तर ारकारन् नाकायाट् �ालह 
ताणारह ला ाोफत उपलबध क्लह तर तुमहह ती घयाल का? 
4.8 “ If the Government were to make the 
injectable vaccine available free of cost, 
would you take it?” तर ारकारन् इंत्कचनंयार् �ालह 
ताणारह ला ाोफत उपलबध क्लह तर तर तुमहह ती घयाल 
का? 
Tick one only: Tick one only: 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
 
*Narrative:_________________________________________ 
______________________________________ 
 
*Narrative:_________________________________________ 
______________________________________ 
  
4.9 “In 2010, when everyone was very 
concerned about Swine flu and wanted to 
get a vaccine, this high demand led to a 
shortage in supplies of nasal spray 
vaccines. As a result, they could be obtained 
only at very high prices. If there were 
another outbreak of Swine flu, and the nasal 
spray vaccine could only be purchased by 
paying Rs. 300, would you buy it?” २०१० ामय् 
अची प�रिसथती आलह होती कक सयाईन फल ूाुळ् ागळ् 
काळतीत पोल् होत् आ�ण ागळयांना ला घयायची इच्ा 
होती तयााळ्ु या नाकायाट् �ालया ताणारया लाीला खूप 
ाागणी याढलह आ�ण पुरयठयाामय् तुटयोा �नाारण 
झालयााुळ् पुर्चा लाी उपलबध नवहतया. हयााुळ् या लाी 
तासती �कातीन् �यकलया तात होतया.तर पुनहा एखााह 
सयाईन फलूची  ााथ आलह आ�ण नाकायाट् �ालह ताणारह 
ला ३०० रपयाला �यकत घयायी लागणार अा्ल तर तुमहह 
अची ला �यकत घयाल का? 
4.9 “In 2010, when everyone was very 
concerned about Swine flu and wanted to 
get a vaccine, this high demand led to a 
shortage in supplies of injectable vaccines. 
As a result, they could be obtained only at 
very high prices. If there were another 
outbreak of Swine flu, and the injectable 
vaccine could only be purchased by paying 
Rs. 1000, would you buy it?” २०१० ामय् अची 
प�रिसथती आलह होती कक सयाईन फलू ाळ्ु ागळ् काळतीत 
पोल् होत ्आ�ण ागळयांना ला घयायची इच्ा होती 
तयााुळ् इंत्कचनंयार् �ालया ताणारया लाीला खूप ाागणी 
याढलह आ�ण पुरयठयाामय् तुटयोा �नाारण झालयााळ्ु 
पुर्चा लाी उपलबध नवहतया. हयााुळ् या लाी तासती 
�कातीन ्�यकलया तात होतया.तर पुनहा एखााह सयाईन 
फलूची  ााथ आलह आ�ण इंत्कचनंयार् �ालह ताणारह ला 
१००० रपयाला �यकत घयायी लागणार अा्ल तर तुमहह 
अची ला �यकत घयाल का? 
Tick one only: Tick one only: 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
3 Yes 2 Possibly 1 Uncertain 0 No 
 
 
*Narrative:_________________________________________ 
______________________________________ 
 
*Narrative:_________________________________________ 
______________________________________ 
 
{If questions about the injectable vaccine were 
not already asked, proceed with question 4.6 in 
the right-hand column. Otherwise proceed with 
question 4.10 below.} 
 
{If questions about the nasal spray vaccine were 
not already asked, proceed with question 4.6 in 
the left-hand column. Otherwise proceed with 
question 4.10 below.} 
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4.10  “Who in your family would you vaccinate against Swine flu, as a priority?” तुाचया कुटंुााामय् 
तुमहह कोणाला पाधानयान् सयाईन फलू प�तांधक ला ंयाल? 
Tick all that apply OR tick only “No one” OR tick only “Cannot say.” Do not probe. 
1 Children 2 Adults 3 Elderly 4 Persons with a             chronic illness 
5 Pregnant 
women 6 No one 
98 Other, 
specify__________ 
99 Cannot 
say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
5 Pandemic experience 
5.1 “In general, who is most likely to get Swine flu? Is it men or women? Adults or children? 
Urban residents or rural residents? Rich, poor or middle class people?” Why?  ााधारणपण् 
कोणाला सयाईन फलू होणयाचा ांभय/ चकयता तासत आह्? का? सती कक पुरष? पौढ वयकती का लहान ाुल्? 
चहरात राहणार् लोक का गााीण भागात राहणार्? शीांत, ामयायग�य का गरहा लोक?  
Tick one response only for each of the following three questions: 
Sex  1 Men  2 Women  3 Neither   
     
Age  1 Adults  2 Children  3 Neither   
     
Area  1 Urban 2 Rural 3 Neither  
      
Tick all that apply OR “All/None” 
Social class 1 Rich 2 Poor 3 Middle class 4 All / None 
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
5.2 “Did you or anyone in your household have Swine flu during the pandemic in 2009/2010?” 
तुमहाला �कंया तुाचया ारातील इतर कोणाला २००९-१० चया ाहुतक् ा्चाामय् आल्लया अचा ाायरा्�चक ााथी 
ामय् सयाईनफलू झाला होता का?  
Tick all that apply: 
1 Self  2  Children (<14 yrs)  3 Elderly (>65) 
4  Others in household  
(15 – 65 yrs) 5 No one got it 99  Cannot say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
5.3 “Did you or anyone in your household have Swine flu during the recent outbreak this year, in 
March- April 2012?” यंााचया ााचर - ए�पल २०१२ चया ााथी ामय् तुमहाला �कंया तुाचया ारात कोणाला 
सयाईनफलू झाला होता का?  
Tick all that apply: 
1 Self  2  Children (<14 yrs)   3  Elderly (>65) 
4  Others in household (15 – 
65 yrs) 5 No one got it 99  Cannot say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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{If neither the respondent nor anyone in the family had Swine flu (Q 5.2 or Q 5.3), go to Q 5.6.}  
5.4 “What did you or your family do at home for this (these) person(s) with Swine flu in 
either outbreak?” सयाईनफलू झाल्लया वयकतीााठठ तुमहह �कया ारातील इतरांनी कोणत ्ारगुती 
उपचार क्ल् ? 
Based on the respondent’s account tick home-based treatment categories in the appropriate column indicating a 
spontaneous response to the open-ended question above. Tick all that apply OR tick only “Nothing,” OR tick only 
“Cannot say.” Do not probe further. 
Home-based treatment  2009-2010 Pandemic 
2012 
Outbreak 
1 Nothing काहहच नाहह   
2 Drink warm liquids गरा प्य्   
3 Gargling गुळणया करण्   
4 Vapour inhalation याफ ा्ण्   
5 Cold compress गार पाणयाचया पटय्ा ठ्यण्   
6 Strength-providing foods ताका याढयणार् पााथर खाण्   
7 Herbal remedies (roots, bark, leaves, flowers) यनौषधी/ औषधी यनसपती  कंा, 
ाुळ्, पान्, फुल्), काढा इतयााहंचा यापर करण् 
 
 
8 Self-prescribed ayurvedic/unani medicines सयततहून आययु� ाक/ यनुानी औषध् 
ा्ण् 
 
 
9 Self-prescribed homeopathic medicines  सयततहून हो�ाओपॅथी औषध् ा्ण्   
10 Self-prescribed allopathic drugs  सयततहून अॅलोपॅथी औषध् ा्ण्   
11 Prayers, pooja, bhajan पाथरना,पतूा,भतन करण्    
98 Other, इतर specify:_________________ / _________________   
99 Cannot say  ाांगता य्त नाहह   
 
Narrative: ________________________________________________________________  
 ______________________________________________________________________  
5.5 “What kind of help outside, if any, did you or your family get for the person(s) with 
Swine flu in either outbreak?” तुमहह �कंया तुाचया कुटंुाातील ाासयांनी या सयाईन फलूचया कोणतयाहह 
ााथी ारमयान औषधोपचाराााठठ ाराााह्रहल कोणाकोणाची य काय ाात ा्तलह यााबल आमहाला ाांगाल काय? 
Based on the respondent’s account tick home-based treatment categories in the appropriate column indicating a 
spontaneous response to the open-ended question above. Tick all that apply, OR tick only “Nothing,” OR tick only 
“Cannot Say.” Do not probe further. 
Outside help- seeking 2009-2010 Pandemic 
2012 
Outbreak 
1 No outside help ााह्रन कुठलहहह ाात न ा्ण्   
2 Private health facility / doctor खातगी ायाखाना, हॉिसपटल,  ोॉकटर    
3 Government health facility / doctor ारकारह ायाखाना, हॉिसपटल,  ोॉकटर   
4 Local health-worker सथा�नक आरोगय कारचारह   
5 Informal help from a friend, neighbour or relative �ात,च्तारह �कंया नात्याईकांकोून ाात 
ाागण्/ा्ण् 
 
 
6 Consult with a Chemist / Pharmacist क्�ासटचा/ औषध �यक्तयाचा ालला ा्ण्   
7 Traditional healers (vaidu, jhadi-booti wala) पारंपा�रक याै,ू हकका, तोी-ाटुहयाला   
8 Faith healers (devrishi, bhagat) ा्यॠषी, भगत   
98 Other, इतर specify:_________________ / _________________   
99 Cannot say वुंयतु यात ्ु्ह   
 
Narrative: ________________________________________________________________  
 ______________________________________________________________________  
 ______________________________________________________________________  
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5.6 “Have you ever taken a vaccine to prevent Swine flu?” सयाईन फलू होऊ नय् महणून तुमहह कधी ला 
ा्तलह आह् का? 
Tick one only: 
3 Yes   2 Possibly   1 Uncertain  0 No  
 
Narrative: ________________________________________________________________________  
______________________________________________________________________________
______________________________________________________________________________ 
5.7  “Has anyone else in your household ever taken a vaccine to prevent Swine flu?” तुाचया ारातील 
इतर कोणी सयाईन फल ूप�तांधक ला ा्तलह आह् का? 
Tick one only: 
3 Yes   2 Possibly   1 Uncertain  0 No  
{If “yes” or “possibly,” fill in all details about vaccine recipient(s) in table below} 
 Sex Age   Sex Age   Sex Age  
1 Spouse         
   
      
2 Child         
   
      
3 Parent         
   
      
4 Other_____________         
 
Narrative: ________________________________________________________________________  
______________________________________________________________________________
______________________________________________________________________________ 
5.8 “For you or anyone in your household who did not take the vaccine for Swine flu, were there 
any particular reasons not to take it? Can you explain why some (or all) did not take it?” तुमहह 
�कया ारातील कोणी सयाईन फल ूप�तांधक ला न ा्णयाच ्काहह �यच्ष कारण आह् का? ला न ा्णयाच् कारण तुमहह ाांगू 
चकाल का? 
 
*Narrative: _______________________________________________________________________  
______________________________________________________________________________
______________________________________________________________________________ 
Tick all that apply OR tick only “Cannot say.”: 
Reasons for not taking influenza vaccine Tick 
1 General dislike of injections इंत्कचनची भीती/ नायो  
2 Concern about nasal spray as new mode of administration नाकायाट् ला ा्णयाची पदत नयीन अालयान् तयाााात भीती   
3 General avoidance of medications चकयतो औषध् ा्ण् टाळणयाची यतृती  
4 Sufficient precautionary measures already taken प�ताधं करणयाााठठ पर्ुची काळती ा्तलह  
5 Low risk attributed to Influenza/  Lack of perception of own risk सयततला फलू होणयाची चकयता काी याटण्  
6 Fear of adverse reactions �रअॅकचन य्णयाची भीती   
7 Doubts about vaccine effectiveness लाीचया प�रणााकारकत्ाबल चंका  
8 Costs of vaccine लाीची �कंात  
9 Health care provider did not recommend, or discouraged it ोॉकटरांनी लाीाबल न ाां�गतलयााुळ्/ परायतृत क्लयााुळ्  
10 Doesn’t know about the vaccine लाीाबल ाा�हती नाण्  
11 Doesn’t know how or where to get the vaccine ला कोठ् �ाळत् आ�ण कची घयायची याााात ाा�हती नाण्  
12 No time to take the vaccine ला घयायला य्ळ नाण्    
13 Vaccine shortage due to high demand तासत ाागणीाुळ् लाीचा तुटयोा  
98 Other, इतर specify:______    
99 Cannot say ाांगता य्त नाहह   
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5.9 “Has your health care provider ever recommended your taking a vaccine to protect against 
Swine flu?” तुाचया ोॉकटरांनी तुमहाला सयाईन फलूपााून ाचाय करणयाााठठ कधी ला ा्णयाचा ालला �ाला 
आह् का? 
Tick one only: 
 3 Yes   2 Possibly   1 Uncertain  0  No  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
5.10 “Are there any particular problems that affect people who take the Swine Flu vaccine, either 
the nasal spray or injection?” सयाईन फलूचया, नाकायाट् �ालया ताणारया �कंया इंत्कचनंयारा �ालया 
ताणारया लाीाुळ्, ला ा्णारयाला काहह �यच्ष ताा होतील का? / होऊ चकतील का? 
Tick all that apply OR tick only “No problem” OR tick only “Cannot say.” Do not probe. 
Problems caused by vaccines  Nasal spray 
Injection 
1 No problem   
2 Stuffy nose, runny nose or sneezing  नाक च�ाण्, नाकातून पाणी य्ण्, �चकंा य्ण्    
3 Pain, swelling or discomfort at injection site or in the nose इंत्कचन �ाल्लया तागी अथया नाकात 
ाखुण्, ाूत, असयसथ याटण्  का्तरह होण्) 
  
4 Muscle pain or joint pain सनाय ूअथया ाांध् ाखुी    
5 Fever ताप   
6 Infection/abscess ाांगर /गाठ   
7 Scar यण   
8 Paralysis or Guillain-Barre syndrome (GB Syndrome) अधा�गयाय ू   
9 Not speaking (autism) सयागनता    
10 Sterility नपुांकतय   
11 Miscarriage गभर पोण्/ गभरपात    
12 Death ातृय ू   
98 Other, इतर specify:_______________________  /  ______________________    
99 Cannot say   
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
5.11 “Which one of these vaccines (nasal spray or injection) do you think would be safer for you? 
… Why?” नाकायाट् अथया इंत्कचनंयारा �ालया ताणारया सयाईन फलूचया लाी प्कक कुठलह ला तुमहाला 
तुाचयाााठठ ाुर��त याटत ् ? ....का? 
Tick one only: 
 3  Nasal spray safer  2  Injection safer   1  Both equally safe  0  Neither is safe  99 Cannot say 
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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5.12 “We have now asked you many questions about [P] who had the Swine flu. Please recall the 
problems of [K], who I asked about before that. As it turned out, [K] was found to have had 
the regular flu, which affects many people every year, but not the Swine flu. Do you think a 
vaccine might have prevented [K]’s illness?” आता पय�त आमहह तुमहाला [पी  ा�ल ार्च प्न �यचारल् 
जयाला सयाईन फलू झाला होता. तया आधी आपण [क्  चया तााांा�ल ाोललो होतो, तयााबल परत ाोलूयात. 
तयाच अां झालं कक, [क्  ला ााधा फलू झालयाच ्�ााून आल् कक तो ार यष� ारयाच लोकांना होतो, तो सयाईन 
फलू नवहता . तुमहाला अां याटत ्का कक ला  ा्तलयााुळ् [क्  चा हया ाामया फलूपााून ाचाय झाला अाता?  
Tick one only: 
 3 Yes   2 Possibly   1 Uncertain  0  No  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
5.13 “Have you ever taken a vaccine to prevent the regular flu, like the problem that [K] had?”  
[क्  ला ताा ााधा फलू झाला होता तचा ाामया फलू ााठठ तुमहह कधीहह ला ा्तलह आह् का? 
Tick one only: 
 3 Yes   2 Possibly   1 Uncertain  0  No  
{If ‘yes’ or ‘possibly’, enquire further, otherwise skip to section 6}  
5.14 “If so, how many times and when?” तर हो तर, �कती य्ळा आ�ण क्वहा यााबल 
ाांगाल का?  
Number of times :  times   
     
Date 1 (mm-yyyy)             -  Date 3 (mm-yyyy)             - 
     
Date 2 (mm-yyyy)             -  Date 4 (mm-yyyy)             - 
Narrative: ____________________________________________________________  
 _________________________________________________________________  
 _________________________________________________________________  
 
6 Other Vaccine Experience  
“So far we have been talking about Swine flu and seasonal flu vaccines. The following few 
questions will be about vaccines for other illnesses.” आतापय�त आपण सयाईन फलू य ाामया फलूचया 
लाींाबल ाोलत होतो, यापुढहल प्न इतर आतारांयरहल लाींाबल अातील.     
6.1 “Have you or anyone else in your household ever taken any vaccine for any illness तुमहह �कंया 
तुाचया ारातील इतर कोणी कुठलयाहह आतारांााठठ कुठलह ला ा्तलह आह् का?  
Tick one only: 
3 Yes   2 Possibly   1 Uncertain  0 No  
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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6.2 “Based on your experience, do you think (any) vaccines are generally helpful?” तुाचया 
अनुभयायरन तुमहाला याटत ्का कक ााधारणतत कुठलहहह ला उपयुकत अात?् 
Tick one only: 
3 Yes   2 Possibly   1 Uncertain  0 No  
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
6.3 “ Has your health care provider ever urged you personally to take a vaccine for protection 
against any illness?” तुाचया ोॉकटरांनी आतारांपााून ाचाय करणयाााठठ कधीहह कोणतीहह ला ा्णयाचा 
आगह क्ला आह् का?  
Tick one only: 
 3 Yes   2 Possibly   1 Uncertain  0  No  
 
*Narrative: _______________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
6.4 “Even if vaccines are effective, do you think that they are also likely to cause problems or 
side-effects?” तरह लाी प�रणााकारक अालया तरह तयांच ्काहह ताा/ ाु् प�रणाा अातात अा् तुमहाला 
याटत ्का?  
Tick one only: 
3 Yes   2 Possibly   1 Uncertain  0 No  
 
Narrative: ________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
{If “yes” or “possibly,” enquire further, otherwise skip to section 7} 
6.5 “If so, what might these problems be?” (तर हो ) तर काय ताा/ ाु् प�रणाा होत अातील ? 
 Tick all that apply or tick only “Cannot say.” 
Problems caused by vaccines  Tick 
1 Pain, swelling or discomfort at injection site or in the nose इंत्कचन �ाल्लया तागी 
अथया नाकात ाखुण्, ाूत, असयसथ याटण्  का्तरह होण्) 
 
2 Fever ताप  
3 Infection/abscess ाांगर, गाठ  
4 Scar वण  
5 Paralysis or Guillain-Barre syndrome (GB Syndrome) अधा�गयायचूा झटका  
6 Not speaking (autism) सयागनता  
7 Sterility नपुांकतय  
8 Miscarriage गभर पोण्/ गभरपात  
9 Death ातृय ु  
98 Other, इतर specify:______    
99 Cannot say ाांगता य्त नाहह   
 
Narrative: __________________________________________________________________  
 _______________________________________________________________________  
 _______________________________________________________________________  
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7 Concluding advice from respondent 
7.1 “Is there anything else you can tell me about the health problems we have discussed or 
about your experience with vaccinations? Any further comments, advice or suggestions will 
be appreciated.” आपण आततापय�त चचार क्ल्लया आरोगय ाासयांाबल  ााधा फलू/ सयाईन फलूाबल) 
तुमहाला अतून काहह ाांगायच् आह् का? याााात तुाचया काहह ाूचना �कंया ालला आह् का?  
 
*Narrative: ______________________________________________________________________________  
 _____________________________________________________________________________________  
 _____________________________________________________________________________________  
 _____________________________________________________________________________________  
 _____________________________________________________________________________________  
 
Interview end time (hh:mm)  
I: Consent form signed? (tick) 1 Signature 2 Thumb print 3 Neither 
I: Team (circle appropriate) A    B    C    D 
I: Audio recording taped? (tick) 1 Yes 2 No 3 Partial 
Interviewer (name)  
Narrative recorder (name)  
N: File name on recorder  
Interviewer copy checked by (date/initials)  
Narrative copy checked by (date/initials)  
Narratives translated & typed (date)  
1st Data entry (date/initials)  
2nd Data entry (date/initials)  
 
Additional comments from the interview team 
 
Notes concerning the participant’s interest and the quality of the interview, and other noteworthy features and details of this interview: 
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
 _____________________________________________________________________________  
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Respiratory Illness Prevention Study: Vignettes 
MALE, YOUNG 
Prakash was a young man 25 years-of-age who lived in a place very similar to yours. In 
January 2010 he fell sick with a sore throat, runny nose and bad pains throughout his 
body.  He also had a bad cough and a constant high fever that wouldn’t go away. He was 
very tired, and he was unable to continue with his work. A few other people in his 
community also seemed to have the same illness, and there were reports about many 
cases like that on TV and in the local newspapers. The neighbours urged Prakash to go to 
a big government hospital for tests to find out what his problem was.   
तरुणमुलगा 
प्रकाशराा्ा२५ावषरर् रा तरा  तशमाहरश र  अकर्ाजरगीाहरश ो.ा२०१०ासरलच्राजरानवरहमा मशह्र ा
 ो आजरहम पडलर.ात्र्राघसर द खर्लर लरगलर, ार् वरशूालरगलनाआ�रात्र्नासवराअंगाद खूाात्रलराखूपा
वनदाराशो ाशोत्र.ात्रलराखो्लरशमा रलराशो राआ�रात्रलरास  ाअसररहरा रपा्रशमाजर ाानश र.ाा
त्रलरा खूपाथ्वराआल्राना  ोा होज्ीा्र ना्राक् ाानश र.ा त्रच्राप�हसहर ीलाआरखीा्रशमा
लो्रंारा त्रच्रसरहखर्ा आजरहा  रलरा शो रा आ�रा मटनशमा वहा आ�र सथराा्ा पनपहा  मूाा अकरा
आजरहरच्रा खूपा न् सनसा असल्रच्रा बर त्रा न् ा शोत्र.ा त्रच्रा कनजरज्रंाीा त्रलरा  ोा्रा सह्रहमा
दवरखरह्र ाजरऊा,ा त्रसा्र्ा रसराआजरहा रलराआशना शनास जस्रसरयाा परसरीा्रााघनाअसरा
सललरामदलर.ाा
 
MALE, OLD 
Prabhakar was a middle-aged man 55 years-of-age who lived in a place very similar to 
yours. In January 2010 he fell sick with a sore throat, runny nose and bad pains 
throughout his body.  He also had a bad cough and a constant high fever that wouldn’t go 
away. He was very tired, and he was unable to continue with his work. A few other people 
in his community also seemed to have the same illness, and there were reports about 
many cases like that on TV and in the local newspapers. The neighbours urged Prabhakar 
to go to a big government hospital for tests to find out what his problem was.   
मध्मम्यीणगगृ हस 
प्र्हा शना ा्ा ५५ा वषरर् ना  म् व्ीाा ग शसथा   तशमा हरश र  अकर्ा जरगीा हरश र .ा २०१०ा सरलच्रा
जरानवरहमा मशह्र ा नाआजरहम पडलन.ात्रं्राघसर द खर्लर लरगलर, ार् वरशूालरगलनाआ�रात्रं्नासवराअंगा
द खूाात्रंारा खूपावनदाराशो ाशोत्र.ा त्रंाराखो्लरशमा रलराशो राआ�रात्रंारास  ाअसररहरा रपा
्रशमाजर ाानश र.ाात्रंाराखूपाथ्वराआल्राना नाहोज्ीा्र ना्राक् ाानश न.ात्रंच्राप�हसहर ीला
आरखीा्रशमालो्रंारात्रंच्रसरहखर्ाआजरहा रलराशो राआ�रामटनशमावहाआ�र सथराा्ापनपहा मूाा
अकराआजरहरच्राखूपा न् सनसाअसल्रच्राबर त्रा न् ाशोत्र.ात्रंच्राकनजरज्रंाीात्रंारा ोा्रासह्रहमा
दवरखरह्र ाजरऊा,ात्रंारा्र्ा रसराआजरहा रलराआशनाशनास जस्रसरयाा परसरीा्रााक्राअसरा
सललरामदलर.ाा
2 
 
FEMALE, YOUNG 
Pradnya was a young woman 25 years-of-age who lived in a place very similar to yours. In 
January 2010 she fell sick with a sore throat, runny nose and bad pains throughout her 
body.  She also had a bad cough and a constant high fever that wouldn’t go away. She 
was very tired, and she was unable to continue with her work. A few other people in her 
community also seemed to have the same illness, and there were reports about many 
cases like that on TV and in the local newspapers. The neighbours urged Pradnya to go to 
a big government hospital for tests to find out what her problem was.  ा
तरुणमुलगयण 
प्र  शमा ा्ा २५ा वषर�्ीा  तरा   लगीा   तशमा हरश र  अकर्ा ्रगर  हरश न.ा २०१०ा सरलच्रा जरानवरहमा
 मशह्र ा  ी आजरहम पडलम.ा ा ्रा घसर द खर्लर लरगलर, ार् वरशूा लरगलनाआ�रा ा ्ना सवरा अंगा द खूाा
ा लराखूपावनदाराशो ाशोत्र.ाा लराखो्लरशमा रलराशो राआ�राा लरास  ाअसररहरा रपा्रशमाजर ा
ानश र.ााा लराखूपाथ्वराआल्राना ीाहोज्ीा्र ना्राक् ाानश ी.ाा च्राप�हसहर ीलाआरखीा
्रशमा लो्रंारा ा च्रसरहखर्ाआजरहा रलरा शो राआ�रा मटनशमा वहाआ�र सथराा्ा पनपहा  मूााअकरा
आजरहरच्रा खूपा न् सनसा असल्रच्रा बर त्रा न् ा शोत्र.ा ा च्रा कनजरज्रंाीा ा लरा  ोा्रा सह्रहमा
दवरखरह्र ाजरऊा,ा ा लरा्र्ा  रसराआजरहा रलराआशना शना स जस्रसरयाा  परसरीा्रााघनाअसरा
सललरामदलर.ा 
 
FEMALE, OLD 
Pratibha was an middle-aged woman 55 years-of-age who lived in a place very similar to 
yours. In January 2010 she fell sick with a sore throat, runny nose and bad pains 
throughout her body.  She also had a bad cough and a constant high fever that wouldn’t 
go away. She was very tired, and she was unable to continue with her work. A few other 
people in her community also seemed to have the same illness, and there were reports 
about many cases like that on TV and in the local newspapers. The neighbours urged 
Pratibha to go to a big government hospital for tests to find out what her problem was. 
मध्मम्यीणममृलाण 
पा ्र ्रा ा्ा ५५ वषररच्रा  म् व्ीा बरईा   तशमा हरश र  अकर्ा ्रगर  ा हरश र .ा २०१०ा सरलच्रा
जरानवरहमा मशह्र ात्राआजरहम पडल्र.ात्रं्राघसर द खर्लर लरगलर, ार् वरशूालरगलनाआ�रात्रं्नासवरा
अंगाद खूाात्रंारा खूपावनदाराशो ाशोत्र.ा त्रंाराखो्लरशमा रलराशो राआ�रात्रंारास  ाअसररहरा
 रपा्रशमाजर ाानश र.ाात्रंाराखूपाथ्वराआल्रानात्राहोज्ीा्र ना्राक् ाानशत्र,ात्रंच्रा
स रजर ीलाआरखीा्रशमालो्रंारात्रंच्रसरहखर्ाआजरहा रलराशो राआ�रामटनशमावहाआ�र सथराा्ा
पनपहा मूााअकराआजरहरच्रा खूपा न् सनसाअसल्रच्राबर त्रा न् ाशोत्र.ा त्रंच्राकनजरज्रंाीा त्रंारा
 ोा्रासह्रहमादवरखरह्र ाजरऊा,ात्रंारा्र्ा रसराआजरहा रलराआशनाशनास जस्रसरयाा परसरीा
्रााक्राअसरासललरामदलर.ा 
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